PMID- 31980144
OWN - NLM
STAT- MEDLINE
DCOM- 20200219
LR  - 20200219
IS  - 1769-6917 (Electronic)
IS  - 0007-4551 (Linking)
VI  - 107
IP  - 1
DP  - 2020 Jan
TI  - [HIV and cancer: Update 2020].
PG  - 21-29
LID - S0007-4551(20)30003-5 [pii]
LID - 10.1016/j.bulcan.2020.01.001 [doi]
AB  - The HIV infection remains a serious public health concern in France and around the 
      world. Cancers are frequent among people living with HIV (PLWH) and have become the 
      leading cause of mortality among this population in France. Certain 
      non-AIDS-defining cancers are much more common among PLWH, such as anal carcinoma, 
      Hodgkin lymphoma, hepatocellular carcinoma and lung cancer. The incidence of cancer 
      among PLWH depending on various factors, virological control under combined 
      antiretrovial therapies (cART), exposure prevention to oncogenic virus and toxics 
      are of utmost importance, such as the implementation of specific screening 
      programmes. Drug interactions between cART and oncologic treatments can lead to 
      serious adverse effects or to a reduction in the therapeutic effects, therefore they 
      require a close monitoring. The PLWH have been excluded from the oncologic clinical 
      trials assessing the efficacy and toxicity profile of the immune checkpoints 
      inhibitors (ICPi) because of an increased theoretical risk of inducing adverse 
      events and a feared lack of efficacy in the immunocompromised population. However, 
      the mostly retrospective clinical data reporting the use of ICPi among PLWH are 
      somewhat reassuring with a safety and efficacy profile similar to what observed in 
      HIV-negative patients. Regarding the "shock and kill" anti-HIV effects of ICPi, the 
      preliminary clinical data available are still modest and relatively disappointing 
      despite encouraging results obtained in vitro. HIV-associated cancers represent a 
      particular care challenge due to the multiple comorbidities in the population and 
      the high risk of drug interactions, thus the CANCERVIH national network is of 
      particular interest within this context.
CI  - Copyright © 2020 Société Française du Cancer. Published by Elsevier Masson SAS. All 
      rights reserved.
FAU - Abbar, Baptiste
AU  - Abbar B
AD  - AP-HP, Sorbonne Université, Inserm, institut Pierre Louis d'épidémiologie et de 
      Santé Publique, équipe Theravir, hôpitaux universitaires Pitié Salpêtrière - 
      Charles-Foix, oncologie médicale, 75013 Paris, France.
FAU - Veyri, Marianne
AU  - Veyri M
AD  - AP-HP, Sorbonne Université, Inserm, institut Pierre Louis d'épidémiologie et de 
      Santé Publique, équipe Theravir, hôpitaux universitaires Pitié Salpêtrière - 
      Charles-Foix, oncologie médicale, 75013 Paris, France.
FAU - Solas, Caroline
AU  - Solas C
AD  - AP-HM Timone, service de pharmacocinétique et toxicologie, Inserm 1207, IRD 190, EFS 
      IRBA, unité des virus emergents, Aix Marseille université, Marseille, France.
FAU - Poizot-Martin, Isabelle
AU  - Poizot-Martin I
AD  - AP-HM Sainte-Marguerite, Aix-Marseille université, Inserm, IRD, SESSTIM, sciences 
      économiques et sociales de la santé et traitement de l'information médicale, Service 
      d'Immunohématologie clinique, Marseille, France.
FAU - Spano, Jean-Philippe
AU  - Spano JP
AD  - AP-HP, Sorbonne Université, Inserm, institut Pierre Louis d'épidémiologie et de 
      Santé Publique, équipe Theravir, hôpitaux universitaires Pitié Salpêtrière - 
      Charles-Foix, oncologie médicale, 75013 Paris, France. Electronic address: 
      jean-philippe.spano@aphp.fr.
LA  - fre
PT  - Journal Article
PT  - Review
TT  - VIH et cancer : mise au point en 2020.
DEP - 20200121
PL  - France
TA  - Bull Cancer
JT  - Bulletin du cancer
JID - 0072416
RN  - 0 (Anti-HIV Agents)
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Anti-HIV Agents/pharmacology
MH  - Antineoplastic Agents/pharmacology
MH  - Anus Neoplasms/diagnosis/drug therapy
MH  - Drug Interactions
MH  - France
MH  - HIV Infections/*complications/drug therapy/epidemiology
MH  - *HIV Long-Term Survivors
MH  - Humans
MH  - Immunotherapy, Adoptive/methods
MH  - Lung Neoplasms/diagnosis/mortality
MH  - Neoplasms/*diagnosis/drug therapy/epidemiology/immunology
OTO - NOTNLM
OT  - Cancer
OT  - Drug interactions
OT  - Dépistage
OT  - Epidemiology
OT  - HIV
OT  - Immune checkpoint inhibitor
OT  - Inhibiteurs des checkpoints immunitaires
OT  - Interactions médicamenteuses
OT  - Neoplasm
OT  - Screening
OT  - VIH
OT  - Épidémiologie
EDAT- 2020/01/26 06:00
MHDA- 2020/02/20 06:00
CRDT- 2020/01/26 06:00
PHST- 2019/12/27 00:00 [received]
PHST- 2020/01/06 00:00 [revised]
PHST- 2020/01/06 00:00 [accepted]
PHST- 2020/01/26 06:00 [pubmed]
PHST- 2020/02/20 06:00 [medline]
PHST- 2020/01/26 06:00 [entrez]
AID - S0007-4551(20)30003-5 [pii]
AID - 10.1016/j.bulcan.2020.01.001 [doi]
PST - ppublish
SO  - Bull Cancer. 2020 Jan;107(1):21-29. doi: 10.1016/j.bulcan.2020.01.001. Epub 2020 Jan 
      21.

PMID- 27627120
OWN - NLM
STAT- MEDLINE
DCOM- 20171031
LR  - 20181113
IS  - 1518-8345 (Electronic)
IS  - 0104-1169 (Print)
IS  - 0104-1169 (Linking)
VI  - 24
IP  - 0
DP  - 2016 Sep 9
TI  - Tuberculosis control in people living with HIV/AIDS.
PG  - e2798
LID - S0104-11692016000100410 [pii]
LID - 10.1590/1518-8345.1187.2798 [doi]
LID - e2798
AB  - OBJECTIVE: to analyze the offering of health actions and services for the control of 
      tuberculosis for people living with HIV/AIDS being followed up in the Specialized 
      Care Services for HIV/AIDS in Ribeirão Preto, SP, Brazil. METHOD: quantitative, 
      exploratory survey study. Participated 253 people living with HIV/AIDS followed up 
      by this service, considering as inclusion criteria: individuals older than 18 years 
      living in the city and not inmates. Data collection was conducted from January 2012 
      to May 2013 through interviews with the support of a specific instrument. Data were 
      analyzed using indicators and a composite index. RESULTS: the offering of services 
      for the control of tuberculosis in people living with HIV/AIDS by municipal services 
      was considered as intermediate, reinforcing the need for better planning for 
      comprehensive assistance, coordination of professionals in teams and among the 
      services network, in addition to professional training and continuing education. 
      CONCLUSION: it is necessary to implement strategies that promote shared actions 
      between TB and HIV / AIDS programs and between different services in order to 
      strengthen the local care network, aimed at producing an individualized care, 
      comprehensive and responsive. OBJETIVO: analisar a oferta das ações e serviços de 
      saúde para o controle da tuberculose nas pessoas vivendo com HIV/aids em seguimento 
      pelos Serviços de Atenção Especializada ao HIV/aids de Ribeirão Preto, SP, Brasil. 
      MÉTODO: estudo quantitativo, exploratório, do tipo inquérito. Participaram 253 
      pessoas vivendo com HIV/aids em seguimento nos serviços, considerando os critérios 
      de inclusão: indivíduos maiores de 18 anos, residentes no município e não 
      pertencentes ao sistema prisional. A coleta de dados foi realizada no período de 
      janeiro/2012 a maio/2013, por meio de entrevistas com apoio de um instrumento 
      específico. Os dados foram analisados mediante indicadores e índice composto. 
      RESULTADOS: a oferta de ações e serviços para o controle da tuberculose nas pessoas 
      vivendo com HIV/aids pelos serviços do município foi considerada regular, reforçando 
      a necessidade de melhor planejamento da assistência de forma integral, articulação 
      dos profissionais nas equipes e entre os serviços da rede, além da formação 
      profissional e educação permanente. CONCLUSÃO: faz-se necessário a implementação de 
      estratégias que favoreçam ações compartilhadas entre os programas de tuberculose e 
      HIV/aids e entre os diferentes serviços, com o intuito de fortalecer a rede local de 
      atenção objetivando a produção de um cuidado singular, integral e resolutivo. 
      OBJETIVO: analizar la oferta de acciones y servicios de salud para el control de la 
      tuberculosis en las personas viviendo con VIH-SIDA acompañadas por los Servicios de 
      Atención Especializada al VIH-SIDA de Ribeirao Preto, SP, Brasil. MÉTODO: estudio 
      cuantitativo, exploratorio, de tipo encuesta. Participaron 253 personas viviendo con 
      VIH-SIDA seguidas por estos servicios, considerando como criterios de inclusión: 
      individuos mayores de 18 años, residentes en el municipio y no ser del sistema de 
      prisiones. La recolección de datos fue realizada en el periodo de enero de 2012 a 
      mayo de 2013, por medio de entrevistas guiadas por un instrumento especifico. Los 
      datos fueron analizados mediante indicadores y un índice compuesto. RESULTADOS: la 
      oferta de acciones y servicios para el control de la tuberculosis en personas 
      viviendo con VIH-SIDA fue considerada intermedia, reforzando la necesidad de mejorar 
      la planificación de la asistencia en forma integral, la articulación de los 
      profesionales en los equipos y entre los servicios de la red, además de la formación 
      profesional y la educación permanente. CONCLUSIÓN: se hace necesaria la 
      implementación de estrategias que favorezcan las acciones compartidas entre los 
      programas de tuberculosis y VIH-SIDA y entre los diferentes servicios, con el fin de 
      fortalecer la red local de atención para producir un cuidado personalizado, integral 
      y resolutivo.
FAU - Magnabosco, Gabriela Tavares
AU  - Magnabosco GT
AD  - PhD, Post-doctoral fellow, Escola de Enfermagem de Ribeirão Preto, Universidade de 
      São Paulo, PAHO/WHO Collaborating Centre for Nursing Research Development, Ribeirão 
      Preto, SP, Brazil.
FAU - Lopes, Lívia Maria
AU  - Lopes LM
AD  - MSc, Doctoral student, Escola de Enfermagem de Ribeirão Preto, Universidade de São 
      Paulo, PAHO/WHO Collaborating Centre for Nursing Research Development, Ribeirão 
      Preto, SP, Brazil.
FAU - Andrade, Rubia Laine de Paula
AU  - Andrade RL
AD  - PhD, RN, Escola de Enfermagem de Ribeirão Preto, Universidade de São Paulo, PAHO/WHO 
      Collaborating Centre for Nursing Research Development, Ribeirão Preto, SP, Brazil.
FAU - Brunello, Maria Eugênia Firmino
AU  - Brunello ME
AD  - PhD, Professor, Escola de Enfermagem de Ribeirão Preto, Universidade de São Paulo, 
      PAHO/WHO Collaborating Centre for Nursing Research Development, Ribeirão Preto, SP, 
      Brazil.
FAU - Monroe, Aline Aparecida
AU  - Monroe AA
AD  - PhD, Professor, Escola de Enfermagem de Ribeirão Preto, Universidade de São Paulo, 
      PAHO/WHO Collaborating Centre for Nursing Research Development, Ribeirão Preto, SP, 
      Brazil.
FAU - Villa, Tereza Cristina Scatena
AU  - Villa TC
AD  - PhD, Full Professor, Escola de Enfermagem de Ribeirão Preto, Universidade de São 
      Paulo, PAHO/WHO Collaborating Centre for Nursing Research Development, Ribeirão 
      Preto, SP, Brazil.
LA  - eng
LA  - por
LA  - spa
PT  - Journal Article
DEP - 20160909
TA  - Rev Lat Am Enfermagem
JT  - Revista latino-americana de enfermagem
JID - 9420934
MH  - Acquired Immunodeficiency Syndrome/complications
MH  - Adult
MH  - Brazil
MH  - HIV Infections/*complications
MH  - Humans
MH  - Tuberculosis/*complications/*prevention & control
PMC - PMC5048724
EDAT- 2016/09/15 06:00
MHDA- 2017/11/01 06:00
CRDT- 2016/09/15 06:00
PHST- 2015/07/30 00:00 [received]
PHST- 2016/03/15 00:00 [accepted]
PHST- 2016/09/15 06:00 [entrez]
PHST- 2016/09/15 06:00 [pubmed]
PHST- 2017/11/01 06:00 [medline]
AID - S0104-11692016000100410 [pii]
AID - 10.1590/1518-8345.1187.2798 [doi]
PST - epublish
SO  - Rev Lat Am Enfermagem. 2016 Sep 9;24(0):e2798. doi: 10.1590/1518-8345.1187.2798.

PMID- 30979771
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200310
IS  - 1715-5258 (Electronic)
IS  - 0008-350X (Print)
IS  - 0008-350X (Linking)
VI  - 65
IP  - 4
DP  - 2019 Apr
TI  - [Not Available].
PG  - e145-e146
FAU - Heendeniya, Amila
AU  - Heendeniya A
AD  - Résidente en maladies infectieuses à l'Université de Toronto, en Ontario.
FAU - Tumarkin, Ethan
AU  - Tumarkin E
AD  - Termine sa résidence en médecine interne à l'Université de Toronto, en Ontario.
FAU - Bogoch, Isaac I
AU  - Bogoch II
AD  - Professeur agrégé au Département de médecine de l'Université de Toronto, médecin 
      membre du personnel à la Division de médecine interne et de maladies infectieuses au 
      University Health Network de Toronto, et médecin-chef de la clinique de prévention 
      du VIH à l'Hôpital général de Toronto.
LA  - fre
PT  - Journal Article
TT  - Prophylaxie préexposition contre le VIH en soins de première ligne et en milieu 
      communautaire au Canada.
TA  - Can Fam Physician
JT  - Canadian family physician Medecin de famille canadien
JID - 0120300
SB  - IM
PMC - PMC6467655
EDAT- 2019/04/14 06:00
MHDA- 2019/04/14 06:01
CRDT- 2019/04/14 06:00
PHST- 2019/04/14 06:00 [entrez]
PHST- 2019/04/14 06:00 [pubmed]
PHST- 2019/04/14 06:01 [medline]
AID - 65/4/e145 [pii]
AID - e145 [pii]
PST - ppublish
SO  - Can Fam Physician. 2019 Apr;65(4):e145-e146.

PMID- 31034383
OWN - NLM
STAT- MEDLINE
DCOM- 20200611
LR  - 20200611
IS  - 1474-4457 (Electronic)
IS  - 1473-3099 (Linking)
VI  - 19
IP  - 5
DP  - 2019 May
TI  - A new social sciences network for infectious threats.
PG  - 461-463
LID - S1473-3099(19)30159-8 [pii]
LID - 10.1016/S1473-3099(19)30159-8 [doi]
FAU - Giles-Vernick, Tamara
AU  - Giles-Vernick T
AD  - Emerging Diseases Epidemiology Unit, Institut Pasteur, 75015 Paris, France. 
      Electronic address: tamara.giles-vernick@pasteur.fr.
FAU - Kutalek, Ruth
AU  - Kutalek R
AD  - Department of Social and Preventive Medicine, Center for Public Health, Medical 
      University of Vienna, Vienna, Austria.
FAU - Napier, David
AU  - Napier D
AD  - Department of Anthropology, Centre for Applied Global Citizenship, University 
      College London, London, UK.
FAU - Kaawa-Mafigiri, David
AU  - Kaawa-Mafigiri D
AD  - Department of Public Health, Makerere University, Kampala, Uganda.
FAU - Dückers, Michel
AU  - Dückers M
AD  - Netherlands Institute for Health Services Research, Utrecht, Netherlands.
FAU - Paget, John
AU  - Paget J
AD  - Netherlands Institute for Health Services Research, Utrecht, Netherlands.
FAU - Ahmed, Syed Masud
AU  - Ahmed SM
AD  - James P Grant School of Public Health, BRAC University, Dhaka, Bangladesh.
FAU - Cheah, Phaik Yeong
AU  - Cheah PY
AD  - MORU Tropical Health Network and Department of Bioethics and Engagement, Mahidol 
      University, Bangkok, Thailand.
FAU - Desclaux, Alice
AU  - Desclaux A
AD  - Centre Régional de Recherche et de Formation à la Prise en Charge Clinique du VIH et 
      des Pathologies Infectieuses, Dakar, Senegal; Institut de Recherche pour le 
      Développement, Montpellier, France.
FAU - De Vries, Daniel
AU  - De Vries D
AD  - Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands.
FAU - Hardon, Anita
AU  - Hardon A
AD  - Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands.
FAU - MacGregor, Hayley
AU  - MacGregor H
AD  - Institute of Development Studies, University of Sussex, Sussex, UK.
FAU - Pell, Christopher
AU  - Pell C
AD  - Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands.
FAU - Rashid, Sabina F
AU  - Rashid SF
AD  - James P Grant School of Public Health, BRAC University, Dhaka, Bangladesh.
FAU - Rodyna, Roman
AU  - Rodyna R
AD  - Public Health Center of the Ministry of Health of Ukraine, Kyiv, Ukraine.
FAU - Schultsz, Constance
AU  - Schultsz C
AD  - Institut de Recherche pour le Développement, Montpellier, France.
FAU - Sow, Khoudia
AU  - Sow K
AD  - Centre Régional de Recherche et de Formation à la Prise en Charge Clinique du VIH et 
      des Pathologies Infectieuses, Dakar, Senegal.
FAU - Wilkinson, Annie
AU  - Wilkinson A
AD  - Institute of Development Studies, University of Sussex, Sussex, UK.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Lancet Infect Dis
JT  - The Lancet. Infectious diseases
JID - 101130150
SB  - IM
MH  - Communicable Disease Control/*methods/organization & administration
MH  - Communicable Diseases/epidemiology/transmission
MH  - Disease Outbreaks/*prevention & control
MH  - Disease Transmission, Infectious/prevention & control
MH  - Drug Resistance, Microbial
MH  - Humans
MH  - International Cooperation
MH  - *Social Sciences/organization & administration
EDAT- 2019/04/30 06:00
MHDA- 2020/06/12 06:00
CRDT- 2019/04/30 06:00
PHST- 2019/03/05 00:00 [received]
PHST- 2019/03/29 00:00 [accepted]
PHST- 2019/04/30 06:00 [entrez]
PHST- 2019/04/30 06:00 [pubmed]
PHST- 2020/06/12 06:00 [medline]
AID - S1473-3099(19)30159-8 [pii]
AID - 10.1016/S1473-3099(19)30159-8 [doi]
PST - ppublish
SO  - Lancet Infect Dis. 2019 May;19(5):461-463. doi: 10.1016/S1473-3099(19)30159-8.

PMID- 31104740
OWN - NLM
STAT- MEDLINE
DCOM- 20190710
LR  - 20190710
IS  - 1524-4733 (Electronic)
IS  - 1098-3015 (Linking)
VI  - 22
IP  - 5
DP  - 2019 May
TI  - Health Technology Assessment Challenges in Oncology: 20 Years of Value in Health.
PG  - 593-600
LID - S1098-3015(19)30033-6 [pii]
LID - 10.1016/j.jval.2019.01.001 [doi]
AB  - BACKGROUND: Oncology treatments have changed from chemotherapies to targeted 
      therapies and more recently immuno-oncology. This has posed special challenges in 
      the field of health technology assessment (HTA): capturing quality of life (QOL) 
      associated with toxicity due to chemotherapy, crossover upon progression in targeted 
      therapy trials, and survival extrapolation for immuno-oncology drugs. OBJECTIVES: To 
      showcase 20 years of Value in Health (ViH) publications in oncology. METHODS: A 
      review was undertaken of oncology articles published in ViH from May 1998 to August 
      2018. Full-length articles published in ViH with the keywords "oncology," "cancer," 
      "h(a)ematology," and "malignancy" were included for review. Conference abstracts 
      were excluded. RESULTS: Four major themes were identified: (1) QOL and the 
      development of multiple functional assessment of cancer therapy tools and mapping 
      instruments; (2) analysis of clinical evidence using indirect comparisons, network 
      analyses, and adjustment for crossovers; (3) modeling, Markov models, partitioned 
      survival models, and extrapolation methods; and (4) financial implications and how 
      to deal with uncertainty, introduction of conditional reimbursement, managed entry, 
      and risk share agreements. DISCUSSION: This review article highlights the important 
      role ViH has played in disseminating HTA research in oncology. A few key issues loom 
      on the horizon: precision medicine, further development and practical application of 
      new QOL measures, methods for translating clinical evidence, and exploration of 
      modeling techniques. For a better understanding of the complex interplay between 
      access and financial risk management, ViH will no doubt continue to promote 
      pioneering research in HTA and oncology.
CI  - Copyright © 2019 ISPOR–The Professional Society for Health Economics and Outcomes 
      Research. Published by Elsevier Inc. All rights reserved.
FAU - Kim, Hansoo
AU  - Kim H
AD  - Monash University, Melbourne, Victoria, Australia. Electronic address: 
      hansoo.kim@monash.edu.
FAU - Goodall, Stephen
AU  - Goodall S
AD  - University of Technology Sydney, Sydney, New South Wales, Australia.
FAU - Liew, Danny
AU  - Liew D
AD  - Monash University, Melbourne, Victoria, Australia.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Value Health
JT  - Value in health : the journal of the International Society for Pharmacoeconomics and 
      Outcomes Research
JID - 100883818
SB  - IM
MH  - *Cost-Benefit Analysis
MH  - Humans
MH  - Immunotherapy
MH  - Medical Oncology/*methods
MH  - Neoplasms
MH  - *Quality of Life
MH  - *Technology Assessment, Biomedical/economics/methods
OTO - NOTNLM
OT  - *cost-effectiveness
OT  - *cost-utility
OT  - *health technology assessment
OT  - *oncology
OT  - *quality of life
EDAT- 2019/05/21 06:00
MHDA- 2019/07/11 06:00
CRDT- 2019/05/21 06:00
PHST- 2018/08/31 00:00 [received]
PHST- 2018/12/19 00:00 [revised]
PHST- 2019/01/06 00:00 [accepted]
PHST- 2019/05/21 06:00 [entrez]
PHST- 2019/05/21 06:00 [pubmed]
PHST- 2019/07/11 06:00 [medline]
AID - S1098-3015(19)30033-6 [pii]
AID - 10.1016/j.jval.2019.01.001 [doi]
PST - ppublish
SO  - Value Health. 2019 May;22(5):593-600. doi: 10.1016/j.jval.2019.01.001.

PMID- 34403699
OWN - NLM
STAT- MEDLINE
DCOM- 20211117
LR  - 20211117
IS  - 1083-351X (Electronic)
IS  - 0021-9258 (Print)
IS  - 0021-9258 (Linking)
VI  - 297
IP  - 3
DP  - 2021 Sep
TI  - Frame-shifted APOBEC3A encodes two alternative proapoptotic proteins that target the 
      mitochondrial network.
PG  - 101081
LID - S0021-9258(21)00884-X [pii]
LID - 10.1016/j.jbc.2021.101081 [doi]
LID - 101081
AB  - The human APOBEC3A (A3A) cytidine deaminase is a powerful DNA mutator enzyme 
      recognized as a major source of somatic mutations in tumor cell genomes. However, 
      there is a discrepancy between APOBEC3A mRNA levels after interferon stimulation in 
      myeloid cells and A3A detection at the protein level. To understand this difference, 
      we investigated the expression of two novel alternative "A3Alt" proteins encoded in 
      the +1-shifted reading frame of the APOBEC3A gene. A3Alt-L and its shorter isoform 
      A3Alt-S appear to be transmembrane proteins targeted to the mitochondrial 
      compartment that induce membrane depolarization and apoptosis. Thus, the APOBEC3A 
      gene represents a new example wherein a single gene encodes two proapoptotic 
      proteins, A3A cytidine deaminases that target the genome and A3Alt proteins that 
      target mitochondria.
CI  - Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Caval, Vincent
AU  - Caval V
AD  - Molecular Retrovirology Unit, Institut Pasteur, Paris, France. Electronic address: 
      vincent.caval@pasteur.fr.
FAU - Suspène, Rodolphe
AU  - Suspène R
AD  - Molecular Retrovirology Unit, Institut Pasteur, Paris, France.
FAU - Khalfi, Pierre
AU  - Khalfi P
AD  - Molecular Retrovirology Unit, Institut Pasteur, Paris, France; Sorbonne Université, 
      Complexité du Vivant, ED515, Paris, France.
FAU - Gaillard, Julien
AU  - Gaillard J
AD  - Morphogenèse et Antigénicité du VIH et des Virus des Hépatites, Inserm-U1259 MAVIVH, 
      Université de Tours and CHRU de Tours, Tours, France; Plate-Forme IBiSA des 
      Microscopies, PPF ASB, Université de Tours and CHRU de Tours, Tours, France.
FAU - Caignard, Grégory
AU  - Caignard G
AD  - UMR Virologie, INRAE, Ecole Nationale Vétérinaire d'Alfort, Laboratoire de santé 
      animale d'Alfort, Anses, Université Paris-Est, Maisons-Alfort, France.
FAU - Vitour, Damien
AU  - Vitour D
AD  - UMR Virologie, INRAE, Ecole Nationale Vétérinaire d'Alfort, Laboratoire de santé 
      animale d'Alfort, Anses, Université Paris-Est, Maisons-Alfort, France.
FAU - Roingeard, Philippe
AU  - Roingeard P
AD  - Morphogenèse et Antigénicité du VIH et des Virus des Hépatites, Inserm-U1259 MAVIVH, 
      Université de Tours and CHRU de Tours, Tours, France; Plate-Forme IBiSA des 
      Microscopies, PPF ASB, Université de Tours and CHRU de Tours, Tours, France.
FAU - Vartanian, Jean-Pierre
AU  - Vartanian JP
AD  - Molecular Retrovirology Unit, Institut Pasteur, Paris, France.
FAU - Wain-Hobson, Simon
AU  - Wain-Hobson S
AD  - Molecular Retrovirology Unit, Institut Pasteur, Paris, France.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210814
TA  - J Biol Chem
JT  - The Journal of biological chemistry
JID - 2985121R
RN  - 0 (Apoptosis Regulatory Proteins)
RN  - 0 (Proteins)
RN  - 0 (RNA, Messenger)
RN  - 9007-49-2 (DNA)
RN  - EC 3.5.4.5 (APOBEC3A protein, human)
RN  - EC 3.5.4.5 (Cytidine Deaminase)
SB  - IM
MH  - Apoptosis/genetics
MH  - Apoptosis Regulatory Proteins/genetics
MH  - Cytidine Deaminase/*genetics/metabolism/*physiology
MH  - DNA/genetics
MH  - Frameshift Mutation/genetics
MH  - Gene Expression/genetics
MH  - Gene Expression Regulation/genetics
MH  - Genome/genetics
MH  - Humans
MH  - Mitochondria/*genetics/metabolism
MH  - Mutation/genetics
MH  - Proteins/*genetics/metabolism/*physiology
MH  - RNA, Messenger/genetics
MH  - Reading Frames/genetics
PMC - PMC8424220
OTO - NOTNLM
OT  - *A3Alt
OT  - *APOBEC3A
OT  - *apoptosis
OT  - *mitochondria
COIS- Conflict of interest The authors declare that they have no conflicts of interest 
      with the contents of this article.
EDAT- 2021/08/18 06:00
MHDA- 2021/11/18 06:00
CRDT- 2021/08/17 20:13
PHST- 2021/03/26 00:00 [received]
PHST- 2021/08/04 00:00 [revised]
PHST- 2021/08/12 00:00 [accepted]
PHST- 2021/08/18 06:00 [pubmed]
PHST- 2021/11/18 06:00 [medline]
PHST- 2021/08/17 20:13 [entrez]
AID - S0021-9258(21)00884-X [pii]
AID - 101081 [pii]
AID - 10.1016/j.jbc.2021.101081 [doi]
PST - ppublish
SO  - J Biol Chem. 2021 Sep;297(3):101081. doi: 10.1016/j.jbc.2021.101081. Epub 2021 Aug 
      14.

PMID- 32186799
OWN - NLM
STAT- MEDLINE
DCOM- 20200323
LR  - 20200323
IS  - 1660-9379 (Print)
IS  - 1660-9379 (Linking)
VI  - 16
IP  - 686
DP  - 2020 Mar 18
TI  - [Integration of sexual medicine into the care of HIV patients].
PG  - 539-542
AB  - HIV affection affects sexual function, sexual health and relationships as well as 
      mental health and quality of life. Due to the importance of sexual health for each 
      individual and in order to ensure optimal and quality care, we have assessed the 
      demand for sexual health and advise not only among HIV patients but also among 
      professionals in this area and nursing staff. The results showed that sexuality was 
      important both for patients and caregivers. Also, we did find out that carers want 
      to create a better professional network with the aim of redirecting patients to 
      specialists according to their specific needs. Carers have also expressed a desire 
      to have relevant training in sexology and sexual health to achieve this.
FAU - Bolmont, Mylène
AU  - Bolmont M
AD  - Faculté de psychologie, Université de Genève, 1211 Genève 4.
AD  - Faculté de médecine, Université de Genève, 1211 Genève 4.
FAU - Bianchi-Demicheli, Francesco
AU  - Bianchi-Demicheli F
AD  - Faculté de psychologie, Université de Genève, 1211 Genève 4.
AD  - Faculté de médecine, Université de Genève, 1211 Genève 4.
AD  - Unité de médecine sexuelle et sexologie, HUG, 1211 Genève 14.
AD  - Consultation de médecine sexuelle, Service de gynécologie, CHUV, 1011 Lausanne.
FAU - Calmy, Alexandra
AU  - Calmy A
AD  - Unité de médecine sexuelle et sexologie, HUG, 1211 Genève 14.
AD  - Département des spécialités de médecine, HUG, 1211 Genève 14.
LA  - fre
PT  - Journal Article
PT  - Review
TT  - Intégration de la médecine sexuelle dans le cadre de la prise en charge de patients 
      souffrant du VIH.
PL  - Switzerland
TA  - Rev Med Suisse
JT  - Revue medicale suisse
JID - 101219148
SB  - IM
MH  - Caregivers
MH  - HIV Infections/nursing/*psychology/*therapy
MH  - Humans
MH  - Quality of Life
MH  - Sexual Behavior/*psychology
MH  - *Sexual Health
MH  - Sexuality/*psychology
COIS- Les auteurs n’ont déclaré aucun conflit d’intérêts en relation avec cet article.
EDAT- 2020/03/19 06:00
MHDA- 2020/03/24 06:00
CRDT- 2020/03/19 06:00
PHST- 2020/03/19 06:00 [entrez]
PHST- 2020/03/19 06:00 [pubmed]
PHST- 2020/03/24 06:00 [medline]
AID - RMS0686-005 [pii]
PST - ppublish
SO  - Rev Med Suisse. 2020 Mar 18;16(686):539-542.

PMID- 34812744
OWN - NLM
STAT- MEDLINE
DCOM- 20211230
LR  - 20211230
IS  - 1473-6527 (Electronic)
IS  - 0951-7375 (Linking)
VI  - 35
IP  - 1
DP  - 2022 Feb 1
TI  - The impact of coronavirus disease 2019 on people with HIV.
PG  - 9-14
LID - 10.1097/QCO.0000000000000799 [doi]
AB  - PURPOSE OF REVIEW: The COVID-19 pandemic materialized in 2020, the year the 
      international community had expected to meet the interim targets to end AIDS by 
      2030. Forty years into the HIV pandemic, the COVID-19 pandemic challenges the 
      achievements made in HIV and may even reverse some of them. RECENT FINDINGS: This 
      article provides an overview of the impact of COVID-19 on people with, and at risk 
      of, HIV infection. It addresses where the global response to HIV was expected to be 
      by 2020, analyzes the impact of COVID-19 on HIV-related outcomes and reviews the 
      impact of HIV on COVID-19 related outcomes. SUMMARY: The COVID-19 pandemic has had a 
      profound impact on the response to HIV infection through disruption of prevention, 
      testing, and access to antiretroviral treatment, as well as on the management of 
      long-term HIV and mental health. This negative impact has been unequal throughout 
      the world and across populations and deepens inequities in health. HIV does not 
      increase Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) susceptibility 
      once confounders are taken into account and inconsistencies are reported regarding 
      its direct role on clinical severity. In post-COVID-19 scenarios, new models for HIV 
      testing and care are likely to be consolidated. Monitoring responses needs 
      high-quality epidemiological data and collaborative research.
CI  - Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Del Amo, Julia
AU  - Del Amo J
AD  - División de control de VIH, ITS, Hepatitis virales y Tuberculosis. Ministry of 
      Health, Madrid, Spain.
AD  - AIDS Research Network. Ciber de Enfermedades Infecciosas. Institute of Health Carlos 
      III Madrid, Spain.
FAU - Diaz, Asuncion
AU  - Diaz A
AD  - División de control de VIH, ITS, Hepatitis virales y Tuberculosis. Ministry of 
      Health, Madrid, Spain.
AD  - AIDS Research Network. Ciber de Enfermedades Infecciosas. Institute of Health Carlos 
      III Madrid, Spain.
AD  - National Center for Epidemiology, Institute of Health Carlos III (ISCIII), Madrid, 
      Spain.
FAU - Polo, Rosa
AU  - Polo R
AD  - División de control de VIH, ITS, Hepatitis virales y Tuberculosis. Ministry of 
      Health, Madrid, Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Curr Opin Infect Dis
JT  - Current opinion in infectious diseases
JID - 8809878
SB  - IM
MH  - *COVID-19
MH  - *HIV Infections/complications/drug therapy/epidemiology
MH  - Humans
MH  - Mental Health
MH  - Pandemics/prevention & control
MH  - SARS-CoV-2
EDAT- 2021/11/24 06:00
MHDA- 2021/12/31 06:00
CRDT- 2021/11/23 12:18
PHST- 2021/11/24 06:00 [pubmed]
PHST- 2021/12/31 06:00 [medline]
PHST- 2021/11/23 12:18 [entrez]
AID - 00001432-900000000-98991 [pii]
AID - 10.1097/QCO.0000000000000799 [doi]
PST - ppublish
SO  - Curr Opin Infect Dis. 2022 Feb 1;35(1):9-14. doi: 10.1097/QCO.0000000000000799.

PMID- 33592129
OWN - NLM
STAT- MEDLINE
DCOM- 20210701
LR  - 20210701
IS  - 1537-2995 (Electronic)
IS  - 0041-1132 (Linking)
VI  - 61
IP  - 4
DP  - 2021 Apr
TI  - HIV transmission network analysis allows identifying unreported risk factors in 
      HIV-positive blood donors in France.
PG  - 1191-1201
LID - 10.1111/trf.16290 [doi]
AB  - OBJECTIVES: As sex between men is a major route of human immunodeficiency virus 
      (HIV) infection in most western countries, restrictive deferral rules for blood 
      donation have largely been implemented regarding men having sex with men (MSM). 
      Here, we sought here to assign unreported HIV risk factors in blood donors (BDs) and 
      reevaluated the MSM-associated fraction of HIV transfusion residual risk (%RR(MSM) 
      ). METHODS: We applied a genetic distance-based approach to infer an HIV 
      transmission network for 384 HIV sequences from French BDs and 1337 HIV sequences 
      from individuals with known risk factors (ANRS PRIMO primary HIV infection cohort). 
      We validated the possibility of assigning a risk factor according to clustering 
      using assortative mixing. Finally, we recalculated the %RR(MSM) . RESULTS: A total 
      of 81 of 284 (28.5%) male and 5 of 100 (5%) female BDs belonged to a cluster; 72 
      (88.9%) of the 81 male BDs belonged to MSM clusters. After cluster correction, 8 of 
      67 (11.9%), 4 of 21 (19.0%), and 19 of 88 (21.6%) HIV-positive (HIV+) male BDs with 
      heterosexual, other, or unknown risk factors could be reclassified as MSM, 
      accounting for 10.9% of the total HIV+ male BDs. Overall, 139 of 284 HIV+ male 
      donors (48.9%) could be considered MSM between 2000 and 2016 in France. Between 2005 
      and 2016, the %RR(MSM) increase varied from 0 to 19%, without differing 
      significantly from the %RR(MSM) before reclassification. CONCLUSION: Network 
      inference can be used to complement declaration data on risk factors for HIV 
      infection in BDs. This approach, complementary to behavioral studies, is a valuable 
      tool to evaluate the effect of changes in deferral criteria on BD compliance.
CI  - © 2021 AABB.
FAU - Cappy, Pierre
AU  - Cappy P
AUID- ORCID: 0000-0001-8540-2196
AD  - Département des Agents Transmissibles par le Sang, CNR Risques Infectieux 
      Transfusionnels, Institut National de la Transfusion Sanguine (INTS), Paris, France.
FAU - Chaillon, Antoine
AU  - Chaillon A
AD  - Division of Infectious Diseases, University of California San Diego, La Jolla, 
      California, USA.
FAU - Pillonel, Josiane
AU  - Pillonel J
AUID- ORCID: 0000-0003-1350-776X
AD  - Département des maladies infectieuses, Santé publique France, Saint-Maurice, France.
FAU - Essat, Asma
AU  - Essat A
AD  - INSERM CESP U1018, Université Paris Sud, Université Paris Saclay, Le 
      Kremlin-Bicêtre, France.
FAU - Chaix, Marie-Laure
AU  - Chaix ML
AD  - Service de Virologie, CNR VIH, Hôpital Saint-Louis, APHP - INSERM U944, Université 
      de Paris, Paris, France.
FAU - Meyer, Laurence
AU  - Meyer L
AD  - INSERM CESP U1018, Université Paris Sud, Université Paris Saclay, Le 
      Kremlin-Bicêtre, France.
AD  - Service de Santé Publique, Hôpital Bicêtre, APHP, Le Kremlin Bicêtre, France.
FAU - Barin, Francis
AU  - Barin F
AD  - Laboratoire de Virologie, Laboratoire associé au CNR VIH, CHRU de Tours - INSERM 
      U1259, Université de Tours, Tours, France.
FAU - Tiberghien, Pierre
AU  - Tiberghien P
AD  - Etablissement Français du Sang, La Plaine St Denis, France.
AD  - UMR 1098 INSERM, Université de Franche-Comté, Etablissement Français du Sang, 
      Besançon, France.
FAU - Laperche, Syria
AU  - Laperche S
AD  - Département des Agents Transmissibles par le Sang, CNR Risques Infectieux 
      Transfusionnels, Institut National de la Transfusion Sanguine (INTS), Paris, France.
LA  - eng
PT  - Journal Article
DEP - 20210216
PL  - United States
TA  - Transfusion
JT  - Transfusion
JID - 0417360
SB  - IM
MH  - Adult
MH  - Blood Donors/statistics & numerical data
MH  - Blood Transfusion/legislation & jurisprudence/*standards
MH  - Case-Control Studies
MH  - Donor Selection/legislation & jurisprudence/methods
MH  - Female
MH  - France/epidemiology
MH  - HIV Infections/*transmission
MH  - HIV Seropositivity/epidemiology/*genetics/transmission
MH  - Homosexuality, Male/*statistics & numerical data
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Risk Factors
MH  - Social Network Analysis
OTO - NOTNLM
OT  - *HIV infection
OT  - *blood donor deferral
OT  - *public health
OT  - *risk factors
OT  - *transmission network
EDAT- 2021/02/17 06:00
MHDA- 2021/07/02 06:00
CRDT- 2021/02/16 17:11
PHST- 2020/12/04 00:00 [revised]
PHST- 2020/07/02 00:00 [received]
PHST- 2020/12/05 00:00 [accepted]
PHST- 2021/02/17 06:00 [pubmed]
PHST- 2021/07/02 06:00 [medline]
PHST- 2021/02/16 17:11 [entrez]
AID - 10.1111/trf.16290 [doi]
PST - ppublish
SO  - Transfusion. 2021 Apr;61(4):1191-1201. doi: 10.1111/trf.16290. Epub 2021 Feb 16.

PMID- 29251281
OWN - NLM
STAT- MEDLINE
DCOM- 20180702
LR  - 20181202
IS  - 2173-9110 (Electronic)
IS  - 1135-5727 (Linking)
VI  - 91
DP  - 2017 Dec 18
TI  - [Cobatest network: users' characteristics of community-based voluntary,counselling 
      and testing centres in Spain.].
LID - e201712048 [pii]
AB  - OBJECTIVE: The COBATEST network (European network of community-based voluntary, 
      counselling and testing centers) allows standardized collection of information to 
      monitor HIV testing at these centers. The objective was to describe the performance 
      of the Spanish centers of the COBATEST network and the epidemiological profile of 
      its users, and to analyze the factors associated with having an earlier HIV test. 
      METHODS: Descriptive analysis of the data collected in the 19 Spanish centers that 
      used the common information collection tools during the year 2015. A multivariate 
      logistic regression model was used to identify factors associated with having an 
      earlier test. RESULTS: A total of 6,077 HIV rapid tests were performed and 1.8% were 
      reactive (3.0% MSM, 3.1% SW, 2.3% PWID, 0.6% heterosexual). 82.1% of the reactives 
      were referred to perform a confirmatory test and 94 (97.9%) were HIV positive, of 
      whom 54% were diverted to the health system. 38% said they had never been tested for 
      HIV. Factors associated with having a previous HIV test were: being over 20 years 
      old; being HSH, SW, or PWID; being foreign; having used condoms at the last 
      penetration; having had an STI in the last year; and having been in jail. 
      CONCLUSIONS: The results show the great potential of these services to reach people 
      who have never been tested for HIV. The HIV cases are concentrated in vulnerable 
      groups. It is necessary to improve the linkage of diagnosed people to health care 
      services.
FAU - Ribas Baltrons, Josep
AU  - Ribas Baltrons J
AD  - Centro de Estudios Epidemiológicos del VIH y otras ITS de Cataluña 
      (CEEISCAT)/Agencia de Salud Pública de Cataluña (ASPCAT), Badalona.
AD  - Universitat de Barcelona, Barcelona.
FAU - Fernàndez-López, Laura
AU  - Fernàndez-López L
AD  - Centro de Estudios Epidemiológicos del VIH y otras ITS de Cataluña 
      (CEEISCAT)/Agencia de Salud Pública de Cataluña (ASPCAT), Badalona.
AD  - CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
FAU - Casabona I Barbarà, Jordi
AU  - Casabona I Barbarà J
AD  - Centro de Estudios Epidemiológicos del VIH y otras ITS de Cataluña 
      (CEEISCAT)/Agencia de Salud Pública de Cataluña (ASPCAT), Badalona.
AD  - CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
CN  - Grupo red COBATEST España.
LA  - spa
PT  - Journal Article
PT  - Multicenter Study
TT  - Red COBATEST: Características de los usuarios de los centros comunitarios de 
      diagnóstico y orientación para el VIH en España.
DEP - 20171218
PL  - Spain
TA  - Rev Esp Salud Publica
JT  - Revista espanola de salud publica
JID - 9600212
SB  - IM
MH  - Adult
MH  - Aged
MH  - Counseling/*statistics & numerical data
MH  - Female
MH  - HIV Infections/*diagnosis/epidemiology/*therapy
MH  - HIV Seropositivity
MH  - Health Services Accessibility
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - Mass Screening
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Spain
MH  - Vulnerable Populations
MH  - Young Adult
OTO - NOTNLM
OT  - Community testing
OT  - HIV
OT  - HIV infections/diagnosis
OT  - Point-of-care testing
OT  - Risk behaviour
OT  - Spain
OT  - VCT
COIS- Disclosure The authors report no conflicts of interest in this work.
FIR - Baroja, Jordi
IR  - Baroja J
FIR - Colomera, Patrícia
IR  - Colomera P
FIR - Camí, Jessica
IR  - Camí J
FIR - Andreo, Lorena
IR  - Andreo L
FIR - Adán, Elena
IR  - Adán E
FIR - Morales, Adriana
IR  - Morales A
FIR - Villegas, Luís
IR  - Villegas L
FIR - Rafel, Anna
IR  - Rafel A
FIR - Quezadas, Jaime
IR  - Quezadas J
FIR - Capitán, Alberto
IR  - Capitán A
FIR - Collignon, Julia
IR  - Collignon J
FIR - Griñán, Elena
IR  - Griñán E
FIR - Meroño, Mercè
IR  - Meroño M
FIR - Lara, Anna
IR  - Lara A
FIR - Roqueta, Joaquim
IR  - Roqueta J
FIR - Mejías, William
IR  - Mejías W
FIR - Otón, Araceli
IR  - Otón A
FIR - Romero, Lluís
IR  - Romero L
FIR - Aguilar, Toni
IR  - Aguilar T
FIR - Prado, Eva Mª
IR  - Prado EM
FIR - Martin, Carmen
IR  - Martin C
FIR - Reyes, Juan José
IR  - Reyes JJ
FIR - Reyes, Sonia
IR  - Reyes S
FIR - García, Rocío
IR  - García R
FIR - Talavera, Julia
IR  - Talavera J
FIR - Valiente, Marina
IR  - Valiente M
FIR - Salmerón, Pere
IR  - Salmerón P
FIR - Brook-Hart, Esteban
IR  - Brook-Hart E
FIR - Pérez, Alexandra
IR  - Pérez A
FIR - Herrero, Gema
IR  - Herrero G
FIR - Barrios, Juan Ramon
IR  - Barrios JR
FIR - Varela, Laura
IR  - Varela L
FIR - Calvo, Aitor
IR  - Calvo A
FIR - Solier, Sara
IR  - Solier S
FIR - Luque, Elena
IR  - Luque E
FIR - Biot, Pamela
IR  - Biot P
FIR - Gomez, Manuel
IR  - Gomez M
EDAT- 2017/12/19 06:00
MHDA- 2018/07/03 06:00
CRDT- 2017/12/19 06:00
PHST- 2017/06/06 00:00 [received]
PHST- 2017/11/02 00:00 [accepted]
PHST- 2017/12/19 06:00 [entrez]
PHST- 2017/12/19 06:00 [pubmed]
PHST- 2018/07/03 06:00 [medline]
AID - e201712048 [pii]
PST - epublish
SO  - Rev Esp Salud Publica. 2017 Dec 18;91:e201712048.

PMID- 29548534
OWN - NLM
STAT- MEDLINE
DCOM- 20180329
LR  - 20180329
IS  - 1769-6917 (Electronic)
IS  - 0007-4551 (Linking)
VI  - 105
IP  - 3
DP  - 2018 Mar
TI  - [HIV and cancer : What's new in 2017?].
PG  - 256-262
LID - S0007-4551(18)30055-9 [pii]
LID - 10.1016/j.bulcan.2018.02.002 [doi]
AB  - Since the era of combined antiretroviral therapy, life expectancy of people living 
      with HIV has been improved and is associated with a change in causes of death. 
      Cancer, both AIDS-defining or non-AIDS-defining cancers, has become the leading 
      cause of death in people living with HIV associated with an increase in the 
      incidence of some cancers compared to the general population. Epidemiology and the 
      identification of risk factors is a crucial issue, particularly to determine the 
      most appropriate prevention and screening strategies in this population. In the 
      absence of dedicated clinical trials, the cancer management in these patients is 
      based on general recommendations, with specific attention to comorbidities and drug 
      interactions. In addition, the development of new innovative therapies such as 
      immunotherapy with inhibitory antibodies of immune checkpoints receptor represents a 
      hope for the patient care, both infected or not with HIV. In this context, the 
      establishment of the national network CancerVIH makes sense, allowing the 
      establishment of multi-disciplinary consultation meetings involving all the 
      practitioners involved in the care of these patients with cancer, as well as the 
      constitution of a national cohort and the promotion of dedicated trials, to improve 
      and optimize the management for these patients.
CI  - Copyright © 2018 Société Française du Cancer. Published by Elsevier Masson SAS. All 
      rights reserved.
FAU - Gobert, Aurélien
AU  - Gobert A
AD  - Assistance publique-Hôpitaux de Paris, hôpital Pitié-Salpêtrière, service 
      d'oncologie médicale, 47, boulevard de l'Hôpital, 75013 Paris, France. Electronic 
      address: aurelien.gobert@aphp.fr.
FAU - Veyri, Marianne
AU  - Veyri M
AD  - Assistance publique-Hôpitaux de Paris, hôpital Pitié-Salpêtrière, service 
      d'oncologie médicale, 47, boulevard de l'Hôpital, 75013 Paris, France.
FAU - Poizot-Martin, Isabelle
AU  - Poizot-Martin I
AD  - Assistance publique-Hôpitaux de Marseille, CHU Sainte-Marguerite, service 
      d'immuno-hématologie clinique, 20, avenue Viton, 13274 Marseille, France.
FAU - Lavolé, Armelle
AU  - Lavolé A
AD  - Hôpital Tenon, service de pneumologie, 4, rue de la Chine, 75020 Paris, France.
FAU - Solas, Caroline
AU  - Solas C
AD  - Assistance publique-Hôpitaux de Marseille, hôpital de la Timone, service de 
      pharmacocinétique toxicocinétique, 264, rue Saint-Pierre, 13005 Marseille, France.
FAU - Paliche, Romain
AU  - Paliche R
AD  - Assistance publique-Hôpitaux de Paris, hôpital Pitié-Salpêtrière, service des 
      maladies infectieuses et tropicales, 47, boulevard de l'Hôpital, 75013 Paris, 
      France.
FAU - Katlama, Christine
AU  - Katlama C
AD  - Assistance publique-Hôpitaux de Paris, hôpital Pitié-Salpêtrière, service des 
      maladies infectieuses et tropicales, 47, boulevard de l'Hôpital, 75013 Paris, 
      France.
FAU - Costagliola, Dominique
AU  - Costagliola D
AD  - Institut Pierre-Louis d'épidémiologie et de santé publique (IPLESP UMRS 1136), 
      Sorbonne-universités, UPMC université Paris-06, Inserm, 75013 Paris, France.
FAU - Spano, Jean-Philippe
AU  - Spano JP
AD  - Assistance publique-Hôpitaux de Paris, hôpital Pitié-Salpêtrière, service 
      d'oncologie médicale, 47, boulevard de l'Hôpital, 75013 Paris, France; Institut 
      Pierre-Louis d'épidémiologie et de santé publique (IPLESP UMRS 1136), 
      Sorbonne-universités, UPMC université Paris-06, Inserm, 75013 Paris, France.
LA  - fre
PT  - Journal Article
PT  - Review
TT  - Cancer et VIH : actualités 2017.
DEP - 20180313
PL  - France
TA  - Bull Cancer
JT  - Bulletin du cancer
JID - 0072416
RN  - 0 (Anti-HIV Agents)
SB  - IM
MH  - Anti-HIV Agents/therapeutic use
MH  - Cancer Care Facilities/organization & administration
MH  - Cause of Death
MH  - Chronic Disease
MH  - Comorbidity
MH  - Drug Interactions
MH  - Female
MH  - HIV Infections/complications/mortality/*therapy
MH  - Humans
MH  - Immunotherapy/methods
MH  - Life Expectancy
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/complications/*drug therapy
MH  - Patient Care Team/organization & administration
MH  - Risk Factors
OTO - NOTNLM
OT  - Cancer
OT  - Dépistage
OT  - HIV
OT  - Immune therapy
OT  - Immunothérapie
OT  - Screening
OT  - VIH
EDAT- 2018/03/20 06:00
MHDA- 2018/03/30 06:00
CRDT- 2018/03/18 06:00
PHST- 2017/11/14 00:00 [received]
PHST- 2018/02/01 00:00 [revised]
PHST- 2018/02/02 00:00 [accepted]
PHST- 2018/03/20 06:00 [pubmed]
PHST- 2018/03/30 06:00 [medline]
PHST- 2018/03/18 06:00 [entrez]
AID - S0007-4551(18)30055-9 [pii]
AID - 10.1016/j.bulcan.2018.02.002 [doi]
PST - ppublish
SO  - Bull Cancer. 2018 Mar;105(3):256-262. doi: 10.1016/j.bulcan.2018.02.002. Epub 2018 
      Mar 13.

PMID- 25403143
OWN - NLM
STAT- MEDLINE
DCOM- 20160113
LR  - 20210802
IS  - 1573-3254 (Electronic)
IS  - 1090-7165 (Print)
IS  - 1090-7165 (Linking)
VI  - 19
IP  - 6
DP  - 2015 Jun
TI  - Women Connected to at Risk Indian Men Who Have Sex with Men: An Unexplored Network.
PG  - 1031-6
LID - 10.1007/s10461-014-0946-1 [doi]
AB  - Little is known about the women connected to Indian MSM and their impact on HIV 
      risk. We surveyed 240 Indian MSM, who identified their social networks (n = 7,092). 
      Women (n = 1,321) comprised 16.7 % of the network, with 94.7 % representing 
      non-sexual connections. MSM were classified as having low, moderate, or high female 
      network proportion. MSM with moderate female network proportion (8-24 % total 
      network) had significantly lowered odds of HIV seropositivity (AOR = 0.24, 95 % CI = 
      0.1-0.6). This suggests moderate proportions of female connections could mediate HIV 
      risk. HIV prevention interventions in India could consider the greater involvement 
      of women among their target audiences. Se sabe poco sobre las mujeres conectadas a 
      HSH en India y su impacto en el riesgo de VIH. Se encuestó a 240 HSH indios, quienes 
      identificaron sus redes sociales (n = 7,092). Las mujeres (n = 1,321) formaron al 
      16.7 % de la red, del cual el 94.7 % representa conexiones no sexuales. Los HSH se 
      clasificaron como baja, moderada o alta proporción de red femenina. HSH con 
      proporción moderada de red femenina (8-24 % del red total) tuvieron un riesgo 
      significativamente reducido de seropositividad de VIH (AOR = 0,24; IC 95 % = 
      0,1-0,6). Esto sugiere que tener una proporción moderada de contactos femeninos 
      podría atenuar el riesgo de VIH. Las intervenciones de prevención del VIH en India 
      podrían considerar una mayor participación de las mujeres en su público objetivo.
FAU - Satyanarayan, Sammita
AU  - Satyanarayan S
AD  - Pritzker School of Medicine, University of Chicago, Chicago, USA.
FAU - Kapur, Abhinav
AU  - Kapur A
FAU - Azhar, Sameena
AU  - Azhar S
FAU - Yeldandi, Vijay
AU  - Yeldandi V
FAU - Schneider, John A
AU  - Schneider JA
LA  - eng
GR  - UL1 TR000430/TR/NCATS NIH HHS/United States
GR  - R21AI098599/AI/NIAID NIH HHS/United States
GR  - R21 AI098599/AI/NIAID NIH HHS/United States
GR  - R21 HD068352/HD/NICHD NIH HHS/United States
GR  - R21HD068352/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
TA  - AIDS Behav
JT  - AIDS and behavior
JID - 9712133
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Cross-Sectional Studies
MH  - Female
MH  - HIV Infections/*prevention & control/transmission
MH  - Health Surveys
MH  - Homosexuality, Male/*statistics & numerical data
MH  - Humans
MH  - India
MH  - Logistic Models
MH  - Male
MH  - *Sexual Partners
MH  - *Social Networking
MH  - *Women's Health
MH  - Young Adult
PMC - PMC4436083
MID - NIHMS643195
EDAT- 2014/11/19 06:00
MHDA- 2016/01/14 06:00
CRDT- 2014/11/19 06:00
PHST- 2014/11/19 06:00 [entrez]
PHST- 2014/11/19 06:00 [pubmed]
PHST- 2016/01/14 06:00 [medline]
AID - 10.1007/s10461-014-0946-1 [doi]
PST - ppublish
SO  - AIDS Behav. 2015 Jun;19(6):1031-6. doi: 10.1007/s10461-014-0946-1.

PMID- 34452700
OWN - NLM
STAT- MEDLINE
DCOM- 20211027
LR  - 20211027
IS  - 1769-6917 (Electronic)
IS  - 0007-4551 (Linking)
VI  - 108
IP  - 10
DP  - 2021 Oct
TI  - Do people living with HIV face more secondary cancers than general population: From 
      the French CANCERVIH network.
PG  - 908-914
LID - S0007-4551(21)00282-4 [pii]
LID - 10.1016/j.bulcan.2021.01.026 [doi]
AB  - INTRODUCTION: People living with HIV (PLWHIV) are at a higher risk of cancer 
      compared to the general population. With improved cancer treatments and the 
      increased life expectancy of PLWHIV, the incidence of second cancers is also 
      expected to increase. METHODS: We reviewed the cases of PLWHIV with cancer that have 
      been presented to the CANCERVIH national multidisciplinary board since 2014. We 
      included all cases with a history of cancer, and studied the incidence and types of 
      second cancers. RESULTS: In total, 719 cases were reviewed, out of which 94 (13%) 
      had a history of at least one cancer. For the first primary cancers, 46 (49%) were 
      AIDS-defining cancers (ADCs) and 48 (51%) were non-AIDS-defining cancers (NADCs). 
      Kaposi sarcoma (33%) and NHL (15%) occurred most frequently as first cancers. Among 
      the first cancers that were ADCs, 15% of the second cancers were NHL, 11% anal canal 
      cancers, 9% bladder and 9% Hodgkin lymphomas. Among the first cancers that were 
      NADCs, 38% of the second cancers were lung cancers, 8% bladder, 8% head and neck and 
      8% NHL. DISCUSSION: With the aging of PLWHIV, the incidence of second and subsequent 
      cancers is expected to increase in this population. Immuno-virological control 
      should be maintained. Increased surveillance, early prevention and screening 
      programs should be offered to all PLWHIV, including those with an undetectable HIV 
      viral load and/or immune restoration.
CI  - Copyright © 2021 Société Française du Cancer. Published by Elsevier Masson SAS. All 
      rights reserved.
FAU - Veyri, Marianne
AU  - Veyri M
AD  - AP-HP, Sorbonne université, hôpitaux universitaires 
      Pitié-Salpêtrière - Charles-Foix, oncologie médicale, INSERM, institut Pierre-Louis 
      d'épidémiologie et de santé publique, équipe Theravir, Paris, France. Electronic 
      address: marianne.veyri@aphp.fr.
FAU - Lavolé, Armelle
AU  - Lavolé A
AD  - AP-HP, Sorbonne université, hôpital Tenon, service de pneumologie, GRC n(o) 4, 
      Theranoscan, Paris, France.
FAU - Choquet, Sylvain
AU  - Choquet S
AD  - AP-HP, hôpitaux universitaires Pitié-Salpêtrière - Charles-Foix, hématologie 
      clinique, Paris, France.
FAU - Costagliola, Dominique
AU  - Costagliola D
AD  - Sorbonne université, INSERM, institut Pierre-Louis d'épidémiologie et de santé 
      publique (IPLESP), Paris, France.
FAU - Solas, Caroline
AU  - Solas C
AD  - AP-HM, Aix-Marseille université, hôpital La Timone, laboratoire de pharmacocinétique 
      et toxicologie, INSERM 1207, IRD 190, UVE, Marseille, France.
FAU - Katlama, Christine
AU  - Katlama C
AD  - AP-HP, Sorbonne université, hôpitaux universitaires 
      Pitié-Salpêtrière - Charles-Foix, institut Pierre-Louis d'épidémiologie et de santé 
      publique, INSERM, équipe Theravir, maladies infectieuses et tropicales, Paris, 
      France.
FAU - Poizot-Martin, Isabelle
AU  - Poizot-Martin I
AD  - Aix-Marseille université, AP-HM, hôpital Sainte-Marguerite, service 
      d'immuno-hématologie clinique, INSERM, IRD, sciences économiques & sociales de la 
      santé & traitement de l'information médicale (SESSTIM), Marseille, France.
FAU - Spano, Jean-Philippe
AU  - Spano JP
AD  - AP-HP, Sorbonne université, hôpitaux universitaires 
      Pitié-Salpêtrière - Charles-Foix, institut Pierre-Louis d'épidémiologie et de santé 
      publique, INSERM, équipe Theravir, oncologie médicale, Paris, France.
LA  - eng
PT  - Letter
PT  - Observational Study
DEP - 20210824
PL  - France
TA  - Bull Cancer
JT  - Bulletin du cancer
JID - 0072416
SB  - IM
MH  - Adult
MH  - Anus Neoplasms/epidemiology
MH  - Bile Duct Neoplasms/epidemiology
MH  - Colorectal Neoplasms/epidemiology
MH  - Female
MH  - France/epidemiology
MH  - HIV Long-Term Survivors/*statistics & numerical data
MH  - Head and Neck Neoplasms/epidemiology
MH  - Hodgkin Disease/epidemiology
MH  - Humans
MH  - Incidence
MH  - Life Expectancy
MH  - Liver Neoplasms/epidemiology
MH  - Lung Neoplasms/epidemiology
MH  - Lymphoma, Non-Hodgkin/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Neoplasms, Second Primary/*epidemiology
MH  - Sarcoma, Kaposi/epidemiology
MH  - Urinary Bladder Neoplasms/epidemiology
OTO - NOTNLM
OT  - AIDS-defining cancers
OT  - Cancers classant-SIDA
OT  - Cancers non-classant-SIDA
OT  - HIV
OT  - Non-AIDS-defining cancers
OT  - Second cancer
OT  - VIH
EDAT- 2021/08/29 06:00
MHDA- 2021/10/28 06:00
CRDT- 2021/08/28 05:24
PHST- 2020/12/01 00:00 [received]
PHST- 2021/01/21 00:00 [revised]
PHST- 2021/01/21 00:00 [accepted]
PHST- 2021/08/29 06:00 [pubmed]
PHST- 2021/10/28 06:00 [medline]
PHST- 2021/08/28 05:24 [entrez]
AID - S0007-4551(21)00282-4 [pii]
AID - 10.1016/j.bulcan.2021.01.026 [doi]
PST - ppublish
SO  - Bull Cancer. 2021 Oct;108(10):908-914. doi: 10.1016/j.bulcan.2021.01.026. Epub 2021 
      Aug 24.

PMID- 25443036
OWN - NLM
STAT- MEDLINE
DCOM- 20150422
LR  - 20190609
IS  - 1560-7917 (Electronic)
IS  - 1025-496X (Linking)
VI  - 19
IP  - 47
DP  - 2014 Nov 27
TI  - Trends in HIV testing, prevalence among first-time testers, and incidence in 
      most-at-risk populations in Spain: the EPI-VIH Study, 2000 to 2009.
PG  - 20971
LID - 20971 [pii]
AB  - During 2000 to 2009, data on people undergoing HIV testing and on those newly 
      diagnosed with HIV were collected in a network of 20 Spanish clinics specialising in 
      sexually transmitted infections and/or HIV testing and counselling. The number of 
      tests performed, overall and disaggregated by different variables, was obtained. HIV 
      prevalence among first-time testers and HIV incidence among repeat testers were 
      calculated. To evaluate trends, joinpoint regression models were fitted. In total, 
      236,939 HIV tests were performed for 165,745 individuals. Overall HIV prevalence 
      among persons seeking HIV testing was 2.5% (95% CI: 2.4 to 2.6). Prevalence was 
      highest in male sex workers who had sex with other men (19.0% (95% CI: 16.7 to 
      21.4)) and was lowest in female sex workers (0.8% (95% CI: 0.7 to 0.9)). Significant 
      trends in prevalence were observed in men who have sex with men (MSM) (increasing) 
      and heterosexual individuals (decreasing). The incidence analysis included 30,679 
      persons, 64,104 person-years (py) of follow-up and 642 seroconversions. The overall 
      incidence rate (IR) was 1.0/100 py (95% CI: 0.9/100 to 1.1/100). Incidence was 
      significantly higher in men and transgender females than in women (1.8/100 py (95% 
      CI: 1.6 to 1.9), 1.2/100 py (95% CI: 0.5 to 2.8) and 0.1/100 py (95% CI: 0.09 to 
      0.2) respectively) and increased with age until 35–39 years. IRs in MSM and people 
      who inject drugs were significantly greater than in heterosexual individuals 
      (2.5/100 py (95% CI: 2.3 to 2.7), 1.6/100 py (95% CI: 1.1 to 2.2) and 0.1/100 py 
      (95% CI: 0.09 to 0.2) respectively), and an upward trend was observed in MSM. Our 
      results call for HIV prevention to be reinforced in MSM and transgender women in 
      Spain.
FAU - Diez, M
AU  - Diez M
AD  - Plan Nacional sobre el sida, Ministerio de Sanidad, Servicios Sociales e Igualdad, 
      Madrid, Spain.
FAU - Bleda, M J
AU  - Bleda MJ
FAU - Varela, J R
AU  - Varela JR
FAU - Ordonana, J
AU  - Ordonana J
FAU - Azpiri, M A
AU  - Azpiri MA
FAU - Vall, M
AU  - Vall M
FAU - Santos, C
AU  - Santos C
FAU - Viloria, L
AU  - Viloria L
FAU - de Armas, C
AU  - de Armas C
FAU - Urena, J M
AU  - Urena JM
FAU - Trullen, J
AU  - Trullen J
FAU - Pueyo, I
AU  - Pueyo I
FAU - Martinez, B
AU  - Martinez B
FAU - Puerta, T
AU  - Puerta T
FAU - Vera, M
AU  - Vera M
FAU - Sanz, I
AU  - Sanz I
FAU - Junquera, M L
AU  - Junquera ML
FAU - Landa, M C
AU  - Landa MC
FAU - Martinez, E
AU  - Martinez E
FAU - Camara, M M
AU  - Camara MM
FAU - Belda, J
AU  - Belda J
FAU - Bru, F J
AU  - Bru FJ
FAU - Diaz, A
AU  - Diaz A
CN  - EPI-VIH Study Group
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141127
PL  - Sweden
TA  - Euro Surveill
JT  - Euro surveillance : bulletin Europeen sur les maladies transmissibles = European 
      communicable disease bulletin
JID - 100887452
SB  - IM
MH  - AIDS Serodiagnosis/*statistics & numerical data
MH  - Adolescent
MH  - Adult
MH  - Antiretroviral Therapy, Highly Active
MH  - Cohort Studies
MH  - Female
MH  - HIV Infections/diagnosis/drug therapy/*epidemiology
MH  - HIV Seroprevalence/*trends
MH  - Heterosexuality/*statistics & numerical data
MH  - Homosexuality, Male/*statistics & numerical data
MH  - Humans
MH  - Incidence
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Prevalence
MH  - Sex Workers
MH  - Sexual Behavior
MH  - Sexually Transmitted Diseases/diagnosis/epidemiology
MH  - Spain/epidemiology
MH  - Substance Abuse, Intravenous
MH  - Transgender Persons
MH  - Vulnerable Populations
MH  - Young Adult
EDAT- 2014/12/03 06:00
MHDA- 2015/04/23 06:00
CRDT- 2014/12/03 06:00
PHST- 2014/12/03 06:00 [entrez]
PHST- 2014/12/03 06:00 [pubmed]
PHST- 2015/04/23 06:00 [medline]
AID - 20971 [pii]
AID - 10.2807/1560-7917.es2014.19.47.20971 [doi]
PST - epublish
SO  - Euro Surveill. 2014 Nov 27;19(47):20971. doi: 10.2807/1560-7917.es2014.19.47.20971.

PMID- 31093179
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200225
IS  - 1680-5348 (Electronic)
IS  - 1020-4989 (Print)
IS  - 1020-4989 (Linking)
VI  - 42
DP  - 2018
TI  - [HIV/Aids management at the primary care level in Brazil: a challenge for the 
      Unified Health System?Cuidados de pacientes VIH / SIDA y atención primaria en 
      Brasil: desafíos para la atención en el Sistema Único de Salud?].
PG  - e151
LID - 10.26633/RPSP.2018.151 [doi]
LID - e151
AB  - In Brazil, the Unified Health System (SUS) entails the establishment of hierarchical 
      and regionalized networks coordinated from the primary health care (PHC) level, 
      which is also the entry point into the system. Recently, as a result of new 
      guidelines and experiences in Brazil, PCH has been assigned a more substantial role 
      in the care and management of people living with HIV/Aids, tasks traditionally 
      performed at specialized clinics. The present article contextualizes and 
      problematizes this recent process of decentralized care to people living the 
      HIV/Aids in the context of the SUS. Since 2011, new diagnostic technologies (such as 
      rapid testing)) have been become available at PHC units in Brazil, expanding access 
      to testing and promoting an increase in the number of HIV diagnoses performed at the 
      PHC level. Since 2013, new guidelines and recommendations have also supported the 
      management of people with HIV/Aids in PHC units. The present article examines the 
      relationship between PHC and specialized care, issues of access, stigma, and 
      confidentiality within PHC, and the mode of organization and functioning of family 
      health teams, especially the formal link between residents in catchment areas and 
      health teams and workers. In conclusion, many challenges - moral, ethical, 
      technical, organizational, and political - have to be faced in order to increase 
      access and quality of care in the context of PHC for people living with HIV/Aids in 
      Brazil.
FAU - Melo, Eduardo Alves
AU  - Melo EA
AD  - Fundação Oswaldo Cruz, Escola Nacional de Saúde Pública (ENSP), Rio de Janeiro (RJ), 
      Brasil.
FAU - Maksud, Ivia
AU  - Maksud I
AD  - Fundação Oswaldo Cruz, Instituto Fernandes Figueira, Rio de Janeiro (RJ), Brasil.
FAU - Agostini, Rafael
AU  - Agostini R
AD  - Fundação Oswaldo Cruz, Instituto Fernandes Figueira, Rio de Janeiro (RJ), Brasil.
LA  - por
PT  - English Abstract
PT  - Journal Article
TT  - Cuidado, HIV/Aids e atenção primária no Brasil: desafio para a atenção no Sistema 
      Único de Saúde?
DEP - 20181127
TA  - Rev Panam Salud Publica
JT  - Revista panamericana de salud publica = Pan American journal of public health
JID - 9705400
PMC - PMC6386111
OAB - Publisher: Abstract available from the publisher.
OABL- por
OTO - NOTNLM
OT  - Brazil
OT  - Primary health care
OT  - acquired immunodeficiency syndrome
OT  - comprehensive health care
COIS- Conflitos de interesse. Nada declarado pelos autores.
EDAT- 2019/05/17 06:00
MHDA- 2019/05/17 06:01
CRDT- 2019/05/17 06:00
PHST- 2017/12/24 00:00 [received]
PHST- 2018/08/13 00:00 [accepted]
PHST- 2019/05/17 06:00 [entrez]
PHST- 2019/05/17 06:00 [pubmed]
PHST- 2019/05/17 06:01 [medline]
AID - RPSP.2018.151 [pii]
AID - 10.26633/RPSP.2018.151 [doi]
PST - epublish
SO  - Rev Panam Salud Publica. 2018 Nov 27;42:e151. doi: 10.26633/RPSP.2018.151. 
      eCollection 2018.

PMID- 26021187
OWN - NLM
STAT- MEDLINE
DCOM- 20171020
LR  - 20181202
IS  - 1578-1852 (Electronic)
IS  - 0213-005X (Linking)
VI  - 34
IP  - 2
DP  - 2016 Feb
TI  - Characteristics of HIV infected individuals traveling abroad. Results from the 
      +REDIVI Collaborative Network.
PG  - 108-13
LID - S0213-005X(15)00146-9 [pii]
LID - 10.1016/j.eimc.2015.03.023 [doi]
AB  - INTRODUCTION: The improvement in the prognosis of HIV infection, coupled with the 
      increase in international travel and migration, has led to a rising number of HIV 
      infected travelers. The objective of this study was to describe the epidemiological 
      and clinical features of returning travelers, according to their HIV status. 
      METHODS: An observational prospective study was conducted including travelers and 
      immigrants who traveled to visit friends and relatives (VFRs) registered in the 
      +REDIVI collaborative network (January-2009; October-2014). +REDIVI is a national 
      network that registers information regarding infections imported by travelers and 
      immigrants at 21 different centers using a standardized protocol. RESULTS: A total 
      of 3464 travellers were identified: 72 were HIV+ (2.1%) and 3.392 HIV- (98%). HIV+ 
      vs. HIV- travelers were often older (40.5y vs. 34.2y P=.001), VFRs (79.1% vs. 44.4%; 
      P<.001), and consulted less for pre-travel advice (27% vs. 37%; P=.078). The main 
      destinations for both groups were sub-Saharan Africa and Latin America. The most 
      frequent reasons for consultation after travel were fever, request for a health 
      examination, gastrointestinal complaints, and abnormal laboratory tests (mainly 
      eosinophilia and anemia), which differed between groups. The most frequent diagnoses 
      in HIV+ travelers were malaria (38.8%), newly diagnosed HIV infection (25%), and 
      intestinal parasites (19.4%), while for HIV- travelers the main diagnoses were 
      "healthy" (17.9%), malaria (14%), and intestinal parasites (17.3%). CONCLUSIONS: The 
      typical profile of an HIV+ traveler in +REDIVI was that of a VFR traveler who did 
      not seek pre-travel advice and made high-risk trips. This may increase the chance of 
      acquiring travel-related infections which may pose a special risk for HIV-infected 
      travelers. The post-travel visit was a good opportunity for HIV infection screening.
CI  - Copyright © 2015 Elsevier España, S.L.U. y Sociedad Española de Enfermedades 
      Infecciosas y Microbiología Clínica. All rights reserved.
FAU - Pérez-Molina, Jose A
AU  - Pérez-Molina JA
AD  - Hospital Universitario Ramon y Cajal, IRYCIS, Madrid, Spain. Electronic address: 
      jose.perezmolina@gmail.com.
FAU - Martinez-Perez, Angela
AU  - Martinez-Perez A
AD  - Hospital Universitario Ramon y Cajal, IRYCIS, Madrid, Spain.
FAU - Serre, Nuria
AU  - Serre N
AD  - Unitat de Salut Internacional Drassanes, PROSICS, Barcelona, Spain.
FAU - Treviño, Begoña
AU  - Treviño B
AD  - Unitat de Salut Internacional Drassanes, PROSICS, Barcelona, Spain.
FAU - Ruiz-Giardín, José Manuel
AU  - Ruiz-Giardín JM
AD  - Hospital Universitario de Fuenlabrada, Madrid, Spain.
FAU - Torrús, Diego
AU  - Torrús D
AD  - Hospital General Universitario de Alicante, Alicante, Spain.
FAU - Goikoetxea, Josune
AU  - Goikoetxea J
AD  - Hospital Universitario Cruces de Barakaldo, Bilbao, Spain.
FAU - Echevarría, Esteban Martín
AU  - Echevarría EM
AD  - Hospital Universitario de Guadalajara, Guadalajara, Spain.
FAU - Malmierca, Eduardo
AU  - Malmierca E
AD  - Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain.
FAU - Rojo, Gerardo
AU  - Rojo G
AD  - Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain.
FAU - Calabuig, Eva
AU  - Calabuig E
AD  - Hospital Universitario La Fe de Valencia, Valencia, Spain.
FAU - Gutierrez, Belén
AU  - Gutierrez B
AD  - Hospital Universitario Virgen de La Macarena de Sevilla, Sevilla, Spain.
FAU - Norman, Francesca
AU  - Norman F
AD  - Hospital Universitario Ramon y Cajal, IRYCIS, Madrid, Spain.
FAU - Lopez-Velez, Rogelio
AU  - Lopez-Velez R
AD  - Hospital Universitario Ramon y Cajal, IRYCIS, Madrid, Spain.
CN  - +REDIVI Collaborative Network
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20150526
PL  - Spain
TA  - Enferm Infecc Microbiol Clin
JT  - Enfermedades infecciosas y microbiologia clinica
JID - 9104081
SB  - IM
MH  - Adult
MH  - Emigrants and Immigrants
MH  - Female
MH  - HIV Infections/*epidemiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Referral and Consultation
MH  - Registries
MH  - Risk Assessment
MH  - *Travel
OTO - NOTNLM
OT  - AIDS
OT  - Epidemiology
OT  - Epidemiología
OT  - HIV
OT  - Sida
OT  - Travelers
OT  - VFR
OT  - VIH
OT  - Viajeros
FIR - Aguilera, Paloma
IR  - Aguilera P
FIR - Cuadrado, José María
IR  - Cuadrado JM
FIR - Cuadros, Juan Antonio
IR  - Cuadros JA
FIR - de Henares, Alcalá
IR  - de Henares A
FIR - Domínguez, Ángel
IR  - Domínguez Á
FIR - Gálvez, Rubén
IR  - Gálvez R
FIR - García, Magdalena
IR  - García M
FIR - Gomez i Prat, Jordi
IR  - Gomez i Prat J
FIR - Martín Echevarría, Esteban
IR  - Martín Echevarría E
FIR - Martínez, María
IR  - Martínez M
FIR - Mena Ribas, Ana
IR  - Mena Ribas A
FIR - Molina, Israel
IR  - Molina I
FIR - Monge, Begoña
IR  - Monge B
FIR - Sanchez Montalvá, Adriá
IR  - Sanchez Montalvá A
FIR - Mora-Rillo, Marta
IR  - Mora-Rillo M
FIR - Moreno Velazquez, Liliana M
IR  - Moreno Velazquez LM
FIR - Pérez de Ayala, Ana
IR  - Pérez de Ayala A
FIR - Pou, Diana
IR  - Pou D
FIR - Rodríguez Guardado, Azucena
IR  - Rodríguez Guardado A
FIR - Salvador, Fernando
IR  - Salvador F
FIR - Soriano, Antoni
IR  - Soriano A
FIR - Suárez, Inés
IR  - Suárez I
FIR - Wikman, Philip
IR  - Wikman P
EDAT- 2015/05/30 06:00
MHDA- 2017/10/21 06:00
CRDT- 2015/05/30 06:00
PHST- 2014/12/29 00:00 [received]
PHST- 2015/03/22 00:00 [revised]
PHST- 2015/03/24 00:00 [accepted]
PHST- 2015/05/30 06:00 [entrez]
PHST- 2015/05/30 06:00 [pubmed]
PHST- 2017/10/21 06:00 [medline]
AID - S0213-005X(15)00146-9 [pii]
AID - 10.1016/j.eimc.2015.03.023 [doi]
PST - ppublish
SO  - Enferm Infecc Microbiol Clin. 2016 Feb;34(2):108-13. doi: 
      10.1016/j.eimc.2015.03.023. Epub 2015 May 26.

PMID- 20441644
OWN - NLM
STAT- MEDLINE
DCOM- 20160423
LR  - 20181201
IS  - 0995-3914 (Print)
IS  - 0995-3914 (Linking)
VI  - 21 Spec No 2
DP  - 2010 Feb 16
TI  - [Not Available].
PG  - 129-39
AB  - In developed countries, the lives of HIV seropositive patients have not been 
      unaffected by the technological revolution initiated by internet. HIV seropositive 
      patients use the Web as a tool for searching information, meeting other Web users 
      and developing social networks. In July 2008, taking advantage of the advent of Web 
      technology 2.0, AIDES, a non-profit organization dedicated to fighting AIDS, 
      launched Seronet, a website premised on a communitarian objective that aims to 
      improve access to knowledge, provide a forum for sharing individual experience of 
      the disease and break the cycle of isolation. Despite certain limitations, a 
      relatively wide support network has gradually developed around Seronet. The 
      long-term impact of this network on isolation, the development of autonomy, and the 
      encouragement of a communitarian involvement of HIV-positive patients in terms of 
      healthcare will need to be assessed.
FAU - Rojas Castro, Daniela
AU  - Rojas Castro D
FAU - Le Gall, Jean-Marie
AU  - Le Gall JM
FAU - Jablonski, Olivier
AU  - Jablonski O
LA  - fre
PT  - Journal Article
TT  - Améliorer la santé des personnes séropositives au VIH : SERONET, un nouvel outil de 
      l'approche communautaire.
PL  - France
TA  - Sante Publique
JT  - Sante publique (Vandoeuvre-les-Nancy, France)
JID - 9216153
SB  - IM
MH  - Humans
MH  - *Internet
MH  - Social Media
MH  - *Social Support
EDAT- 2010/02/16 00:00
MHDA- 2016/04/24 06:00
CRDT- 2010/05/06 06:00
PHST- 2010/05/06 06:00 [entrez]
PHST- 2010/02/16 00:00 [pubmed]
PHST- 2016/04/24 06:00 [medline]
PST - ppublish
SO  - Sante Publique. 2010 Feb 16;21 Spec No 2:129-39.

PMID- 22805136
OWN - NLM
STAT- MEDLINE
DCOM- 20121002
LR  - 20181201
IS  - 0767-0974 (Print)
IS  - 0767-0974 (Linking)
VI  - 28
IP  - 6-7
DP  - 2012 Jun-Jul
TI  - [Interleukin-21: a key cytokine for controlling HIV and other chronic viral 
      infections].
PG  - 605-11
LID - 10.1051/medsci/2012286013 [doi]
AB  - The differentiation, homeostatic proliferation and effector functions of different 
      immune cells are controlled, to a large extent, by cytokines. Viruses often cause 
      immune response dysfunctions by causing defects in the cytokine networks. The 
      defects are often manifested by altered cytokine secretion and/or responsiveness to 
      the cytokine. Among these cytokines, Interleukin-21 (IL-21) is a relatively recently 
      discovered cytokine, which is mainly produced by CD4(+) T cells in the body, and 
      exerts multiple and pleiotropic effects on various immune cells. Recent studies have 
      shown that the cytokine is indispensable for controlling chronic viral infections. 
      This review summarizes current knowledges concerning the biological effects of this 
      cytokine on different components of the immune system. We also discuss how it 
      contributes toward mounting efficient antiviral immunity and controlling chronic 
      viral infections, especially HIV-1. The IL-1 cytokine represents a novel therapeutic 
      agent for virus-infected patients as well as an adjuvant in antiviral vaccination 
      strategies.
CI  - © 2012 médecine/sciences – Inserm / SRMS.
FAU - Iannello, Alexandre
AU  - Iannello A
AD  - Département de microbiologie et d'immunologie, Université de Montréal, Montréal, 
      Québec H3T 1C5, Canada. alexandre.iannello@gmail.com
FAU - Allam, Ossama
AU  - Allam O
FAU - Samarani, Suzanne
AU  - Samarani S
FAU - Ahmad, Ali
AU  - Ahmad A
LA  - fre
PT  - Journal Article
PT  - Review
TT  - L'interleukine-21, une cytokine clé dans le contrôle du VIH et d'autres infections 
      virales chroniques.
DEP - 20120716
PL  - France
TA  - Med Sci (Paris)
JT  - Medecine sciences : M/S
JID - 8710980
RN  - 0 (Interleukins)
RN  - MKM3CA6LT1 (interleukin-21)
SB  - IM
MH  - Adaptive Immunity/genetics
MH  - Chronic Disease
MH  - HIV Infections/immunology/*prevention & control
MH  - HIV-1/drug effects/*immunology
MH  - Humans
MH  - Interleukins/genetics/*physiology/*therapeutic use
MH  - Models, Biological
MH  - Vaccination/methods
MH  - Virus Diseases/immunology/*prevention & control
EDAT- 2012/07/19 06:00
MHDA- 2012/10/04 06:00
CRDT- 2012/07/19 06:00
PHST- 2012/07/19 06:00 [entrez]
PHST- 2012/07/19 06:00 [pubmed]
PHST- 2012/10/04 06:00 [medline]
AID - medsci2012286-7p605 [pii]
AID - 10.1051/medsci/2012286013 [doi]
PST - ppublish
SO  - Med Sci (Paris). 2012 Jun-Jul;28(6-7):605-11. doi: 10.1051/medsci/2012286013. Epub 
      2012 Jul 16.

PMID- 34324783
OWN - NLM
STAT- MEDLINE
DCOM- 20210923
LR  - 20210923
IS  - 1468-1293 (Electronic)
IS  - 1464-2662 (Print)
IS  - 1464-2662 (Linking)
VI  - 22
IP  - 9
DP  - 2021 Oct
TI  - COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study.
PG  - 867-876
LID - 10.1111/hiv.13145 [doi]
AB  - OBJECTIVES: We compared the characteristics and clinical outcomes of hospitalized 
      individuals with COVID-19 with [people with HIV (PWH)] and without (non-PWH) HIV 
      co-infection in Spain during the first wave of the pandemic. METHODS: This was a 
      retrospective matched cohort study. People with HIV were identified by reviewing 
      clinical records and laboratory registries of 10 922 patients in active-follow-up 
      within the Spanish HIV Research Network (CoRIS) up to 30 June 2020. Each 
      hospitalized PWH was matched with five non-PWH of the same age and sex randomly 
      selected from COVID-19@Spain, a multicentre cohort of 4035 patients hospitalized 
      with confirmed COVID-19. The main outcome was all-cause in-hospital mortality. 
      RESULTS: Forty-five PWH with PCR-confirmed COVID-19 were identified in CoRIS, 21 of 
      whom were hospitalized. A total of 105 age/sex-matched controls were selected from 
      the COVID-19@Spain cohort. The median age in both groups was 53 (Q1-Q3, 46-56) 
      years, and 90.5% were men. In PWH, 19.1% were injecting drug users, 95.2% were on 
      antiretroviral therapy, 94.4% had HIV-RNA < 50 copies/mL, and the median (Q1-Q3) CD4 
      count was 595 (349-798) cells/μL. No statistically significant differences were 
      found between PWH and non-PWH in number of comorbidities, presenting signs and 
      symptoms, laboratory parameters, radiology findings and severity scores on 
      admission. Corticosteroids were administered to 33.3% and 27.4% of PWH and non-PWH, 
      respectively (P = 0.580). Deaths during admission were documented in two (9.5%) PWH 
      and 12 (11.4%) non-PWH (P = 0.800). CONCLUSIONS: Our findings suggest that 
      well-controlled HIV infection does not modify the clinical presentation or worsen 
      clinical outcomes of COVID-19 hospitalization.
CI  - © 2021 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of 
      British HIV Association.
FAU - Díez, Cristina
AU  - Díez C
AD  - Unidad de Enfermedades Infecciosas/VIH, Hospital General Universitario Gregorio 
      Marañón, Madrid, Spain.
AD  - Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM, Madrid, Spain.
FAU - Del Romero-Raposo, Jorge
AU  - Del Romero-Raposo J
AD  - Centro Nacional de Epidemiología, Instituto de Salud Carlos III, Madrid, Spain.
FAU - Mican, Rafael
AU  - Mican R
AD  - Unidad de VIH, Servicio de Medicina Interna, Hospital Universitario La Paz, Madrid, 
      Spain.
AD  - Instituto de Investigación Hospital Universitario La Paz (IdiPAZ, Madrid, Spain.
FAU - López, Juan C
AU  - López JC
AD  - Unidad de Enfermedades Infecciosas/VIH, Hospital General Universitario Gregorio 
      Marañón, Madrid, Spain.
AD  - Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM, Madrid, Spain.
FAU - Blanco, José R
AU  - Blanco JR
AUID- ORCID: 0000-0002-4268-0150
AD  - Servicio de Medicina Interna, Hospital Universitario San Pedro - CIBIR de Logroño, 
      Logroño, Spain.
FAU - Calzado, Sonia
AU  - Calzado S
AD  - Unidad de Enfermedades Infecciosas, Hospital Universitario Parc Tauli, Sabadell, 
      Spain.
FAU - Samperiz, Gloria
AU  - Samperiz G
AUID- ORCID: 0000-0003-0693-2266
AD  - Unidad de Enfermedades Infecciosas, Hospital Universitario Miguel Servet, Zaragoza, 
      Spain.
FAU - Portilla, Joaquín
AU  - Portilla J
AD  - Unidad de Enfermedades Infecciosas, Hospital General Universitario de Alicante, 
      Alicante, Spain.
FAU - García-Fraile, Lucio J
AU  - García-Fraile LJ
AD  - Sección de Enfermedades Infecciosas, Hospital Universitario La Princesa, Madrid, 
      Spain.
FAU - Gutiérrez, Félix
AU  - Gutiérrez F
AD  - Unidad de Enfermedades Infecciosas, Hospital General Universitario de Elche, Elche, 
      Spain.
FAU - Gómez-Sirvent, Juan L
AU  - Gómez-Sirvent JL
AD  - Sección de Infecciones, Hospital Universitario de Canarias, Tenerife, Spain.
FAU - Suárez-García, Inés
AU  - Suárez-García I
AUID- ORCID: 0000-0002-7016-716X
AD  - Grupo de Enfermedades Infecciosas, Departamento de Medicina Interna, Hospital 
      Universitario Infanta Sofía, Madrid, Spain.
AD  - Facultad de Medicina, Universidad Europea de Madrid, Madrid, Spain.
FAU - Amador, Concha
AU  - Amador C
AD  - Unidad de Enfermedades Infecciosas, Hospital de la Marina Baixa, Alicante, Spain.
FAU - Novella, María
AU  - Novella M
AD  - Unidad de Enfermedades Infecciosas, Hospital Universitario Príncipe de Asturias, 
      Alcalá de Henares, Spain.
FAU - Arribas, Jose R
AU  - Arribas JR
AD  - Unidad de VIH, Servicio de Medicina Interna, Hospital Universitario La Paz, Madrid, 
      Spain.
AD  - Instituto de Investigación Hospital Universitario La Paz (IdiPAZ, Madrid, Spain.
FAU - Moreno, Santiago
AU  - Moreno S
AD  - Servicio de Enfermedades Infecciosas, Hospital Universitario Ramón y Cajal, Madrid, 
      Spain.
AD  - Facultad de Medicina, Universidad de Alcalá, Madrid, Spain.
AD  - Instituto Ramón y Cajal de Investigación Sanitaria (irycis, Madrid, Spain.
FAU - González-García, Juan
AU  - González-García J
AD  - Unidad de VIH, Servicio de Medicina Interna, Hospital Universitario La Paz, Madrid, 
      Spain.
AD  - Instituto de Investigación Hospital Universitario La Paz (IdiPAZ, Madrid, Spain.
FAU - Jarrín, Inmaculada
AU  - Jarrín I
AD  - Centro Nacional de Epidemiología, Instituto de Salud Carlos III, Madrid, Spain.
FAU - Berenguer, Juan
AU  - Berenguer J
AUID- ORCID: 0000-0001-8541-8200
AD  - Unidad de Enfermedades Infecciosas/VIH, Hospital General Universitario Gregorio 
      Marañón, Madrid, Spain.
AD  - Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM, Madrid, Spain.
CN  - for CoRIS
LA  - eng
GR  - Instituto de Salud Carlos III/
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20210729
TA  - HIV Med
JT  - HIV medicine
JID - 100897392
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Anti-HIV Agents)
SB  - IM
MH  - Adolescent
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-HIV Agents/therapeutic use
MH  - CD4 Lymphocyte Count
MH  - COVID-19/drug therapy/*epidemiology/mortality
MH  - Child
MH  - Child, Preschool
MH  - Drug Users/*statistics & numerical data
MH  - Female
MH  - HIV Infections/drug therapy/*epidemiology/mortality
MH  - Hospitalization/*statistics & numerical data
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Spain/epidemiology
MH  - Young Adult
PMC - PMC8444663
OTO - NOTNLM
OT  - *COVID-19
OT  - *Coronavirus
OT  - *HIV
OT  - *SARS-CoV-2
COIS- JCL reports honoraria for advice or public speaking from Gilead, MSD, Janssen and 
      ViiV Healthcare. JRB reports honoraria for advice or public speaking from Abbvie, 
      Gilead, MSD, Janssen and ViiV Healthcare, and grants from Gilead. LJG‐F reports 
      honoraria for advice or public speaking from MSD and grants from GILEAD. FG reports 
      honoraria for advice or public speaking from Janssen and ViiV Healthcare. IS‐G 
      reports honoraria for advice or public speaking from Gilead, MSD and ViiV 
      Healthcare. JRA reports honoraria for advice or public speaking from Alexa, Gilead, 
      MSD, Janssen, Serono, Teva and ViiV Healthcare, and grants from Alexa, Gilead, 
      Janssen, MSD, Serono, Teva and ViiV Healthcare. SM reports honoraria for advice or 
      public speaking from Gilead, MSD, Janssen and ViiV Healthcare, and grants from 
      Gilead, MSD and ViiV Healthcare. JG‐G reports honoraria for advice or public 
      speaking from Gilead, MSD, Janssen and ViiV Healthcare. IJ reports honoraria for 
      advice or public speaking from Gilead and ViiV Healthcare, and grants from MSD. JB 
      reports honoraria for advice or public speaking from Abbvie, Gilead, MSD, Janssen 
      and ViiV Healthcare, and grants from Abbvie, Gilead, MSD and ViiV Healthcare. CD, 
      JDR‐R, RM, SC, GS, JP, LJG‐F, JLG‐S, CA and MN have nothing to disclose. This work 
      was supported by the Instituto de Salud Carlos III (ISCII) (grant no. COV20/00108) 
      and the Spanish AIDS Research Network (RD16/0025), which is included in the Spanish 
      I+D+I Plan and is co‐funded by ISCIII‐Subdirección General de Evaluación and 
      European Funding for Regional Development (FEDER).
FIR - Moreno, Santiago
IR  - Moreno S
FIR - Jarrín, Inma
IR  - Jarrín I
FIR - Dalmau, David
IR  - Dalmau D
FIR - Navarro, Maria Luisa
IR  - Navarro ML
FIR - González, Maria Isabel
IR  - González MI
FIR - Garcia, Federico
IR  - Garcia F
FIR - Poveda, Eva
IR  - Poveda E
FIR - Iribarren, Jose Antonio
IR  - Iribarren JA
FIR - Gutiérrez, Félix
IR  - Gutiérrez F
FIR - Rubio, Rafael
IR  - Rubio R
FIR - Vidal, Francesc
IR  - Vidal F
FIR - González, Juan
IR  - González J
FIR - Muñoz-Fernández, M Ángeles
IR  - Muñoz-Fernández MÁ
FIR - Jarrin, Inmaculada
IR  - Jarrin I
FIR - Alejos, Belén
IR  - Alejos B
FIR - Moreno, Cristina
IR  - Moreno C
FIR - Iniesta, Carlos
IR  - Iniesta C
FIR - Rava, Marta
IR  - Rava M
FIR - Izquierdo, Rebeca
IR  - Izquierdo R
FIR - Muñoz-Fernández, M Ángeles
IR  - Muñoz-Fernández MÁ
FIR - Consuegra Fernández, Irene
IR  - Consuegra Fernández I
FIR - Merino, Esperanza
IR  - Merino E
FIR - García, Gema
IR  - García G
FIR - Portilla, Irene
IR  - Portilla I
FIR - Agea, Iván
IR  - Agea I
FIR - Sánchez-Payá, José
IR  - Sánchez-Payá J
FIR - Rodríguez, Juan Carlos
IR  - Rodríguez JC
FIR - Gimeno, Lina
IR  - Gimeno L
FIR - Giner, Livia
IR  - Giner L
FIR - Díez, Marcos
IR  - Díez M
FIR - Carreres, Melissa
IR  - Carreres M
FIR - Reus, Sergio
IR  - Reus S
FIR - Boix, Vicente
IR  - Boix V
FIR - Torrús, Diego
IR  - Torrús D
FIR - López Lirola, Ana
IR  - López Lirola A
FIR - García, Dácil
IR  - García D
FIR - Díaz-Flores, Felicitas
IR  - Díaz-Flores F
FIR - Gómez, Juan Luis
IR  - Gómez JL
FIR - Alonso, María Del Mar
IR  - Alonso MDM
FIR - Pelazas, Ricardo
IR  - Pelazas R
FIR - Hernández, Jehovana
IR  - Hernández J
FIR - Alemán, María Remedios
IR  - Alemán MR
FIR - Hernández, María Inmaculada
IR  - Hernández MI
FIR - Asensi, Víctor
IR  - Asensi V
FIR - Valle, Eulalia
IR  - Valle E
FIR - Rivas Carmenado, María Eugenia
IR  - Rivas Carmenado ME
FIR - Suárez-Zarracina, Tomás
IR  - Suárez-Zarracina T
FIR - Pérez Is, Laura
IR  - Pérez Is L
FIR - Rubio, Rafael
IR  - Rubio R
FIR - Pulido, Federico
IR  - Pulido F
FIR - Bisbal, Otilia
IR  - Bisbal O
FIR - Hernando, Asunción
IR  - Hernando A
FIR - Domínguez, Lourdes
IR  - Domínguez L
FIR - Rial, David
IR  - Rial D
FIR - Bermejo, Laura
IR  - Bermejo L
FIR - Santacreu, Mireia
IR  - Santacreu M
FIR - Iribarren, José Antonio
IR  - Iribarren JA
FIR - Arrizabalaga, Julio
IR  - Arrizabalaga J
FIR - Aramburu, María José
IR  - Aramburu MJ
FIR - Camino, Xabier
IR  - Camino X
FIR - Rodríguez-Arrondo, Francisco
IR  - Rodríguez-Arrondo F
FIR - von Wichmann, Miguel Ángel
IR  - von Wichmann MÁ
FIR - Pascual Tomé, Lidia
IR  - Pascual Tomé L
FIR - Goenaga, Miguel Ángel
IR  - Goenaga MÁ
FIR - Bustinduy, Mª Jesús
IR  - Bustinduy MJ
FIR - Azkune, Harkaitz
IR  - Azkune H
FIR - Ibarguren, Maialen
IR  - Ibarguren M
FIR - Lizardi, Aitziber
IR  - Lizardi A
FIR - Kortajarena, Xabier
IR  - Kortajarena X
FIR - Umerez Igartua, Maitane
IR  - Umerez Igartua M
FIR - Masiá, Mar
IR  - Masiá M
FIR - Padilla, Sergio
IR  - Padilla S
FIR - Robledano, Catalina
IR  - Robledano C
FIR - Colomé, Joan Gregori
IR  - Colomé JG
FIR - Adsuar, Araceli
IR  - Adsuar A
FIR - Pascual, Rafael
IR  - Pascual R
FIR - Fernández, Marta
IR  - Fernández M
FIR - García, José Alberto
IR  - García JA
FIR - Barber, Xavier
IR  - Barber X
FIR - Re, Vanessa Agullo
IR  - Re VA
FIR - Abellán, Javier Garcia
IR  - Abellán JG
FIR - Pascual Pérez, Reyes
IR  - Pascual Pérez R
FIR - Roca, María
IR  - Roca M
FIR - Muga, Roberto
IR  - Muga R
FIR - Sanvisens, Arantza
IR  - Sanvisens A
FIR - Fuster, Daniel
IR  - Fuster D
FIR - López, Juan Carlos
IR  - López JC
FIR - Gutiérrez, Isabel
IR  - Gutiérrez I
FIR - Ramírez, Margarita
IR  - Ramírez M
FIR - Padilla, Belén
IR  - Padilla B
FIR - Gijón, Paloma
IR  - Gijón P
FIR - Aldamiz-Echevarría, Teresa
IR  - Aldamiz-Echevarría T
FIR - Tejerina, Francisco
IR  - Tejerina F
FIR - Parras, Francisco José
IR  - Parras FJ
FIR - Balsalobre, Pascual
IR  - Balsalobre P
FIR - Diez, Cristina
IR  - Diez C
FIR - Latorre, Leire Pérez
IR  - Latorre LP
FIR - Fanciulli, Chiara
IR  - Fanciulli C
FIR - Vidal, Francesc
IR  - Vidal F
FIR - Peraire, Joaquín
IR  - Peraire J
FIR - Viladés, Consuelo
IR  - Viladés C
FIR - Veloso, Sergio
IR  - Veloso S
FIR - Vargas, Montserrat
IR  - Vargas M
FIR - Olona, Montserrat
IR  - Olona M
FIR - Rull, Anna
IR  - Rull A
FIR - Alba, Verónica
IR  - Alba V
FIR - Yeregui, Elena
IR  - Yeregui E
FIR - Masip, Jenifer
IR  - Masip J
FIR - Reverté, Laia
IR  - Reverté L
FIR - Montero, Marta
IR  - Montero M
FIR - López-Aldeguer, José
IR  - López-Aldeguer J
FIR - Blanes, Marino
IR  - Blanes M
FIR - Tasias Pitarch, María
IR  - Tasias Pitarch M
FIR - Castro Hernández, Iván
IR  - Castro Hernández I
FIR - Calabuig, Eva
IR  - Calabuig E
FIR - Cuéllar, Sandra
IR  - Cuéllar S
FIR - Salavert Lletí, Miguel
IR  - Salavert Lletí M
FIR - Fernández Navarro, Juan
IR  - Fernández Navarro J
FIR - González-Garcia, Juan
IR  - González-Garcia J
FIR - Arnalich, Francisco
IR  - Arnalich F
FIR - Busca, Carmen
IR  - Busca C
FIR - Cano, Joanna
IR  - Cano J
FIR - Cardiñanos, Julen
IR  - Cardiñanos J
FIR - Castro, Juan Miguel
IR  - Castro JM
FIR - Delgado Hierro, Ana
IR  - Delgado Hierro A
FIR - Escosa, Luis
IR  - Escosa L
FIR - Herranz, Pedro
IR  - Herranz P
FIR - Hontañón, Víctor
IR  - Hontañón V
FIR - García-Bujalance, Silvia
IR  - García-Bujalance S
FIR - García López-Hortelano, Milagros
IR  - García López-Hortelano M
FIR - González-Baeza, Alicia
IR  - González-Baeza A
FIR - de Miguel, Rosa
IR  - de Miguel R
FIR - Martín-Carbonero, Maria Luz
IR  - Martín-Carbonero ML
FIR - Mayoral, Mario
IR  - Mayoral M
FIR - Mellado, Maria Jose
IR  - Mellado MJ
FIR - Micán, Rafael
IR  - Micán R
FIR - Montejano, Rocio
IR  - Montejano R
FIR - Montes, María Luisa
IR  - Montes ML
FIR - Moreno, Victoria
IR  - Moreno V
FIR - Pérez-Valero, Ignacio
IR  - Pérez-Valero I
FIR - Rúa Cebrián, Guadalupe
IR  - Rúa Cebrián G
FIR - Rodés, Berta
IR  - Rodés B
FIR - Sainz, Talia
IR  - Sainz T
FIR - Sendagorta, Elena
IR  - Sendagorta E
FIR - Valencia, Eulalia
IR  - Valencia E
FIR - Oteo, José Antonio
IR  - Oteo JA
FIR - Ibarra, Valvanera
IR  - Ibarra V
FIR - Metola, Luis
IR  - Metola L
FIR - Sanz, Mercedes
IR  - Sanz M
FIR - Pérez-Martínez, Laura
IR  - Pérez-Martínez L
FIR - Arazo, Piedad
IR  - Arazo P
FIR - Sampériz, Gloria
IR  - Sampériz G
FIR - Dalmau, David
IR  - Dalmau D
FIR - Jaén, Angels
IR  - Jaén A
FIR - Sanmartí, Montse
IR  - Sanmartí M
FIR - Cairó, Mireia
IR  - Cairó M
FIR - Martinez-Lacasa, Javier
IR  - Martinez-Lacasa J
FIR - Velli, Pablo
IR  - Velli P
FIR - Font, Roser
IR  - Font R
FIR - Martinez, Marina
IR  - Martinez M
FIR - Aiello, Francesco
IR  - Aiello F
FIR - Rivero Marcotegui, Maria
IR  - Rivero Marcotegui M
FIR - Repáraz, Jesús
IR  - Repáraz J
FIR - de León Cano, María Teresa
IR  - de León Cano MT
FIR - Pierola, Beatriz
IR  - Pierola B
FIR - Amengual, María José
IR  - Amengual MJ
FIR - Navarro, Gemma
IR  - Navarro G
FIR - Cervantes, Manel
IR  - Cervantes M
FIR - Calzado, Sonia
IR  - Calzado S
FIR - Navarro Vilasaro, Marta
IR  - Navarro Vilasaro M
FIR - de Los Santos, Ignacio
IR  - de Los Santos I
FIR - Sanz Sanz, Jesús
IR  - Sanz Sanz J
FIR - Salas, Ana
IR  - Salas A
FIR - Sarriá, Cristina
IR  - Sarriá C
FIR - Garcia-Fraile, Lucio J
IR  - Garcia-Fraile LJ
FIR - Martín Gayo, Enrique
IR  - Martín Gayo E
FIR - Moreno, Santiago
IR  - Moreno S
FIR - Casado, José Luis
IR  - Casado JL
FIR - Dronda, Fernando
IR  - Dronda F
FIR - Moreno, Ana
IR  - Moreno A
FIR - Pérez Elías, Maria Jesús
IR  - Pérez Elías MJ
FIR - Gutiérrez, Carolina
IR  - Gutiérrez C
FIR - Madrid, Nadia
IR  - Madrid N
FIR - Del Campo, Santos
IR  - Del Campo S
FIR - Serrano, Sergio
IR  - Serrano S
FIR - Vivancos, Maria Jesús
IR  - Vivancos MJ
FIR - Martínez Sanz, Javier
IR  - Martínez Sanz J
FIR - Anxa Urroz, Usua
IR  - Anxa Urroz U
FIR - Velasco, Tamara
IR  - Velasco T
FIR - Vallejo, Alejandro
IR  - Vallejo A
FIR - Bernal, Enrique
IR  - Bernal E
FIR - Cano Sanchez, Alfredo
IR  - Cano Sanchez A
FIR - Alcaráz, Antonia
IR  - Alcaráz A
FIR - Bravo Urbieta, Joaquín
IR  - Bravo Urbieta J
FIR - Muñoz Perez, Ángeles
IR  - Muñoz Perez Á
FIR - Alcaraz, Maria Jose
IR  - Alcaraz MJ
FIR - Villalba, Maria Del Carmen
IR  - Villalba MDC
FIR - García, Federico
IR  - García F
FIR - Hernández Quero, José
IR  - Hernández Quero J
FIR - Muñoz Medina, Leopoldo
IR  - Muñoz Medina L
FIR - Alvarez, Marta
IR  - Alvarez M
FIR - Chueca, Natalia
IR  - Chueca N
FIR - Vinuesa, David
IR  - Vinuesa D
FIR - Martinez-Montes, Clara
IR  - Martinez-Montes C
FIR - Guerrero, Carlos
IR  - Guerrero C
FIR - de Salazar Gonzalez, Adolfo
IR  - de Salazar Gonzalez A
FIR - Fuentes, Ana
IR  - Fuentes A
FIR - Del Romero, Jorge
IR  - Del Romero J
FIR - Raposo Utrilla, Montserrat
IR  - Raposo Utrilla M
FIR - Rodríguez, Carmen
IR  - Rodríguez C
FIR - Puerta, Teresa
IR  - Puerta T
FIR - Carrió, Juan Carlos
IR  - Carrió JC
FIR - Vera, Mar
IR  - Vera M
FIR - Ballesteros, Juan
IR  - Ballesteros J
FIR - Ayerdi, Oskar
IR  - Ayerdi O
FIR - Antela, Antonio
IR  - Antela A
FIR - Losada, Elena
IR  - Losada E
FIR - Riera, Melchor
IR  - Riera M
FIR - Peñaranda, María
IR  - Peñaranda M
FIR - Ribas, Mª Angels
IR  - Ribas MA
FIR - Campins, Antoni A
IR  - Campins AA
FIR - Vidal, Carmen
IR  - Vidal C
FIR - Fanjul, Francisco
IR  - Fanjul F
FIR - Murillas, Javier
IR  - Murillas J
FIR - Homar, Francisco
IR  - Homar F
FIR - Vilchez, Helem H
IR  - Vilchez HH
FIR - Martin, Maria Luisa
IR  - Martin ML
FIR - Payeras, Antoni
IR  - Payeras A
FIR - Santos, Jesús
IR  - Santos J
FIR - Gómez Ayerbe, Cristina
IR  - Gómez Ayerbe C
FIR - Viciana, Isabel
IR  - Viciana I
FIR - Palacios, Rosario
IR  - Palacios R
FIR - Pérez López, Carmen
IR  - Pérez López C
FIR - Gonzalez-Domenec, Carmen Maria
IR  - Gonzalez-Domenec CM
FIR - Viciana, Pompeyo
IR  - Viciana P
FIR - Espinosa, Nuria
IR  - Espinosa N
FIR - López-Cortés, Luis Fernando
IR  - López-Cortés LF
FIR - Podzamczer, Daniel
IR  - Podzamczer D
FIR - Imaz, Arkaitz
IR  - Imaz A
FIR - Tiraboschi, Juan
IR  - Tiraboschi J
FIR - Silva, Ana
IR  - Silva A
FIR - Saumoy, María
IR  - Saumoy M
FIR - Prieto, Paula
IR  - Prieto P
FIR - Ribera, Esteban
IR  - Ribera E
FIR - Curran, Adrian
IR  - Curran A
FIR - Olalla, Julián
IR  - Olalla J
FIR - Pérez Stachowski, Javier
IR  - Pérez Stachowski J
FIR - Del Arco, Alfonso
IR  - Del Arco A
FIR - de la Torre, Javier
IR  - de la Torre J
FIR - Prada, José Luis
IR  - Prada JL
FIR - García de Lomas, José María
IR  - García de Lomas JM
FIR - Martínez, Onofre Juan
IR  - Martínez OJ
FIR - Vera, Francisco J
IR  - Vera FJ
FIR - Martínez, Lorena
IR  - Martínez L
FIR - García, Josefina
IR  - García J
FIR - Alcaraz, Begoña
IR  - Alcaraz B
FIR - Jimeno, Amaya
IR  - Jimeno A
FIR - Castro, Ángeles
IR  - Castro Á
FIR - Pernas, Berta
IR  - Pernas B
FIR - Mena, Álvaro
IR  - Mena Á
FIR - Muñoz, Josefa
IR  - Muñoz J
FIR - Zubero, Miren Zuriñe
IR  - Zubero MZ
FIR - Baraia-Etxaburu, Josu Mirena
IR  - Baraia-Etxaburu JM
FIR - Ibarra, Sofía
IR  - Ibarra S
FIR - Ferrero, Oscar Luis
IR  - Ferrero OL
FIR - López de Munain, Josefina
IR  - López de Munain J
FIR - Cámara, Mª Mar
IR  - Cámara MM
FIR - de la Peña, Mireia
IR  - de la Peña M
FIR - Lopez, Miriam
IR  - Lopez M
FIR - López Azkarreta, Iñigo
IR  - López Azkarreta I
FIR - Galera, Carlos
IR  - Galera C
FIR - Albendin, Helena
IR  - Albendin H
FIR - Pérez, Aurora
IR  - Pérez A
FIR - Iborra, Asunción
IR  - Iborra A
FIR - Moreno, Antonio
IR  - Moreno A
FIR - Merlos, Maria Angustias
IR  - Merlos MA
FIR - Vidal, Asunción
IR  - Vidal A
FIR - Meca, Marisa
IR  - Meca M
FIR - Pasquau, Francisco
IR  - Pasquau F
FIR - Ena, Javier
IR  - Ena J
FIR - Benito, Concha
IR  - Benito C
FIR - Fenoll, Vicenta
IR  - Fenoll V
FIR - Gil Anguita, Concepción
IR  - Gil Anguita C
FIR - Algado, José Tomás
IR  - Algado JT
FIR - Malmierca, Eduardo
IR  - Malmierca E
FIR - González-Ruano, Patricia
IR  - González-Ruano P
FIR - Martín Rodrigo, Dolores
IR  - Martín Rodrigo D
FIR - Ruiz Seco, Mª Pilar
IR  - Ruiz Seco MP
FIR - Omar, Mohamed
IR  - Omar M
FIR - Gómez Vidal, María Amparo
IR  - Gómez Vidal MA
FIR - de Zarraga, Miguel Alberto
IR  - de Zarraga MA
FIR - Estrada, Vicente
IR  - Estrada V
FIR - Téllez, Maria Jesús
IR  - Téllez MJ
FIR - Vergas, Jorge
IR  - Vergas J
FIR - Pérez-Somarriba, Juncal
IR  - Pérez-Somarriba J
FIR - Górgolas, Miguel
IR  - Górgolas M
FIR - Cabello, Alfonso
IR  - Cabello A
FIR - Álvarez, Beatriz
IR  - Álvarez B
FIR - Prieto, Laura
IR  - Prieto L
FIR - Sanz Moreno, José
IR  - Sanz Moreno J
FIR - Arranz, Alberto
IR  - Arranz A
FIR - Hernández Gutiérrez, Cristina
IR  - Hernández Gutiérrez C
FIR - Galindo, María José
IR  - Galindo MJ
FIR - Vilalta, Ramón Fernando
IR  - Vilalta RF
FIR - Ferrer, Ana
IR  - Ferrer A
FIR - Rivero Román, Antonio
IR  - Rivero Román A
FIR - Rivero Juárez, Antonio
IR  - Rivero Juárez A
FIR - López, Pedro
IR  - López P
FIR - Machuca, Isabel
IR  - Machuca I
FIR - Frias, Mario
IR  - Frias M
FIR - Camacho, Angela
IR  - Camacho A
FIR - Cervero, Miguel
IR  - Cervero M
FIR - Torres, Rafael
IR  - Torres R
FIR - Pineda, Juan A
IR  - Pineda JA
FIR - Rincón, Pilar
IR  - Rincón P
FIR - Macías, Juan
IR  - Macías J
FIR - Merchante, Nicolás
IR  - Merchante N
FIR - Real, Luis Miguel
IR  - Real LM
FIR - Corma Gomez, Anais
IR  - Corma Gomez A
FIR - Fernández Fuertes, Marta
IR  - Fernández Fuertes M
FIR - Gonzalez-Serna, Alejandro
IR  - Gonzalez-Serna A
FIR - Poveda, Eva
IR  - Poveda E
FIR - Pérez, Alexandre
IR  - Pérez A
FIR - Crespo, Manuel
IR  - Crespo M
FIR - Morano, Luis
IR  - Morano L
FIR - Miralles, Celia
IR  - Miralles C
FIR - Ocampo, Antonio
IR  - Ocampo A
FIR - Pousada, Guillermo
IR  - Pousada G
EDAT- 2021/07/30 06:00
MHDA- 2021/09/24 06:00
CRDT- 2021/07/29 17:43
PHST- 2021/05/19 00:00 [received]
PHST- 2021/06/28 00:00 [accepted]
PHST- 2021/07/30 06:00 [pubmed]
PHST- 2021/09/24 06:00 [medline]
PHST- 2021/07/29 17:43 [entrez]
AID - HIV13145 [pii]
AID - 10.1111/hiv.13145 [doi]
PST - ppublish
SO  - HIV Med. 2021 Oct;22(9):867-876. doi: 10.1111/hiv.13145. Epub 2021 Jul 29.

PMID- 33630465
OWN - NLM
STAT- Publisher
LR  - 20210430
IS  - 1528-1140 (Electronic)
IS  - 0003-4932 (Linking)
DP  - 2020 Dec 29
TI  - Prophylactic Mesh Reinforcement for Prevention of Midline Incisional Hernias: A 
      Publication Bias Adjusted Meta-analysis.
LID - 10.1097/SLA.0000000000004729 [doi]
AB  - OBJECTIVE: To systematically review the published literature on the use of 
      prophylactic mesh reinforcement of midline laparotomy closures for prevention of 
      ventral incisional hernias (VIH) SUMMARY BACKGROUND DATA:: VIH are common 
      complications of abdominal surgery. Prophylactic mesh has been proposed as an 
      adjunct to prevent their occurrence. METHODS: PubMed, Embase, Scopus and Cochrane 
      were reviewed for randomized controlled trials (RCTs) that compared prophylactic 
      mesh reinforcement versus conventional suture closure of midline abdominal surgery. 
      Primary outcome was the incidence of VIH at post-operative follow-up ≥24 months. 
      Secondary outcomes included surgical site infection (SSI) and surgical site 
      occurrence (SSO). Pooled risk ratios were obtained through random effect 
      meta-analyses and adjusted for publication bias. Network meta-analyses were 
      performed to compare mesh types and locations. RESULTS: Of 1969 screened articles, 
      twelve RCTs were included. On meta-analysis there was a lower incidence of VIH with 
      prophylactic mesh (11.1%vs21.3%, RR = 0.32; 95%CI = 0.19-0.55, P < 0.001) however 
      publication bias was highly likely. When adjusted for this bias, prophylactic mesh 
      had a more conservative effect (RR = 0.52; 95%CI = 0.39-0.70). There was no 
      difference in risk of SSI (9.1%vs8.9%, RR = 1.08, 95%CI = 0.82-1.43; P = 0.118), 
      however, prophylactic mesh increased the risk of SSO (14.2%vs8.9%, RR = 1.57, 95%CI 
      = 1.19-2.05; P < 0.001). CONCLUSION: Current RCTs suggest that in mid-term follow-up 
      prophylactic mesh prevents VIH with increased risk for SSO. There is limited 
      long-term data and substantial publication bias.
FAU - Olavarria, Oscar A
AU  - Olavarria OA
AD  - *Department of Surgery, Lyndon B. Johnson General Hospital, McGovern Medical School 
      at UTHealth, (Houston, TX) †Center for Surgical Trials and Evidence-Based Practice, 
      McGovern Medical School at UTHealth, (Houston, TX) ‡Department of Pediatrics, 
      McGovern Medical School at UTHealth, (Houston, TX) §Center for Clinical Research and 
      Evidence Based Medicine, McGovern Medical School at UTHealth, (Houston, TX).
FAU - Dhanani, Naila H
AU  - Dhanani NH
FAU - Bernardi, Karla
AU  - Bernardi K
FAU - Holihan, Julie L
AU  - Holihan JL
FAU - Bell, Cynthia S
AU  - Bell CS
FAU - Ko, Tien C
AU  - Ko TC
FAU - Liang, Mike K
AU  - Liang MK
LA  - eng
PT  - Journal Article
DEP - 20201229
PL  - United States
TA  - Ann Surg
JT  - Annals of surgery
JID - 0372354
SB  - IM
EDAT- 2021/02/26 06:00
MHDA- 2021/02/26 06:00
CRDT- 2021/02/25 13:46
PHST- 2021/02/25 13:46 [entrez]
PHST- 2021/02/26 06:00 [pubmed]
PHST- 2021/02/26 06:00 [medline]
AID - 10.1097/SLA.0000000000004729 [doi]
PST - aheadofprint
SO  - Ann Surg. 2020 Dec 29. doi: 10.1097/SLA.0000000000004729.

PMID- 32869457
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210204
IS  - 1758-2652 (Electronic)
IS  - 1758-2652 (Linking)
VI  - 23 Suppl 5
IP  - Suppl 5
DP  - 2020 Sep
TI  - Young people are experts and leaders in the HIV response.
PG  - e25569
LID - 10.1002/jia2.25569 [doi]
LID - e25569
FAU - Rufurwadzo, Tinashe G
AU  - Rufurwadzo TG
AUID- ORCID: 0000-0002-6392-7204
AD  - Global Network of Young People Living with HIV (Y+ Global), Harare, Zimbabwe.
FAU - Inarukundo, Audrey
AU  - Inarukundo A
AUID- ORCID: 0000-0003-2973-8714
AD  - Réseau National des Jeunes Vivant avec le VIH (RNJ+), Bujumbura, Burundi.
FAU - Noviyanti, Ikka
AU  - Noviyanti I
AUID- ORCID: 0000-0003-2756-9478
AD  - Youth LEAD Asia Pacific Network of Young Key Populations, Bangkok, Thailand.
FAU - Subero, Miguel A
AU  - Subero MA
AUID- ORCID: 0000-0002-1441-8868
AD  - Regional Network of Youth living with HIV, Latin America and the Caribbean (J+LAC), 
      México City, Mexico.
LA  - eng
PT  - Journal Article
TA  - J Int AIDS Soc
JT  - Journal of the International AIDS Society
JID - 101478566
SB  - IM
PMC - PMC7459163
OTO - NOTNLM
OT  - *HIV
OT  - *adolescents
OT  - *advocacy
OT  - *leadership
OT  - *peer support
OT  - *sexual and reproductive health and rights
OT  - *young people
EDAT- 2020/09/02 06:00
MHDA- 2020/09/02 06:01
CRDT- 2020/09/02 06:00
PHST- 2020/06/07 00:00 [received]
PHST- 2020/06/14 00:00 [accepted]
PHST- 2020/09/02 06:00 [entrez]
PHST- 2020/09/02 06:00 [pubmed]
PHST- 2020/09/02 06:01 [medline]
AID - JIA225569 [pii]
AID - 10.1002/jia2.25569 [doi]
PST - ppublish
SO  - J Int AIDS Soc. 2020 Sep;23 Suppl 5(Suppl 5):e25569. doi: 10.1002/jia2.25569.

PMID- 33714539
OWN - NLM
STAT- MEDLINE
DCOM- 20210414
LR  - 20210414
IS  - 1769-6917 (Electronic)
IS  - 0007-4551 (Linking)
VI  - 108
IP  - 4
DP  - 2021 Apr
TI  - [Survey on HIV, HBV and HCV screening practices in cancerology, France].
PG  - 369-376
LID - S0007-4551(21)00045-X [pii]
LID - 10.1016/j.bulcan.2020.11.019 [doi]
AB  - HIV testing is recommended at time of cancer diagnosis, HBV and HCV screening 
      because of the risk of reactivation with certain anticancer drugs.This is a 
      cross-sectional study. The objectives were to assess the screening practices in 
      cancer patients and the satisfaction of professionals in the event of use of the 
      CancerHIV network. A questionnaire drafted by the CancerHIV expert and the 
      OncoPaca-Corse Regional Cancer Network (RCN) was distributed in the region at the 
      end of 2018 (part 1: V1) before being extended to the national level via the 
      CancerHIV network (part 2: V2). Participation reached 160 and 130 respondents (V1 
      and V2, respectively). At the initial cancer assessment, 23% of respondents declared 
      that they systematically screened for HIV at V1 (V2: 17%), 25% for HBV (V2: 20%) and 
      24% for HCV (V2: 19%). Before immunotherapy, the rates were 54% for HIV in V1 (V2: 
      52%), 57% for HBV (V2: 60%) and 55% for HCV (V2: 57%). Among the respondents, 
      satisfaction when requesting a regional or national remedy was high (almost 100%). 
      Screening for HIV, HBV and HCV allows supervised prescription of immunosuppressive 
      or cytotoxic treatment to a potentially immunosuppressed patient. This study, 
      resulting of an original collaboration between a RCN and a national expert network, 
      underlines the lack of screening at the 2 examined stages of patient care, and the 
      need for raising practitioners' awareness to recommendations.
CI  - Copyright © 2021 Société Française du Cancer. Published by Elsevier Masson SAS. All 
      rights reserved.
FAU - Taouqi, Myriam
AU  - Taouqi M
AD  - Réseau régional de cancérologie Oncopaca-Corse, 270, boulevard de Sainte-Marguerite, 
      13009 Marseille, France.
FAU - Veyri, Marianne
AU  - Veyri M
AD  - Sorbonne Université, Inserm, institut Pierre Louis d'épidémiologie et de Santé 
      Publique (iPLESP), AP-HP, hôpital Pitié-Salpêtrière, service d'oncologie médicale, 
      47-83, boulevard de l'Hôpital, 75013 Paris, France.
FAU - Brégigeon, Sylvie
AU  - Brégigeon S
AD  - Aix-Marseille Université, AP-HM, hôpital Sainte-Marguerite, Service 
      d'immuno-hématologie clinique, 270, boulevard de Sainte-Marguerite, 13009 Marseille, 
      France.
FAU - Pibarot, Michèle
AU  - Pibarot M
AD  - Réseau régional de cancérologie Oncopaca-Corse, 270, boulevard de Sainte-Marguerite, 
      13009 Marseille, France.
FAU - Solas, Caroline
AU  - Solas C
AD  - Aix-Marseille Université, AP-HM, Inserm, CRCM, SMARTc, hôpital La Timone, 
      laboratoire de pharmacocinétique et toxicologie, 264, rue Saint-Pierre 13385 
      Marseille, France.
FAU - Makinson, Alain
AU  - Makinson A
AD  - Inserm U1175, département des maladies infectieuses et tropicales, CHU de 
      Montpellier, Université de Montpellier, 191, avenue du Doyen Giraud, 34295 
      Montpellier cedex 5, France.
FAU - Marcelin, Anne-Geneviève
AU  - Marcelin AG
AD  - Sorbonne Université, Inserm, institut Pierre Louis d'épidémiologie et de Santé 
      Publique (iPLESP), AP-HP, hôpital Pitié-Salpêtrière, service de virologie, 47-83, 
      boulevard de l'Hôpital, 75013 Paris, France.
FAU - Choquet, Sylvain
AU  - Choquet S
AD  - Service d'hématologie clinique, hôpitaux universitaires Pitié-Salpêtrière-C. Foix, 
      AP-HP, 47-83, boulevard de l'hôpital, 75013 Paris, France.
FAU - Spano, Jean-Philippe
AU  - Spano JP
AD  - Sorbonne Université, Inserm, institut Pierre Louis d'épidémiologie et de Santé 
      Publique (iPLESP), AP-HP, hôpital Pitié-Salpêtrière, service d'oncologie médicale, 
      47-83, boulevard de l'Hôpital, 75013 Paris, France.
FAU - Poizot-Martin, Isabelle
AU  - Poizot-Martin I
AD  - Aix-Marseille Université, AP-HM, Inserm, IRD, SESSTIM (sciences économiques & 
      sociales de la santé & traitement de l'information médicale), hôpital 
      Sainte-Marguerite, service d'immuno-hématologie clinique, 270, boulevard de 
      Sainte-Marguerite, 13009 Marseille, France. Electronic address: 
      Isabelle.Poizot@ap-hm.fr.
LA  - fre
PT  - Journal Article
TT  - Enquête sur la pratique du dépistage du VIH, VHB et VHC en cancérologie, France.
DEP - 20210310
PL  - France
TA  - Bull Cancer
JT  - Bulletin du cancer
JID - 0072416
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Antineoplastic Agents/adverse effects/pharmacology
MH  - Cross-Sectional Studies
MH  - Female
MH  - France/epidemiology
MH  - HIV/physiology
MH  - HIV Infections/complications/*diagnosis/epidemiology
MH  - Hepacivirus/physiology
MH  - Hepatitis B/complications/*diagnosis/epidemiology
MH  - Hepatitis B virus/physiology
MH  - Hepatitis C/complications/*diagnosis/epidemiology
MH  - Humans
MH  - Immunotherapy/adverse effects
MH  - Male
MH  - Mass Screening/*methods/statistics & numerical data
MH  - Neoplasms/*complications/therapy
MH  - Surveys and Questionnaires
MH  - Virus Activation/drug effects/immunology
OTO - NOTNLM
OT  - Cancer
OT  - Dépistage
OT  - HBV
OT  - HCV
OT  - HIV
OT  - Screening
OT  - VHB
OT  - VHC
OT  - VIH
EDAT- 2021/03/15 06:00
MHDA- 2021/04/15 06:00
CRDT- 2021/03/14 20:33
PHST- 2020/08/26 00:00 [received]
PHST- 2020/11/05 00:00 [revised]
PHST- 2020/11/16 00:00 [accepted]
PHST- 2021/03/15 06:00 [pubmed]
PHST- 2021/04/15 06:00 [medline]
PHST- 2021/03/14 20:33 [entrez]
AID - S0007-4551(21)00045-X [pii]
AID - 10.1016/j.bulcan.2020.11.019 [doi]
PST - ppublish
SO  - Bull Cancer. 2021 Apr;108(4):369-376. doi: 10.1016/j.bulcan.2020.11.019. Epub 2021 
      Mar 10.

PMID- 29910148
OWN - NLM
STAT- MEDLINE
DCOM- 20201022
LR  - 20210521
IS  - 2529-993X (Electronic)
IS  - 2529-993X (Linking)
VI  - 37
IP  - 10
DP  - 2019 Dec
TI  - HIV pre-exposure prophylaxis (PrEP) in Spain: political and administrative 
      situation.
PG  - 656-660
LID - S0213-005X(18)30199-X [pii]
LID - 10.1016/j.eimc.2018.05.012 [doi]
AB  - This study focuses on actions at the political and administrative level in Spain in 
      relation to the implementation of pre-exposure prophylaxis (PrEP). We analysed a 
      whole range of different formal initiatives taken by the political and 
      administrative actors involved. The information was obtained from official public 
      data sources. As of February 2018, PrEP had not been implemented. The decision is 
      dependent on both state and regional governments. The Ministry of Health and some 
      Autonomous Regions are working on different interventions, but without providing an 
      implementation timetable. The political parties have kept a very low profile in 
      terms of initiatives related to the implementation of PrEP. From a legal point of 
      view, proceedings are passing back and forth with the extension of the patent. The 
      role of intergovernmental and interdepartmental institutions is very important for 
      the implementation of PrEP in Spain.
CI  - Copyright © 2018 Elsevier España, S.L.U. and Sociedad Española de Enfermedades 
      Infecciosas y Microbiología Clínica. All rights reserved.
FAU - García, Luis Miguel
AU  - García LM
AD  - Centro Nacional de Epidemiología, Instituto de Salud Carlos III, Madrid, España; 
      Spanish Network of Excellence on HIV Research, RIS, España. Electronic address: 
      lmgarcia@isciii.es.
FAU - Iniesta, Carlos
AU  - Iniesta C
AD  - Centro Nacional de Epidemiología, Instituto de Salud Carlos III, Madrid, España; 
      Spanish Network of Excellence on HIV Research, RIS, España.
FAU - Garrido, Jorge
AU  - Garrido J
AD  - Apoyo Positivo, Madrid, España.
FAU - Fuster, María José
AU  - Fuster MJ
AD  - Spanish Network of Excellence on HIV Research, RIS, España; SEISIDA, Madrid, España.
FAU - Pujol, Ferran
AU  - Pujol F
AD  - BCN CheckPoint, Barcelona, España.
FAU - Meulbroek, Michael
AU  - Meulbroek M
AD  - BCN CheckPoint, Barcelona, España.
FAU - Poveda, Toni
AU  - Poveda T
AD  - CESIDA, Madrid, España.
FAU - Riera, Melchor
AU  - Riera M
AD  - Spanish Network of Excellence on HIV Research, RIS, España; Servicio de Medicina 
      Interna-Infecciosas, Hospital Son Espases, Palma de Mallorca, España.
FAU - Antela, Antonio
AU  - Antela A
AD  - Spanish Network of Excellence on HIV Research, RIS, España; Unidad de Enfermedades 
      Infecciosas, Hospital Clínico Universitario, Santiago de Compostela, España.
FAU - Moreno, Santiago
AU  - Moreno S
AD  - Spanish Network of Excellence on HIV Research, RIS, España; Servicio de Enfermedades 
      Infecciosas, Hospital Ramón y Cajal, Madrid, España; GeSIDA, Madrid, España.
FAU - Dalmau, David
AU  - Dalmau D
AD  - Spanish Network of Excellence on HIV Research, RIS, España; SEISIDA, Madrid, España; 
      Grupo de Investigación VIH+/SIDA, Hospital Universitario Mútua Terrassa, Terrassa, 
      España.
FAU - Rivero, Antonio
AU  - Rivero A
AD  - Spanish Network of Excellence on HIV Research, RIS, España; Unidad de Gestión 
      Clínica de Enfermedades Infecciosas, Hospital Universitario Reina Sofía, Córdoba, 
      España; GeSIDA, Madrid, España.
FAU - García, Diego
AU  - García D
AD  - Adhara, Sevilla, España.
FAU - Espacio, Ramón
AU  - Espacio R
AD  - CESIDA, Madrid, España.
FAU - Del Amo, Julia
AU  - Del Amo J
AD  - Centro Nacional de Epidemiología, Instituto de Salud Carlos III, Madrid, España; 
      Spanish Network of Excellence on HIV Research, RIS, España; SEISIDA, Madrid, España.
LA  - eng
LA  - spa
PT  - Journal Article
TT  - Profilaxis preexposición al VIH en España: situación política y administrativa.
DEP - 20180615
PL  - Spain
TA  - Enferm Infecc Microbiol Clin (Engl Ed)
JT  - Enfermedades infecciosas y microbiologia clinica (English ed.)
JID - 101777541
SB  - IM
MH  - *Government
MH  - HIV Infections/*prevention & control
MH  - Humans
MH  - Pre-Exposure Prophylaxis/*organization & administration
MH  - Spain
OTO - NOTNLM
OT  - Elaboración de políticas
OT  - Policy-making
OT  - Politics
OT  - Política pública
OT  - Políticas
OT  - Pre-exposure prophylaxis
OT  - Profilaxis preexposición
OT  - Public policy
EDAT- 2018/06/19 06:00
MHDA- 2020/10/23 06:00
CRDT- 2018/06/19 06:00
PHST- 2018/04/19 00:00 [received]
PHST- 2018/05/07 00:00 [revised]
PHST- 2018/05/08 00:00 [accepted]
PHST- 2018/06/19 06:00 [pubmed]
PHST- 2020/10/23 06:00 [medline]
PHST- 2018/06/19 06:00 [entrez]
AID - S0213-005X(18)30199-X [pii]
AID - 10.1016/j.eimc.2018.05.012 [doi]
PST - ppublish
SO  - Enferm Infecc Microbiol Clin (Engl Ed). 2019 Dec;37(10):656-660. doi: 
      10.1016/j.eimc.2018.05.012. Epub 2018 Jun 15.

PMID- 26035011
OWN - NLM
STAT- MEDLINE
DCOM- 20160222
LR  - 20160511
IS  - 1947-5543 (Electronic)
IS  - 1947-5543 (Linking)
VI  - 13
IP  - 3
DP  - 2015 Jun
TI  - Specific legislation on biobanks in Spain.
PG  - 207-11
LID - 10.1089/bio.2014.0070 [doi]
AB  - Spain has enacted specific legislation concerning biobanks. This legislation 
      regulates how biobanks should be set up, how they should operate, and the 
      requirements they need to comply with. The main objective of this legislation is to 
      keep a good balance between scientific progress and respect for the rights and 
      freedom of individuals participating in research. Therefore, this legislation lays 
      down a series of basic principles, for instance, the principle to inform donors 
      accurately i) on the deposit of samples in terms of the objectives and implications 
      of their donation and on the need to obtain written consents; ii) on the obligation 
      to establish consistent procedures to guarantee the confidentiality of personal data 
      associated with and obtained from biological samples; iii) on the concept of free 
      sample donation either by donors or by biobanks; iv) on the need for consistent 
      procedures to deposit samples and data in biobanks; and v) for acts of donation and 
      data for research projects to be performed correctly. Although this Spanish 
      legislation fulfills its objectives, it has some drawbacks; mainly it overprotects 
      research participants. This issue should be analyzed in future revisions of the 
      legislation.
FAU - García-Merino, Isabel Ma
AU  - García-Merino IM
AD  - Hospital General Universitario Gregorio Marañón. BioBanco VIH HGM, Plataforma de 
      Laboratorio. Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain. 
      Networking Research Center on Bioengineering, Biomaterials and Nanomedicine 
      (CIBER-BBN), Madrid, Spain.
FAU - Consuegra, Irene
AU  - Consuegra I
AD  - Hospital General Universitario Gregorio Marañón. BioBanco VIH HGM, Plataforma de 
      Laboratorio. Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain. 
      Networking Research Center on Bioengineering, Biomaterials and Nanomedicine 
      (CIBER-BBN), Madrid, Spain.
FAU - Jiménez, José Luís
AU  - Jiménez JL
AD  - Hospital General Universitario Gregorio Marañón. BioBanco VIH HGM, Plataforma de 
      Laboratorio. Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain. 
      Networking Research Center on Bioengineering, Biomaterials and Nanomedicine 
      (CIBER-BBN), Madrid, Spain.
FAU - Muñoz-Fernández, Ma Ángeles
AU  - Muñoz-Fernández MÁ
AD  - Hospital General Universitario Gregorio Marañón. BioBanco VIH HGM, Plataforma de 
      Laboratorio. Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain. 
      Networking Research Center on Bioengineering, Biomaterials and Nanomedicine 
      (CIBER-BBN), Madrid, Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Biopreserv Biobank
JT  - Biopreservation and biobanking
JID - 101507284
SB  - IM
MH  - Biological Specimen Banks/*legislation & jurisprudence
MH  - Humans
MH  - Informed Consent
MH  - *Legislation as Topic
MH  - Spain
MH  - Tissue Donors
EDAT- 2015/06/04 06:00
MHDA- 2016/02/24 06:00
CRDT- 2015/06/03 06:00
PHST- 2015/06/03 06:00 [entrez]
PHST- 2015/06/04 06:00 [pubmed]
PHST- 2016/02/24 06:00 [medline]
AID - 10.1089/bio.2014.0070 [doi]
PST - ppublish
SO  - Biopreserv Biobank. 2015 Jun;13(3):207-11. doi: 10.1089/bio.2014.0070.

PMID- 33735910
OWN - NLM
STAT- MEDLINE
DCOM- 20220113
LR  - 20220113
IS  - 1698-6997 (Electronic)
IS  - 1139-6121 (Linking)
VI  - 23
IP  - 4
DP  - 2021 Dec 29
TI  - A Systematic Review of Magnetic Resonance Imaging Studies in Perinatally 
      HIV-Infected Individuals.
PG  - 167-185
LID - 10.24875/AIDSRev.20000088 [doi]
AB  - Over the past few years, neuroimaging studies have been performed in young adults 
      with perinatally acquired HIV (PHIV) to study the impact of HIV infection on the 
      central nervous system (CNS), but no recent review have been published. This review 
      aims to identify brain areas where PHIV eems to have greater impact taking into 
      account demographic, behavioral, and clinical characteristics in PHIV infected 
      patients. For this purpose, PubMed and Medline searches were carried out which 
      included studies from 2010 to April 2020. We performed a systematic review and 
      included 26 articles using structural (brain morphometry and diffusion tensor 
      imaging) and functional magnetic resonance imaging methods involving 1182 
      PHIV-infected participants. Ample evidence has been provided of HIV effects on 
      underlying brain structure. However, information recorded in the studies is commonly 
      incomplete and results sometimes contradictory. In addition to future improvements 
      and dissemination of tools for the developing brain MRI processing and analysis, the 
      inclusion of data related to HIV infection itself (including clinical and 
      immunovirological characteristics as well as detailed information about 
      antiretroviral treatment such as age at ART initiation) may be of vital importance 
      to the better understanding of the impact of the disease on CNS.
FAU - Martín-Bejarano, Manuela
AU  - Martín-Bejarano M
AD  - Department of Paediatrics, Fundación de Investigación Biomédica Hospital Clínico San 
      Carlos, Cohorte Nacional de VIH pediátrica de la RED RIS (CoRISpe), Madrid, Spain.
FAU - Ruiz-Saez, Beatriz
AU  - Ruiz-Saez B
AD  - Molecular Immunobiology Laboratory, HIV Spanish Biobank, Hospital Gregorio Marañón, 
      Madrid, Spain.
FAU - Martinez-de-Aragón, Ana
AU  - Martinez-de-Aragón A
AD  - Radiology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
FAU - Melero, Helena
AU  - Melero H
AD  - Laboratorio de Análisis de Imagen Médica y Biometría (LAIMBIO), Universidad Rey Juan 
      Carlos, Madrid, Spain.
FAU - Zamora, Berta
AU  - Zamora B
AD  - Paediatric Neuropsychology Department, Hospital Universitario 12 De Octubre, Madrid, 
      Spain.
FAU - Malpica, Norberto A
AU  - Malpica NA
AD  - Laboratorio de Análisis de Imagen Médica y Biometría (LAIMBIO), Universidad Rey Juan 
      Carlos, Madrid, Spain.
FAU - Ramos, Jose T
AU  - Ramos JT
AD  - Paediatric Infectious Diseases Department, Hospital Clínico San Carlos and 
      Translational Research Network in Pediatric Infectious Diseases (RITIP), Madrid, 
      Spain.
FAU - Gonzalez-Tomé, Maria I
AU  - Gonzalez-Tomé MI
AD  - Paediatric Infectious Diseases Department, Hospital Universitario 12 De Octubre and 
      NeuroCoRISpe Project, included in CoRIspe (Spanish National Cohort of Paediatric 
      HIV), Madrid, Spain.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20211229
PL  - Spain
TA  - AIDS Rev
JT  - AIDS reviews
JID - 101134876
RN  - 0 (Anti-Retroviral Agents)
SB  - IM
MH  - Anti-Retroviral Agents/therapeutic use
MH  - Brain/diagnostic imaging
MH  - Diffusion Tensor Imaging
MH  - *HIV Infections/drug therapy
MH  - Humans
MH  - Infectious Disease Transmission, Vertical
MH  - Magnetic Resonance Imaging
MH  - Young Adult
OTO - NOTNLM
OT  - *HIV/AIDS
OT  - *Perinatal.
OT  - *Young adults
OT  - *Magnetic resonance imaging
OT  - *Neuroimaging
EDAT- 2021/03/19 06:00
MHDA- 2022/01/14 06:00
CRDT- 2021/03/18 20:28
PHST- 2021/03/18 20:28 [entrez]
PHST- 2021/03/19 06:00 [pubmed]
PHST- 2022/01/14 06:00 [medline]
AID - 10.24875/AIDSRev.20000088 [doi]
PST - epublish
SO  - AIDS Rev. 2021 Dec 29;23(4):167-185. doi: 10.24875/AIDSRev.20000088.

PMID- 24274101
OWN - NLM
STAT- MEDLINE
DCOM- 20140212
LR  - 20211021
IS  - 1471-2458 (Electronic)
IS  - 1471-2458 (Linking)
VI  - 13
DP  - 2013 Nov 25
TI  - Gonorrhoea diagnoses in a network of STI clinics in Spain during the period 
      2006-2010: differences by sex and transmission route.
PG  - 1093
LID - 10.1186/1471-2458-13-1093 [doi]
AB  - BACKGROUND: Gonorrhoea infection is one of the most common bacterial sexually 
      transmitted infections and an important cause of morbidity and serious 
      complications. The objectives of this paper are: a) to describe gonorrhoea cases 
      diagnosed in a network of 15 (out of 16) STI clinics in Spain during 2006-2010; b) 
      to analyse differences among men who have sex with men (MSM), men who have sex 
      exclusively with women (MSW) and women; and c) to evaluate factors associated to 
      with HIV co-infection. METHODS: All gonorrhoea cases diagnosed in the network were 
      included (25.7% of total cases notified in Spain). Data were collected by clinical 
      staff. Descriptive/bivariate analyses were carried out stratifying by sex and 
      transmission category; association and trends were evaluated using the chi-square 
      test. Factors associated with HIV co-infection were estimated using a logistic 
      regression model. RESULTS: 2385 cases were included: 55.3% among MSM, 31.3% among 
      MSW and 13.3% among females; cases among MSM increased from 55.8% in 2006 to 62.9% 
      in 2010 while no trends were found among the other two groups.Most MSM cases were 
      Spaniards (72%), aged 25-34 years (46%), 49% reported previous STI and 25% 
      concurrent STI (excluding HIV); casual partners were the commonest source of 
      infection, and 21% of cases had rectal gonorrhoea. MSW cases did not differ from MSM 
      by age, origin or source of infection, but frequencies of prior or concurrent STI 
      were lower. Female cases were younger than male, were mostly foreigners (58%), and 
      41% were sex workers; concurrent STI (other than HIV) were diagnosed in 30%; 20.4% 
      had symptoms (72.5% and 89.2% in MSM and MSW), and pharyngeal location was present 
      in 30%.HIV co-infection was highest in MSM (20.9%). Co-infection was associated with 
      age > 35 years, low educational level, being Western European or Latin-American, 
      being MSM, having previous or concurrent STI and reporting contact with an 
      HIV-infected partner; it was inversely associated with female sex. CONCLUSION: 
      Differences by sex, transmission route and origin should be considered when 
      implementing care and preventive programmes for gonorrhoea, and MSM are a priority 
      group for intervention, in particular HIV-infected MSM.
FAU - Diaz, Asuncion
AU  - Diaz A
AD  - Instituto de Salud Carlos III, Área de Epidemiología del VIH y comportamientos de 
      riesgo, Centro Nacional de Epidemiologia, C/ Monforte de Lemos, 5, 28029 Madrid, 
      Spain. adiaz@isciii.es.
FAU - Garriga, Cesar
AU  - Garriga C
FAU - Varela, Jose Antonio
AU  - Varela JA
FAU - Fernández, Elisa
AU  - Fernández E
FAU - Sanz, Isabel
AU  - Sanz I
FAU - Boronat, Josep
AU  - Boronat J
FAU - Gual, Fuensanta
AU  - Gual F
FAU - Colomo, Concepcion
AU  - Colomo C
FAU - López de Munain, Josefina
AU  - López de Munain J
FAU - Esteban, Valentin
AU  - Esteban V
FAU - Junquera, Maria Luisa
AU  - Junquera ML
FAU - Martínez, Blanca
AU  - Martínez B
FAU - Pueyo, Isabel
AU  - Pueyo I
FAU - Suárez, Justo
AU  - Suárez J
FAU - Barberá, Maria Jesus
AU  - Barberá MJ
FAU - Arando, Maider
AU  - Arando M
FAU - Ureña, Jose Manuel
AU  - Ureña JM
FAU - Diez, Mercedes
AU  - Diez M
CN  - STI Study Group
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131125
TA  - BMC Public Health
JT  - BMC public health
JID - 100968562
SB  - IM
MH  - Adult
MH  - Coinfection
MH  - Female
MH  - Gonorrhea/*diagnosis/transmission
MH  - HIV Infections/complications
MH  - Health Facilities/*statistics & numerical data
MH  - Heterosexuality/statistics & numerical data
MH  - Homosexuality, Male/statistics & numerical data
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Risk Factors
MH  - Sex Factors
MH  - Spain
MH  - Young Adult
PMC - PMC4222879
FIR - Diaz, A
IR  - Diaz A
FIR - Diez, M
IR  - Diez M
FIR - Garriga, C
IR  - Garriga C
FIR - Suarez, J
IR  - Suarez J
FIR - Ureña, J M
IR  - Ureña JM
FIR - Castro, E
IR  - Castro E
FIR - Benavides, V
IR  - Benavides V
FIR - Gómez, M
IR  - Gómez M
FIR - Martínez, B
IR  - Martínez B
FIR - García, M A
IR  - García MA
FIR - Godoy, L
IR  - Godoy L
FIR - Pueyo, I
IR  - Pueyo I
FIR - Ruiz, E
IR  - Ruiz E
FIR - Redondo, C
IR  - Redondo C
FIR - Martinez, C
IR  - Martinez C
FIR - Sánchez, D
IR  - Sánchez D
FIR - Varela, J A
IR  - Varela JA
FIR - López, C
IR  - López C
FIR - Otero, L
IR  - Otero L
FIR - Junquera, M L
IR  - Junquera ML
FIR - Cuesta, M
IR  - Cuesta M
FIR - Vázquez, F
IR  - Vázquez F
FIR - Carreño, F
IR  - Carreño F
FIR - Gil, L
IR  - Gil L
FIR - Barberá, M J
IR  - Barberá MJ
FIR - Arellano, E
IR  - Arellano E
FIR - Saladié, P
IR  - Saladié P
FIR - Armengol, P
IR  - Armengol P
FIR - Arando, M
IR  - Arando M
FIR - Vall, M
IR  - Vall M
FIR - Gosch, M
IR  - Gosch M
FIR - Álvarez, M A
IR  - Álvarez MA
FIR - Vives, A
IR  - Vives A
FIR - Oliveira, I
IR  - Oliveira I
FIR - Euba, G
IR  - Euba G
FIR - Börjesson, S
IR  - Börjesson S
FIR - Boronat, J
IR  - Boronat J
FIR - Bru, F J
IR  - Bru FJ
FIR - Colomo, C
IR  - Colomo C
FIR - Comunión, A
IR  - Comunión A
FIR - Martín, R
IR  - Martín R
FIR - Marinero, S
IR  - Marinero S
FIR - del Romero, J
IR  - del Romero J
FIR - Puerta, T
IR  - Puerta T
FIR - Rodríguez, C
IR  - Rodríguez C
FIR - Vera, M
IR  - Vera M
FIR - Menéndez, B
IR  - Menéndez B
FIR - Ballesteros, J
IR  - Ballesteros J
FIR - Clavo, P
IR  - Clavo P
FIR - Belda, J
IR  - Belda J
FIR - Fernández, E
IR  - Fernández E
FIR - Zafra, T
IR  - Zafra T
FIR - Colomina, S
IR  - Colomina S
FIR - Galán, E
IR  - Galán E
FIR - Gual, F
IR  - Gual F
FIR - Balagué, J
IR  - Balagué J
FIR - Cámara, M
IR  - Cámara M
FIR - López de Munain, J
IR  - López de Munain J
FIR - Aparicio, N
IR  - Aparicio N
FIR - Aizpuru, A
IR  - Aizpuru A
FIR - Basurto, H
IR  - Basurto H
FIR - Esteban, V
IR  - Esteban V
FIR - Cisterna, R
IR  - Cisterna R
FIR - Ezpeleta, G
IR  - Ezpeleta G
FIR - Álava, J A
IR  - Álava JA
FIR - Basurto, H
IR  - Basurto H
FIR - Sanz, I
IR  - Sanz I
FIR - Camino, X
IR  - Camino X
FIR - Gómez-Pintado, P
IR  - Gómez-Pintado P
EDAT- 2013/11/28 06:00
MHDA- 2014/02/13 06:00
CRDT- 2013/11/27 06:00
PHST- 2013/05/16 00:00 [received]
PHST- 2013/11/18 00:00 [accepted]
PHST- 2013/11/27 06:00 [entrez]
PHST- 2013/11/28 06:00 [pubmed]
PHST- 2014/02/13 06:00 [medline]
AID - 1471-2458-13-1093 [pii]
AID - 10.1186/1471-2458-13-1093 [doi]
PST - epublish
SO  - BMC Public Health. 2013 Nov 25;13:1093. doi: 10.1186/1471-2458-13-1093.

PMID- 34506362
OWN - NLM
STAT- MEDLINE
DCOM- 20211230
LR  - 20211230
IS  - 1944-7884 (Electronic)
IS  - 1525-4135 (Linking)
VI  - 88
IP  - 2
DP  - 2021 Oct 1
TI  - Performance Analysis of Three Commercial Kits Designed for RNA Quantification of 
      HIV-1 Group O Variants.
PG  - 220-227
LID - 10.1097/QAI.0000000000002753 [doi]
AB  - BACKGROUND: The genetic divergence of HIV-1 group O is high relative to pandemic 
      group M, which could impact detection and quantification of plasma RNA. Recent 
      commercial kits for RNA quantification seem to show good performances in HIV-1/O, 
      but discrepancies are still observed. Here, we compare the performances of 3 
      commercial assays for the RNA quantification of HIV-1/O. METHODS: We studied the RNA 
      quantification of 117 clinical samples using Abbott RealTime HIV-1, Cepheid Xpert 
      HIV-1 Viral Load, or Roche Cobas TaqMan HIV-1 v2. First, we conducted a qualitative 
      description, and second, we focused on a quantitative analysis of the results above 
      40 cp/mL. The degree of agreement between methods and the strength of the 
      correlation of viral load determination were estimated using Bland-Altman plot and 
      Passing-Bablok regression with the Spearman coefficient, respectively. RESULTS: Our 
      2-by-2 analysis showed that the Abbott and Cepheid assays were very close in terms 
      of correlation and dispersion of points, whereas Roche presented higher values in 
      the highest range of quantification (>5 log10). The Cepheid assay combined better 
      correlation with the consensus value and a lower dispersion of values, leading to an 
      overall better performance of quantification. The quantification was still impacted 
      by intragroup genetic diversity with, here, 1 strain (YBF26). CONCLUSIONS: Using a 
      new approach to compare the performances of RNA quantification between more than 2 
      techniques, we demonstrated that Cepheid could be the most suitable assay for 
      HIV-1/O quantification, although the results from all assays remained strain 
      dependent.
CI  - Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Alessandri-Gradt, Elodie
AU  - Alessandri-Gradt E
AD  - Normandie Univ, UNIROUEN, EA2656, GRAM 2.0, et CHU de Rouen, Laboratoire de 
      Virologie associé au CNR du VIH, Rouen, France; and.
FAU - Unal, Guillemette
AU  - Unal G
AD  - Normandie Univ, UNIROUEN, EA2656, GRAM 2.0, et CHU de Rouen, Laboratoire de 
      Virologie associé au CNR du VIH, Rouen, France; and.
FAU - Baron, Adeline
AU  - Baron A
AD  - CHU de Rouen, Laboratoire de Virologie associé au CNR du VIH, Rouen, France.
FAU - Leoz, Marie
AU  - Leoz M
AD  - Normandie Univ, UNIROUEN, EA2656, GRAM 2.0, et CHU de Rouen, Laboratoire de 
      Virologie associé au CNR du VIH, Rouen, France; and.
FAU - Gueudin, Marie
AU  - Gueudin M
AD  - Normandie Univ, UNIROUEN, EA2656, GRAM 2.0, et CHU de Rouen, Laboratoire de 
      Virologie associé au CNR du VIH, Rouen, France; and.
FAU - Plantier, Jean-Christophe
AU  - Plantier JC
AD  - Normandie Univ, UNIROUEN, EA2656, GRAM 2.0, et CHU de Rouen, Laboratoire de 
      Virologie associé au CNR du VIH, Rouen, France; and.
CN  - RES-O Network
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Acquir Immune Defic Syndr
JT  - Journal of acquired immune deficiency syndromes (1999)
JID - 100892005
RN  - 0 (RNA, Viral)
RN  - 0 (Reagent Kits, Diagnostic)
SB  - IM
MH  - HIV Infections/*diagnosis
MH  - HIV Seropositivity
MH  - HIV-1/*genetics/isolation & purification
MH  - Humans
MH  - RNA, Viral/*genetics
MH  - Reagent Kits, Diagnostic/*standards
MH  - Real-Time Polymerase Chain Reaction
MH  - Reproducibility of Results
MH  - Sensitivity and Specificity
MH  - Viral Load
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2021/09/11 06:00
MHDA- 2021/12/31 06:00
CRDT- 2021/09/10 17:17
PHST- 2020/12/23 00:00 [received]
PHST- 2021/05/24 00:00 [accepted]
PHST- 2021/09/10 17:17 [entrez]
PHST- 2021/09/11 06:00 [pubmed]
PHST- 2021/12/31 06:00 [medline]
AID - 00126334-202110010-00015 [pii]
AID - 10.1097/QAI.0000000000002753 [doi]
PST - ppublish
SO  - J Acquir Immune Defic Syndr. 2021 Oct 1;88(2):220-227. doi: 
      10.1097/QAI.0000000000002753.

PMID- 20488936
OWN - NLM
STAT- MEDLINE
DCOM- 20100806
LR  - 20200411
IS  - 1473-5644 (Electronic)
IS  - 0022-2615 (Linking)
VI  - 59
IP  - Pt 8
DP  - 2010 Aug
TI  - Pulmonary tuberculosis due to Mycobacterium microti: a study of six recent cases in 
      France.
PG  - 984-989
LID - 10.1099/jmm.0.019372-0 [doi]
AB  - Human tuberculosis caused by Mycobacterium microti is rare, but its prevalence and 
      clinical significance may have been underestimated. To the best of our knowledge, 21 
      cases have been reported in the literature in the last decade. We report six recent 
      pulmonary cases caused by M. microti over a period of 5 years detected in French 
      clinical mycobacteriology laboratories of the hospital network. Our data confirm the 
      potential of M. microti to cause clinical illness in immunocompetent patients. M. 
      microti grew slowly from specimens, delaying the final microbiological diagnosis. 
      Therefore, patients with tuberculosis caused by M. microti could benefit from the 
      use of rapid diagnostic molecular techniques directly on clinical samples. From a 
      review of the literature and this study, a classical antituberculous therapy seems 
      effective in treating patients with M. microti disease.
FAU - Panteix, G
AU  - Panteix G
AD  - Laboratoire Biomnis, 19 Avenue Tony Garnier, 69007 Lyon, France.
FAU - Gutierrez, M C
AU  - Gutierrez MC
AD  - Institut Pasteur de Lille, INSERM U629, 1 Rue du Professeur Calmette, 59021 Lille, 
      France.
FAU - Boschiroli, M L
AU  - Boschiroli ML
AD  - Unité Zoonoses Bactériennes, Agence Française de Sécurité Sanitaire des Aliments, 23 
      Avenue du Général de Gaulle, 94706 Maisons-Alfort Cedex, France.
FAU - Rouviere, M
AU  - Rouviere M
AD  - Laboratoire de Biologie, Centre Hospitalier Général Gui de Chauliac de Mende, Avenue 
      du 8 Mai 1945, BP 10, 48010 Mende Cedex, France.
FAU - Plaidy, A
AU  - Plaidy A
AD  - Laboratoire de Biologie, Centre Hospitalier de Vichy, Boulevard Deniere, BP 2757, 
      03207 Vichy Cedex, France.
FAU - Pressac, D
AU  - Pressac D
AD  - Laboratoire de Biologie, Centre Hospitalier de Tulle, 3 Place Maschat, BP 160, 19012 
      Tulle Cedex, France.
FAU - Porcheret, H
AU  - Porcheret H
AD  - Laboratoire de Biologie, Centre Hospitalier Robert Ballanger (CHRB), 93602 
      Aulnay-Sous-Bois Cedex, France.
FAU - Chyderiotis, G
AU  - Chyderiotis G
AD  - Laboratoire Biomnis, 19 Avenue Tony Garnier, 69007 Lyon, France.
FAU - Ponsada, M
AU  - Ponsada M
AD  - Laboratoire Biomnis, 19 Avenue Tony Garnier, 69007 Lyon, France.
FAU - Van Oortegem, K
AU  - Van Oortegem K
AD  - Service de Pneumologie, Centre Hospitalier Général Gui de Chauliac de Mende, Avenue 
      du 8 Mai 1945, BP 10, 48010 Mende Cedex, France.
FAU - Salloum, S
AU  - Salloum S
AD  - Service de Pneumologie, Centre Hospitalier de Vendome, 41106 Vendome Cedex, France.
FAU - Cabuzel, S
AU  - Cabuzel S
AD  - Service de Médecine Interne et Pneumologie, Centre Hospitalier d'Aubenas, 9 Chemin 
      de Bois Vignal, BP 146, 07205 Aubenas, France.
FAU - Bañuls, A L
AU  - Bañuls AL
AD  - GEMI, UMR CNRS-IRD 2724, Centre IRD de Montpellier, France.
FAU - Van de Perre, P
AU  - Van de Perre P
AD  - Université Montpellier 1, EA 4205 'Transmission, Pathogenèse et Prévention de 
      l'Infection par le VIH', and Laboratoire de Bactériologie-Virologie Arnaud de 
      Villeneuve, 371 Avenue du Doyen Gaston Giraud, F-34295 Montpellier Cedex 5, France.
FAU - Godreuil, S
AU  - Godreuil S
AD  - Université Montpellier 1, EA 4205 'Transmission, Pathogenèse et Prévention de 
      l'Infection par le VIH', and Laboratoire de Bactériologie-Virologie Arnaud de 
      Villeneuve, 371 Avenue du Doyen Gaston Giraud, F-34295 Montpellier Cedex 5, France.
AD  - GEMI, UMR CNRS-IRD 2724, Centre IRD de Montpellier, France.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20100520
PL  - England
TA  - J Med Microbiol
JT  - Journal of medical microbiology
JID - 0224131
RN  - 0 (Antitubercular Agents)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antitubercular Agents/therapeutic use
MH  - Child
MH  - Female
MH  - France
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mycobacterium/classification/*isolation & purification
MH  - Tuberculosis, Pulmonary/*diagnosis/drug therapy/*microbiology
RF  - 13
EDAT- 2010/05/22 06:00
MHDA- 2010/08/07 06:00
CRDT- 2010/05/22 06:00
PHST- 2010/05/22 06:00 [entrez]
PHST- 2010/05/22 06:00 [pubmed]
PHST- 2010/08/07 06:00 [medline]
AID - 10.1099/jmm.0.019372-0 [doi]
PST - ppublish
SO  - J Med Microbiol. 2010 Aug;59(Pt 8):984-989. doi: 10.1099/jmm.0.019372-0. Epub 2010 
      May 20.

PMID- 16455504
OWN - NLM
STAT- MEDLINE
DCOM- 20060214
LR  - 20110405
IS  - 1769-6917 (Electronic)
IS  - 0007-4551 (Linking)
VI  - 93
IP  - 1
DP  - 2006 Jan
TI  - [Non-AIDS-defining malignancies in HIV patients: clinical features and 
      perspectives].
PG  - 37-42
AB  - Eventhough the advent of highly active antiretroviral therapy (HAART) has 
      dramatically improved patient outcome and provided a significant shrinking of the 
      cases and severity of opportunistic infections, AIDS malignancies have become 
      responsible of a new vexing challenge in HIV patient care and cure. Indeed, 
      malignant tumors currently rank among the leading cause of morbidity and mortality 
      in patients infected with HIV. In addition to the AIDS-malignancies, non-AIDS 
      defining tumors have a higher incidence than the general population such as Hodgkin 
      disease, lung cancer, cutaneaous cancer and anal cancer. These malignant tumors are 
      generally characterized by a more aggressive behaviour at diagnosis and a poorer 
      outcome compared with the same tumors in the general population. Although recent 
      therapeutic advances have been made in chemotherapy, combinations with 
      antiretroviral agents, for many of these malignancies the pronostic remains poor and 
      there is a deeply lack of current therapeutic guidelines for these cancer patients 
      care and cure. These recommendations might be the fruit of a new networking between 
      HIV specialists and oncologists and of an improving knowledge of the pathogenesis 
      and clinical features of these AIDS non-defining tumors.
FAU - Spano, Jean-Philippe
AU  - Spano JP
AD  - Département d'oncologie médicale, GH Pitié-Salpêtrière, AP-HP, Paris, France. 
      jean-philippe.spano@psl.ap-hopparis.fr
FAU - Carcelain, Guislaine
AU  - Carcelain G
FAU - Katlama, Christine
AU  - Katlama C
FAU - Costagliola, Dominique
AU  - Costagliola D
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Les nouvelles tumeurs malignes du patient infecté par le VIH: aspects cliniques et 
      perspectives.
PL  - France
TA  - Bull Cancer
JT  - Bulletin du cancer
JID - 0072416
SB  - IM
MH  - Antiretroviral Therapy, Highly Active
MH  - HIV Infections/*complications/*diagnosis
MH  - Humans
MH  - Morbidity
MH  - Neoplasms/etiology/*physiopathology/*virology
MH  - Prognosis
RF  - 48
EDAT- 2006/02/04 09:00
MHDA- 2006/02/16 09:00
CRDT- 2006/02/04 09:00
PHST- 2005/12/12 00:00 [received]
PHST- 2005/12/15 00:00 [accepted]
PHST- 2006/02/04 09:00 [pubmed]
PHST- 2006/02/16 09:00 [medline]
PHST- 2006/02/04 09:00 [entrez]
PST - ppublish
SO  - Bull Cancer. 2006 Jan;93(1):37-42.

PMID- 32347645
OWN - NLM
STAT- MEDLINE
DCOM- 20210811
LR  - 20210811
IS  - 1365-2893 (Electronic)
IS  - 1352-0504 (Linking)
VI  - 27
IP  - 9
DP  - 2020 Sep
TI  - Response to direct-acting antivirals for hepatitis C treatment in vertically HIV/HCV 
      co-infected patients.
PG  - 955-958
LID - 10.1111/jvh.13308 [doi]
AB  - Direct-acting antivirals (DAAs) for HCV treatment have improved tolerance and 
      efficacy among adults, but experience in vertical transmission is scarce. In our 
      vertically HIV/HCV co-infected youth cohort of 58 patients, DAA achieved excellent 
      rates of cure among naïve and pretreated individuals. Treating vertically infected 
      seems important as 29.6% displayed advanced fibrosis at treatment initiation.
CI  - © 2020 John Wiley & Sons Ltd.
FAU - Carrasco, Itzíar
AU  - Carrasco I
AUID- ORCID: 0000-0002-9974-3378
AD  - Hospital General Universitario Gregorio Marañón and Gregorio Marañón Research 
      Institute (IiSGM), Madrid, Spain.
AD  - Universidad Complutense de Madrid, Madrid, Spain.
FAU - Sainz, Talía
AU  - Sainz T
AUID- ORCID: 0000-0002-5301-0945
AD  - Hospital Universitario La Paz and La Paz Research Institute (IdiPAZ), Madrid, Spain.
FAU - Frick, Marie Antoinette
AU  - Frick MA
AD  - Hospital Vall d'Hebron, Barcelona, Spain.
FAU - Jiménez de Ory, Santiago
AU  - Jiménez de Ory S
AD  - Hospital General Universitario Gregorio Marañón and Gregorio Marañón Research 
      Institute (IiSGM), Madrid, Spain.
FAU - Fortuny, Claudia
AU  - Fortuny C
AD  - Hospital Sant Joan de Déu, Barcelona, Spain.
FAU - Burgos, Joaquin
AU  - Burgos J
AD  - Hospital Vall d'Hebron, Barcelona, Spain.
FAU - Montero, Marta
AU  - Montero M
AD  - Hospital Universitario y Politécnico de La Fe, Valencia, Spain.
FAU - Gavilán, César
AU  - Gavilán C
AD  - Hospital San Juan de Alicante, Sant Joan d'Alacant, Spain.
FAU - Falcón, María Dolores
AU  - Falcón MD
AD  - Hospital Virgen del Rocío, Sevilla, Spain.
FAU - Couceiro, José Antonio
AU  - Couceiro JA
AD  - Complejo Hospitalario de Pontevedra, Pontevedra, Spain.
FAU - Bernardino, José Ignacio
AU  - Bernardino JI
AD  - Hospital Universitario La Paz and La Paz Research Institute (IdiPAZ), Madrid, Spain.
FAU - Bisbal, Otilia
AU  - Bisbal O
AD  - Hospital 12 de Octubre, Madrid, Spain.
FAU - Guerrero, Carmelo
AU  - Guerrero C
AD  - Hospital Miguel Servet, Zaragoza, Spain.
FAU - Aldámiz-Echevarría, María Teresa
AU  - Aldámiz-Echevarría MT
AD  - Hospital General Universitario Gregorio Marañón and Gregorio Marañón Research 
      Institute (IiSGM), Madrid, Spain.
FAU - Berenguer, Juan
AU  - Berenguer J
AUID- ORCID: 0000-0001-8541-8200
AD  - Hospital General Universitario Gregorio Marañón and Gregorio Marañón Research 
      Institute (IiSGM), Madrid, Spain.
FAU - Navarro, María Luisa
AU  - Navarro ML
AD  - Hospital General Universitario Gregorio Marañón and Gregorio Marañón Research 
      Institute (IiSGM), Madrid, Spain.
AD  - Universidad Complutense de Madrid, Madrid, Spain.
CN  - the Pediatric National AIDS Research Network of Spain (CoRISpe) integrated in the 
      Translational Research Network in Pediatric Infectious Diseases (RITIP)
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200522
PL  - England
TA  - J Viral Hepat
JT  - Journal of viral hepatitis
JID - 9435672
RN  - 0 (Antiviral Agents)
SB  - IM
MH  - Adolescent
MH  - *Antiviral Agents/therapeutic use
MH  - *Coinfection/drug therapy
MH  - *HIV Infections/drug therapy
MH  - *Hepatitis C/drug therapy
MH  - Humans
OTO - NOTNLM
OT  - *HCV treatment
OT  - *VIH/VHC co-infection
OT  - *children and adolescents
OT  - *direct-acting antivirals
OT  - *vertical transmission
EDAT- 2020/04/30 06:00
MHDA- 2021/08/12 06:00
CRDT- 2020/04/30 06:00
PHST- 2019/11/06 00:00 [received]
PHST- 2020/03/23 00:00 [revised]
PHST- 2020/04/05 00:00 [accepted]
PHST- 2020/04/30 06:00 [pubmed]
PHST- 2021/08/12 06:00 [medline]
PHST- 2020/04/30 06:00 [entrez]
AID - 10.1111/jvh.13308 [doi]
PST - ppublish
SO  - J Viral Hepat. 2020 Sep;27(9):955-958. doi: 10.1111/jvh.13308. Epub 2020 May 22.

PMID- 26364856
OWN - NLM
STAT- MEDLINE
DCOM- 20180308
LR  - 20181202
IS  - 1578-1852 (Electronic)
IS  - 0213-005X (Linking)
VI  - 34
IP  - 6
DP  - 2016 Jun-Jul
TI  - Clinical, epidemiological and treatment failure data among HIV-1 non-B-infected 
      patients in the Spanish AIDS Research Network Cohort.
PG  - 353-60
LID - S0213-005X(15)00291-8 [pii]
LID - 10.1016/j.eimc.2015.07.016 [doi]
AB  - INTRODUCTION: The prevalence of HIV-1 non-B variants is increasing in Spain, showing 
      a higher number of transmitted drug resistance mutations (TDR) since 2002. This 
      study presents the features of non-B-infected patients enrolled in the cohort of 
      antiretroviral treatment (ART) naïve HIV-infected patients included in the Research 
      Network on HIV/AIDS (CoRIS). METHODS: The study includes a selected group of HIV-1 
      non-B-infected subjects from 670 subjects with pol sequences collected from 2004 to 
      2008 in the CoRIS cohort. Epidemiological-clinical-virological data were analyzed 
      since cohort entry until October 2011, considering the presence or absence of 
      treatment failure (TF). RESULTS: Eighty two non-B infected subjects with known HIV-1 
      variants were selected from 2004 to 2008 in the CoRIS cohort, being mainly female, 
      immigrants, infected by recombinant viruses, and by heterosexual route. They had an 
      intermediate TDR rate (9.4%), a high rate of TF (25.6%), of losses to follow-up 
      (35%), of coinfections (32.9%), and baseline CD4+ counts ≥350cells/mm(3) (61.8%). 
      Non-B subjects with TF showed higher rates of heterosexual infection (85.7% vs. 
      69.5%, p<0.05), tuberculosis (30.8% vs. 9.1%, p=0.10) and hepatitis C (23.8% vs. 
      13.9%, p=0.34) coinfections and lower rates of syphilis (0% vs. 21.9%, p<0.05), and 
      had more frequently received first-line ART including protease inhibitors (PIs) than 
      patients without TF (70% vs. 30%, p<0.05). Interestingly, infection with non-B 
      variants reduced the risk of TDR to nucleoside reverse transcriptase inhibitors and 
      increased the risk to PIs. CONCLUSION: HIV-1 non-B-infected patients in Spain had a 
      particular epidemiological and clinical profile that should be considered during 
      their clinical management.
CI  - Copyright © 2015 Elsevier España, S.L.U. and Sociedad Española de Enfermedades 
      Infecciosas y Microbiología Clínica. All rights reserved.
FAU - Torrecilla García, Esther
AU  - Torrecilla García E
AD  - HIV-1 Molecular Epidemiology Laboratory, Microbiology and Parasitology Department, 
      Hospital Universitario Ramón y Cajal-Instituto Ramón y Cajal de Investigación 
      Sanitaria (IRYCIS). CIBER en Epidemiología y Salud Pública (CIBERESP), Madrid, 
      Spain.
FAU - Yebra Sanz, Gonzalo
AU  - Yebra Sanz G
AD  - HIV-1 Molecular Epidemiology Laboratory, Microbiology and Parasitology Department, 
      Hospital Universitario Ramón y Cajal-Instituto Ramón y Cajal de Investigación 
      Sanitaria (IRYCIS). CIBER en Epidemiología y Salud Pública (CIBERESP), Madrid, 
      Spain.
FAU - Llácer-Delicado, Teresa
AU  - Llácer-Delicado T
AD  - HIV-1 Molecular Epidemiology Laboratory, Microbiology and Parasitology Department, 
      Hospital Universitario Ramón y Cajal-Instituto Ramón y Cajal de Investigación 
      Sanitaria (IRYCIS). CIBER en Epidemiología y Salud Pública (CIBERESP), Madrid, 
      Spain.
FAU - Rubio García, Rafael
AU  - Rubio García R
AD  - HIV Unit, Hospital Universitario 12 de octubre, Madrid, Spain.
FAU - González-García, Juan
AU  - González-García J
AD  - Infectious Diseases Unit, Hospital Universitario La Paz, Madrid, Spain.
FAU - García García, Federico
AU  - García García F
AD  - Microbiology Department, Hospital Universitario San Cecilio, Granada, Spain.
FAU - López-Aldeguer, José
AU  - López-Aldeguer J
AD  - Infectious Diseases Unit, Hospital La Fe, Valencia, Spain.
FAU - Asensi Álvarez, Víctor
AU  - Asensi Álvarez V
AD  - Infectious Diseases Unit, Hospital Universitario Central de Asturias, Oviedo, Spain.
FAU - Holguín Fernández, África
AU  - Holguín Fernández Á
AD  - HIV-1 Molecular Epidemiology Laboratory, Microbiology and Parasitology Department, 
      Hospital Universitario Ramón y Cajal-Instituto Ramón y Cajal de Investigación 
      Sanitaria (IRYCIS). CIBER en Epidemiología y Salud Pública (CIBERESP), Madrid, 
      Spain. Electronic address: africa.holguin@salud.madrid.org.
CN  - Cohort of the Spanish AIDS Research Network (CoRIS)
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20150911
PL  - Spain
TA  - Enferm Infecc Microbiol Clin
JT  - Enfermedades infecciosas y microbiologia clinica
JID - 9104081
RN  - 0 (Anti-HIV Agents)
SB  - IM
MH  - Acquired Immunodeficiency Syndrome/epidemiology
MH  - Adult
MH  - Anti-HIV Agents/therapeutic use
MH  - Drug Resistance, Viral
MH  - Emigrants and Immigrants
MH  - Female
MH  - HIV Infections/drug therapy/*epidemiology/transmission
MH  - *HIV-1/genetics
MH  - Humans
MH  - Male
MH  - Spain/epidemiology
MH  - Treatment Failure
OTO - NOTNLM
OT  - Antiretroviral treatment (ART)
OT  - CoRIS
OT  - Epidemiology
OT  - Epidemiología
OT  - Fracaso terapéutico (FT) al primer TAR
OT  - HIV-1
OT  - Non-B variants
OT  - Therapeutic failure (TF) to first ART
OT  - Tratamiento antiretroviral (TAR)
OT  - VIH-1
OT  - Variantes no-B
EDAT- 2015/09/15 06:00
MHDA- 2018/03/09 06:00
CRDT- 2015/09/15 06:00
PHST- 2015/02/26 00:00 [received]
PHST- 2015/07/24 00:00 [revised]
PHST- 2015/07/27 00:00 [accepted]
PHST- 2015/09/15 06:00 [entrez]
PHST- 2015/09/15 06:00 [pubmed]
PHST- 2018/03/09 06:00 [medline]
AID - S0213-005X(15)00291-8 [pii]
AID - 10.1016/j.eimc.2015.07.016 [doi]
PST - ppublish
SO  - Enferm Infecc Microbiol Clin. 2016 Jun-Jul;34(6):353-60. doi: 
      10.1016/j.eimc.2015.07.016. Epub 2015 Sep 11.

PMID- 34916518
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220105
IS  - 2373-8057 (Print)
IS  - 2373-8057 (Electronic)
IS  - 2373-8057 (Linking)
VI  - 7
IP  - 1
DP  - 2021 Dec 16
TI  - Contributions of sex, depression, and cognition on brain connectivity dynamics in 
      Parkinson's disease.
PG  - 117
LID - 10.1038/s41531-021-00257-9 [doi]
LID - 117
AB  - Alterations in time-varying functional connectivity (FC) have been found in 
      Parkinson's disease (PD) patients. To date, very little is known about the influence 
      of sex on brain FC in PD patients and how this could be related to disease severity. 
      The first objective was to evaluate the influence of sex on dynamic FC 
      characteristics in PD patients and healthy controls (HC), while the second aim was 
      to investigate the temporal patterns of dynamic connectivity related to PD motor and 
      non-motor symptoms. Ninety-nine PD patients and sixty-two HC underwent a 
      neuropsychological and clinical assessment. Rs-fMRI and T1-weighted MRI were also 
      acquired. Dynamic FC analyses were performed in the GIFT toolbox. Dynamic FC 
      analyses identified two States: State I, characterized by within-network positive 
      coupling; and State II that showed between-network connectivity, mostly involving 
      somatomotor and visual networks. Sex differences were found in dynamic indexes in HC 
      but these differences were not observed in PD. Hierarchical clustering analysis 
      identified three phenotypically distinct PD subgroups: (1) Subgroup A was 
      characterized by mild motor symptoms; (2) Subgroup B was characterized by depressive 
      and motor symptoms; (3) Subgroup C was characterized by cognitive and motor 
      symptoms. Results revealed that changes in the temporal properties of connectivity 
      were related to the motor/non-motor outcomes of PD severity. Findings suggest that 
      while in HC sex differences may play a certain role in dynamic connectivity 
      patterns, in PD patients, these effects may be overcome by the neurodegenerative 
      process. Changes in the temporal properties of connectivity in PD were mainly 
      related to the clinical markers of PD severity.
CI  - © 2021. The Author(s).
FAU - Diez-Cirarda, Maria
AU  - Diez-Cirarda M
AUID- ORCID: 0000-0001-6768-189X
AD  - Brain Health Imaging Centre, Campbell Family Mental Health Research Institute, 
      Centre for Addiction and Mental Health, University of Toronto, Toronto, ON, Canada. 
      maria.diecirarda@gmail.com.
AD  - E.J. Safra Parkinson Disease Program & Movement Disorder Unit, Neurology Division; 
      Krembil Brain Institute, University Health Network, University of Toronto, Toronto, 
      ON, Canada. maria.diecirarda@gmail.com.
AD  - Neurodegenerative Diseases Group, Biocruces Bizkaia Health Research Institute, 
      Barakaldo, Spain. maria.diecirarda@gmail.com.
FAU - Gabilondo, Iñigo
AU  - Gabilondo I
AUID- ORCID: 0000-0001-6045-2840
AD  - Neurodegenerative Diseases Group, Biocruces Bizkaia Health Research Institute, 
      Barakaldo, Spain.
AD  - IKERBASQUE, The Basque Foundation for Science, Bilbao, Spain.
FAU - Ibarretxe-Bilbao, Naroa
AU  - Ibarretxe-Bilbao N
AD  - Department of Psychology, Faculty of Health Sciences, University of Deusto, Bilbao, 
      Spain.
FAU - Gómez-Esteban, Juan Carlos
AU  - Gómez-Esteban JC
AD  - Neurodegenerative Diseases Group, Biocruces Bizkaia Health Research Institute, 
      Barakaldo, Spain.
AD  - Neurology Department, Cruces University Hospital, Barakaldo, Spain.
FAU - Kim, Jinhee
AU  - Kim J
AUID- ORCID: 0000-0002-1019-7455
AD  - Brain Health Imaging Centre, Campbell Family Mental Health Research Institute, 
      Centre for Addiction and Mental Health, University of Toronto, Toronto, ON, Canada.
AD  - E.J. Safra Parkinson Disease Program & Movement Disorder Unit, Neurology Division; 
      Krembil Brain Institute, University Health Network, University of Toronto, Toronto, 
      ON, Canada.
FAU - Lucas-Jiménez, Olaia
AU  - Lucas-Jiménez O
AUID- ORCID: 0000-0002-7715-3764
AD  - Department of Psychology, Faculty of Health Sciences, University of Deusto, Bilbao, 
      Spain.
FAU - Del Pino, Rocio
AU  - Del Pino R
AD  - Neurodegenerative Diseases Group, Biocruces Bizkaia Health Research Institute, 
      Barakaldo, Spain.
FAU - Peña, Javier
AU  - Peña J
AUID- ORCID: 0000-0002-0041-7020
AD  - Department of Psychology, Faculty of Health Sciences, University of Deusto, Bilbao, 
      Spain.
FAU - Ojeda, Natalia
AU  - Ojeda N
AD  - Department of Psychology, Faculty of Health Sciences, University of Deusto, Bilbao, 
      Spain.
FAU - Mihaescu, Alexander
AU  - Mihaescu A
AD  - Brain Health Imaging Centre, Campbell Family Mental Health Research Institute, 
      Centre for Addiction and Mental Health, University of Toronto, Toronto, ON, Canada.
AD  - E.J. Safra Parkinson Disease Program & Movement Disorder Unit, Neurology Division; 
      Krembil Brain Institute, University Health Network, University of Toronto, Toronto, 
      ON, Canada.
FAU - Valli, Mikaeel
AU  - Valli M
AUID- ORCID: 0000-0002-4059-2333
AD  - Brain Health Imaging Centre, Campbell Family Mental Health Research Institute, 
      Centre for Addiction and Mental Health, University of Toronto, Toronto, ON, Canada.
AD  - E.J. Safra Parkinson Disease Program & Movement Disorder Unit, Neurology Division; 
      Krembil Brain Institute, University Health Network, University of Toronto, Toronto, 
      ON, Canada.
FAU - Acera, Maria Angeles
AU  - Acera MA
AD  - Neurodegenerative Diseases Group, Biocruces Bizkaia Health Research Institute, 
      Barakaldo, Spain.
FAU - Cabrera-Zubizarreta, Alberto
AU  - Cabrera-Zubizarreta A
AD  - OSATEK, MR Unit, Hospital of Galdakao, Galdakao, Bilbao, Spain.
FAU - Gómez-Beldarrain, Maria Angeles
AU  - Gómez-Beldarrain MA
AD  - Neurology Service, Hospital of Galdakao, Galdakao, Bilbao, Spain.
FAU - Strafella, Antonio P
AU  - Strafella AP
AD  - Brain Health Imaging Centre, Campbell Family Mental Health Research Institute, 
      Centre for Addiction and Mental Health, University of Toronto, Toronto, ON, Canada. 
      Antonio.Strafella@camh.ca.
AD  - E.J. Safra Parkinson Disease Program & Movement Disorder Unit, Neurology Division; 
      Krembil Brain Institute, University Health Network, University of Toronto, Toronto, 
      ON, Canada. Antonio.Strafella@camh.ca.
LA  - eng
GR  - MOP-136778/Canadian HIV Trials Network, Canadian Institutes of Health Research 
      (Réseau canadien pour les essais VIH des IRSC)/
PT  - Journal Article
DEP - 20211216
TA  - NPJ Parkinsons Dis
JT  - NPJ Parkinson's disease
JID - 101675390
PMC - PMC8677758
COIS- A.P.S. is a consultant for Hoffman La Roche; received honoraria from GE Health Care 
      Canada LTD, Hoffman La Roche. The remaining authors declare no competing interests.
EDAT- 2021/12/18 06:00
MHDA- 2021/12/18 06:01
CRDT- 2021/12/17 06:20
PHST- 2020/08/16 00:00 [received]
PHST- 2021/11/19 00:00 [accepted]
PHST- 2021/12/17 06:20 [entrez]
PHST- 2021/12/18 06:00 [pubmed]
PHST- 2021/12/18 06:01 [medline]
AID - 10.1038/s41531-021-00257-9 [pii]
AID - 257 [pii]
AID - 10.1038/s41531-021-00257-9 [doi]
PST - epublish
SO  - NPJ Parkinsons Dis. 2021 Dec 16;7(1):117. doi: 10.1038/s41531-021-00257-9.

PMID- 28109341
OWN - NLM
STAT- MEDLINE
DCOM- 20180205
LR  - 20180205
IS  - 1879-1972 (Electronic)
IS  - 1054-139X (Linking)
VI  - 60
IP  - 2S2
DP  - 2017 Feb
TI  - Leadership and Innovation-Listening to and Learning From Young People in Burundi.
PG  - S7-S9
LID - S1054-139X(16)30865-5 [pii]
LID - 10.1016/j.jadohealth.2016.11.012 [doi]
AB  - This commentary describes young people's leadership from the perspective of a 
      youth-led organization in the Link Up project in Burundi, Réseau National des Jeunes 
      vivant avec le VIH. It describes processes that enable young people to guide, 
      influence, deliver, and improve health service provision; the challenges faced by 
      Réseau National des Jeunes vivant avec le VIH and how they are addressing these 
      challenges.
CI  - Copyright © 2016 Society for Adolescent Health and Medicine. Published by Elsevier 
      Inc. All rights reserved.
FAU - Nininahazwe, Cédric
AU  - Nininahazwe C
AD  - Réseau National des Jeunes vivant avec le VIH (RNJ+), Burundi. Electronic address: 
      gcaswell@aidsalliance.org.
FAU - Alesi, Jacquelyne
AU  - Alesi J
AD  - Uganda Network of Young People Living With HIV (UNYPA), Kampala, Uganda.
FAU - Caswell, Georgina
AU  - Caswell G
AD  - International HIV/AIDS Alliance (IHAA), Brighton, United Kingdom.
FAU - Lumumba, Musah
AU  - Lumumba M
AD  - Uganda Youth Coalition on Adolescent Sexual and Reproductive Health Rights and HIV 
      (CYSRA), Kampala, Uganda.
FAU - Mellin, Julie
AU  - Mellin J
AD  - Global Youth Coalition on HIV/AIDS (a Program of the Public Health Institute), New 
      York, New York.
FAU - Ndayizeye, Nicholas-Monalisa
AU  - Ndayizeye NM
AD  - Humure, Bujumbura, Burundi.
FAU - Orza, Luisa
AU  - Orza L
AD  - ATHENA Network, United Kingdom.
FAU - Rahimi, Michaela
AU  - Rahimi M
AD  - Global Youth Coalition on HIV/AIDS (a Program of the Public Health Institute), New 
      York, New York.
FAU - Westerhof, Nienke
AU  - Westerhof N
AD  - STOP AIDS NOW!, Amsterdam, The Netherlands.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Adolesc Health
JT  - The Journal of adolescent health : official publication of the Society for 
      Adolescent Medicine
JID - 9102136
SB  - IM
MH  - Adolescent
MH  - Burundi
MH  - Female
MH  - HIV Infections/psychology
MH  - Health Services Accessibility/*standards
MH  - Humans
MH  - *Leadership
MH  - Male
MH  - Mentoring
MH  - Program Development
MH  - Reproductive Health/*education
MH  - Reproductive Health Services/standards
MH  - Reproductive Rights/*education
MH  - Sexual Behavior/psychology
OTO - NOTNLM
OT  - Adolescents
OT  - Burundi
OT  - HIV
OT  - Meaningful youth participation
OT  - Peer to peer
OT  - Sexual and reproductive health and rights (SRHR)
OT  - Young people
EDAT- 2017/01/23 06:00
MHDA- 2018/02/06 06:00
CRDT- 2017/01/23 06:00
PHST- 2016/11/16 00:00 [received]
PHST- 2016/11/17 00:00 [accepted]
PHST- 2017/01/23 06:00 [entrez]
PHST- 2017/01/23 06:00 [pubmed]
PHST- 2018/02/06 06:00 [medline]
AID - S1054-139X(16)30865-5 [pii]
AID - 10.1016/j.jadohealth.2016.11.012 [doi]
PST - ppublish
SO  - J Adolesc Health. 2017 Feb;60(2S2):S7-S9. doi: 10.1016/j.jadohealth.2016.11.012.

PMID- 25884148
OWN - NLM
STAT- MEDLINE
DCOM- 20151216
LR  - 20190609
IS  - 1560-7917 (Electronic)
IS  - 1025-496X (Linking)
VI  - 20
IP  - 14
DP  - 2015 Apr 9
TI  - Effects of region of birth, educational level and age on late presentation among men 
      who have sex with men newly diagnosed with HIV in a network of STI/HIV counselling 
      and testing clinics in Spain.
LID - 21088 [pii]
AB  - This paper analyses late presentation (LP) of HIV infection, and its determinants, 
      among men who have sex with men (MSM) in Spain, newly diagnosed with HIV (2003-2011) 
      in 15 sexually transmitted infection/HIV counselling and testing clinics. LP was 
      defined as <350 CD4 cells/µL or AIDS. In total, 3,081 MSM were included (2,499 
      having CD4/AIDS); overall LP was 25.3%. LP was higher in men older than 34 years, 
      those not previously HIV-tested (adjusted odds ratio (aOR):3.1; 95% confidence 
      intervals (CI):2.3-4.2) , and those tested > 12 months before diagnosis (12-24 
      months (aOR:1.4; 95% CI:1.0-2.0); > 24 months (aOR:2.2; 95% CI:1.7-3.0)). LP was 
      less likely in MSM reporting a known HIV-infected partner as infection source or 
      symptoms compatible with acute retroviral syndrome. 'Region of birth' interacted 
      with 'educational level' and 'steady partner as infection source': only African and 
      Latin-American MSM with low educational level were more likely to present late; 
      Latin-American men attributing their infection to steady partner, but no other MSM, 
      had LP more frequently. In Spain, HIV testing among MSM should be promoted, 
      especially those > 34 years old and migrants with low educational level. The current 
      recommendation that MSM be tested at least once a year is appropriate.
FAU - Diaz, A
AU  - Diaz A
AD  - area de Vigilancia del VIH y comportamientos de riesgo, Centro Nacional de 
      Epidemiologia, Instituto de Salud Carlos III, Madrid, Spain.
FAU - del Romero, J
AU  - del Romero J
FAU - Rodriguez, C
AU  - Rodriguez C
FAU - Alastrue, I
AU  - Alastrue I
FAU - Belda, J
AU  - Belda J
FAU - Bru, F J
AU  - Bru FJ
FAU - Cámara, M M
AU  - Cámara MM
FAU - Junquera, M L
AU  - Junquera ML
FAU - Sanz, I
AU  - Sanz I
FAU - Viloria, L J
AU  - Viloria LJ
FAU - Gil, L
AU  - Gil L
FAU - Martínez, E
AU  - Martínez E
FAU - Gual, F
AU  - Gual F
FAU - Landa, M C
AU  - Landa MC
FAU - Pueyo, I
AU  - Pueyo I
FAU - Ureña, J M
AU  - Ureña JM
FAU - Martínez, B
AU  - Martínez B
FAU - Varela, J A
AU  - Varela JA
FAU - Polo, A
AU  - Polo A
FAU - Azpiri, M A
AU  - Azpiri MA
FAU - Diez, M
AU  - Diez M
CN  - EPI-VIH Study Group
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150409
PL  - Sweden
TA  - Euro Surveill
JT  - Euro surveillance : bulletin Europeen sur les maladies transmissibles = European 
      communicable disease bulletin
JID - 100887452
SB  - IM
MH  - Adult
MH  - Africa/ethnology
MH  - Age of Onset
MH  - Community Health Centers
MH  - Counseling
MH  - *Delayed Diagnosis
MH  - Educational Status
MH  - HIV Infections/*diagnosis/ethnology/transmission
MH  - *Homosexuality, Male
MH  - Humans
MH  - Latin America/ethnology
MH  - Male
MH  - Middle Aged
MH  - Sexual Partners
MH  - Sexually Transmitted Diseases/diagnosis
MH  - Spain/epidemiology
FIR - Diez, M
IR  - Diez M
FIR - Diaz, A
IR  - Diaz A
FIR - Herrando, I
IR  - Herrando I
FIR - Nogueras, P
IR  - Nogueras P
FIR - Castro, E
IR  - Castro E
FIR - Jimenez, M J
IR  - Jimenez MJ
FIR - Martínez, B
IR  - Martínez B
FIR - García, M A
IR  - García MA
FIR - Godoy, L
IR  - Godoy L
FIR - Pueyo, I
IR  - Pueyo I
FIR - Ruiz, E
IR  - Ruiz E
FIR - Redondo, C
IR  - Redondo C
FIR - Martínez, C
IR  - Martínez C
FIR - Sánchez, D
IR  - Sánchez D
FIR - Varela, J A
IR  - Varela JA
FIR - López, C
IR  - López C
FIR - Otero, L
IR  - Otero L
FIR - Junquera, M L
IR  - Junquera ML
FIR - Cuesta, M
IR  - Cuesta M
FIR - Vázquez, F
IR  - Vázquez F
FIR - Carreño, F
IR  - Carreño F
FIR - Bru, F J
IR  - Bru FJ
FIR - Colomo, C
IR  - Colomo C
FIR - Comunión, A
IR  - Comunión A
FIR - Chacón, P
IR  - Chacón P
FIR - Belda, J
IR  - Belda J
FIR - Fernández, E
IR  - Fernández E
FIR - Zafra, T
IR  - Zafra T
FIR - Colomina, S
IR  - Colomina S
FIR - Galán, E
IR  - Galán E
FIR - Alastrué, J I
IR  - Alastrué JI
FIR - Santos, C
IR  - Santos C
FIR - Tasa, T
IR  - Tasa T
FIR - Juan, A
IR  - Juan A
FIR - Fernandez, E
IR  - Fernandez E
FIR - Domenech, E
IR  - Domenech E
FIR - Mitjans, L
IR  - Mitjans L
FIR - Trullen, J
IR  - Trullen J
FIR - Fenosa, A
IR  - Fenosa A
FIR - Polo, A
IR  - Polo A
FIR - Silvestre, E
IR  - Silvestre E
FIR - Cámara, M M
IR  - Cámara MM
FIR - López de Munain, J
IR  - López de Munain J
FIR - Aparicio, M N
IR  - Aparicio MN
FIR - Aizpuru, M A
IR  - Aizpuru MA
FIR - Sanz, I
IR  - Sanz I
FIR - Camino, X
IR  - Camino X
FIR - Viloria, L J
IR  - Viloria LJ
FIR - Fernández, M C
IR  - Fernández MC
FIR - de Vierna, M
IR  - de Vierna M
FIR - Estébanez, A
IR  - Estébanez A
FIR - Alvarez, D
IR  - Alvarez D
FIR - del Rio, F
IR  - del Rio F
FIR - del Romero, J
IR  - del Romero J
FIR - Rodríguez, C
IR  - Rodríguez C
FIR - Puerta, T
IR  - Puerta T
FIR - Clavo, P
IR  - Clavo P
FIR - García, S
IR  - García S
FIR - del Corral, S
IR  - del Corral S
FIR - Menéndez, B
IR  - Menéndez B
FIR - Neila, M A
IR  - Neila MA
FIR - Jerez, N
IR  - Jerez N
FIR - Raposo, M
IR  - Raposo M
FIR - Ballesteros, J
IR  - Ballesteros J
FIR - Vera, M
IR  - Vera M
FIR - Gual, F
IR  - Gual F
FIR - Landa, M C
IR  - Landa MC
FIR - Yagüe, H
IR  - Yagüe H
FIR - Sánchez, P
IR  - Sánchez P
FIR - Gaztambide, A
IR  - Gaztambide A
FIR - Huarte, I
IR  - Huarte I
FIR - Sesma, E
IR  - Sesma E
FIR - Benito, J
IR  - Benito J
FIR - Azpiri, M A
IR  - Azpiri MA
FIR - Martínez, E
IR  - Martínez E
FIR - Metola, L
IR  - Metola L
FIR - Quiñones, C
IR  - Quiñones C
FIR - Ramalle, E
IR  - Ramalle E
FIR - Ibarra, V
IR  - Ibarra V
FIR - Otero, J A
IR  - Otero JA
EDAT- 2015/04/18 06:00
MHDA- 2015/12/19 06:00
CRDT- 2015/04/18 06:00
PHST- 2015/04/18 06:00 [entrez]
PHST- 2015/04/18 06:00 [pubmed]
PHST- 2015/12/19 06:00 [medline]
AID - 21088 [pii]
AID - 10.2807/1560-7917.es2015.20.14.21088 [doi]
PST - epublish
SO  - Euro Surveill. 2015 Apr 9;20(14):21088. doi: 10.2807/1560-7917.es2015.20.14.21088.

PMID- 32635221
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Electronic)
IS  - 2077-0383 (Linking)
VI  - 9
IP  - 7
DP  - 2020 Jul 3
TI  - Hepatitis C Virus Influences HIV-1 Viral Splicing in Coinfected Patients.
LID - 10.3390/jcm9072091 [doi]
LID - 2091
AB  - Coinfection with hepatitis C virus (HCV) influences HIV reservoir size. However, it 
      is unknown whether this coinfection also induces a higher provirus transcription. 
      Viral transcription is promoted by synergy between cellular factors such as NF-κB 
      and the viral regulator Tat. The impact of HCV coinfection on HIV provirus 
      transcription was analyzed in resting (r)CD4 T+ cells (CD3+CD4+CD25-CD69-HLADR-) and 
      rCD4 T cells-depleted PBMCs (rCD4 T- PBMCs) from a multicenter cross-sectional study 
      of 115 cART-treated HIV patients: 42 HIV+/HCV+ coinfected individuals (HIV+/HCV+), 
      34 HIV+ patients with HCV spontaneous clearance (HIV+/HCV-) and 39 HIV patients 
      (HIV+). Viral transcription was assessed in total RNA through the quantification of 
      unspliced, single spliced, and multiple spliced viral mRNAs by qPCR. Linear 
      correlations between viral reservoir size and viral splicing were determined. A 
      3-fold increase of multiple spliced transcripts in rCD4 T+ cells of HIV+/HCV+ 
      patients was found compared to HIV+ individuals (p < 0.05). As Tat is synthesized by 
      multiple splicing, the levels of Tat were also quantified in these patients. 
      Significant differences in single and multiple spliced transcripts were also 
      observed in rCD4 T- PBMCs. Levels of multiple spliced mRNAs were increased in rCD4 
      T+ cells isolated from HIV+/HCV+ subjects, which could indicate a higher Tat 
      activity in these cells despite their resting state.
FAU - Martínez-Román, Paula
AU  - Martínez-Román P
AD  - Laboratory of Reference and Research on Viral Hepatitis, National Center of 
      Microbiology, Institute of Health Carlos III, 28220 Majadahonda, Madrid, Spain.
FAU - López-Huertas, María Rosa
AU  - López-Huertas MR
AD  - AIDS Immunopathology Unit, National Center of Microbiology, Institute of Health 
      Carlos III, 28220 Majadahonda, Madrid, Spain.
AD  - Servicio de Enfermedades Infecciosas, Instituto Ramón y Cajal de Investigación 
      Sanitaria (IRYCIS) and Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain.
FAU - Crespo-Bermejo, Celia
AU  - Crespo-Bermejo C
AD  - Laboratory of Reference and Research on Viral Hepatitis, National Center of 
      Microbiology, Institute of Health Carlos III, 28220 Majadahonda, Madrid, Spain.
FAU - Arca-Lafuente, Sonia
AU  - Arca-Lafuente S
AUID- ORCID: 0000-0003-4750-0988
AD  - Laboratory of Reference and Research on Viral Hepatitis, National Center of 
      Microbiology, Institute of Health Carlos III, 28220 Majadahonda, Madrid, Spain.
FAU - Cortegano, Isabel
AU  - Cortegano I
AD  - Department of Immunology, Centro Nacional de Microbiología, Instituto de Salud 
      Carlos III (ISCIII), 28220 Majadahonda, Madrid, Spain.
FAU - Valle-Millares, Daniel
AU  - Valle-Millares D
AD  - Laboratory of Reference and Research on Viral Hepatitis, National Center of 
      Microbiology, Institute of Health Carlos III, 28220 Majadahonda, Madrid, Spain.
FAU - Gaspar, María Luisa
AU  - Gaspar ML
AD  - Department of Immunology, Centro Nacional de Microbiología, Instituto de Salud 
      Carlos III (ISCIII), 28220 Majadahonda, Madrid, Spain.
FAU - Martín-Carbonero, Luz
AU  - Martín-Carbonero L
AD  - Department of Infectious Diseases, Instituto de Investigación Sanitaria Hospital de 
      la Paz (IdiPAZ), 28046 Madrid, Spain.
FAU - Domínguez-Domínguez, Lourdes
AU  - Domínguez-Domínguez L
AD  - Unidad VIH, Servicio de Medicina Interna, Instituto de Investigación Biomédica del 
      Hospital Doce de Octubre (imas12), 28041 Madrid, Spain.
FAU - Ryan, Pablo
AU  - Ryan P
AUID- ORCID: 0000-0002-4212-7419
AD  - Department of Infectious Diseases, Infanta Leonor Hospital, 28031 Madrid, Spain.
FAU - de Los Santos, Ignacio
AU  - de Los Santos I
AD  - Servicio de Medicina Interna-Infecciosas, Hospital Universitario de La Princesa, 
      28006 Madrid, Spain.
FAU - de la Fuente-Moral, Sara
AU  - de la Fuente-Moral S
AD  - Servicio de Medicina Interna, Hospital Puerta de Hierro, 28222 Madrid, Spain.
FAU - Fernández-Rodríguez, Amanda
AU  - Fernández-Rodríguez A
AUID- ORCID: 0000-0002-5110-2213
AD  - Laboratory of Reference and Research on Viral Hepatitis, National Center of 
      Microbiology, Institute of Health Carlos III, 28220 Majadahonda, Madrid, Spain.
FAU - Coiras, Mayte
AU  - Coiras M
AD  - AIDS Immunopathology Unit, National Center of Microbiology, Institute of Health 
      Carlos III, 28220 Majadahonda, Madrid, Spain.
FAU - Briz, Verónica
AU  - Briz V
AUID- ORCID: 0000-0003-2297-5098
AD  - Laboratory of Reference and Research on Viral Hepatitis, National Center of 
      Microbiology, Institute of Health Carlos III, 28220 Majadahonda, Madrid, Spain.
LA  - eng
GR  - RD16CIII/0002/0001 and RD16CIII/0002/0002/The SPANISH AIDS Research Network - 
      ISCIII/
GR  - (CP14/CIII/00010)/A.F.R. is supported by the Miguel Servet programme from Fondo de 
      Investigación Sanitaria (ISCIII)/
GR  - PI15CIII/00031 and PI18CIII/00020/Instituto de Salud Carlos III to VB and AFR/
GR  - (SAF2016-78480-R)/Spanish Ministry of Economy and Competitiveness to MC/
PT  - Journal Article
DEP - 20200703
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC7408928
OTO - NOTNLM
OT  - HIV reservoir
OT  - HIV/HCV
OT  - Tat
OT  - coinfection
OT  - qPCR
OT  - resting CD4+ T lymphocytes
OT  - viral splicing
COIS- The authors declare no competing interests.
EDAT- 2020/07/09 06:00
MHDA- 2020/07/09 06:01
CRDT- 2020/07/09 06:00
PHST- 2020/06/24 00:00 [received]
PHST- 2020/06/29 00:00 [revised]
PHST- 2020/06/29 00:00 [accepted]
PHST- 2020/07/09 06:00 [entrez]
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2020/07/09 06:01 [medline]
AID - jcm9072091 [pii]
AID - jcm-09-02091 [pii]
AID - 10.3390/jcm9072091 [doi]
PST - epublish
SO  - J Clin Med. 2020 Jul 3;9(7):2091. doi: 10.3390/jcm9072091.

PMID- 30222706
OWN - NLM
STAT- MEDLINE
DCOM- 20191014
LR  - 20200930
IS  - 1944-7884 (Electronic)
IS  - 1525-4135 (Linking)
VI  - 79 Suppl 1
DP  - 2018 Oct 1
TI  - Logics of Commitment in Vaccine Trials of the ANRS Cohorts 1992-2001.
PG  - S59-S68
LID - 10.1097/QAI.0000000000001809 [doi]
AB  - In France, participation in vaccine trials is necessarily a personal act that is not 
      intended to be made public. It does not involve any direct act of solidarity nor 
      does it require any protest or demanding behavior. On the contrary, it requires 
      unconditional compliance with the research protocols. However, it is a form of 
      individual commitment, which is part of a range of social motives that determine the 
      various forms of voluntary involvement in the fight against AIDS: financial 
      donations, voluntary work in associations, political activism, etc. In this study, 
      we use the application letters of the people who responded to the annual recruitment 
      campaigns launched by the Agence Nationale de Recherche sur le Sida et les Hépatites 
      (ANRS) to take part as volunteers in vaccine trials related to the fight against 
      HIV. At the end of a selection process, a certain number of people were recruited 
      every year between 1991 and 2001 and included in a "volunteer network" [The 
      application materials were anonymized by the ANRS before they were sent to us. The 
      network is defined as a group of volunteers (based on the model of blood and bone 
      marrow donors) who have direct contact with the researchers in the form of a 
      partnership and not the classic relationship of therapeutic dependence, are aware of 
      the absence of any direct benefit and of the risks involved, are informed regularly 
      about changes in research, and have the possibility to get to know each other during 
      annual meetings and to share their experiences, hopes, and any disappointments. 
      Selection was performed in a general manner for the purpose of inclusion in the 
      "network" and not for a particular trial. The uniqueness of the network facilitates 
      the distribution of volunteers between trials for the varying needs of the protocols 
      while reinforcing a sense of integration intended to maintain their motivation.]. In 
      addition to the application materials, we add a series of informational interviews 
      with several people in charge of recruitment for the decade studied, as well as 
      about a dozen biographical interviews with volunteers included in the network [The 
      data were made available as part of a research project of the ANRS (2003), 
      transformations des logiques de l'engagement dans la lutte contre le sida: motifs, 
      facteurs et conséquences biographiques de l'engagement dans les essais vaccinaux, 
      (Transformations in the basis of commitment in the fight against AIDS: reasons, 
      factors, and biographical consequences of engagement in vaccine trials), in which 
      Philippe Blanchard and Anne Marijnen collaborated for some of the statistics, 
      informational interviews with recruiters, and life histories of a group of 
      volunteers. Véronique Doré and Yves Souteyrand, through their efforts, were able to 
      remove all obstacles to the collection and processing of information. For this, we 
      thank them warmly. This article was taken from a lecture given during a study day on 
      June 12, 2015, in cooperation with the Vaccine Research Institute, entitled Du 
      recrutement pour à l'engagement dans la recherche: Interactions et médiations 
      constitutives des recherches en prévention contre le VIH au Nord (Recruitment for 
      engagement in research: interactions and mediations in research on the prevention of 
      HIV in Western Countries). It also benefited from the comments of participants.]. 
      The research consisted of an exploration of 2 connected aspects: the rationale 
      behind voluntary engagement (the act of submitting an application) and the rationale 
      underlying the recruitment (the work involved in the selection process of people by 
      the ANRS). In most studies, the determinants of engagement are identified based on 
      an analysis of the attributes of the selected volunteers but without showing whether 
      these attributes distinguish them from applicants who were not selected. In 
      addition, "motivations" for engagement are usually collected a posteriori. In this 
      case, the corpus of initial application letters offers the possibility of comparing 
      one population of applicants with the people who were eventually included in the 
      network and distinguishing those who dropped out or refused to be included.
FAU - Fillieule, Olivier
AU  - Fillieule O
AD  - Université de Lausanne (IEPHI-CRAPUL), Switzerland and CRPS-CESSP (Paris 
      1-Sorbonne), France.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Acquir Immune Defic Syndr
JT  - Journal of acquired immune deficiency syndromes (1999)
JID - 100892005
RN  - 0 (AIDS Vaccines)
SB  - IM
MH  - AIDS Vaccines/*immunology
MH  - Adolescent
MH  - Adult
MH  - *Clinical Trials as Topic
MH  - Cohort Studies
MH  - Female
MH  - France
MH  - Guideline Adherence
MH  - HIV/*immunology
MH  - HIV Infections/*prevention & control
MH  - Humans
MH  - Logic
MH  - Male
MH  - Middle Aged
MH  - Social Class
MH  - Socioeconomic Factors
MH  - Volunteers
MH  - Young Adult
EDAT- 2018/09/18 06:00
MHDA- 2019/10/15 06:00
CRDT- 2018/09/18 06:00
PHST- 2018/09/18 06:00 [entrez]
PHST- 2018/09/18 06:00 [pubmed]
PHST- 2019/10/15 06:00 [medline]
AID - 00126334-201810011-00009 [pii]
AID - 10.1097/QAI.0000000000001809 [doi]
PST - ppublish
SO  - J Acquir Immune Defic Syndr. 2018 Oct 1;79 Suppl 1:S59-S68. doi: 
      10.1097/QAI.0000000000001809.

PMID- 32402003
OWN - NLM
STAT- MEDLINE
DCOM- 20201022
LR  - 20201022
IS  - 1678-4464 (Electronic)
IS  - 0102-311X (Linking)
VI  - 36
IP  - 5
DP  - 2020
TI  - Affective relations and treatment adherence for HIV and problematic drug use 
      (Argentina, 2014-2016).
PG  - e00035919
LID - S0102-311X2020000505004 [pii]
LID - 10.1590/0102-311x00035919 [doi]
AB  - The article analyzes interactions between therapeutic experiences and affective 
      relations in the history of patients with chronic health conditions: persons with 
      problematic drug use receiving therapeutic care in religious devices and persons 
      with HIV under clinical care and antiretroviral therapy. The article uses a 
      qualitative methodology based on in-depth interviews. The hypothesis is that the 
      treatments (pharmacological or psychological) usually prove insufficient to provide 
      adequate therapeutic responses to these two chronic conditions. Both groups 
      acknowledged the central importance of affective dimensions for adherence to the 
      proposed treatment regimens and a comprehensive (and thus more effective) approach 
      to HIV and drug addictions. The article concludes by presenting a notion of 
      adherence that extrapolates individual behavior involving mere compliance with 
      prescribed treatments. Adherence is less a personal than a collective experience, in 
      which family, peer networks, and professionals and other therapeutic reference 
      persons play a central role.
FAU - Jones, Daniel
AU  - Jones D
AD  - Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina.
FAU - Cunial, Santiago Luján
AU  - Cunial SL
AD  - Universidad de Buenos Aires, Buenos Aires, Argentina.
LA  - eng
LA  - spa
PT  - Journal Article
TT  - Los vínculos afectivos en la adherencia a tratamientos por VIH y por consumos 
      problemáticos de drogas (Argentina, 2014-2016).
DEP - 20200508
PL  - Brazil
TA  - Cad Saude Publica
JT  - Cadernos de saude publica
JID - 8901573
RN  - 0 (Anti-HIV Agents)
SB  - IM
MH  - *Anti-HIV Agents
MH  - Argentina
MH  - *HIV Infections
MH  - Humans
MH  - *Patient Compliance
MH  - *Substance-Related Disorders
EDAT- 2020/05/14 06:00
MHDA- 2020/10/23 06:00
CRDT- 2020/05/14 06:00
PHST- 2019/02/25 00:00 [received]
PHST- 2019/10/31 00:00 [accepted]
PHST- 2020/05/14 06:00 [entrez]
PHST- 2020/05/14 06:00 [pubmed]
PHST- 2020/10/23 06:00 [medline]
AID - S0102-311X2020000505004 [pii]
AID - 10.1590/0102-311x00035919 [doi]
PST - ppublish
SO  - Cad Saude Publica. 2020;36(5):e00035919. doi: 10.1590/0102-311x00035919. Epub 2020 
      May 8.

PMID- 32909370
OWN - NLM
STAT- MEDLINE
DCOM- 20210510
LR  - 20210510
IS  - 1758-2652 (Electronic)
IS  - 1758-2652 (Linking)
VI  - 23
IP  - 9
DP  - 2020 Sep
TI  - Persistent HIV-controllers are more prone to spontaneously clear HCV: a 
      retrospective cohort study.
PG  - e25607
LID - 10.1002/jia2.25607 [doi]
LID - e25607
AB  - INTRODUCTION: HIV-controllers have the ability to spontaneously maintain viraemia at 
      low or undetectable levels in the absence of antiretroviral treatment. Furthermore, 
      HIV-controllers seem to have a superior capacity to spontaneously clear hepatitis C 
      virus (HCV) compared to non HIV-controllers. Some of these subjects eventually lose 
      HIV-controller status (transient controllers), whereas some HIV-controllers show a 
      persistent natural HIV control (persistent controllers). We aimed to analyse whether 
      persistent controllers have superior capacity to spontaneously clear HCV compared to 
      transient controllers. METHODS: We recruited HIV-controllers from January 1981 up to 
      October 2016 with available antibodies to HCV (anti-HCV) data (n = 744). Factors 
      associated with HIV spontaneous control in relation to HCV status were analysed in 
      persistent and transient HIV-controllers with anti-HCV positive (n = 202 and n = 138 
      respectively) in comparison with 1700 HCV positive non HIV-controllers recruited 
      from January 1981 up to March 2018, bivariate and multivariate analyses, following a 
      logistic regression model, were applied. In addition, the factors related to the 
      loss and time to lose HIV-controller status were explored (n = 744) using Log rank 
      test and Kaplan-Meier curves, in this case the multivariate analysis consisted in a 
      Cox regression model. RESULTS: A higher frequency of HCV spontaneous clearance was 
      found in persistent HIV-controllers (25.5%) compared to non-controllers (10.2%). 
      After adjusting for potential confounders, as sex, age, HIV transmission risk, 
      CD4(+) T-cell nadir and time of follow-up, HCV clearance was independently 
      associated with persistent HIV spontaneous control (p = 0.002; OR (95% CI) = 2.573 
      (1.428 to 4.633)), but not with transient spontaneous control (p = 0.119; 1.589 
      (0.888 to 2.845)). Furthermore, persistent HIV-controllers were more likely to 
      spontaneously clear the HCV in comparison with transient controllers (p = 0.027; 
      0.377 (0.159 to 0.893). Finally, not to lose or lengthen the time of losing this 
      control was independently associated with HCV spontaneous clearance (p = 0.010; 
      0.503 (0.297 to 0.850). CONCLUSIONS: This study shows an association between 
      spontaneous persistent HIV-control and HCV spontaneous clearance. The study findings 
      support the idea of preserved immune mechanisms in persistent HIV control implicated 
      in HCV spontaneous clearance. These results highlight persistent HIV-controllers but 
      not transient controllers as a good model of functional HIV cure.
CI  - © 2020 The Authors. Journal of the International AIDS Society published by John 
      Wiley & Sons Ltd on behalf of the International AIDS Society.
FAU - Dominguez-Molina, Beatriz
AU  - Dominguez-Molina B
AD  - Enfermedades Infecciosas, Microbiología Clínica y Medicina Preventiva. Instituto de 
      Biomedicina de Sevilla/Hospital Universitario Virgen del Rocío/CSIC/Universidad de 
      Sevilla, Sevilla, Spain.
AD  - Laboratorio de Inmunovirologia, Instituto de Biomedicina de Sevilla (IBiS), Hospital 
      Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain.
FAU - Tarancon-Diez, Laura
AU  - Tarancon-Diez L
AD  - Enfermedades Infecciosas, Microbiología Clínica y Medicina Preventiva. Instituto de 
      Biomedicina de Sevilla/Hospital Universitario Virgen del Rocío/CSIC/Universidad de 
      Sevilla, Sevilla, Spain.
AD  - Laboratorio de Inmunovirologia, Instituto de Biomedicina de Sevilla (IBiS), Hospital 
      Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain.
FAU - Milanés-Guisado, Yusnelkis
AU  - Milanés-Guisado Y
AD  - Enfermedades Infecciosas, Microbiología Clínica y Medicina Preventiva. Instituto de 
      Biomedicina de Sevilla/Hospital Universitario Virgen del Rocío/CSIC/Universidad de 
      Sevilla, Sevilla, Spain.
FAU - Genebat, Miguel
AU  - Genebat M
AD  - Laboratorio de Inmunovirologia, Instituto de Biomedicina de Sevilla (IBiS), Hospital 
      Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain.
AD  - Servicio de Urgencias, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
FAU - Resino, Salvador
AU  - Resino S
AUID- ORCID: 0000-0001-8783-0450
AD  - Unidad de Infección Viral e Inmunidad, Centro Nacional de TOUCH FOR FMicrobiología, 
      Instituto de Salud Carlos III, Madrid, Spain.
FAU - Rodriguez, Carmen
AU  - Rodriguez C
AD  - Centro Sanitario Sandoval, IdlSSC, Madrid, España.
FAU - Gonzalez-García, Juan
AU  - Gonzalez-García J
AD  - Unidad de VIH, Hospital Universitario La Paz-IdiPaz, Madrid, Spain.
FAU - Rallón, Norma
AU  - Rallón N
AD  - Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Universidad Autónoma de 
      Madrid (IIS-FJD, UAM), Spain.
AD  - Hospital Universitario Rey Juan Carlos, Móstoles, Spain.
FAU - Pernas, Maria
AU  - Pernas M
AUID- ORCID: 0000-0003-2966-0160
AD  - Unidad de Virologia Molecular, Laboratorio de Referencia e Investigación en 
      Retrovirus, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, 
      Spain.
FAU - Casado, Concepción
AU  - Casado C
AD  - Unidad de Virologia Molecular, Laboratorio de Referencia e Investigación en 
      Retrovirus, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, 
      Spain.
FAU - Lopez-Galíndez, Cecilio
AU  - Lopez-Galíndez C
AD  - Unidad de Virologia Molecular, Laboratorio de Referencia e Investigación en 
      Retrovirus, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, 
      Spain.
FAU - León, Agathe
AU  - León A
AD  - Departmento de Enfermedades Infecciosas, Hospital Clinic de Barcelona, Hospital 
      Clinic de Barcelona, Barcelona, Spain.
FAU - Benito, Jose M
AU  - Benito JM
AD  - Hospital Universitario Rey Juan Carlos, Móstoles, Spain.
AD  - Unidad de Virologia Molecular, Laboratorio de Referencia e Investigación en 
      Retrovirus, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, 
      Spain.
FAU - García, Felipe
AU  - García F
AD  - Departmento de Enfermedades Infecciosas, Hospital Clinic de Barcelona, Hospital 
      Clinic de Barcelona, Barcelona, Spain.
FAU - Del Romero, Jorge
AU  - Del Romero J
AD  - Centro Sanitario Sandoval, IdlSSC, Madrid, España.
FAU - Viciana, Pompeyo
AU  - Viciana P
AD  - Enfermedades Infecciosas, Microbiología Clínica y Medicina Preventiva. Instituto de 
      Biomedicina de Sevilla/Hospital Universitario Virgen del Rocío/CSIC/Universidad de 
      Sevilla, Sevilla, Spain.
FAU - Lopez-Cortes, Luis F
AU  - Lopez-Cortes LF
AD  - Enfermedades Infecciosas, Microbiología Clínica y Medicina Preventiva. Instituto de 
      Biomedicina de Sevilla/Hospital Universitario Virgen del Rocío/CSIC/Universidad de 
      Sevilla, Sevilla, Spain.
FAU - Leal, Manuel
AU  - Leal M
AD  - Laboratorio de Inmunovirologia, Instituto de Biomedicina de Sevilla (IBiS), Hospital 
      Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain.
AD  - Servicio de Medicina Interna, Hospital Viamed, Santa Ángela de la Cruz, Seville, 
      Spain.
FAU - Ruiz-Mateos, Ezequiel
AU  - Ruiz-Mateos E
AUID- ORCID: 0000-0001-6747-7813
AD  - Enfermedades Infecciosas, Microbiología Clínica y Medicina Preventiva. Instituto de 
      Biomedicina de Sevilla/Hospital Universitario Virgen del Rocío/CSIC/Universidad de 
      Sevilla, Sevilla, Spain.
CN  - ECRIS integrated in the Spanish AIDS Research Network
AD  - Enfermedades Infecciosas, Microbiología Clínica y Medicina Preventiva. Instituto de 
      Biomedicina de Sevilla/Hospital Universitario Virgen del Rocío/CSIC/Universidad de 
      Sevilla, Sevilla, Spain.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
TA  - J Int AIDS Soc
JT  - Journal of the International AIDS Society
JID - 101478566
SB  - IM
MH  - Adult
MH  - CD4-Positive T-Lymphocytes/immunology
MH  - Female
MH  - HIV Infections/*immunology/virology
MH  - HIV Long-Term Survivors/statistics & numerical data
MH  - HIV-1/genetics/immunology/physiology
MH  - Hepacivirus/genetics/*immunology/physiology
MH  - Hepatitis C/*immunology/virology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Young Adult
PMC - PMC7507465
OTO - NOTNLM
OT  - *HCV
OT  - *HCV spontaneous clearance
OT  - *HIV
OT  - *HIV-controllers
OT  - *persistent
OT  - *transient
EDAT- 2020/09/11 06:00
MHDA- 2021/05/11 06:00
CRDT- 2020/09/10 05:40
PHST- 2020/03/04 00:00 [received]
PHST- 2020/06/29 00:00 [revised]
PHST- 2020/07/07 00:00 [accepted]
PHST- 2020/09/10 05:40 [entrez]
PHST- 2020/09/11 06:00 [pubmed]
PHST- 2021/05/11 06:00 [medline]
AID - JIA225607 [pii]
AID - 10.1002/jia2.25607 [doi]
PST - ppublish
SO  - J Int AIDS Soc. 2020 Sep;23(9):e25607. doi: 10.1002/jia2.25607.

PMID- 30718512
OWN - NLM
STAT- MEDLINE
DCOM- 20190410
LR  - 20200309
IS  - 2041-1723 (Electronic)
IS  - 2041-1723 (Linking)
VI  - 10
IP  - 1
DP  - 2019 Feb 4
TI  - CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic 
      small cell carcinoma of the ovary.
PG  - 558
LID - 10.1038/s41467-018-06958-9 [doi]
LID - 558
AB  - Inactivating mutations in SMARCA4 (BRG1), a key SWI/SNF chromatin remodelling gene, 
      underlie small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). To reveal 
      its druggable vulnerabilities, we perform kinase-focused RNAi screens and uncover 
      that SMARCA4-deficient SCCOHT cells are highly sensitive to the inhibition of 
      cyclin-dependent kinase 4/6 (CDK4/6). SMARCA4 loss causes profound downregulation of 
      cyclin D1, which limits CDK4/6 kinase activity in SCCOHT cells and leads to in vitro 
      and in vivo susceptibility to CDK4/6 inhibitors. SCCOHT patient tumors are deficient 
      in cyclin D1 yet retain the retinoblastoma-proficient/p16(INK4a)-deficient profile 
      associated with positive responses to CDK4/6 inhibitors. Thus, our findings indicate 
      that CDK4/6 inhibitors, approved for a breast cancer subtype addicted to CDK4/6 
      activation, could be repurposed to treat SCCOHT. Moreover, our study suggests a 
      novel paradigm whereby critically low oncogene levels, caused by loss of a driver 
      tumor suppressor, may also be exploited therapeutically.
FAU - Xue, Yibo
AU  - Xue Y
AUID- ORCID: 0000-0003-4252-4446
AD  - Department of Biochemistry, McGill University, Montreal, QC, H3G 1Y6, Canada.
AD  - The Rosalind & Morris Goodman Cancer Research Centre, McGill University, Montreal, 
      QC, H3A 1A3, Canada.
FAU - Meehan, Brian
AU  - Meehan B
AD  - Department of Pediatrics, McGill University, Montreal, QC, H4A 3J1, Canada.
AD  - Research Institute of McGill University Health Centre Montreal Children's Hospital, 
      Montreal, QC, H4A 3J1, Canada.
FAU - Macdonald, Elizabeth
AU  - Macdonald E
AD  - Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON, K1Y 
      4E9, Canada.
AD  - Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, K1H 
      8M5, Canada.
FAU - Venneti, Sriram
AU  - Venneti S
AD  - Pathology and Neuropathology, University of Michigan Medical School, Ann Arbor, MI, 
      48109-0605, USA.
FAU - Wang, Xue Qing D
AU  - Wang XQD
AD  - Department of Biochemistry, McGill University, Montreal, QC, H3G 1Y6, Canada.
FAU - Witkowski, Leora
AU  - Witkowski L
AD  - Department of Human Genetics, McGill University, Montreal, QC, H3A 0C7, Canada.
AD  - Department of Medical Genetics, Jewish General Hospital, McGill University, 
      Montreal, QC, H3T 1E2, Canada.
AD  - Lady Davis Institute, McGill University, Montreal, QC, H3T 1E2, Canada.
AD  - Department of Medical Genetics and Cancer Research Program, Research Institute of 
      the McGill University Health Centre, McGill University, Montreal, QC, H4A 3JI, 
      Canada.
FAU - Jelinic, Petar
AU  - Jelinic P
AUID- ORCID: 0000-0002-7361-5239
AD  - Gynecologic Oncology, Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical 
      Center, New York, NY, 10016, USA.
FAU - Kong, Tim
AU  - Kong T
AD  - Department of Biochemistry, McGill University, Montreal, QC, H3G 1Y6, Canada.
AD  - The Rosalind & Morris Goodman Cancer Research Centre, McGill University, Montreal, 
      QC, H3A 1A3, Canada.
FAU - Martinez, Daniel
AU  - Martinez D
AD  - Children's Hospital of Philadelphia Research Institute, Philadelphia, PA, 19104, 
      USA.
FAU - Morin, Geneviève
AU  - Morin G
AD  - Department of Biochemistry, McGill University, Montreal, QC, H3G 1Y6, Canada.
AD  - The Rosalind & Morris Goodman Cancer Research Centre, McGill University, Montreal, 
      QC, H3A 1A3, Canada.
FAU - Firlit, Michelle
AU  - Firlit M
AD  - Gynecologic Oncology, Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical 
      Center, New York, NY, 10016, USA.
FAU - Abedini, Atefeh
AU  - Abedini A
AD  - Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON, K1Y 
      4E9, Canada.
AD  - Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, K1H 
      8M5, Canada.
FAU - Johnson, Radia M
AU  - Johnson RM
AD  - Department of Biochemistry, McGill University, Montreal, QC, H3G 1Y6, Canada.
AD  - The Rosalind & Morris Goodman Cancer Research Centre, McGill University, Montreal, 
      QC, H3A 1A3, Canada.
FAU - Cencic, Regina
AU  - Cencic R
AD  - Department of Biochemistry, McGill University, Montreal, QC, H3G 1Y6, Canada.
AD  - The Rosalind & Morris Goodman Cancer Research Centre, McGill University, Montreal, 
      QC, H3A 1A3, Canada.
FAU - Patibandla, Jay
AU  - Patibandla J
AD  - Gynecologic Oncology, Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical 
      Center, New York, NY, 10016, USA.
FAU - Chen, Hongbo
AU  - Chen H
AD  - School of Pharmaceutical Sciences (Shenzhen), Sun Yat-Sat University, 510275, 
      Guangzhou, China.
FAU - Papadakis, Andreas I
AU  - Papadakis AI
AD  - Department of Biochemistry, McGill University, Montreal, QC, H3G 1Y6, Canada.
AD  - The Rosalind & Morris Goodman Cancer Research Centre, McGill University, Montreal, 
      QC, H3A 1A3, Canada.
FAU - Auguste, Aurelie
AU  - Auguste A
AD  - Department of Cancer Medicine, Gustave Roussy, INSERM U981, 94800, Villejuif, 
      France.
FAU - de Rink, Iris
AU  - de Rink I
AD  - Genomics Core Facility, The Netherlands Cancer Institute, 1066 CX, Amsterdam, The 
      Netherlands.
FAU - Kerkhoven, Ron M
AU  - Kerkhoven RM
AD  - Genomics Core Facility, The Netherlands Cancer Institute, 1066 CX, Amsterdam, The 
      Netherlands.
FAU - Bertos, Nicholas
AU  - Bertos N
AD  - Department of Biochemistry, McGill University, Montreal, QC, H3G 1Y6, Canada.
AD  - The Rosalind & Morris Goodman Cancer Research Centre, McGill University, Montreal, 
      QC, H3A 1A3, Canada.
FAU - Gotlieb, Walter H
AU  - Gotlieb WH
AD  - Division of Gynecologic Oncology, Segal Cancer Center, Jewish General Hospital, 
      McGill University, Montreal, QC, H3T 1E2, Canada.
FAU - Clarke, Blaise A
AU  - Clarke BA
AD  - Department of Laboratory Medicine and Pathobiology, University of Toronto, 
      University Health Network, Toronto, ON, M5G 2C4, Canada.
FAU - Leary, Alexandra
AU  - Leary A
AD  - Department of Cancer Medicine, Gustave Roussy, INSERM U981, 94800, Villejuif, 
      France.
FAU - Witcher, Michael
AU  - Witcher M
AD  - Department of Oncology, McGill University, Montreal, QC, H3T 1E2, Canada.
AD  - Department of Experimental Medicine, McGill University, Montreal, QC, H3T 1E2, 
      Canada.
AD  - Lady Davis Institute, Jewish General Hospital, Montreal, QC, H3T 1E2, Canada.
AD  - Segal Cancer Centre, Jewish General Hospital, Montreal, QC, H3T 1E2, Canada.
FAU - Guiot, Marie-Christine
AU  - Guiot MC
AD  - Department of Pathology, Montreal Neurological Hospital/Institute, McGill University 
      Health Centre, Montreal, QC, H3A 2B4, Canada.
FAU - Pelletier, Jerry
AU  - Pelletier J
AD  - Department of Biochemistry, McGill University, Montreal, QC, H3G 1Y6, Canada.
AD  - The Rosalind & Morris Goodman Cancer Research Centre, McGill University, Montreal, 
      QC, H3A 1A3, Canada.
FAU - Dostie, Josée
AU  - Dostie J
AD  - Department of Biochemistry, McGill University, Montreal, QC, H3G 1Y6, Canada.
FAU - Park, Morag
AU  - Park M
AD  - Department of Biochemistry, McGill University, Montreal, QC, H3G 1Y6, Canada.
AD  - The Rosalind & Morris Goodman Cancer Research Centre, McGill University, Montreal, 
      QC, H3A 1A3, Canada.
FAU - Judkins, Alexander R
AU  - Judkins AR
AD  - Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, 
      Keck School of Medicine of University of Southern California, Los Angeles, CA, 
      90027, USA.
FAU - Hass, Ralf
AU  - Hass R
AUID- ORCID: 0000-0002-2481-7547
AD  - Biochemistry and Tumor Biology Laboratory, Department of Gynecology and Obstetrics, 
      Medical University Hannover, 30625, Hannover, Germany.
FAU - Levine, Douglas A
AU  - Levine DA
AUID- ORCID: 0000-0003-1038-8232
AD  - Gynecologic Oncology, Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical 
      Center, New York, NY, 10016, USA.
FAU - Rak, Janusz
AU  - Rak J
AD  - Department of Pediatrics, McGill University, Montreal, QC, H4A 3J1, Canada.
AD  - Research Institute of McGill University Health Centre Montreal Children's Hospital, 
      Montreal, QC, H4A 3J1, Canada.
FAU - Vanderhyden, Barbara
AU  - Vanderhyden B
AD  - Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON, K1Y 
      4E9, Canada.
AD  - Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, K1H 
      8M5, Canada.
FAU - Foulkes, William D
AU  - Foulkes WD
AUID- ORCID: 0000-0001-7427-4651
AD  - Department of Human Genetics, McGill University, Montreal, QC, H3A 0C7, Canada. 
      william.foulkes@mcgill.ca.
AD  - Department of Medical Genetics, Jewish General Hospital, McGill University, 
      Montreal, QC, H3T 1E2, Canada. william.foulkes@mcgill.ca.
AD  - Lady Davis Institute, McGill University, Montreal, QC, H3T 1E2, Canada. 
      william.foulkes@mcgill.ca.
AD  - Department of Medical Genetics and Cancer Research Program, Research Institute of 
      the McGill University Health Centre, McGill University, Montreal, QC, H4A 3JI, 
      Canada. william.foulkes@mcgill.ca.
FAU - Huang, Sidong
AU  - Huang S
AUID- ORCID: 0000-0002-2838-4726
AD  - Department of Biochemistry, McGill University, Montreal, QC, H3G 1Y6, Canada. 
      sidong.huang@mcgill.ca.
AD  - The Rosalind & Morris Goodman Cancer Research Centre, McGill University, Montreal, 
      QC, H3A 1A3, Canada. sidong.huang@mcgill.ca.
LA  - eng
GR  - W81XWH-15-1-0497/DOD | Congressionally Directed Medical Research Programs 
      (CDMRP)/International
GR  - MOP-130540/Gouvernement du Canada | Canadian Institutes of Health Research 
      (Instituts de Recherche en Santé du Canada)/International
GR  - PJT-156233/Canadian HIV Trials Network, Canadian Institutes of Health Research 
      (Réseau canadien pour les essais VIH des IRSC)/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190204
TA  - Nat Commun
JT  - Nature communications
JID - 101528555
RN  - 0 (Aminopyridines)
RN  - 0 (Benzimidazoles)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Piperazines)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Purines)
RN  - 0 (Pyridines)
RN  - 0 (RNA, Small Interfering)
RN  - 0 (Transcription Factors)
RN  - 136601-57-5 (Cyclin D1)
RN  - 60UAB198HK (abemaciclib)
RN  - EC 3.6.1.- (SMARCA4 protein, human)
RN  - EC 3.6.4.- (DNA Helicases)
RN  - G9ZF61LE7G (palbociclib)
RN  - TK8ERE8P56 (ribociclib)
SB  - IM
MH  - Aminopyridines/therapeutic use
MH  - Animals
MH  - Benzimidazoles/therapeutic use
MH  - Carcinoma, Small Cell/*drug therapy/*metabolism
MH  - Cell Line, Tumor
MH  - Cell Survival/drug effects/genetics
MH  - Chromatin Immunoprecipitation
MH  - Cyclin D1/*deficiency/metabolism
MH  - DNA Helicases/genetics/*metabolism
MH  - Female
MH  - Humans
MH  - Hypercalcemia/drug therapy/metabolism
MH  - Mice
MH  - Mice, SCID
MH  - Nuclear Proteins/genetics/*metabolism
MH  - Ovarian Neoplasms/drug therapy/metabolism
MH  - Piperazines/therapeutic use
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - Purines/therapeutic use
MH  - Pyridines/therapeutic use
MH  - RNA, Small Interfering/genetics
MH  - Transcription Factors/genetics/*metabolism
PMC - PMC6361890
COIS- The authors declare no competing interests.
EDAT- 2019/02/06 06:00
MHDA- 2019/04/11 06:00
CRDT- 2019/02/06 06:00
PHST- 2018/04/24 00:00 [received]
PHST- 2018/10/04 00:00 [accepted]
PHST- 2019/02/06 06:00 [entrez]
PHST- 2019/02/06 06:00 [pubmed]
PHST- 2019/04/11 06:00 [medline]
AID - 10.1038/s41467-018-06958-9 [pii]
AID - 6958 [pii]
AID - 10.1038/s41467-018-06958-9 [doi]
PST - epublish
SO  - Nat Commun. 2019 Feb 4;10(1):558. doi: 10.1038/s41467-018-06958-9.

PMID- 31746078
OWN - NLM
STAT- MEDLINE
DCOM- 20201002
LR  - 20201002
IS  - 1365-3156 (Electronic)
IS  - 1360-2276 (Linking)
VI  - 25
IP  - 2
DP  - 2020 Feb
TI  - Hepatitis B and C in the adult population of Bissau, Guinea-Bissau: a 
      cross-sectional survey.
PG  - 255-263
LID - 10.1111/tmi.13335 [doi]
AB  - OBJECTIVE: Hepatitis B virus (HBV) and hepatitis C virus (HCV) are prevalent in West 
      Africa. To address the WHO 2030 goals of a 90% reduction in incidence and a 65% 
      reduction in mortality for both infections, we assessed the prevalence of HBV and 
      HCV from surveys in the general population. METHODS: Participants in this 
      cross-sectional survey were included from randomly selected houses in a demographic 
      surveillance site in Bissau, Guinea-Bissau. Participants were interviewed and had a 
      blood sample drawn for viral analyses (HBsAg, anti-HBs, anti-HBc, anti-HCV and HCV 
      RNA). Risk factors of HBV and HCV infection were determined by binomial regression 
      adjusted for sex and age. RESULTS: A total of 2715 participants were included in 
      this study. The overall HBsAg prevalence was 18.7% (95% CI: 17.3-20.2%). HBsAg was 
      associated with male sex (adjusted risk ratio (aRR): 1.64), and prevalence decreased 
      with age >34 years. HBV exposure was found in 91.9% of participants. Although 72.6% 
      of individuals without sexual debut had been exposed to HBV, ever engaging in a 
      sexual relationship was associated with higher risk of HBV exposure (aRR 1.18). The 
      anti-HCV prevalence was 0.5% (95% CI: 0.3-0.9%), and 78.6% of those had detectable 
      HCV RNA. Risk factors for anti-HCV sero-positivity were age above 55 (aRR 10.60), a 
      history of blood transfusion (aRR 5.07) and being in a polygamous marriage (aRR 
      3.52). CONCLUSION: In Guinea-Bissau initiatives to implement treatment and 
      widespread testing are needed to reach the WHO 2030 goals.
CI  - © 2019 John Wiley & Sons Ltd.
FAU - Hønge, Bo Langhoff
AU  - Hønge BL
AD  - Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau.
AD  - Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark.
AD  - Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
FAU - Olesen, Jens Steen
AU  - Olesen JS
AD  - Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau.
AD  - Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
FAU - Jensen, Mads Mose
AU  - Jensen MM
AD  - Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau.
AD  - Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
FAU - Jespersen, Sanne
AU  - Jespersen S
AD  - Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau.
AD  - Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
FAU - da Silva, Zacarias José
AU  - da Silva ZJ
AD  - Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau.
AD  - National Public Health Laboratory, Bissau, Guinea-Bissau.
FAU - Rodrigues, Amabélia
AU  - Rodrigues A
AD  - Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau.
FAU - Laursen, Alex Lund
AU  - Laursen AL
AD  - Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
FAU - Wejse, Christian
AU  - Wejse C
AD  - Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau.
AD  - Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
AD  - GloHAU, Center for Global Health, School of Public Health, Aarhus University, 
      Aarhus, Denmark.
FAU - Krarup, Henrik
AU  - Krarup H
AD  - Section of Molecular Diagnostics, Clinical Biochemistry, Aalborg University 
      Hospital, Aalborg, Denmark.
FAU - Aaby, Peter
AU  - Aaby P
AD  - Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau.
FAU - Erikstrup, Christian
AU  - Erikstrup C
AD  - Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark.
LA  - eng
GR  - Aase og Ejnar Danielsens Fond/International
GR  - Aage og Johanne Louis-Hansens Fond/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20191120
PL  - England
TA  - Trop Med Int Health
JT  - Tropical medicine & international health : TM & IH
JID - 9610576
SB  - IM
MH  - Adult
MH  - Cross-Sectional Studies
MH  - Female
MH  - Guinea-Bissau/epidemiology
MH  - Hepatitis B/*epidemiology
MH  - Hepatitis C/*epidemiology
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Prevalence
MH  - Risk Factors
OTO - NOTNLM
OT  - *Guinea-Bissau
OT  - *Guinée-Bissau
OT  - *HIV
OT  - *HIV-2
OT  - *HTLV
OT  - *VIH
OT  - *VIH-2
OT  - *hepatitis B
OT  - *hepatitis C
OT  - *hépatite B
OT  - *hépatite C
EDAT- 2019/11/21 06:00
MHDA- 2020/10/03 06:00
CRDT- 2019/11/21 06:00
PHST- 2019/11/21 06:00 [pubmed]
PHST- 2020/10/03 06:00 [medline]
PHST- 2019/11/21 06:00 [entrez]
AID - 10.1111/tmi.13335 [doi]
PST - ppublish
SO  - Trop Med Int Health. 2020 Feb;25(2):255-263. doi: 10.1111/tmi.13335. Epub 2019 Nov 
      20.

PMID- 35090156
OWN - NLM
STAT- Publisher
LR  - 20220128
IS  - 1944-7884 (Electronic)
IS  - 1525-4135 (Linking)
DP  - 2022 Jan 26
TI  - Patients' experiences and opinions after de-simplification of their single-tablet 
      regimens for the treatment of HIV infection: a survey in a multicentre cohort.
LID - 10.1097/QAI.0000000000002923 [doi]
AB  - OBJECTIVES: The aims of this study were to describe patients' experiences after 
      single-tablet regimen (STR) de-simplification, and its impact on self-reported 
      treatment adherence and quality of life. METHODS: We performed a survey among all 
      patients from the multicenter cohort of the Spanish HIV/AIDS Network (CoRIS) who had 
      de-simplified the STRs dolutegravir/abacavir/lamivudine (DGT/ABC/3TC) or 
      rilpivirine/tenofovir disoproxil fumarate/emtricitabine (RPV/TDF/FTC) to their 
      separate components (DTG+generic ABC/3TC or RPV+generic TDF/FTC, respectively) 
      between December 2016 and November 2018. RESULTS: Among 216 patients who fulfilled 
      inclusion criteria, 138 (63.9%) completed the questionnaire. The majority (78.3%) 
      knew what generic drugs are, only 8.7% thought that treatment with two pills is less 
      effective than treatment with an STR, and 67.4% agreed that it is reasonable to take 
      two pills instead of one for HIV treatment in order to decrease costs for the 
      healthcare system.After de-simplification, 13.0% of the patients stated they had 
      more secondary effects, 8.0% had forgotten one or more doses more frequently than 
      before, and 10.9% had sometimes forgotten to take one pill, but not the other. A 
      proportion of 30.4% reported not being happy to take more pills a day and 10.1% 
      experienced a worse quality of life after the treatment de-simplification. 
      CONCLUSIONS: After STR de-simplification, most patients had a fair knowledge about 
      generic antiretrovirals , and they agreed to de-simplify their STR in order to 
      decrease costs. Although almost a third of the respondents were not happy to take 
      two pills a day, only a minority reported worse adherence or quality of life.
CI  - Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Suárez-García, Inés
AU  - Suárez-García I
AD  - Infectious Diseases Group. Department of Internal Medicine. Hospital Universitario 
      Infanta Sofía, Madrid, Spain. Faculty of Biomedical Sciences. Universidad Europea, 
      Madrid, Spain. CIBER de Enfermedades Infecciosas, Spain. Centro Nacional de 
      Epidemiología. Instituto de Salud Carlos III, Madrid, Spain. Department of Hospital 
      Pharmacy. Hospital Universitario Infanta Sofía, Madrid, Spain. Consortium for 
      Biomedical Research in Epidemiology & Public Health (CIBERESP), Instituto de Salud 
      Carlos III, Madrid, Spain. Presidency. Coordinadora Estatal de VIH y sida (CESIDA), 
      Madrid, Spain. Grupo de Trabajo sobre Tratamientos del VIH (gTt-VIH), Barcelona, 
      Spain. Department of Infectious Diseases, Hospital Universitario Basurto, Bilbao, 
      Spain. Infectious Diseases Unit. Hospital Universitario de Donostia, Donostia, 
      Spain. Infections Section. Hospital Universitario de Canarias, Santa Cruz de 
      Tenerife, Spain, Infectious Diseases Unit. Hospital Reina Sofía, Murcia, Spain. 
      Complejo Hospitalario de Navarra, Pamplona, Spain. Hospital General Universitario 
      Santa Lucía, Cartagena, Spain. Unidad de Enfermedades Infecciosas/VIH, Hospital 
      General Universitario Gregorio Marañón, Madrid, Spain. Department of Infectious 
      Diseases, Hospital Virgen de la Victoria, Málaga, Spain. Department of Internal 
      Medicine, Hospital Costa del Sol, Marbella, Spain.
FAU - Ruiz-Algueró, Marta
AU  - Ruiz-Algueró M
FAU - Alejos, Belén
AU  - Alejos B
FAU - García-Yubero, Cristina
AU  - García-Yubero C
FAU - Belza, Ma José
AU  - Belza MJ
FAU - Espacio, Ramón
AU  - Espacio R
FAU - Hernández, Juanse
AU  - Hernández J
FAU - Sánchez, Josefa Muñoz
AU  - Sánchez JM
FAU - Garaialde, Ainhoa
AU  - Garaialde A
FAU - Socas, María Del Mar Alonso
AU  - Socas MDMA
FAU - Alcaraz, Antonia
AU  - Alcaraz A
FAU - Ruiz de Galarreta, Beatriz Pierola
AU  - Ruiz de Galarreta BP
FAU - Martínez Madrid, Onofre Juan
AU  - Martínez Madrid OJ
FAU - Cuéllar, Isabel Gutiérrez
AU  - Cuéllar IG
FAU - Gómez-Ayerbe, Cristina
AU  - Gómez-Ayerbe C
FAU - Olalla, Julián
AU  - Olalla J
FAU - Jarrín, I
AU  - Jarrín I
LA  - eng
PT  - Journal Article
DEP - 20220126
PL  - United States
TA  - J Acquir Immune Defic Syndr
JT  - Journal of acquired immune deficiency syndromes (1999)
JID - 100892005
SB  - IM
COIS- Conflicts of Interest and Sources of Funding: ISG has received conference or speaker 
      fees from Viiv, MSD and Gilead. CGY has received conference fees from Gilead and 
      Janssen. IJ has received teaching fees from Viiv and advisory fees from Gilead. All 
      other authors: none to declare., This study was funded by the Instituto de Salud 
      Carlos III (EPY 115/18 and Acción Estratégica en Salud, PI17/00774) and co-funded by 
      the European Regional Development Fund, “A way to make Europe”. CoRIS is supported 
      by the Instituto de Salud Carlos III through the Red Temática de Investigación 
      Cooperativa en Sida (RD06/006, RD12/0017/0018 and RD16/0002/0006) as part of the 
      Plan Nacional I+D+i and co-financed by Instituto de Salud Carlos III-Subdirección 
      General de Evaluación and the European Regional Development Fund.
EDAT- 2022/01/29 06:00
MHDA- 2022/01/29 06:00
CRDT- 2022/01/28 20:04
PHST- 2022/01/28 20:04 [entrez]
PHST- 2022/01/29 06:00 [pubmed]
PHST- 2022/01/29 06:00 [medline]
AID - 00126334-900000000-95704 [pii]
AID - 10.1097/QAI.0000000000002923 [doi]
PST - aheadofprint
SO  - J Acquir Immune Defic Syndr. 2022 Jan 26. doi: 10.1097/QAI.0000000000002923.

PMID- 33847637
OWN - NLM
STAT- MEDLINE
DCOM- 20210428
LR  - 20210428
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 100
IP  - 15
DP  - 2021 Apr 16
TI  - Effects of perinatal HIV-infection on the cortical thickness and subcortical gray 
      matter volumes in young adulthood.
PG  - e25403
LID - 10.1097/MD.0000000000025403 [doi]
LID - e25403
AB  - Brain atrophy has been observed in perinatally HIV-infected patients (PHIV) despite 
      initiation on combined antiretroviral treatment (cART), but neuroimaging studies are 
      limited. We aimed to evaluate cortical thickness (CT) and subcortical gray matter 
      (GM) volumes of PHIV youths with stable immunovirological situation and with a 
      normal daily performance.A prospective cross-sectional study was conducted. A total 
      of 25 PHIV patients on cART and 25 HIV-negative (HIV-) controls matched by age, sex, 
      level of education, and socioeconomic status underwent a magnetic resonance imaging 
      scan. CAT12 toolbox was used to extract CT values from T1w images using 
      parcellations from Desikan-Killiany atlas (DK40). To measure regional brain volumes, 
      native segmented images were parceled in regions of interest according to the 
      Neuromorphometrics Atlas. Neuropsychological assessment and psychopathological 
      symptoms were documented.Fifty participants were included (60% females, median age 
      20 years [interquartile range, IQR 19-23], 64% Whites). No differences regarding 
      neuropsychological tests or psychopathological symptoms were found between groups 
      (all P > .05). All participants presented an average performance in the Fluid 
      Intelligence (FI) test (PHIV mean: -0.12, HIV- mean: 0.24), When comparing CT, 
      PHIV-infected patients showed thinner cortices compared with their peers in fusiform 
      gyrus (P = .000, P = .009), lateral-orbitofrontal gyrus (P = .006, P = .0024), and 
      right parsobitalis gyrus (P = .047). Regarding subcortical GM volumes, PHIV patients 
      showed lower right amygdala (P = .014) and left putamen (P = .016) volumes when 
      compared with HIV- controls. Within the PHIV group, higher CD4 count was associated 
      with higher volumes in right putamen (B = 0.00000038, P = .045). Moreover, increased 
      age at cART initiation and lower nadir CD4 count was associated with larger volumes 
      in left accumbens (B = 0.0000046, P = .033; B = -0.00000008, P = .045, 
      respectively).PHIV patients showed thinner cortices of areas in temporal, 
      orbito-frontal and occipital lobes and lower volumes of subcortical GM volumes when 
      compared with the HIV- control group, suggesting cortical and subcortical brain 
      alterations in otherwise neuroasymptomatic patients. Nevertheless, larger and 
      longitudinal studies are required to determine the impact of HIV on brain structure 
      in PHIV patients and to further identify risk and protective factors that could be 
      implicated.
CI  - Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Ruiz-Saez, Beatriz
AU  - Ruiz-Saez B
AUID- ORCID: 0000-0002-4504-6438
AD  - Immunobiology Department, Hospital Universitario Gregorio Marañon, Instituto de 
      Investigación Sanitaria Gregorio Marañón (IisGM).
FAU - García, Manuela Martín-Bejarano
AU  - García MM
AD  - Department of Paediatric Infectious Diseases, Hospital Universitario 12 de Octubre; 
      Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12).
FAU - de Aragon, Ana Martinez
AU  - de Aragon AM
AD  - Radiology Department, Hospital Universitario 12 de Octubre, Madrid.
FAU - Gil-Correa, Mario
AU  - Gil-Correa M
AD  - Laboratorio de Análisis de Imagen Médica y Biometría (LAIMBIO), Universidad Rey Juan 
      Carlos.
FAU - Melero, Helena
AU  - Melero H
AD  - Departamento de Psicobiología y Metodología en Ciencias del Comportamiento - 
      Universidad Complutense de Madrid, Spain, y Laboratorio de Análisis de Imagen Médica 
      y Biometría (LAIMBIO), Universidad Rey Juan Carlos.
FAU - Malpica, Norberto Antonio
AU  - Malpica NA
AD  - Laboratorio de Análisis de Imagen Médica y Biometría (LAIMBIO), Universidad Rey Juan 
      Carlos.
FAU - de Ory, Santiago Jimenez
AU  - de Ory SJ
AD  - Hospital General Universitario Gregorio Marañón. Instituto de Investigación 
      Sanitaria Gregorio Marañón (IisGM).
FAU - Zamora, Berta
AU  - Zamora B
AD  - Paediatric Neuropsychology Department. Hospital Universitario 12 De Octubre, Madrid.
FAU - Guillen, Sara
AU  - Guillen S
AD  - Paediatric Infectious Diseases Department, Hospital Universitario de Getafe, 
      Translational Research Network in Pediatric Infectious Diseases (RITIP).
FAU - Rojo, Pablo
AU  - Rojo P
AD  - Paediatric Infectious Diseases Department. Hospital Universitario 12 De Octubre, 
      Madrid, 28041, Spain. Translational Research Network in Pediatric Infectious 
      Diseases (RITIP), Madrid.
FAU - Falcon-Neyra, Lola
AU  - Falcon-Neyra L
AD  - Paediatric Infectious Diseases, Rheumatology and Immunology Unit, Hospital 
      Universitario Virgen del Rocío, Sevilla.
FAU - Alvarez, Alberto
AU  - Alvarez A
AD  - Radiology Department. Hospital Universitario La Paz.
FAU - Fernandez, Pilar
AU  - Fernandez P
AD  - Radiology Department. Hospital Universitario Gregorio Marañón.
FAU - Lorente-Jareño, María Luisa
AU  - Lorente-Jareño ML
AD  - Radiology Department. Hospital Universitario de Getafe, Carr, Madrid - Toledo, Km 
      Getafe.
FAU - Ramos, Jose Tomas
AU  - Ramos JT
AD  - Paediatric Infectious Diseases Department, Hospital Clínico San Carlos, Madrid, 
      28040, Spain, Translational Research Network in Pediatric Infectious Diseases 
      (RITIP).
FAU - Sainz, Talía
AU  - Sainz T
AD  - Paediatric Infectious and Tropical Diseases Department, Hospital Universitario La 
      Paz. Hospital La Paz Institute For Health Research (Idipaz), Translational Research 
      Network in Pediatric Infectious Diseases (RITIP).
FAU - Velo, Carlos
AU  - Velo C
AD  - Department of Paediatric Infectious Diseases, Hospital Universitario 12 de Octubre; 
      Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12).
FAU - Navarro, Maria Luisa
AU  - Navarro ML
AD  - Paediatric Infectious Diseases Department. Hospital Gregorio Marañon, Translational 
      Research Network in Pediatric Infectious Diseases (RITIP).
FAU - Gonzalez-Tomé, Maria Isabel
AU  - Gonzalez-Tomé MI
AD  - Paediatric Infectious Diseases Department, Hospital Universitario 12 De Octubre, 
      Madrid, Madrid, Spain.
CN  - Cohorte Nacional de VIH pediátrica de la RED RIS (CoRISpe), Madrid, Spain
LA  - eng
GR  - FIS 15/00694/Instituto de Salud Carlos III,Fondos FEDER, Una manera de hacer 
      Europa./
PT  - Journal Article
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Anti-Retroviral Agents)
SB  - IM
MH  - Age Factors
MH  - Anti-Retroviral Agents/therapeutic use
MH  - Atrophy
MH  - Basal Ganglia/diagnostic imaging/pathology
MH  - CD4 Lymphocyte Count
MH  - Cross-Sectional Studies
MH  - Female
MH  - Gray Matter/diagnostic imaging/*pathology
MH  - HIV Infections/drug therapy/epidemiology/*physiopathology/*transmission
MH  - Humans
MH  - Infectious Disease Transmission, Vertical/*statistics & numerical data
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Prospective Studies
MH  - Socioeconomic Factors
MH  - Young Adult
PMC - PMC8051971
COIS- The authors report no conflicts of interest.
EDAT- 2021/04/14 06:00
MHDA- 2021/04/29 06:00
CRDT- 2021/04/13 12:12
PHST- 2020/07/28 00:00 [received]
PHST- 2021/03/15 00:00 [accepted]
PHST- 2021/04/13 12:12 [entrez]
PHST- 2021/04/14 06:00 [pubmed]
PHST- 2021/04/29 06:00 [medline]
AID - 00005792-202104160-00033 [pii]
AID - MD-D-20-07484 [pii]
AID - 10.1097/MD.0000000000025403 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2021 Apr 16;100(15):e25403. doi: 10.1097/MD.0000000000025403.

PMID- 31225728
OWN - NLM
STAT- MEDLINE
DCOM- 20191231
LR  - 20191231
IS  - 1961-9049 (Electronic)
IS  - 0037-9085 (Linking)
VI  - 112
IP  - 1
DP  - 2019
TI  - [HIV Disclosure to the Child/Adolescent in Central and West Francophone Africa].
PG  - 14-21
LID - 10.3166/bspe-2019-0063 [doi]
AB  - We report the attitudes and practices of health care workers involved in the 
      disclosure process to adolescents living with HIV (ALHIV) in a network including 
      West and Central African French-speaking countries, and the experiences of young 
      living with HIV (YLHIV). During a three-day workshop in Abidjan, Côte d'Ivoire, 
      caregivers (doctors, psychologists, social workers) from 19 pediatric HIV treatment 
      sites shared their practices and difficulties, and four YPLHIV their own disclosure 
      experience. Thirty five participants from eight West/Central African countries 
      (Benin, Burkina Faso, Ivory Coast, Cameroon, Mali, Democratic Republic of Congo, 
      Senegal, Togo) contributed: 14 doctors, eight psychologists, six counselors, three 
      social workers. The experience of the centers was variable, but the age at 
      disclosure was late: 34% of 1296 adolescents between 10 and 12 years of age knew 
      their status. The median age at disclosure was 13 years (range: 11-15 years). The 
      practice of the disclosure was often complex, because of multiple factors (fear of 
      the parents of the breaking of the secrecy, lack of communication between 
      professionals). The individual disclosure was the main practice. Four centers 
      practiced HIV disclosure in group sessions to facilitate mirror support, and one 
      used peer-to-peer support. YPLHIV have advocated for an earlier disclosure, from 10 
      years. In West and Central Africa, the process of HIV disclosure remains complex for 
      parents and caregivers, and occurs too late. The development of a good practice 
      guideline for HIV disclosing adapted to socio-cultural contexts should help to 
      improve this process.
FAU - Dahourou, D L
AU  - Dahourou DL
AD  - Centre Muraz, Bobo-Dioulasso, Burkina Faso.
FAU - Masson, D
AU  - Masson D
AD  - Programme Grandir, Paris, France.
FAU - Aka-Dago-Akribi, H
AU  - Aka-Dago-Akribi H
AD  - Département de psychologie, Université Félix Houphouët-Boigny, PACCI, Abidjan, Côte 
      d'Ivoire.
FAU - Gauthier-Lafaye, C
AU  - Gauthier-Lafaye C
AD  - Service universitaire de psychiatrie de l'enfant et de l'adolescent (SUPEA), CHU de 
      Toulouse, Toulouse, France.
FAU - Cacou, C
AU  - Cacou C
AD  - Département de psychologie, Université Félix Houphouët-Boigny, PACCI, Abidjan, Côte 
      d'Ivoire.
FAU - Raynaud, J-P
AU  - Raynaud JP
AD  - Service universitaire de psychiatrie de l'enfant et de l'adolescent (SUPEA), CHU de 
      Toulouse, Toulouse, France.
AD  - INSERM U1027, Université de Toulouse 3, Toulouse, France.
FAU - Moh, C
AU  - Moh C
AD  - Département de psychologie, Université Félix Houphouët-Boigny, PACCI, Abidjan, Côte 
      d'Ivoire.
FAU - Bouah, B
AU  - Bouah B
AD  - Département de psychologie, Université Félix Houphouët-Boigny, PACCI, Abidjan, Côte 
      d'Ivoire.
FAU - Sturm, G
AU  - Sturm G
AD  - Laboratoire cliniques psychopathologique et interculturelle, Université Jean Jaurès 
      Toulouse 2, Toulouse.
FAU - Oga, M
AU  - Oga M
AD  - Programme PACCI, Abidjan.
FAU - Msellati, P
AU  - Msellati P
AD  - IRD, UMI 233, U1175 INSERM, Université de Montpellier, PACCI, Abidjan.
FAU - Leroy, V
AU  - Leroy V
AD  - INSERM U1027, Université de Toulouse 3, Toulouse, France.
CN  - Le Groupe Atelier Annonce Adolescents Afrique
LA  - fre
PT  - Journal Article
TT  - Annonce à l’enfant et à l’adolescent de son statut VIH en Afrique francophone 
      centrale et de l’Ouest.
PL  - France
TA  - Bull Soc Pathol Exot
JT  - Bulletin de la Societe de pathologie exotique (1990)
JID - 9212564
SB  - IM
MH  - Adolescent
MH  - Africa, Central
MH  - Africa, Western
MH  - *Attitude of Health Personnel
MH  - Child
MH  - Disclosure/*standards
MH  - HIV Infections/*psychology
MH  - *Health Knowledge, Attitudes, Practice
MH  - Health Personnel/*psychology
MH  - Humans
OTO - NOTNLM
OT  - Adolescent
OT  - Benin
OT  - Burkina Faso
OT  - Cameroun
OT  - Child
OT  - Côte d’Ivoire
OT  - Democratic Republic of the Congo
OT  - Disclosure
OT  - HIV
OT  - Mali
OT  - Professional practices
OT  - Senegal
OT  - Sub-Saharan Africa
OT  - Togo
COIS- The authors have no conflicts of interest to declare
EDAT- 2019/06/22 06:00
MHDA- 2020/01/01 06:00
CRDT- 2019/06/22 06:00
PHST- 2018/10/26 00:00 [received]
PHST- 2019/02/22 00:00 [accepted]
PHST- 2019/06/22 06:00 [entrez]
PHST- 2019/06/22 06:00 [pubmed]
PHST- 2020/01/01 06:00 [medline]
AID - 10.3166/bspe-2019-0063 [doi]
PST - ppublish
SO  - Bull Soc Pathol Exot. 2019;112(1):14-21. doi: 10.3166/bspe-2019-0063.

PMID- 26698540
OWN - NLM
STAT- MEDLINE
DCOM- 20170102
LR  - 20181202
IS  - 1360-0451 (Electronic)
IS  - 0954-0121 (Linking)
VI  - 28
IP  - 5
DP  - 2016
TI  - Self-reported adherence to antiretroviral therapy in HIV+ population from Bata, 
      Equatorial Guinea.
PG  - 543-53
LID - 10.1080/09540121.2015.1124976 [doi]
AB  - The human immunodeficiency virus (HIV) and the acquired immune deficiency syndrome 
      (AIDS) represent a serious public health problem in Equatorial Guinea, with a 
      prevalence of 6.2% among adults. the high-activity antiretroviral treatment (HAART) 
      coverage data is 10 points below the overall estimate for Sub-Saharan Africa, and 
      only 61% patients continue with HAART 12 months after it started. This study aims to 
      assess HAART adherence and related factors in Litoral Province of Equatorial Guinea. 
      In this cross-sectional study, socio-demographic and clinical data were collected at 
      Regional Hospital of Bata, during June-July 2014. Adherence to treatment was 
      assessed by using the Spanish version of CEAT-VIH. Bivariate and linear regression 
      analyses were employed to assess HAART adherence-related factors. We interviewed 50 
      men (35.5%) and 91 women (64.5%), with a mean age of 47.7 ± 8.9 and 36.2 ± 11.2, 
      respectively (p < .001). Overall, 55% patients had low or insufficient adherence. 
      CEAT-VIH score varied by ethnic group (p = .005). There was a positive correlation 
      between CEAT-VIH score and current CD4 T-cells count (p = .013). The Cronbach's α 
      value was 0.52. To our knowledge, this is the first study to assess HAART adherence 
      in Equatorial Guinea. Internal reliability for CEAT-VIH was low, nonetheless the 
      positive correlation between the CEAT-VIH score and the immunological status of 
      patients add value to our findings. Our results serve as baseline for future 
      research and will also assist stakeholders in planning and undertaking contextual 
      and evidence-based policy initiatives.
FAU - Salmanton-García, Jon
AU  - Salmanton-García J
AD  - a Intern of the Spanish Society of Tropical Medicine and International Health , 
      Madrid , Spain.
FAU - Herrador, Zaida
AU  - Herrador Z
AD  - b National Centre for Tropical Medicine, Instituto de Salud Carlos III (ISCIII) , 
      Madrid , Spain.
AD  - c Tropical Diseases Research Network (RICET in Spanish) , Madrid , Spain.
FAU - Ruiz-Seco, Pilar
AU  - Ruiz-Seco P
AD  - d National Institute of Social Security of Equatorial Guinea (INSESO in Spanish) , 
      Bata , Equatorial Guinea.
FAU - Nzang-Esono, Jesús
AU  - Nzang-Esono J
AD  - b National Centre for Tropical Medicine, Instituto de Salud Carlos III (ISCIII) , 
      Madrid , Spain.
AD  - e Reference Centre for Epidemics Control of Equatorial Guinea (CRCE in Spanish) , 
      Malabo , Equatorial Guinea.
FAU - Bendomo, Veronica
AU  - Bendomo V
AD  - f Reference Unit for Infectious Diseases (UREI in Spanish), Regional Hospital of 
      Bata , Bata , Equatorial Guinea.
FAU - Bashmakovic, Emma
AU  - Bashmakovic E
AD  - f Reference Unit for Infectious Diseases (UREI in Spanish), Regional Hospital of 
      Bata , Bata , Equatorial Guinea.
FAU - Nseng-Nchama, Gloria
AU  - Nseng-Nchama G
AD  - g National Plan Against AIDS (PNLS in Spanish), Ministry of Healthcare and Social 
      Welfare , Malabo , Equatorial Guinea (MINSABS in Spanish).
FAU - Benito, Agustín
AU  - Benito A
AD  - b National Centre for Tropical Medicine, Instituto de Salud Carlos III (ISCIII) , 
      Madrid , Spain.
AD  - c Tropical Diseases Research Network (RICET in Spanish) , Madrid , Spain.
FAU - Aparicio, Pilar
AU  - Aparicio P
AD  - b National Centre for Tropical Medicine, Instituto de Salud Carlos III (ISCIII) , 
      Madrid , Spain.
AD  - c Tropical Diseases Research Network (RICET in Spanish) , Madrid , Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20151224
PL  - England
TA  - AIDS Care
JT  - AIDS care
JID - 8915313
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antiretroviral Therapy, Highly Active/*methods
MH  - Cross-Sectional Studies
MH  - Equatorial Guinea/epidemiology
MH  - Female
MH  - HIV Infections/*drug therapy/epidemiology/psychology
MH  - Humans
MH  - Male
MH  - Medication Adherence/psychology/*statistics & numerical data
MH  - Middle Aged
MH  - Prevalence
MH  - Reproducibility of Results
MH  - Self Report
MH  - Sex Factors
MH  - Socioeconomic Factors
MH  - Treatment Outcome
MH  - Viral Load
OTO - NOTNLM
OT  - CEAT-VIH
OT  - Equatorial Guinea
OT  - HIV
OT  - adherence
OT  - questionnaire
EDAT- 2015/12/25 06:00
MHDA- 2017/01/04 06:00
CRDT- 2015/12/25 06:00
PHST- 2015/12/25 06:00 [entrez]
PHST- 2015/12/25 06:00 [pubmed]
PHST- 2017/01/04 06:00 [medline]
AID - 10.1080/09540121.2015.1124976 [doi]
PST - ppublish
SO  - AIDS Care. 2016;28(5):543-53. doi: 10.1080/09540121.2015.1124976. Epub 2015 Dec 24.

PMID- 30950879
OWN - NLM
STAT- MEDLINE
DCOM- 20200701
LR  - 20200701
IS  - 1473-5571 (Electronic)
IS  - 0269-9370 (Linking)
VI  - 33
IP  - 8
DP  - 2019 Jul 1
TI  - Virological response to integrase strand transfer inhibitor-based antiretroviral 
      combinations in HIV-1 group O-infected patients.
PG  - 1327-1333
LID - 10.1097/QAD.0000000000002215 [doi]
AB  - : Although integrase strand transfer inhibitors (INSTIs) are widely used in HIV-1 
      group M (HIV-1/M) infections, little is known about their efficacy against 
      genetically divergent HIV-1 group O (HIV-1/O) strains. Previous phenotypic works 
      have demonstrated the variable susceptibility of HIV-1/O strains, depending on INSTI 
      drugs. Clinical data are very limited and obtained from a few patients. OBJECTIVES: 
      To investigate the virological success rate of an INSTI-based combination of 
      antiretroviral therapy (cART) in a large population of HIV-1/O-infected patients, 
      and to describe resistance-associated mutations (RAM) at virological failure. 
      METHODS: The virological response of 39 patients receiving INSTI-based cART during 
      their follow-up was analysed i) at the last point of the first INSTI initiation and 
      ii) at their most recent visit. RAM analysis was performed at virological failures. 
      Resistance interpretation was based on the French National Agency of Research on 
      AIDS and viral hepatitis (ANRS) rules. RESULTS: Virological success at both time 
      points of analysis was high, with more than 87% of the patients with undetectable 
      plasma viral load. Among the six patients with virological failure, three selected 
      RAM described for HIV-1/M resistance, and two had already RAM, before INSTI 
      initiation. CONCLUSION: Our results show that HIV-1/O infected patients receiving 
      INSTI-based cART presented a high rate of virological success whatever their 
      previous lines; we have also shown that resistance rules for HIV-1/M could be 
      considered when failure occurs. These data are of importance especially in the 
      context of WHO recommendations for a wider use of this class.
FAU - Alessandri-Gradt, Elodie
AU  - Alessandri-Gradt E
AD  - Normandie Univ, UNIROUEN, EA2656, GRAM, CHU de Rouen, Laboratoire de Virologie 
      associé au CNR du VIH, F-76000 Rouen, France.
FAU - Unal, Guillemette
AU  - Unal G
FAU - Leoz, Marie
AU  - Leoz M
FAU - Plantier, Jean-Christophe
AU  - Plantier JC
CN  - RES-O network
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - AIDS
JT  - AIDS (London, England)
JID - 8710219
RN  - 0 (Anti-Retroviral Agents)
RN  - 0 (HIV Integrase Inhibitors)
RN  - EC 2.7.7.- (HIV Integrase)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anti-Retroviral Agents/*therapeutic use
MH  - Antiretroviral Therapy, Highly Active/*methods
MH  - Drug Resistance, Viral
MH  - Female
MH  - *Genotype
MH  - HIV Infections/*drug therapy
MH  - HIV Integrase/genetics
MH  - HIV Integrase Inhibitors/*therapeutic use
MH  - HIV-1/classification/genetics/*isolation & purification
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mutation
MH  - Treatment Outcome
MH  - Viral Load
MH  - Young Adult
EDAT- 2019/04/06 06:00
MHDA- 2020/07/02 06:00
CRDT- 2019/04/06 06:00
PHST- 2019/04/06 06:00 [pubmed]
PHST- 2020/07/02 06:00 [medline]
PHST- 2019/04/06 06:00 [entrez]
AID - 10.1097/QAD.0000000000002215 [doi]
PST - ppublish
SO  - AIDS. 2019 Jul 1;33(8):1327-1333. doi: 10.1097/QAD.0000000000002215.

PMID- 34152663
OWN - NLM
STAT- MEDLINE
DCOM- 20211015
LR  - 20211015
IS  - 1758-2652 (Electronic)
IS  - 1758-2652 (Linking)
VI  - 24
IP  - 6
DP  - 2021 Jun
TI  - Trends in demographic and clinical characteristics and initiation of antiretroviral 
      therapy among adult patients enrolling in HIV care in the Central Africa 
      International epidemiology Database to Evaluate AIDS (CA-IeDEA) 2004 to 2018.
PG  - e25672
LID - 10.1002/jia2.25672 [doi]
LID - e25672
AB  - INTRODUCTION: The Central Africa International epidemiology Database to Evaluate 
      AIDS (CA-IeDEA) is an open observational cohort study investigating impact, 
      progression and long-term outcomes of HIV/AIDS among people living with HIV (PLWH) 
      in Burundi, Cameroon, Democratic Republic of Congo (DRC), Republic of Congo (ROC) 
      and Rwanda. We describe trends in demographic, clinical and immunological 
      characteristics as well as antiretroviral therapy (ART) use of patients 
      aged > 15 years entering into HIV care in the participating CA-IeDEA site. METHODS: 
      Information on sociodemographic characteristics, height, weight, body mass index 
      (BMI), CD4 cell count, WHO staging and ART status at entry into care from 2004 
      through 2018 were extracted from clinic records of patients aged > 15 years 
      enrolling in HIV care at participating clinics in Burundi, Cameroon, DRC, ROC and 
      Rwanda. We assessed trends in patient characteristics at enrolment in HIV care 
      including ART initiation within the first 30 days after enrolment in care and 
      calculated proportions, means and medians (interquartile ranges) for the main 
      variables of interest. RESULTS: Among 69,176 patients in the CA-IeDEA cohort, 39% 
      were from Rwanda, 24% from ROC, 18% from Cameroon, 14% from Burundi and 5% from DRC. 
      More women (66%) than men enrolled in care and subsequently initiated ART. Women 
      were also younger than men (32 vs. 38 years, P < 0.001) at enrolment and at ART 
      initiation. Trends over time show increases in median CD4 cell count at enrolment 
      from 190 cells/µL in 2004 to 334 cells/µL in 2018 at enrolment. Among those with 
      complete data on CD4 counts (60%), women had a higher median CD4 cell count at care 
      entry than men (229 vs. 249 cells/µL, P < 0.001). Trends in the proportion of 
      patients using ART within 30 days of enrolment at the participating site show an 
      increase from 16% in 2004 to 75% in 2018. CONCLUSIONS: Trends from 2004 to 2018 in 
      the characteristics of patients participating in the CA-IeDEA cohort highlight 
      improvements at entry into care and subsequent ART initiation including after the 
      implementation of Treat All guidelines in the participating sites.
CI  - © 2021 The Authors. Journal of the International AIDS Society published by John 
      Wiley & Sons Ltd on behalf of the International AIDS Society.
FAU - Adedimeji, Adebola A
AU  - Adedimeji AA
AUID- ORCID: 0000-0002-8012-9124
AD  - Department of Epidemiology and Population Health, Albert Einstein College of 
      Medicine/Montefiore Medical Center, Bronx, NY, USA.
FAU - Hoover, Donald R
AU  - Hoover DR
AD  - Department of Statistics, Rutgers University, Piscataway, NJ, USA.
FAU - Shi, Qiuhu
AU  - Shi Q
AD  - Department of Public Health, School of Health Sciences and Practice, New York 
      Medical College, Valhalla, NY, USA.
FAU - Kim, Hae-Young
AU  - Kim HY
AD  - Department of Public Health, School of Health Sciences and Practice, New York 
      Medical College, Valhalla, NY, USA.
FAU - Brazier, Ellen
AU  - Brazier E
AUID- ORCID: 0000-0002-8514-1958
AD  - School of Public Health, City University of New York, New York, NY, USA.
FAU - Ross, Jonathan
AU  - Ross J
AUID- ORCID: 0000-0001-6126-3048
AD  - Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.
FAU - Murenzi, Gad
AU  - Murenzi G
AD  - Division of Clinical Education, Rwanda Military Hospital, Kanombe, Kigali, Rwanda.
FAU - Twizere, Christella
AU  - Twizere C
AUID- ORCID: 0000-0003-1102-5564
AD  - Centre National de Reference en Matière de VIH/SIDA, Bujumbura, Burundi.
FAU - Lelo, Patricia
AU  - Lelo P
AD  - Pediatric Hospital Kalembe Lembe, Kinshasa, Democratic Republic of Congo.
FAU - Nsonde, Dominique
AU  - Nsonde D
AD  - CTA Brazzaville, Brazzaville, Republic of Congo.
FAU - Ajeh, Rogers
AU  - Ajeh R
AD  - Clinical Research Education, Networking and Consultancy, Yaounde, Cameroon.
FAU - Dzudie, Anastase
AU  - Dzudie A
AD  - Clinical Research Education, Networking and Consultancy, Yaounde, Cameroon.
FAU - Nash, Denis
AU  - Nash D
AD  - School of Public Health, City University of New York, New York, NY, USA.
FAU - Yotebieng, Marcel
AU  - Yotebieng M
AD  - Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.
FAU - Anastos, Kathryn
AU  - Anastos K
AD  - Department of Epidemiology and Population Health, Albert Einstein College of 
      Medicine/Montefiore Medical Center, Bronx, NY, USA.
AD  - Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.
CN  - Central Africa IeDEA Consortium
LA  - eng
GR  - U01 AI096299/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, N.I.H., Extramural
TA  - J Int AIDS Soc
JT  - Journal of the International AIDS Society
JID - 101478566
RN  - 0 (Anti-HIV Agents)
SB  - IM
MH  - *Acquired Immunodeficiency Syndrome/drug therapy
MH  - Adult
MH  - Africa, Central/epidemiology
MH  - Aged
MH  - *Anti-HIV Agents/therapeutic use
MH  - CD4 Lymphocyte Count
MH  - Demography
MH  - Female
MH  - *HIV Infections/drug therapy/epidemiology
MH  - Humans
MH  - Male
PMC - PMC8216247
OTO - NOTNLM
OT  - *ARV
OT  - *Africa
OT  - *HIV care continuum
OT  - *HIV epidemiology
OT  - *cohort studies
OT  - *low- and middle-income countries
FIR - Pélagie, Nimbona
IR  - Pélagie N
FIR - Gateretse, Patrick
IR  - Gateretse P
FIR - Munezero, Jeanine
IR  - Munezero J
FIR - Nitereka, Valentin
IR  - Nitereka V
FIR - Niyongabo, Théodore
IR  - Niyongabo T
FIR - Twizere, Christelle
IR  - Twizere C
FIR - Bukuru, Hélène
IR  - Bukuru H
FIR - Nahimana, Thierry
IR  - Nahimana T
FIR - Baransaka, Elysée
IR  - Baransaka E
FIR - Barasukana, Patrice
IR  - Barasukana P
FIR - Kabanda, Eugene
IR  - Kabanda E
FIR - Manirakiza, Martin
IR  - Manirakiza M
FIR - Ndikumwenayo, François
IR  - Ndikumwenayo F
FIR - Biziragusenyuka, Jérémie
IR  - Biziragusenyuka J
FIR - Munezero, Ange Marie Michelline
IR  - Munezero AMM
FIR - Mbuh, Tabeyang
IR  - Mbuh T
FIR - Njie, Kinge Thompson
IR  - Njie KT
FIR - Tchassem, Edmond
IR  - Tchassem E
FIR - Tsi, Kien-Atsu
IR  - Tsi KA
FIR - Benwi, Mark
IR  - Benwi M
FIR - Ngamani, Marc Lionel
IR  - Ngamani ML
FIR - Nkome, Victorine
IR  - Nkome V
FIR - Sandjong, Falone
IR  - Sandjong F
FIR - Mbuh, Akindeh
IR  - Mbuh A
FIR - Amadou, Djenabou
IR  - Amadou D
FIR - Balkissou, Amadou Dodo
IR  - Balkissou AD
FIR - Ngassam, Eric
IR  - Ngassam E
FIR - Yone, Eric Walter Pefura
IR  - Yone EWP
FIR - Ewanoge, Alice Ndelle
IR  - Ewanoge AN
FIR - Fuhngwa, Norbert
IR  - Fuhngwa N
FIR - Kendowo, Ernestine
IR  - Kendowo E
FIR - Moki, Chris
IR  - Moki C
FIR - Nforniwe, Denis Nsame
IR  - Nforniwe DN
FIR - Akele, Catherine
IR  - Akele C
FIR - Kitetele, Faustin
IR  - Kitetele F
FIR - Tabala, Martine
IR  - Tabala M
FIR - Okitolonda, Emile Wemakoy
IR  - Okitolonda EW
FIR - Ekembe, Cherubin
IR  - Ekembe C
FIR - Diafouka, Merlin
IR  - Diafouka M
FIR - Ekat, Martin Herbas
IR  - Ekat MH
FIR - Mafou, Adolphe
IR  - Mafou A
FIR - Ayinkamiye, Nicole
IR  - Ayinkamiye N
FIR - Igirimbabazi, Jules
IR  - Igirimbabazi J
FIR - Ndamijimana, Emmanuel
IR  - Ndamijimana E
FIR - Habarurema, Emmanuel
IR  - Habarurema E
FIR - Nyiraneza, Marie Luise
IR  - Nyiraneza ML
FIR - Mukamusana, Dorothee
IR  - Mukamusana D
FIR - Tuyisenge, Liliane
IR  - Tuyisenge L
FIR - Kankindi, Catherine
IR  - Kankindi C
FIR - Shyaka, Christian
IR  - Shyaka C
FIR - Ingabire, Marie Grace
IR  - Ingabire MG
FIR - Uwakijijwe, Bonheur
IR  - Uwakijijwe B
FIR - Ndumuhire, Jules
IR  - Ndumuhire J
FIR - Nyirabahutu, Marie Goretti
IR  - Nyirabahutu MG
FIR - Ndoli, Yvette
IR  - Ndoli Y
FIR - Uwamahoro, Oliver
IR  - Uwamahoro O
FIR - Muhayimpundu, Ribakare
IR  - Muhayimpundu R
FIR - Nsanzimana, Sabin
IR  - Nsanzimana S
FIR - Remera, Eric
IR  - Remera E
FIR - Umumararungu, Esperance
IR  - Umumararungu E
FIR - Busingye, Lydia
IR  - Busingye L
FIR - Butera, Alex M
IR  - Butera AM
FIR - Gasana, Josephine
IR  - Gasana J
FIR - Habiryayo, Thierry
IR  - Habiryayo T
FIR - Ingabire, Charles
IR  - Ingabire C
FIR - Kabahizi, Jules
IR  - Kabahizi J
FIR - Kagimbana, Jean Chrysostome
IR  - Kagimbana JC
FIR - Kanyabwisha, Faustin
IR  - Kanyabwisha F
FIR - Kubwimana, Gallican
IR  - Kubwimana G
FIR - Muhoza, Benjamin
IR  - Muhoza B
FIR - Munyaneza, Athanase
IR  - Munyaneza A
FIR - Musabyimana, Francoise
IR  - Musabyimana F
FIR - Mwiza, Francine
IR  - Mwiza F
FIR - Rwibasira, Gallican Nshogoza
IR  - Rwibasira GN
FIR - Sinayobye, Jean d'Amour
IR  - Sinayobye JD
FIR - Tuyisenge, Patrick
IR  - Tuyisenge P
FIR - Benekigeri, Chantal
IR  - Benekigeri C
FIR - Musaninyange, Jacqueline
IR  - Musaninyange J
FIR - Adedimeji, Adebola
IR  - Adedimeji A
FIR - Dilorenzo, Madeline
IR  - Dilorenzo M
FIR - Murchison, Lynn
IR  - Murchison L
FIR - Addison, Diane
IR  - Addison D
FIR - Jones, Heidi
IR  - Jones H
FIR - Kelvin, Elizabeth
IR  - Kelvin E
FIR - Kulkarni, Sarah
IR  - Kulkarni S
FIR - Romo, Matthew
IR  - Romo M
FIR - Tymejczyk, Olga
IR  - Tymejczyk O
FIR - Elul, Batya
IR  - Elul B
FIR - Cai, Xiatao
IR  - Cai X
FIR - Dong, Allan
IR  - Dong A
FIR - Hoover, Don
IR  - Hoover D
FIR - Li, Chunshan
IR  - Li C
FIR - Shi, Qiuhu
IR  - Shi Q
FIR - Agler, Robert
IR  - Agler R
FIR - Lancaster, Kathryn
IR  - Lancaster K
FIR - Kuniholm, Mark
IR  - Kuniholm M
FIR - Edmonds, Andrew
IR  - Edmonds A
FIR - Parcesepe, Angela
IR  - Parcesepe A
FIR - Edwards, Jess
IR  - Edwards J
FIR - Keiser, Olivia
IR  - Keiser O
FIR - Duda, Stephany
IR  - Duda S
FIR - Kimmel, April
IR  - Kimmel A
EDAT- 2021/06/22 06:00
MHDA- 2021/10/16 06:00
CRDT- 2021/06/21 12:33
PHST- 2020/11/17 00:00 [revised]
PHST- 2020/06/25 00:00 [received]
PHST- 2021/01/27 00:00 [accepted]
PHST- 2021/06/21 12:33 [entrez]
PHST- 2021/06/22 06:00 [pubmed]
PHST- 2021/10/16 06:00 [medline]
AID - JIA225672 [pii]
AID - 10.1002/jia2.25672 [doi]
PST - ppublish
SO  - J Int AIDS Soc. 2021 Jun;24(6):e25672. doi: 10.1002/jia2.25672.

PMID- 28624255
OWN - NLM
STAT- MEDLINE
DCOM- 20180615
LR  - 20180615
IS  - 0151-9638 (Print)
IS  - 0151-9638 (Linking)
VI  - 144
IP  - 8-9
DP  - 2017 Aug-Sep
TI  - [Psoriatic patients: Analysis of patients dissatisfied with their management].
PG  - 497-507
LID - S0151-9638(17)30221-1 [pii]
LID - 10.1016/j.annder.2017.03.025 [doi]
AB  - BACKGROUND: The French are frequently regarded as grouchy. In a recent study, we 
      observed a high proportion of patients initially consulting for psoriasis because 
      they were dissatisfied with their previous therapy. We analyzed the characteristics 
      of these patients. PATIENTS AND METHODS: This was a cross-sectional multicenter 
      study in 40 centers belonging to the ResoPso (psoriasis treatment network) 
      multicenter study group, with consecutive inclusions over a period of 11months in 
      2014. All adults (age>18 years) consulting for the first time for psoriasis at a 
      center were included in the study. RESULTS: Among patients, 1205 were included, of 
      whom 249 (20.3%) were consulting because of their dissatisfaction with treatment. In 
      the univariate analysis, these patients were younger (P=0.02) and presented 
      psoriasis that had begun earlier in life (P<0.0001). It consisted mostly of 
      generalized plaque psoriasis (P=0.047) and more severe forms of psoriasis (PASI 
      and/or DLQI score>10, P<0.02). There were fewer cases of psoriatic arthritis 
      (P=0.01). The "dissatisfied" patients reported significantly more frequent use of 
      topical treatments (P<0.0001) and alternative medicines (P=0.02), and more 
      infrequent use of biologics (P=0.006) as well as longer treatment periods 
      (P=0.0005). They consulted at hospitals (P=0.01) and had previously seen more GPs 
      and dermatologists (P≤0.0008). There was no impact of gender on the dissatisfaction 
      profile by either comorbidities (metabolic, blood pressure, alcohol and tobacco 
      consumption, and depression), or socio-economic data. In the multivariate analysis, 
      DLQI>10 (P=0.01; 95% CI: 1.01-1.07) and longer duration of care (P=0.004; 95% CI: 
      1.23-2.99) were associated with dissatisfaction. CONCLUSION: Twenty percent of our 
      psoriatic patients seem dissatisfied with their treatment. It is difficult to draw a 
      specific demographic and socioeconomic profile of dissatisfied patients. Only 
      disease severity and possibly inadequate treatment at the initial consultation are 
      associated with patient dissatisfaction. Explanations related to the individual 
      patients and doctors may be proposed. Finally, while the French may be considered 
      grouchy, the frequency of patient dissatisfaction seen in our study does not appear 
      to be any greater than that observed in other countries.
CI  - Copyright © 2017 Elsevier Masson SAS. All rights reserved.
FAU - Mahé, E
AU  - Mahé E
AD  - Service de dermatologie, centre hospitalier Victor-Dupouy, 69, rue du 
      Lieutenant-Colonel Prud'hon, 95107 Argenteuil cedex, France. Electronic address: 
      emmanuel.mahe@ch-argenteuil.fr.
FAU - Maccari, F
AU  - Maccari F
AD  - Service de dermatologie, hôpital d'instruction des armées Bégin, 69, avenue de 
      Paris, 94160 Saint-Mandé, France.
FAU - Beauchet, A
AU  - Beauchet A
AD  - Département de santé publique, CHU Ambroise-Paré, AP-HP, 9, avenue 
      Charles-de-Gaulle, 92104 Boulogne-Billancourt cedex, France.
FAU - Quiles-Tsimaratos, N
AU  - Quiles-Tsimaratos N
AD  - Service de dermatologie, hôpital Saint-Joseph, 26, boulevard de Louvain, 13285 
      Marseille cedex 08, France.
FAU - Beneton, N
AU  - Beneton N
AD  - Service de dermatologie, centre hospitalier du Mans, 194, avenue Rubillard, 72037 Le 
      Mans, France.
FAU - Parier, J
AU  - Parier J
AD  - Cabinet de dermatologie, 3, avenue de Chanzy, 94210 La Varenne, France.
FAU - Barthelemy, H
AU  - Barthelemy H
AD  - Service de dermatologie, centre hospitalier d'Auxerre, 2, boulevard de Verdun, 89000 
      Auxerre, France.
FAU - Goujon-Henry, C
AU  - Goujon-Henry C
AD  - Service de dermatologie, centre hospitalier Lyon Sud, 165, chemin du Grand-Revoyet, 
      69310 Pierre-Bénite, France.
FAU - Chaby, G
AU  - Chaby G
AD  - Service de dermatologie, hôpital Sud, avenue Laënnec, 80054 Amiens cedex 1, France.
FAU - Thomas-Beaulieu, D
AU  - Thomas-Beaulieu D
AD  - Service de dermatologie, centre hospitalier intercommunal de 
      Poissy/Saint-Germain-en-Laye, 20, rue Armagis, 78100 Saint-Germain-en-Laye, France.
FAU - Géner, G
AU  - Géner G
AD  - Cabinet de dermatologie, 15-17, rue de la République, 91800 Brunoy, France.
FAU - Wagner, L
AU  - Wagner L
AD  - Cabinet de dermatologie, 11, rue Jeanne-d'Arc, 75013 Paris, France.
FAU - Pallure, V
AU  - Pallure V
AD  - Service de médecine interne, centre hospitalier de Perpignan, 20, avenue du 
      Languedoc, 66000 Perpignan, France.
FAU - Devaux, S
AU  - Devaux S
AD  - Service de dermatologie, centre hospitalier de la Côte-Basque, 13, avenue de 
      l'Interne-Jacques-Loeb, 64100 Bayonne, France.
FAU - Vermersch-Langlin, A
AU  - Vermersch-Langlin A
AD  - Service dermatologie/VIH, hôpital Jean-Bernard, BP 479, 59322 Valenciennes cedex, 
      France.
FAU - Pfister, P
AU  - Pfister P
AD  - Cabinet de dermatologie, 6, rue Lamblardie, 75012 Paris, France.
FAU - Jégou, J
AU  - Jégou J
AD  - Service de dermatologie, centre hospitalier Châlons-en-Champagne, 51, rue du 
      Commandant-Derrien, 51000 Châlons-en-Champagne, France.
FAU - Livideanu, C
AU  - Livideanu C
AD  - Service de dermatologie, hôpital Larrey, 4, chemin de Pouvourville, 31059 Toulouse 
      cedex 9, France.
FAU - Sigal, M-L
AU  - Sigal ML
AD  - Service de dermatologie, centre hospitalier Victor-Dupouy, 69, rue du 
      Lieutenant-Colonel Prud'hon, 95107 Argenteuil cedex, France.
CN  - pour le GEM Resopso
LA  - fre
PT  - Journal Article
PT  - Multicenter Study
TT  - Patients atteints de psoriasis : analyse de la population insatisfaite de sa prise 
      en charge.
DEP - 20170616
PL  - France
TA  - Ann Dermatol Venereol
JT  - Annales de dermatologie et de venereologie
JID - 7702013
RN  - 0 (Biological Products)
SB  - IM
MH  - Adult
MH  - Arthritis, Psoriatic/epidemiology/therapy
MH  - Biological Products/therapeutic use
MH  - Cross-Sectional Studies
MH  - Dermatology
MH  - France/epidemiology
MH  - Hospitals, University/statistics & numerical data
MH  - Humans
MH  - Middle Aged
MH  - *Patient Satisfaction
MH  - Psoriasis/diagnosis/*epidemiology/*therapy
MH  - *Quality of Life
MH  - Risk Factors
MH  - Severity of Illness Index
MH  - Time Factors
OTO - NOTNLM
OT  - Dissatisfaction
OT  - Epidemiology
OT  - Insatisfaction
OT  - Patient
OT  - Psoriasis
OT  - Traitement
OT  - Treatment
OT  - Épidémiologie
EDAT- 2017/06/19 06:00
MHDA- 2018/06/16 06:00
CRDT- 2017/06/19 06:00
PHST- 2016/08/29 00:00 [received]
PHST- 2016/12/12 00:00 [revised]
PHST- 2017/03/03 00:00 [accepted]
PHST- 2017/06/19 06:00 [pubmed]
PHST- 2018/06/16 06:00 [medline]
PHST- 2017/06/19 06:00 [entrez]
AID - S0151-9638(17)30221-1 [pii]
AID - 10.1016/j.annder.2017.03.025 [doi]
PST - ppublish
SO  - Ann Dermatol Venereol. 2017 Aug-Sep;144(8-9):497-507. doi: 
      10.1016/j.annder.2017.03.025. Epub 2017 Jun 16.

PMID- 32113706
OWN - NLM
STAT- MEDLINE
DCOM- 20210824
LR  - 20210824
IS  - 2529-993X (Electronic)
IS  - 2529-993X (Linking)
VI  - 38
IP  - 9
DP  - 2020 Nov
TI  - Neurocognitive and quality of life study in perinatally HIV-infected young people 
      and their peers. NeuroCoRISpeS study.
PG  - 417-424
LID - S0213-005X(20)30005-7 [pii]
LID - 10.1016/j.eimc.2020.01.004 [doi]
AB  - BACKGROUND: Assessing the role of HIV and non-HIV related factors is essential for a 
      better understanding of the neurocognitive outcomes in perinatally HIV-infected 
      (PHIV+) young people. The aim of our study was to assess cognition and quality of 
      life (QoL) of a PHIV+ cohort of young people and to compare it with a control group. 
      METHODS: Thirty PHIV+ and 30 HIV(-) healthy young adults matched by age, sex and 
      socioeconomic status completed a protocol that included neurocognitive tests, a 
      psychosocial semi-structured interview and a QoL questionnaire (PedsQL). 
      Neurocognitive domain-specific and domain-general (NPZ-5) Z-scores were calculated. 
      CDC AIDS-defining category C or not C (PHIV+/C, PHIV+/noC) was considered to 
      evaluate differences within the PHIV+ group. Univariate and multivariate analysis 
      were performed. RESULTS: Sixty patients were included; 67% were female; median age 
      (IQR) 19 years (18-21). Regarding PHIV+ young people, 27% showed CDC C category 
      (none encephalopathy), 93% were on ART and 77% had undetectable viral load. No 
      differences regarding occupation were found, although the HIV(-) group repeated less 
      grades (p=0.028) and had a higher education level (p=0.021). No differences were 
      found between PHIV+/noC and HIV(-) participants. However, the PHIV+/C group showed 
      poorer performance than PHIV+/noC (NPZ-5, p=0.037) and HIV(-) subjects (crystallised 
      intelligence, p=0.025; intelligence quotient, p=0.016). Higher nadir CD4+ T-cell 
      count was related to better Z-score in memory (p=0.007) and NPZ-5 (p=0.025). Earlier 
      and longer exposure to ART resulted in better performance in memory (p=0.004) and 
      executive functions (p=0.015), respectively. CONCLUSIONS: No significant differences 
      were found in the neurocognitive profile nor QoL between PHIV+/noC and HIV(-) 
      adolescents; however, PHIV+/C participants obtained lower scores. The use of longer 
      and earlier ART seems to have a beneficial effect.
CI  - Copyright © 2020 Elsevier España, S.L.U. and Sociedad Española de Enfermedades 
      Infecciosas y Microbiología Clínica. All rights reserved.
FAU - García-Navarro, Cristina
AU  - García-Navarro C
AD  - Department of Paediatric Infectious Diseases, Hospital Universitario 12 de Octubre, 
      Madrid, Spain; Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12), 
      Madrid, Spain.
FAU - Martín-Bejarano, Manuela
AU  - Martín-Bejarano M
AD  - Department of Paediatric Infectious Diseases, Hospital Universitario 12 de Octubre, 
      Madrid, Spain; Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12), 
      Madrid, Spain.
FAU - Jimenez de Ory, Santiago
AU  - Jimenez de Ory S
AD  - Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de 
      Investigación Sanitaria Gregorio Marañón (IisGM), Madrid, Spain.
FAU - Zamora, Berta
AU  - Zamora B
AD  - Department of Paediatrics, Hospital Universitario 12 de Octubre, Madrid, Spain.
FAU - Ruiz-Saez, Beatriz
AU  - Ruiz-Saez B
AD  - Molecular Biology and Immunology Laboratory, Hospital General Universitario Gregorio 
      Marañón, Madrid, Spain; Spanish HIV HGM BioBank, Madrid, Spain; Instituto de 
      Investigación Sanitaria Gregorio Marañón (IisGM), Madrid, Spain.
FAU - Velo, Carlos
AU  - Velo C
AD  - Department of Paediatric Infectious Diseases, Hospital Universitario 12 de Octubre, 
      Madrid, Spain; Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12), 
      Madrid, Spain.
FAU - Cuéllar-Flores, Isabel
AU  - Cuéllar-Flores I
AD  - Department of Psychology/Paediatrics, Hospital Universitario Clínico San Carlos, 
      Madrid, Spain.
FAU - Garcia Lopez-Hortelano, Milagros
AU  - Garcia Lopez-Hortelano M
AD  - Department of Pediatric Infectious Diseases, Hospital Universitario La Paz, Madrid, 
      Spain; La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.
FAU - Guillen-Martin, Sara
AU  - Guillen-Martin S
AD  - Department of Pediatric Infectious Diseases, Hospital Universitario de Getafe, 
      Getafe, Madrid, Spain.
FAU - Navarro-Gómez, Maria Luisa
AU  - Navarro-Gómez ML
AD  - Instituto de Investigación Sanitaria Gregorio Marañón (IisGM), Madrid, Spain; 
      Department of Paediatric Infectious Diseases, Hospital Universitario Gregorio 
      Marañón, Madrid, Spain; Complutense University (UCM), Madrid, Spain; Translational 
      Research Network in Pediatric Infectious Diseases (RITIP), Madrid, Spain.
FAU - Ramos, José Tomás
AU  - Ramos JT
AD  - Department of Paediatrics, Hospital Universitario Clínico San Carlos, Madrid, Spain; 
      Departamento de Salud Pública y Materno-Infantil (UCM), Madrid, Spain; Instituto de 
      Investigación Sanitaria Hospital Clínico San Carlos (IdISSC), Madrid, Spain. 
      Electronic address: josetomas.ramos@salud.madrid.org.
FAU - González-Tomé, Maria Isabel
AU  - González-Tomé MI
AD  - Department of Paediatric Infectious Diseases, Hospital Universitario 12 de Octubre, 
      Madrid, Spain.
CN  - Pediatric National AIDS Research Network of Spain (CORISPE)
LA  - eng
LA  - spa
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200226
PL  - Spain
TA  - Enferm Infecc Microbiol Clin (Engl Ed)
JT  - Enfermedades infecciosas y microbiologia clinica (English ed.)
JID - 101777541
SB  - IM
MH  - Adolescent
MH  - *Cognition
MH  - Cohort Studies
MH  - Female
MH  - HIV Infections/drug therapy/*psychology
MH  - Humans
MH  - Infectious Disease Transmission, Vertical
MH  - Male
MH  - *Neuropsychological Tests
MH  - *Quality of Life
MH  - Viral Load
MH  - Young Adult
OTO - NOTNLM
OT  - *HIV
OT  - *Neurocognitive
OT  - *Neurocognitivo
OT  - *Perinatal HIV
OT  - *Transmisión vertical
OT  - *VIH
OT  - *VIH perinatal
OT  - *Vertical transmission
EDAT- 2020/03/03 06:00
MHDA- 2021/08/25 06:00
CRDT- 2020/03/02 06:00
PHST- 2019/07/24 00:00 [received]
PHST- 2019/12/22 00:00 [revised]
PHST- 2020/01/03 00:00 [accepted]
PHST- 2020/03/03 06:00 [pubmed]
PHST- 2021/08/25 06:00 [medline]
PHST- 2020/03/02 06:00 [entrez]
AID - S0213-005X(20)30005-7 [pii]
AID - 10.1016/j.eimc.2020.01.004 [doi]
PST - ppublish
SO  - Enferm Infecc Microbiol Clin (Engl Ed). 2020 Nov;38(9):417-424. doi: 
      10.1016/j.eimc.2020.01.004. Epub 2020 Feb 26.

PMID- 32946262
OWN - NLM
STAT- Publisher
LR  - 20200930
IS  - 1522-1539 (Electronic)
IS  - 0363-6135 (Linking)
DP  - 2020 Sep 18
TI  - Conceptualizing Conduction as a Pliant Vasomotor response: Impact of Ca(2+) fluxes 
      and Ca(2+) Sensitization.
LID - 10.1152/ajpheart.00286.2020 [doi]
AB  - Coordinating blood flow to active tissue requires vasomotor responses to conduct 
      among resistance arteries. Vasomotor spread is governed by the electrical and 
      mechanical properties of vessels; the latter being linked to the sigmoid relations 
      between membrane potential (V(M)), [Ca(2+)], and smooth muscle contractility. 
      Proteins guiding electrical-to-tone translation are subject to regulation; thus, 
      vasomotor conduction could be viewed as "pliant" to the current regulatory state. 
      Using simple in silico approaches, we explored vasomotor pliancy and how the 
      regulation of contractility impacts conduction along a skeletal muscle artery and a 
      branching cerebrovascular network. Initial simulations revealed how limited 
      electromechanical linearity affects the translation of electrical spread into 
      arterial tone. Subtle changes to the V(M)-[Ca(2+)] or [Ca(2+)]-diameter 
      relationship, akin to regulatory alterations in Ca(2+) influx and Ca(2+) 
      sensitivity, modified the distance and amplitude of the conducted vasomotor 
      response. Simultaneous changes to both relationships, consistent with agonist 
      stimulation, augmented conduction although the effect varied with stimulus strength 
      and polarity (depolarization vs hyperpolarization). Final simulations using our 
      cerebrovascular network revealed how localized changes to the V(M)-[Ca(2+)] or 
      [Ca(2+)]-diameter relationships could regionally shape conduction without 
      interfering with the electrical spread. We conclude that regulatory changes to key 
      effector proteins (e.g. L-type Ca(2+) channels, myosin light chain phosphatase), 
      integral to voltage translation, not only impact conducted vasomotor tone but likely 
      blood flow delivery to active tissues.
FAU - Hald, Bjørn Olav
AU  - Hald BO
AD  - Department of Neuroscience, University of Copenhagen, Denmark.
FAU - Welsh, Donald G
AU  - Welsh DG
AD  - Robarts Research Institute and the Department of Physiology & Pharmacology, 
      University of Western Ontario, Canada.
LA  - eng
GR  - 377412/Canadian HIV Trials Network, Canadian Institutes of Health Research (Réseau 
      canadien pour les essais VIH des IRSC)/
GR  - na/Weimann foundation/
PT  - Journal Article
DEP - 20200918
PL  - United States
TA  - Am J Physiol Heart Circ Physiol
JT  - American journal of physiology. Heart and circulatory physiology
JID - 100901228
SB  - IM
OTO - NOTNLM
OT  - Ca2+ Sensitization
OT  - Cytosolic Ca2+
OT  - Electromechanical Coupling
OT  - Intercellular Conduction
OT  - Smooth muscle
EDAT- 2020/09/19 06:00
MHDA- 2020/09/19 06:00
CRDT- 2020/09/18 17:11
PHST- 2020/09/18 17:11 [entrez]
PHST- 2020/09/19 06:00 [pubmed]
PHST- 2020/09/19 06:00 [medline]
AID - 10.1152/ajpheart.00286.2020 [doi]
PST - aheadofprint
SO  - Am J Physiol Heart Circ Physiol. 2020 Sep 18. doi: 10.1152/ajpheart.00286.2020.

PMID- 32005558
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1578-8989 (Electronic)
IS  - 0025-7753 (Linking)
VI  - 155
IP  - 7
DP  - 2020 Oct 9
TI  - Incidence of malignancy in a Spanish cohort of patients infected by the human 
      immunodeficiency virus.
PG  - 288-294
LID - S0025-7753(19)30720-1 [pii]
LID - 10.1016/j.medcli.2019.12.001 [doi]
AB  - INTRODUCTION: A higher incidence of malignancies has been described in patients with 
      HIV infection compared to the general population. PATIENTS AND METHODS: 
      Observational retrospective study in patients with HIV infection followed up at the 
      Vall d'Hebron University Hospital (Barcelona, Spain) between 2009 and 2017. The 
      objective of this research was to estimate the incidence of malignancies in HIV 
      patients and their surveillance. Age and sex-adjusted incidence was compared to the 
      incidence calculated by the Spanish Cancer Registry network (REDECAN) in 2015. 
      RESULTS: We included 2,773 patients (41,238 patients-year). Two hundred and eleven 
      malignancies were diagnosed in 182 patients. Non-AIDS defining cancers accounted for 
      78.2% of the malignancies. The global incidence of cancer was 485 cases per 100,000 
      person-years. Twenty-year mortality rate was 31.2% in patients with cancer and 7.8% 
      in patients without cancer. In men, adjusted for age, the incidence of malignancies 
      was higher than the incidence in the general population (978.4 vs. 641 cases per 
      100,000 person-years, P<.001). The most common malignancies in men were lung cancer, 
      Kaposi sarcoma and Hodgkin lymphoma. In women, the incidence of malignancies was not 
      higher than in the general population (340.6 vs. 404.7 cases per 100,000 
      person-years, P=.27). The most common malignancies among women were lung cancer, 
      head and neck cancer, cervical cancer and Hodgkin's lymphoma. CONCLUSIONS: Men with 
      HIV infection showed a statistically significant higher incidence of malignancies 
      compared to the general Spanish population. Lung cancer was the most common non-AIDS 
      defining cancer.
CI  - Copyright © 2019. Published by Elsevier España, S.L.U.
FAU - Cañas-Ruano, Esperanza
AU  - Cañas-Ruano E
AD  - Vall d'Hebron Institut de Recerca, Barcelona, España; Servicio de Enfermedades 
      Infecciosas, Hospital Universitario Vall d'Hebron, Barcelona, España. Electronic 
      address: mcanas@vhebron.net.
FAU - Martín-Castillo, Mario
AU  - Martín-Castillo M
AD  - Vall d'Hebron Institut de Recerca, Barcelona, España.
FAU - Raventós, Berta
AU  - Raventós B
AD  - Vall d'Hebron Institut de Recerca, Barcelona, España.
FAU - Burgos, Joaquín
AU  - Burgos J
AD  - Vall d'Hebron Institut de Recerca, Barcelona, España; Servicio de Enfermedades 
      Infecciosas, Hospital Universitario Vall d'Hebron, Barcelona, España.
FAU - Curran, Adrià
AU  - Curran A
AD  - Vall d'Hebron Institut de Recerca, Barcelona, España; Servicio de Enfermedades 
      Infecciosas, Hospital Universitario Vall d'Hebron, Barcelona, España.
FAU - Navarro, Jordi
AU  - Navarro J
AD  - Vall d'Hebron Institut de Recerca, Barcelona, España; Servicio de Enfermedades 
      Infecciosas, Hospital Universitario Vall d'Hebron, Barcelona, España.
FAU - García, Jorge
AU  - García J
AD  - Vall d'Hebron Institut de Recerca, Barcelona, España; Servicio de Enfermedades 
      Infecciosas, Hospital Universitario Vall d'Hebron, Barcelona, España.
FAU - Suanzes, Paula
AU  - Suanzes P
AD  - Vall d'Hebron Institut de Recerca, Barcelona, España; Servicio de Enfermedades 
      Infecciosas, Hospital Universitario Vall d'Hebron, Barcelona, España.
FAU - Ribera, Esteban
AU  - Ribera E
AD  - Vall d'Hebron Institut de Recerca, Barcelona, España; Servicio de Enfermedades 
      Infecciosas, Hospital Universitario Vall d'Hebron, Barcelona, España.
FAU - Falcó, Vicenç
AU  - Falcó V
AD  - Vall d'Hebron Institut de Recerca, Barcelona, España; Servicio de Enfermedades 
      Infecciosas, Hospital Universitario Vall d'Hebron, Barcelona, España.
LA  - eng
LA  - spa
PT  - Journal Article
TT  - Incidencia de neoplasias en una cohorte española de pacientes con infección por el 
      virus de la inmunodeficiencia humana.
DEP - 20200128
PL  - Spain
TA  - Med Clin (Barc)
JT  - Medicina clinica
JID - 0376377
SB  - IM
MH  - Female
MH  - HIV
MH  - *HIV Infections/complications/epidemiology
MH  - Humans
MH  - Incidence
MH  - Male
MH  - *Neoplasms/epidemiology
MH  - Retrospective Studies
MH  - *Sarcoma, Kaposi/epidemiology
MH  - Spain/epidemiology
OTO - NOTNLM
OT  - *AIDS defining cancer
OT  - *HIV
OT  - *Malignancy
OT  - *Neoplasia definitoria de sida
OT  - *Neoplasia maligna
OT  - *Neoplasia no definitoria de sida
OT  - *Non-AIDS defining cancer
OT  - *VIH
EDAT- 2020/02/02 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/02/02 06:00
PHST- 2019/06/13 00:00 [received]
PHST- 2019/11/28 00:00 [revised]
PHST- 2019/12/05 00:00 [accepted]
PHST- 2020/02/02 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/02/02 06:00 [entrez]
AID - S0025-7753(19)30720-1 [pii]
AID - 10.1016/j.medcli.2019.12.001 [doi]
PST - ppublish
SO  - Med Clin (Barc). 2020 Oct 9;155(7):288-294. doi: 10.1016/j.medcli.2019.12.001. Epub 
      2020 Jan 28.

PMID- 12836198
OWN - NLM
STAT- MEDLINE
DCOM- 20030731
LR  - 20071115
IS  - 0767-0974 (Print)
IS  - 0767-0974 (Linking)
VI  - 19
IP  - 1
DP  - 2003 Jan
TI  - [The HIV nef and the Kaposi-sarcoma-associated virus K3/K5 proteins: "parasites"of 
      the endocytosis pathway].
PG  - 100-6
AB  - The modulation of plasma membrane proteins involved in the communication with the 
      immune system is a general mechanism developed by viruses to escape the immune 
      response. Most of the studied examples have focused on viral proteins that missort 
      cellular proteins during their biosynthesis. However, an increasing number of 
      examples show that the down-modulation can also be achieved after membrane delivery 
      by targeting into the endocytic pathway. For both human immunodeficiency virus (HIV) 
      and Kaposi sarcoma-associated herpesvirus (KSHV), the proteins required for this 
      process are identified, Nef and K3/K5 respectively. The extensive studies in this 
      field have shown that the mechanisms by which these proteins "parasite" the 
      endocytic pathway are completely different. Nef directly interacts with components 
      of the cellular machinery involved in the vesicular transport between the endocytic 
      compartments, mainly the clathrin adaptor complexes (AP), inducing the misrouting of 
      numerous cellular proteins, including CD4, MHC-I, LIGHT, DC-SIGN, CD28 and MHC-II to 
      the endosomal degradation compartment or the trans Golgi-network. The K3 and K5 
      proteins from KSHV act by inducing the ubiquitylation of the target proteins, such 
      as CMH-I and B7.2, triggering their internalization and subsequent degradation by 
      the highly conserved Tsg101/vps23 ubiquitin-dependent endosomal pathway. While these 
      findings show that the strategies used by viruses to target cellular proteins to the 
      endocytic pathway are extremely diverse, additional investigations are needed for 
      the complete understanding of the specific roles of Nef and K3/K5 in the 
      physiopathology of HIV and KSHV infections, respectively. In addition, these viral 
      factors represent valuable tools to study the pathway they are perturbing.
FAU - Bénichou, Serge
AU  - Bénichou S
AD  - Département de Maladies Infectieuses, Inserm U.567, Cnrs UMR 8104, Institut Cochin, 
      Bâtiment Gustave Roussy, 27, rue du Faubourg Saint-Jacques, 75014 Paris, France. 
      benichou@cochin.inserm.fr
FAU - Benmerah, Alexandre
AU  - Benmerah A
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
TT  - Protéines Nef du VIH et K3/K5 du virus associé au sarcome de Kaposi: des "parasites" 
      de la voie d'endocytose.
PL  - France
TA  - Med Sci (Paris)
JT  - Medecine sciences : M/S
JID - 8710980
RN  - 0 (Antigens, Surface)
RN  - 0 (Gene Products, nef)
RN  - 0 (Immediate-Early Proteins)
RN  - 0 (K3 protein, Kaposi's sarcoma-associated herpesvirus)
RN  - 0 (K5 protein, Human herpesvirus 8)
RN  - 0 (Macromolecular Substances)
RN  - 0 (Multienzyme Complexes)
RN  - 0 (Ubiquitin)
RN  - 0 (Viral Proteins)
RN  - 0 (nef Gene Products, Human Immunodeficiency Virus)
RN  - EC 3.4.22.- (Cysteine Endopeptidases)
RN  - EC 3.4.25.1 (Proteasome Endopeptidase Complex)
SB  - IM
MH  - Amino Acid Motifs
MH  - Animals
MH  - Antigens, Surface/metabolism
MH  - Cysteine Endopeptidases/metabolism
MH  - *Endocytosis
MH  - Gammaherpesvirinae/genetics/physiology
MH  - Gene Products, nef/chemistry/*physiology
MH  - Genes, nef
MH  - HIV Infections/immunology/virology
MH  - HIV-1/genetics/*physiology
MH  - Herpesvirus 8, Human/genetics/*physiology
MH  - Humans
MH  - Immediate-Early Proteins/chemistry/*physiology
MH  - Macromolecular Substances
MH  - Mice
MH  - Multienzyme Complexes/metabolism
MH  - Proteasome Endopeptidase Complex
MH  - Protein Processing, Post-Translational
MH  - Protein Transport/*physiology
MH  - Sarcoma, Kaposi/immunology/virology
MH  - Structure-Activity Relationship
MH  - Ubiquitin/metabolism
MH  - Viral Proteins/chemistry/*physiology
MH  - nef Gene Products, Human Immunodeficiency Virus
RF  - 35
EDAT- 2003/07/03 05:00
MHDA- 2003/08/02 05:00
CRDT- 2003/07/03 05:00
PHST- 2003/07/03 05:00 [pubmed]
PHST- 2003/08/02 05:00 [medline]
PHST- 2003/07/03 05:00 [entrez]
AID - 000763ar [pii]
AID - 10.1051/medsci/2003191100 [doi]
PST - ppublish
SO  - Med Sci (Paris). 2003 Jan;19(1):100-6. doi: 10.1051/medsci/2003191100.

PMID- 34246286
OWN - NLM
STAT- MEDLINE
DCOM- 20210715
LR  - 20210715
IS  - 1742-4755 (Electronic)
IS  - 1742-4755 (Linking)
VI  - 18
IP  - 1
DP  - 2021 Jul 10
TI  - Motherhood and decision-making among women living with HIV in developed countries: a 
      systematic review with qualitative research synthesis.
PG  - 148
LID - 10.1186/s12978-021-01197-6 [doi]
LID - 148
AB  - BACKGROUND: Women living with HIV (WLH) lack evidence-based information about 
      reproductive options while managing pressures from family, clinicians, and 
      communities to give up the idea of having children. As the reproduction intentions 
      of WLH are not well understood, stigmatizing behaviors force them to hide their 
      disease to avoid rejection by their family, partner, and social networks. Compliance 
      with social norms, fear of stigma, and discrimination influence their experience. 
      Current research is individual qualitative studies lacking the synthesis perspective 
      necessary to guide intervention development. The purpose of this study was to 
      synthesize the evidence to explain the reproductive decision-making process for WLH 
      in developed countries. METHODS: A systematic review with qualitative research 
      synthesis was conducted through searches in 10 electronic databases (CINAHL, EMBASE, 
      MEDLINE, Scopus, Social Science Citation Index, Web of Science, Google Scholar, 
      Cuidatge, Cuiden Enfispo, and SciELO). Studies published in journals from 1995 to 
      2019 with qualitative data about reproductive decision-making among WLH in developed 
      countries were eligible for inclusion. Developed country was operationalized by 
      membership in the OECD for comparative conditions of social wellbeing and economic 
      stability. The CASP and JBI checklists for qualitative research were used to assess 
      study quality and methodological integrity. Thematic analysis and qualitative 
      meta-summary techniques were used for the synthesis. RESULTS: Twenty studies from 12 
      developed countries were included in the synthesis. Findings were organized into 3 
      meta-themes from 15 themes and 45 subthemes, including: (1) Shattered identity, (2) 
      Barriers, inequities, and misinformation, (3) Coping, resiliency, and support. 
      Reproductive decision-making was perceived as a complex process influenced by 
      facilitators and barriers. The facilitators helped WLH cope with their new situation 
      to become more resilient, while the barriers made their situation more difficult to 
      manage. CONCLUSION: WLH encounter reproductive decision-making with knowledge 
      deficits and limited social support. An integrated approach to holistic care with 
      comprehensive multidisciplinary counseling is needed to support WLH. Clinicians 
      could benefit from professional development to learn how to be authentically present 
      for WLH, including engaging in conversations, demonstrating compassion, and 
      understanding situations. Evidence-based clinical practice guidelines need to be 
      tailored for the family planning and sexual health needs of WLH.
CI  - © 2021. The Author(s).
FAU - Huertas-Zurriaga, Ariadna
AU  - Huertas-Zurriaga A
AUID- ORCID: 0000-0002-5303-6643
AD  - Hospital Universitari Germans Trias I Pujol, Badalona, 08916, Barcelona, Spain.
AD  - Grupo de Investigación Enfermera en Vulnerabilidad Y Salud (GRIVIS), Universitat 
      Autònoma de Barcelona, Avda. Can Domènech, Edifici M. Despatx M3/213, Bellaterra 
      (Cerdanyola del Vallès), 08193, Barcelona, Spain.
FAU - Palmieri, Patrick A
AU  - Palmieri PA
AUID- ORCID: 0000-0002-0765-0239
AD  - South American Center for Qualitative Research, Universidad Norbert Wiener, Av. 
      Arequipa 444, Torre 2, Piso 4, Lima, 15046, Perú. patrick.palmieri@jbisa.org.
AD  - College of Graduate Health Studies, A. T. Still University, 800 W. Jefferson Street, 
      Kirksville, MO, 63501, USA. patrick.palmieri@jbisa.org.
AD  - Center for Global Nursing, Texas Woman's University, 6700 Fannin St, Houston, TX, 
      77030, USA. patrick.palmieri@jbisa.org.
AD  - EBHC South America: A JBI Affiliated Group, Calle Cartavio 406, Suite 402, Lima, 
      15023, Peru. patrick.palmieri@jbisa.org.
FAU - Edwards, Joan E
AU  - Edwards JE
AUID- ORCID: 0000-0001-5415-1064
AD  - Center for Global Nursing, Texas Woman's University, 6700 Fannin St, Houston, TX, 
      77030, USA.
AD  - Nelda C. Stark College of Nursing, Texas Woman's University, 6700 Fannin St, 
      Houston, TX, 77030, USA.
FAU - Cesario, Sandra K
AU  - Cesario SK
AUID- ORCID: 0000-0002-2804-0878
AD  - Center for Global Nursing, Texas Woman's University, 6700 Fannin St, Houston, TX, 
      77030, USA.
AD  - Nelda C. Stark College of Nursing, Texas Woman's University, 6700 Fannin St, 
      Houston, TX, 77030, USA.
FAU - Alonso-Fernandez, Sergio
AU  - Alonso-Fernandez S
AUID- ORCID: 0000-0002-5968-5214
AD  - Recerca i Innovació en Cures Infermeres, Hospital Universitari Germans Trias I 
      Pujol, Badalona, 08916, Barcelona, Spain.
FAU - Pardell-Dominguez, Lidia
AU  - Pardell-Dominguez L
AUID- ORCID: 0000-0001-9326-9436
AD  - Grupo de Investigación Enfermera en Vulnerabilidad Y Salud (GRIVIS), Universitat 
      Autònoma de Barcelona, Avda. Can Domènech, Edifici M. Despatx M3/213, Bellaterra 
      (Cerdanyola del Vallès), 08193, Barcelona, Spain.
AD  - EBHC South America: A JBI Affiliated Group, Calle Cartavio 406, Suite 402, Lima, 
      15023, Peru.
AD  - Department D'Infermeria, Facultat de Medicina, Universitat Autònoma de Barcelona, 
      Avda. Can Domènech, Edifici M. Despatx M3/213, Bellaterra (Cerdanyola del Vallès), 
      08193, Barcelona, Spain.
FAU - Dominguez-Cancino, Karen A
AU  - Dominguez-Cancino KA
AUID- ORCID: 0000-0002-4264-8476
AD  - EBHC South America: A JBI Affiliated Group, Calle Cartavio 406, Suite 402, Lima, 
      15023, Peru.
AD  - Escuela de Enfermería, Universidad Científica del Sur, Carr. Panamericana Sur 19, 
      Villa EL Salvador, Lima, 15067, Perú.
AD  - Escuela de Salud Pública, Universidad de Chile, Independencia 939, Independencia, 
      8380453, Santiago de Chile, Chile.
FAU - Leyva-Moral, Juan M
AU  - Leyva-Moral JM
AUID- ORCID: 0000-0003-4241-4992
AD  - Grupo de Investigación Enfermera en Vulnerabilidad Y Salud (GRIVIS), Universitat 
      Autònoma de Barcelona, Avda. Can Domènech, Edifici M. Despatx M3/213, Bellaterra 
      (Cerdanyola del Vallès), 08193, Barcelona, Spain.
AD  - EBHC South America: A JBI Affiliated Group, Calle Cartavio 406, Suite 402, Lima, 
      15023, Peru.
AD  - Department D'Infermeria, Facultat de Medicina, Universitat Autònoma de Barcelona, 
      Avda. Can Domènech, Edifici M. Despatx M3/213, Bellaterra (Cerdanyola del Vallès), 
      08193, Barcelona, Spain.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
TT  - Maternidad y toma de decisiones en mujeres que viven con el VIH en países 
      desarrollados: una revisión sistemática con síntesis de investigación cualitativa.
DEP - 20210710
TA  - Reprod Health
JT  - Reproductive health
JID - 101224380
SB  - IM
MH  - Antiretroviral Therapy, Highly Active
MH  - Child
MH  - *Communication
MH  - Developed Countries
MH  - Female
MH  - HIV Infections/drug therapy/*psychology
MH  - *Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Qualitative Research
PMC - PMC8272303
OTO - NOTNLM
OT  - AIDS
OT  - Decision-making
OT  - HIV
OT  - Pregnancy
OT  - Reproductive health
OT  - Women
COIS- The authors declare that they have no competing interests.
EDAT- 2021/07/12 06:00
MHDA- 2021/07/16 06:00
CRDT- 2021/07/11 20:21
PHST- 2020/06/29 00:00 [received]
PHST- 2021/06/24 00:00 [accepted]
PHST- 2021/07/11 20:21 [entrez]
PHST- 2021/07/12 06:00 [pubmed]
PHST- 2021/07/16 06:00 [medline]
AID - 10.1186/s12978-021-01197-6 [pii]
AID - 1197 [pii]
AID - 10.1186/s12978-021-01197-6 [doi]
PST - epublish
SO  - Reprod Health. 2021 Jul 10;18(1):148. doi: 10.1186/s12978-021-01197-6.

PMID- 30679001
OWN - NLM
STAT- MEDLINE
DCOM- 20200930
LR  - 20210521
IS  - 2529-993X (Electronic)
IS  - 2529-993X (Linking)
VI  - 37
IP  - 8
DP  - 2019 Oct
TI  - Risk of cancer in HIV-infected patients in Spain, 2004-2015. The CoRIS cohort study.
PG  - 502-508
LID - S0213-005X(18)30382-3 [pii]
LID - 10.1016/j.eimc.2018.11.011 [doi]
AB  - INTRODUCTION: Cancer is a leading cause of death in individuals with HIV. METHODS: 
      The incidence of cancer in HIV patients of the CoRIS cohort in the 2004-2009 and 
      2010-2015 periods has been analysed and compared to the incidence in the Spanish 
      general population, estimated from data of the Spanish Cancer Registry Network. 
      RESULTS: Between January 2004 and November 2015, 12,239 patients were included in 
      CoRIS and 338 incident cancer cases were diagnosed. The overall incidence of cancer 
      per 100,000 persons-year (95% CI) was 702.39 (629.51-781.42) with no significant 
      differences between the 2periods. A 38% of the incident cancer cases were AIDS 
      defining cancers (ADC) and 62% non-AIDS defining cancers (NADC). In the period 
      2010-2015, there was a significant decrease in the incidence of ADC (standardised 
      incidence ratio [SIR]); 95% CI: 0.38; 0.21-0.66) and NADC predominated. Compared to 
      the general population, the incidence of cancer was double in men with HIV. Higher 
      relative risks were documented (SIR; 95% CI) for Hodgkin's lymphoma in both sexes 
      (males: 8.37, 5.13-14.17; females: 21.83, 2.66-47.79), non-Hodgkin's lymphoma in 
      males (5.30, 2.86-8.45) and cervical cancer (7.43, 3.15-13.87) and head and neck 
      cancer (3.28, 1.21-5.82) in women. CONCLUSIONS: The overall incidence of cancer in 
      individuals with HIV is higher than in the Spanish general population, and it has 
      remained stable since 2004 with a current predominance of NADC. These data suggest 
      that additional efforts should be made in the prevention and the early detection of 
      cancer in these patients.
CI  - Copyright © 2018 Elsevier España, S.L.U. and Sociedad Española de Enfermedades 
      Infecciosas y Microbiología Clínica. All rights reserved.
FAU - García-Abellán, Javier
AU  - García-Abellán J
AD  - Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital General 
      Universitario de Elche y Universidad Miguel Hernández, Alicante, España. Electronic 
      address: javiergarciaabellan@hotmail.com.
FAU - Del Río, Lorena
AU  - Del Río L
AD  - Servicio de Oncología Médica, Hospital General Universitario de San Juan de Alicante 
      y Universidad Miguel Hernández, Alicante, España.
FAU - García, José A
AU  - García JA
AD  - Instituto de Investigación Operativa, Universidad Miguel Hernández, Alicante, 
      España.
FAU - Padilla, Sergio
AU  - Padilla S
AD  - Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital General 
      Universitario de Elche y Universidad Miguel Hernández, Alicante, España.
FAU - Vivancos, María Jesús
AU  - Vivancos MJ
AD  - Servicio de Enfermedades Infecciosas, Hospital Universitario Ramón y Cajal, Madrid, 
      España.
FAU - Del Romero, Jorge
AU  - Del Romero J
AD  - Centro Sanitario Sandoval, Madrid, España.
FAU - Asensi, Víctor
AU  - Asensi V
AD  - Servicio de Enfermedades Infecciosas, Hospital Central de Asturias, Oviedo, España.
FAU - Hernando, Asunción
AU  - Hernando A
AD  - Instituto de Investigación, Hospital Universitario Doce de Octubre. Facultad de 
      Ciencias Biomédicas y de la Salud, Universidad Europea de Madrid, Madrid, España.
FAU - García-Fraile, Lucio
AU  - García-Fraile L
AD  - Servicio de Enfermedades Infecciosas, Hospital Universitario La Princesa, Madrid, 
      España.
FAU - Masiá, Mar
AU  - Masiá M
AD  - Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital General 
      Universitario de Elche y Universidad Miguel Hernández, Alicante, España.
FAU - Gutiérrez, Félix
AU  - Gutiérrez F
AD  - Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital General 
      Universitario de Elche y Universidad Miguel Hernández, Alicante, España.
CN  - la Cohorte de la Red Nacional de Sida (CoRIS)
LA  - eng
LA  - spa
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
TT  - Riesgo de cáncer en personas con VIH en España, 2004-2015. Estudio de la cohorte 
      CoRIS.
DEP - 20190122
PL  - Spain
TA  - Enferm Infecc Microbiol Clin (Engl Ed)
JT  - Enfermedades infecciosas y microbiologia clinica (English ed.)
JID - 101777541
SB  - IM
MH  - Adult
MH  - Cohort Studies
MH  - Female
MH  - HIV Infections/*complications
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/*epidemiology/*etiology
MH  - Risk Assessment
MH  - Spain/epidemiology
MH  - Time Factors
OTO - NOTNLM
OT  - Cancer
OT  - Comorbidities
OT  - Comorbilidades
OT  - Cáncer
OT  - Evento no sida
OT  - HIV
OT  - Malignant neoplasm
OT  - Mortalidad
OT  - Mortality
OT  - Neoplasia maligna
OT  - Non-AIDS event
OT  - Tumor
OT  - Tumour
OT  - VIH
EDAT- 2019/01/27 06:00
MHDA- 2020/10/02 06:00
CRDT- 2019/01/26 06:00
PHST- 2018/08/08 00:00 [received]
PHST- 2018/11/12 00:00 [revised]
PHST- 2018/11/16 00:00 [accepted]
PHST- 2019/01/27 06:00 [pubmed]
PHST- 2020/10/02 06:00 [medline]
PHST- 2019/01/26 06:00 [entrez]
AID - S0213-005X(18)30382-3 [pii]
AID - 10.1016/j.eimc.2018.11.011 [doi]
PST - ppublish
SO  - Enferm Infecc Microbiol Clin (Engl Ed). 2019 Oct;37(8):502-508. doi: 
      10.1016/j.eimc.2018.11.011. Epub 2019 Jan 22.

PMID- 34888660
OWN - NLM
STAT- Publisher
LR  - 20211210
IS  - 1460-2091 (Electronic)
IS  - 0305-7453 (Linking)
DP  - 2021 Dec 9
TI  - Blood microbiome is associated with changes in portal hypertension after successful 
      direct-acting antiviral therapy in patients with HCV-related cirrhosis.
LID - dkab444 [pii]
LID - 10.1093/jac/dkab444 [doi]
AB  - BACKGROUND: Patients with a significant decrease in hepatic venous pressure gradient 
      (HVPG) have a considerable reduction of liver complications and higher survival 
      after HCV eradication. OBJECTIVES: To evaluate the association between the baseline 
      blood microbiome and the changes in HVPG after successful direct-acting antiviral 
      (DAA) therapy in patients with HCV-related cirrhosis. METHODS: We performed a 
      prospective study in 32 cirrhotic patients (21 HIV positive) with clinically 
      significant portal hypertension (HVPG ≥10 mmHg). Patients were assessed at baseline 
      and 48 weeks after HCV treatment completion. The clinical endpoint was a decrease in 
      HVPG of ≥20% or HVPG <12 mmHg at the end of follow-up. Bacterial 16S ribosomal DNA 
      was sequenced using MiSeq Illumina technology, inflammatory plasma biomarkers were 
      investigated using ProcartaPlex immunoassays and the metabolome was investigated 
      using GC-MS. RESULTS: During the follow-up, 47% of patients reached the clinical 
      endpoint. At baseline, those patients had a higher relative abundance of 
      Corynebacteriales and Diplorickettsiales order, Diplorickettsiaceae family, 
      Corynebacterium and Aquicella genus and Undibacterium parvum species organisms and a 
      lower relative abundance of Oceanospirillales and Rhodospirillales order, 
      Halomonadaceae family and Massilia genus organisms compared with those who did not 
      achieve the clinical endpoint according to the LEfSe algorithm. Corynebacteriales 
      and Massilia were consistently found within the 10 bacterial taxa with the highest 
      differential abundance between groups. Additionally, the relative abundance of the 
      Corynebacteriales order was inversely correlated with IFN-γ, IL-17A and TNF-α levels 
      and the Massilia genus with glycerol and lauric acid. CONCLUSIONS: Baseline-specific 
      bacterial taxa are related to an HVPG decrease in patients with HCV-related 
      cirrhosis after successful DAA therapy.
CI  - © The Author(s) 2021. Published by Oxford University Press on behalf of the British 
      Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please 
      email: journals.permissions@oup.com.
FAU - Virseda-Berdices, Ana
AU  - Virseda-Berdices A
AD  - Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología (CNM), 
      Instituto de Salud Carlos III (ISCIII), Majadahonda, Madrid, Spain.
FAU - Brochado-Kith, Oscar
AU  - Brochado-Kith O
AD  - Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología (CNM), 
      Instituto de Salud Carlos III (ISCIII), Majadahonda, Madrid, Spain.
AD  - Centro de Investigación Biomédica en Red en Enfermedades Infecciosas, Instituto de 
      Salud Carlos III (ISCIII), Madrid, Spain.
FAU - Díez, Cristina
AU  - Díez C
AD  - Centro de Investigación Biomédica en Red en Enfermedades Infecciosas, Instituto de 
      Salud Carlos III (ISCIII), Madrid, Spain.
AD  - Unidad de Enfermedades Infecciosas/VIH, Hospital General Universitario 'Gregorio 
      Marañón', Madrid, Spain.
AD  - Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain.
FAU - Hontañon, Victor
AU  - Hontañon V
AD  - Centro de Investigación Biomédica en Red en Enfermedades Infecciosas, Instituto de 
      Salud Carlos III (ISCIII), Madrid, Spain.
AD  - Servicio de Medicina Interna-Unidad de VIH, Hospital Universitario La Paz, Madrid, 
      Spain.
AD  - Instituto de Investigación Sanitaria La Paz (IdiPAZ), Madrid, Spain.
FAU - Berenguer, Juan
AU  - Berenguer J
AUID- ORCID: 0000-0001-8541-8200
AD  - Centro de Investigación Biomédica en Red en Enfermedades Infecciosas, Instituto de 
      Salud Carlos III (ISCIII), Madrid, Spain.
AD  - Unidad de Enfermedades Infecciosas/VIH, Hospital General Universitario 'Gregorio 
      Marañón', Madrid, Spain.
AD  - Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain.
FAU - González-García, Juan
AU  - González-García J
AD  - Centro de Investigación Biomédica en Red en Enfermedades Infecciosas, Instituto de 
      Salud Carlos III (ISCIII), Madrid, Spain.
AD  - Servicio de Medicina Interna-Unidad de VIH, Hospital Universitario La Paz, Madrid, 
      Spain.
AD  - Instituto de Investigación Sanitaria La Paz (IdiPAZ), Madrid, Spain.
FAU - Rojo, David
AU  - Rojo D
AD  - Centre for Metabolomics and Bioanalysis (CEMBIO), Department of Chemistry and 
      Biochemistry, Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, 
      Urbanización Montepríncipe, 28660 Boadilla del Monte, Madrid, Spain.
FAU - Fernández-Rodríguez, Amanda
AU  - Fernández-Rodríguez A
AUID- ORCID: 0000-0002-5110-2213
AD  - Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología (CNM), 
      Instituto de Salud Carlos III (ISCIII), Majadahonda, Madrid, Spain.
AD  - Centro de Investigación Biomédica en Red en Enfermedades Infecciosas, Instituto de 
      Salud Carlos III (ISCIII), Madrid, Spain.
FAU - Ibañez-Samaniego, Luis
AU  - Ibañez-Samaniego L
AD  - Servicio de Aparato Digestivo, Hospital General Universitario 'Gregorio Marañón', 
      Madrid, Spain.
FAU - Llop-Herrera, Elba
AU  - Llop-Herrera E
AD  - Departamento de Gastroenterología, Hospital Universitario Puerta de 
      Hierro-Majadahonda, Majadahonda, Madrid, Spain.
FAU - Olveira, Antonio
AU  - Olveira A
AD  - Servicio de Aparato Digestivo, Hospital Universitario La Paz, Madrid, Spain.
FAU - Perez-Latorre, Leire
AU  - Perez-Latorre L
AD  - Centro de Investigación Biomédica en Red en Enfermedades Infecciosas, Instituto de 
      Salud Carlos III (ISCIII), Madrid, Spain.
AD  - Unidad de Enfermedades Infecciosas/VIH, Hospital General Universitario 'Gregorio 
      Marañón', Madrid, Spain.
AD  - Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain.
FAU - Barbas, Coral
AU  - Barbas C
AD  - Centre for Metabolomics and Bioanalysis (CEMBIO), Department of Chemistry and 
      Biochemistry, Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, 
      Urbanización Montepríncipe, 28660 Boadilla del Monte, Madrid, Spain.
FAU - Rava, Marta
AU  - Rava M
AD  - Unidad de la Cohorte de la Red de Investigación en Sida (CoRIS), Centro Nacional de 
      Epidemiologia (CNE), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
FAU - Resino, Salvador
AU  - Resino S
AUID- ORCID: 0000-0001-8783-0450
AD  - Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología (CNM), 
      Instituto de Salud Carlos III (ISCIII), Majadahonda, Madrid, Spain.
AD  - Centro de Investigación Biomédica en Red en Enfermedades Infecciosas, Instituto de 
      Salud Carlos III (ISCIII), Madrid, Spain.
FAU - Jiménez-Sousa, María Angeles
AU  - Jiménez-Sousa MA
AD  - Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología (CNM), 
      Instituto de Salud Carlos III (ISCIII), Majadahonda, Madrid, Spain.
AD  - Centro de Investigación Biomédica en Red en Enfermedades Infecciosas, Instituto de 
      Salud Carlos III (ISCIII), Madrid, Spain.
LA  - eng
GR  - CP17CIII/00007/Instituto de Salud Carlos III/
GR  - EC11-241/Ministerio de Sanidad, Servicios Sociales e Igualdad/
GR  - RD16/0025/0017/Spanish AIDS Research Network/
GR  - CB21/13/00044/Centro de Investigación Biomédica en Red (CIBER) en Enfermedades 
      Infecciosas/
GR  - INT16/00100/Programa de Intensificación de la Actividad Investigadora en el Sistema 
      Nacional de Salud (I3SNS)/
GR  - RTI2018-095166-B-I00/Ministerio de Ciencia, Innovación y Universidades/
GR  - CP14CIII/00010 to A.F.-R./ISCIII/
PT  - Journal Article
DEP - 20211209
PL  - England
TA  - J Antimicrob Chemother
JT  - The Journal of antimicrobial chemotherapy
JID - 7513617
SB  - IM
EDAT- 2021/12/11 06:00
MHDA- 2021/12/11 06:00
CRDT- 2021/12/10 06:55
PHST- 2021/08/05 00:00 [received]
PHST- 2021/11/08 00:00 [accepted]
PHST- 2021/12/10 06:55 [entrez]
PHST- 2021/12/11 06:00 [pubmed]
PHST- 2021/12/11 06:00 [medline]
AID - 6458069 [pii]
AID - 10.1093/jac/dkab444 [doi]
PST - aheadofprint
SO  - J Antimicrob Chemother. 2021 Dec 9:dkab444. doi: 10.1093/jac/dkab444.

PMID- 11582878
OWN - NLM
STAT- MEDLINE
DCOM- 20011025
LR  - 20061115
IS  - 0025-682X (Print)
IS  - 0025-682X (Linking)
VI  - 61
IP  - 2
DP  - 2001
TI  - [Co-infections of leishmania/HIV in south Europe].
PG  - 187-93
AB  - The Leishmania/HIV co-infection has emerged as a result of the increasing overlap 
      between leishmaniasis (mainly visceral, more rarely cutaneous) and AIDS, which is 
      due to the spread of the AIDS pandemic to rural areas and that of visceral 
      leishmaniasis to suburban areas. Cases of co-infection have so far been reported 
      from 33 countries around the world, most of the cases have been notified in 
      south-western Europe. 1,627 cases have been notified from Spain, France, Italy and 
      Portugal. While Leishmania/HIV co-infection is increasing in eastern Africa, cases 
      of co-infection are expected to diminish in South-western Europe due to the new 
      highly active anti-retroviral therapy (HAART). In 1998, a world wide WHO/UNAIDS 
      surveillance network was established, which now includes 28 member institutions. In 
      south-western Europe, the surveillance system based on 16 institutions is now well 
      established. The systematic use of standardized and recently computerized 
      case-report forms, the central international registry at WHO headquarters, and 
      finally the use of a geographic information system (GIS) for mapping and monitoring 
      co-infections have improved the overall quality of epidemiological data gathering. 
      All member institutions of the network report to WHO on an annual basis. World wide 
      information is analysed and periodically disseminated through international 
      publications. The GIS integrates epidemiological and demographic data sets and 
      allows for the mapping of co-infection cases down to locality level. The system can 
      be used to easily visualise and analyse the spatial distribution of co-infection 
      cases and to permit monitoring of the evolution of the distribution of the cases 
      over time. The risk of co-infected patients, as carriers of Leishmania in the blood, 
      to be a source of infection for the sandfly, has been recently confirmed. Moreover 
      intravenous drug users also transmit the disease through the sharing of needles.
FAU - Desjeux, P
AU  - Desjeux P
AD  - Département de Surveillance et Réponse des Maladies transmissibles, Organisation 
      Mondiale de la Santé (OMS), Genève, Suisse.
FAU - Piot, B
AU  - Piot B
FAU - O'Neill, K
AU  - O'Neill K
FAU - Meert, J P
AU  - Meert JP
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Co-infections à Leishmania/VIH dans le sud de l'Europe.
PL  - France
TA  - Med Trop (Mars)
JT  - Medecine tropicale : revue du Corps de sante colonial
JID - 8710146
SB  - IM
MH  - Acquired Immunodeficiency Syndrome/*complications/diagnosis/drug 
      therapy/epidemiology
MH  - Africa/epidemiology
MH  - Antiretroviral Therapy, Highly Active
MH  - Europe/epidemiology
MH  - Humans
MH  - Leishmaniasis/*complications/diagnosis/epidemiology
RF  - 7
EDAT- 2001/10/05 10:00
MHDA- 2001/10/26 10:01
CRDT- 2001/10/05 10:00
PHST- 2001/10/05 10:00 [pubmed]
PHST- 2001/10/26 10:01 [medline]
PHST- 2001/10/05 10:00 [entrez]
PST - ppublish
SO  - Med Trop (Mars). 2001;61(2):187-93.

PMID- 32502129
OWN - NLM
STAT- MEDLINE
DCOM- 20210715
LR  - 20210715
IS  - 1532-0987 (Electronic)
IS  - 0891-3668 (Linking)
VI  - 39
IP  - 8
DP  - 2020 Aug
TI  - Progressive Decline of the Glomerular Filtration Rate in HIV-infected Children 
      Treated With Tenofovir Disoproxil Fumarate-based Regimens in West and Central 
      Africa.
PG  - 737-739
LID - 10.1097/INF.0000000000002733 [doi]
AB  - A cross-sectional study of 358 HIV-1-infected children and adolescents living in 
      Sub-Saharan Africa treated with tenofovir disoproxil fumarate-based regimens for a 
      median of 1.5 interquartile range [0.6-3.1 years] showed a loss of glomerular 
      filtration rate estimated to be 0.41 mL/min/1.73 m per month of treatment. In 
      contrast, there was no decrease depending on the duration of the previous 
      antiretroviral treatment.
FAU - Diack, Aminata
AU  - Diack A
AD  - From the Pediatric Department, Centre Hospitalier National d'Enfants Pierre Royer, 
      Dakar, Senegal.
FAU - Yonaba, Caroline
AU  - Yonaba C
AD  - Pediatric Department, Centre Hospitalier Yalgado, Ouagadougou, Burkina Faso.
FAU - Coulibaly, Aba
AU  - Coulibaly A
AD  - Pediatric Department, Centre Hospitalier Universitaire Gabriel Toure, Bamako, Mali.
FAU - Ouedraogo, Sylvie
AU  - Ouedraogo S
AD  - Pediatric Department, Centre Hospitalier Pédiatrique Charles De Gaulle, Ouagadougou, 
      Burkina Faso.
FAU - Penda, Ida
AU  - Penda I
AD  - Pediatric Department, Centre Hospitalier La Quintinie, Douala, Cameroon.
FAU - Bukuru, Hélène
AU  - Bukuru H
AD  - Pediatric Department, Centre Hospitalier Kamenge, Bujumbura, Burundi.
FAU - Folquet, Madeleine
AU  - Folquet M
AD  - Pediatric Department, Centre Hospitalier Cocody, Abidjan, Cote d'Ivoire.
FAU - Tanoh Eboua, François
AU  - Tanoh Eboua F
AD  - Pediatric Department, Centre Hospitalier Yopougon, Abidjan, Cote d'Ivoire.
FAU - Sylla, Mariam
AU  - Sylla M
AD  - Pediatric Department, Centre Hospitalier Universitaire Gabriel Toure, Bamako, Mali.
FAU - Blanche, Stéphane
AU  - Blanche S
AD  - Pediatric Department, Hôpital Necker Enfants Malades AP-HP, Paris, France.
FAU - Tejiokem, Mathurin
AU  - Tejiokem M
AD  - Epidemiology and Public Health unit, Centre Pasteur du Cameroun, Yaoundé, Cameroon.
CN  - Enfants VIH Afrique network
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Pediatr Infect Dis J
JT  - The Pediatric infectious disease journal
JID - 8701858
RN  - 0 (Anti-HIV Agents)
RN  - 99YXE507IL (Tenofovir)
SB  - IM
MH  - Adolescent
MH  - Africa South of the Sahara
MH  - Africa, Central
MH  - Anti-HIV Agents/*adverse effects/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Cross-Sectional Studies
MH  - Female
MH  - Glomerular Filtration Rate/*drug effects
MH  - HIV-1/drug effects
MH  - Humans
MH  - Male
MH  - Tenofovir/*adverse effects/*therapeutic use
EDAT- 2020/06/06 06:00
MHDA- 2021/07/16 06:00
CRDT- 2020/06/06 06:00
PHST- 2020/06/06 06:00 [pubmed]
PHST- 2021/07/16 06:00 [medline]
PHST- 2020/06/06 06:00 [entrez]
AID - 00006454-202008000-00019 [pii]
AID - 10.1097/INF.0000000000002733 [doi]
PST - ppublish
SO  - Pediatr Infect Dis J. 2020 Aug;39(8):737-739. doi: 10.1097/INF.0000000000002733.

PMID- 26762688
OWN - NLM
STAT- MEDLINE
DCOM- 20161228
LR  - 20161230
IS  - 1953-8022 (Electronic)
IS  - 1246-7820 (Linking)
VI  - 23
IP  - 1
DP  - 2016 Feb
TI  - [Jean-Jacques Lefrère: A miscarried ambition for blood safety in francophone 
      Africa].
PG  - 45-8
LID - S1246-7820(15)00433-4 [pii]
LID - 10.1016/j.tracli.2015.12.006 [doi]
AB  - The announcement of the death of Professor Jean-Jacques Lefrère caused considerable 
      emotion and surprise within the francophone Africa blood transfusion research 
      network. The group was created in 2007 in Paris. Each member that works within this 
      group wanted to pay their last respects through dedicated publication for a 
      brilliant researcher and writer. The tribute describes the creation of the group, 
      its goals, its operations, its achievements and the prospects of its activities 
      while emphasizing the essential role that Professor Lefrère played within the group.
CI  - Copyright © 2015 Elsevier Masson SAS. All rights reserved.
FAU - Tayou Tagny, C
AU  - Tayou Tagny C
AD  - Faculté de médecine et des sciences biomédicales de l'université de Yaoundé I, BP 
      5739, Yaoundé, Cameroun. Electronic address: tayouclaude@yahoo.fr.
FAU - Laperche, S
AU  - Laperche S
AD  - Département d'études des agents transmissibles par le sang, Institut national de la 
      transfusion sanguine (INTS), Centre national de référence des hépatites virales B et 
      C et du VIH en transfusion, 75015 Paris, France.
FAU - Murphy, E
AU  - Murphy E
AD  - Blood Systems Research Institute, San Francisco, Californie, États-Unis.
CN  - Groupe de recherches transfusionnelles en Afrique francophone
LA  - fre
PT  - Biography
PT  - Historical Article
PT  - Journal Article
TT  - Jean-Jacques Lefrère: une ambition fauchée pour la sécurité transfusionnelle en 
      Afrique francophone.
DEP - 20160104
PL  - France
TA  - Transfus Clin Biol
JT  - Transfusion clinique et biologique : journal de la Societe francaise de transfusion 
      sanguine
JID - 9423846
SB  - IM
MH  - Africa, Western
MH  - Blood Safety/*history
MH  - Congresses as Topic/history
MH  - France
MH  - Goals
MH  - History, 20th Century
MH  - History, 21st Century
MH  - Humans
MH  - Information Services/history/organization & administration
MH  - International Cooperation
MH  - Research/history/organization & administration
MH  - Societies, Scientific
MH  - Transfusion Medicine/*history/organization & administration
PS  - Lefrère JJ
FPS - Lefrère, Jean-Jacques
OTO - NOTNLM
OT  - Afrique francophone
OT  - Blood safety research network
OT  - Francophone Africa
OT  - Groupe de recherches transfusionnelles
OT  - Hommage
OT  - Jean-Jacques Lefrère
OT  - Tribute
FIR - Ahlonsou, F
IR  - Ahlonsou F
FIR - Anani, L
IR  - Anani L
FIR - Atinkpinda, G
IR  - Atinkpinda G
FIR - Lafia, E
IR  - Lafia E
FIR - Totongnon, R
IR  - Totongnon R
FIR - Coulibaly, S
IR  - Coulibaly S
FIR - Dahourou, H
IR  - Dahourou H
FIR - Diallo, S
IR  - Diallo S
FIR - Djim-Madjiù, M
IR  - Djim-Madjiù M
FIR - Domo, Y
IR  - Domo Y
FIR - Hermann, Z
IR  - Hermann Z
FIR - Kabore, I
IR  - Kabore I
FIR - Kiba Koumare, A
IR  - Kiba Koumare A
FIR - Kientega, Y
IR  - Kientega Y
FIR - Nebie, Y
IR  - Nebie Y
FIR - Ouattara, S
IR  - Ouattara S
FIR - Sanou, M
IR  - Sanou M
FIR - Sawadogo, S
IR  - Sawadogo S
FIR - Bizimana, P
IR  - Bizimana P
FIR - Ndorere, L
IR  - Ndorere L
FIR - Nzosaba, D
IR  - Nzosaba D
FIR - Mbanya, D
IR  - Mbanya D
FIR - Mbangue, M
IR  - Mbangue M
FIR - Mole, S
IR  - Mole S
FIR - Tapko, J B
IR  - Tapko JB
FIR - Tayou Tagny, C
IR  - Tayou Tagny C
FIR - Toukam, M
IR  - Toukam M
FIR - Said Fazul, H
IR  - Said Fazul H
FIR - Bokilo, A
IR  - Bokilo A
FIR - Boukatou, G
IR  - Boukatou G
FIR - Dokekias, A
IR  - Dokekias A
FIR - Dolama, F
IR  - Dolama F
FIR - Elenga, J P
IR  - Elenga JP
FIR - Achy Brou, A
IR  - Achy Brou A
FIR - Diané Kouao, M
IR  - Diané Kouao M
FIR - Hyda, J
IR  - Hyda J
FIR - Konaté, S
IR  - Konaté S
FIR - Kpangni, J C
IR  - Kpangni JC
FIR - Nguessan, A
IR  - Nguessan A
FIR - Nguessan-Blao, R
IR  - Nguessan-Blao R
FIR - Sika, M
IR  - Sika M
FIR - Sawadogo, D
IR  - Sawadogo D
FIR - Tchimou, J
IR  - Tchimou J
FIR - Yassonguin, S
IR  - Yassonguin S
FIR - Kouegnigan, L
IR  - Kouegnigan L
FIR - Ndong, J
IR  - Ndong J
FIR - Obame, S
IR  - Obame S
FIR - Tata Baldé, A
IR  - Tata Baldé A
FIR - Herisoa, F
IR  - Herisoa F
FIR - Holianjavony, J
IR  - Holianjavony J
FIR - Hanitriniala, P
IR  - Hanitriniala P
FIR - Rakoto Alson, A
IR  - Rakoto Alson A
FIR - Rasoarimalalanarivo, R
IR  - Rasoarimalalanarivo R
FIR - Razafimahefa, M
IR  - Razafimahefa M
FIR - Ba, A
IR  - Ba A
FIR - Bouréma, K
IR  - Bouréma K
FIR - Cissé, M
IR  - Cissé M
FIR - Diarra, A
IR  - Diarra A
FIR - Fomba, M
IR  - Fomba M
FIR - Gakou, G Y
IR  - Gakou GY
FIR - Guindo, S
IR  - Guindo S
FIR - Guitteye, H
IR  - Guitteye H
FIR - Mounirou, B
IR  - Mounirou B
FIR - Oumar Coulibaly, S
IR  - Oumar Coulibaly S
FIR - Tièman, C
IR  - Tièman C
FIR - Touré, H
IR  - Touré H
FIR - Ciré Ba, B
IR  - Ciré Ba B
FIR - Abdallahi ould Boullahi, M
IR  - Abdallahi ould Boullahi M
FIR - Yahaha, R
IR  - Yahaha R
FIR - Brah, A
IR  - Brah A
FIR - Diallo, K R
IR  - Diallo KR
FIR - Hadiza, S
IR  - Hadiza S
FIR - Mahane Kabirou, A
IR  - Mahane Kabirou A
FIR - Moussa Mayaki, Z
IR  - Moussa Mayaki Z
FIR - Agasa, S
IR  - Agasa S
FIR - Bayongwa, J M
IR  - Bayongwa JM
FIR - Maheshe
IR  - Maheshe
FIR - Kabulo, H
IR  - Kabulo H
FIR - Kakema, C
IR  - Kakema C
FIR - Kapinga, S
IR  - Kapinga S
FIR - Kazadi, R
IR  - Kazadi R
FIR - Kiyombo Nsenga, S
IR  - Kiyombo Nsenga S
FIR - Malenga Nkanga, B
IR  - Malenga Nkanga B
FIR - Mampasi, P
IR  - Mampasi P
FIR - Mayuku, G
IR  - Mayuku G
FIR - Mbelu Kalonji, M
IR  - Mbelu Kalonji M
FIR - Mbensa, G O
IR  - Mbensa GO
FIR - Misingui, P
IR  - Misingui P
FIR - Mukendi, L
IR  - Mukendi L
FIR - Mulapi-Tira, D
IR  - Mulapi-Tira D
FIR - Ndakala, D
IR  - Ndakala D
FIR - Ndjulm Olish, J P
IR  - Ndjulm Olish JP
FIR - Nganga Nkanga, M
IR  - Nganga Nkanga M
FIR - Ngandu Bwangandu, C
IR  - Ngandu Bwangandu C
FIR - Tutala Kinkela, S
IR  - Tutala Kinkela S
FIR - Ramazani, S Y
IR  - Ramazani SY
FIR - Senyana, F
IR  - Senyana F
FIR - Kimenyi, P
IR  - Kimenyi P
FIR - Diallo, T A
IR  - Diallo TA
FIR - Diop, S
IR  - Diop S
FIR - Ndiaye Dieye, T
IR  - Ndiaye Dieye T
FIR - Gadji, M
IR  - Gadji M
FIR - Guèye, Y
IR  - Guèye Y
FIR - Seck, M
IR  - Seck M
FIR - Senghor, A B
IR  - Senghor AB
FIR - Thiam, D
IR  - Thiam D
FIR - Touré, A O
IR  - Touré AO
FIR - Djimadoun, M
IR  - Djimadoun M
FIR - Soureya, Z
IR  - Soureya Z
FIR - Akueté, E A
IR  - Akueté EA
FIR - Awitala, E
IR  - Awitala E
FIR - Feteke, L
IR  - Feteke L
FIR - Magnang, H
IR  - Magnang H
FIR - Mawussi, K
IR  - Mawussi K
FIR - Ségbéna, Y
IR  - Ségbéna Y
FIR - Vovor, A
IR  - Vovor A
FIR - Kezzal, K
IR  - Kezzal K
FIR - Abouyoub, A
IR  - Abouyoub A
FIR - Benajiba, M
IR  - Benajiba M
FIR - Benchemsi, N
IR  - Benchemsi N
FIR - Hajjout, K
IR  - Hajjout K
FIR - Lahjouji, K
IR  - Lahjouji K
FIR - Othmani, H
IR  - Othmani H
FIR - Ben Amor, I
IR  - Ben Amor I
FIR - Gargouri, J
IR  - Gargouri J
FIR - Mojaat Moula, N
IR  - Mojaat Moula N
FIR - Skouri, H
IR  - Skouri H
FIR - Murphy, E
IR  - Murphy E
FIR - Shiboski, C
IR  - Shiboski C
FIR - Laperche, S
IR  - Laperche S
FIR - Lefrère, J J
IR  - Lefrère JJ
FIR - Loua, A
IR  - Loua A
EDAT- 2016/01/15 06:00
MHDA- 2016/12/29 06:00
CRDT- 2016/01/15 06:00
PHST- 2015/12/08 00:00 [received]
PHST- 2016/01/15 06:00 [entrez]
PHST- 2016/01/15 06:00 [pubmed]
PHST- 2016/12/29 06:00 [medline]
AID - S1246-7820(15)00433-4 [pii]
AID - 10.1016/j.tracli.2015.12.006 [doi]
PST - ppublish
SO  - Transfus Clin Biol. 2016 Feb;23(1):45-8. doi: 10.1016/j.tracli.2015.12.006. Epub 
      2016 Jan 4.

PMID- 29851192
OWN - NLM
STAT- MEDLINE
DCOM- 20190312
LR  - 20190312
IS  - 1365-3156 (Electronic)
IS  - 1360-2276 (Linking)
VI  - 23
IP  - 8
DP  - 2018 Aug
TI  - Prevalence and clinical characteristics of CMV coinfection among HIV infected 
      individuals in Guinea-Bissau: a cross-sectional study.
PG  - 896-904
LID - 10.1111/tmi.13082 [doi]
AB  - OBJECTIVES: To describe the prevalence of CMV in a cohort of HIV infected 
      individuals in Guinea-Bissau, West Africa and to evaluate differences in patients' 
      clinical characteristics associated with their CMV status. METHODS: Newly diagnosed 
      HIV infected adults were invited to participate in this cross-sectional study, from 
      May until December 2015. Enrolled patients were interviewed and underwent a full 
      physical examination focusing on CMV disease manifestations. Blood samples were 
      analysed for CMV serology, QuantiFERON-CMV response and CMV DNA. Mortality follow-up 
      were registered for one year after inclusion. RESULTS: In total, 180 patients were 
      enrolled. Anti-CMV IgG positivity was found in 100% (138/138) and 2.8% (4/138) were 
      anti-CMV IgM positive. A positive QuantiFERON-CMV response was found in 85.7% 
      (60/70) of the patients and 60.6% (83/137) had CMV viraemia. QuantiFERON-CMV 
      response and detectable CMV DNA were associated with lower CD4 cell count, older age 
      and upper gastrointestinal complaints. During one year of follow-up, the IRR for 
      death among CMV DNA positive patients was 1.5 (P = 0.5). CONCLUSIONS: CMV 
      coinfection was detected among all enrolled patients and CMV viraemia was highly 
      prevalent. Only age and upper gastrointestinal complaints were associated with the 
      patients' CMV status.
CI  - © 2018 John Wiley & Sons Ltd.
FAU - Grønborg, Helene L
AU  - Grønborg HL
AD  - GloHAU, Department of Public Health, Aarhus University, Aarhus, Denmark.
AD  - Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau.
FAU - Jespersen, Sanne
AU  - Jespersen S
AD  - Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau.
AD  - Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
FAU - Egedal, Johanne H
AU  - Egedal JH
AD  - Institute of Biomedicine, Aarhus University, Aarhus, Denmark.
FAU - Correia, Faustino G
AU  - Correia FG
AD  - Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau.
AD  - National HIV Programme, Ministry of Health, Bissau, Guinea-Bissau.
FAU - Medina, Candida
AU  - Medina C
AD  - National HIV Programme, Ministry of Health, Bissau, Guinea-Bissau.
FAU - Krarup, Henrik
AU  - Krarup H
AD  - Section of Molecular Diagnostics, Clinical Biochemistry, Aalborg University 
      Hospital, Aalborg, Denmark.
FAU - Hønge, Bo L
AU  - Hønge BL
AD  - Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau.
AD  - National HIV Programme, Ministry of Health, Bissau, Guinea-Bissau.
AD  - Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark.
FAU - Wejse, Christian
AU  - Wejse C
AD  - GloHAU, Department of Public Health, Aarhus University, Aarhus, Denmark.
AD  - Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau.
AD  - Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
CN  - Bissau HIV Cohort Study Group
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180619
PL  - England
TA  - Trop Med Int Health
JT  - Tropical medicine & international health : TM & IH
JID - 9610576
SB  - IM
MH  - Adult
MH  - Cohort Studies
MH  - Coinfection/*epidemiology
MH  - Cross-Sectional Studies
MH  - Cytomegalovirus Infections/diagnosis/*epidemiology
MH  - Female
MH  - Guinea-Bissau/epidemiology
MH  - HIV Infections/diagnosis/*epidemiology
MH  - Humans
MH  - Male
MH  - Prevalence
OTO - NOTNLM
OT  - * VIH
OT  - *CMV prevalence
OT  - *Guinea-Bissau
OT  - *Guinée-Bissau
OT  - *HIV
OT  - *caractéristiques cliniques
OT  - *clinical characteristics
OT  - *cytomegalovirus
OT  - *cytomégalovirus
OT  - *mortality
OT  - *mortalité
OT  - *prévalence du CMV
FIR - Rodrigues, Amabelia
IR  - Rodrigues A
FIR - da Silva, David
IR  - da Silva D
FIR - da Silva, Zacarias
IR  - da Silva Z
FIR - Oliviera-Souto, Ines
IR  - Oliviera-Souto I
FIR - Østergaard, Lars
IR  - Østergaard L
FIR - Laursen, Alex
IR  - Laursen A
FIR - Aaby, Peter
IR  - Aaby P
FIR - Fomsgaard, Anders
IR  - Fomsgaard A
FIR - Erikstrup, Christian
IR  - Erikstrup C
EDAT- 2018/06/01 06:00
MHDA- 2019/03/13 06:00
CRDT- 2018/06/01 06:00
PHST- 2018/06/01 06:00 [pubmed]
PHST- 2019/03/13 06:00 [medline]
PHST- 2018/06/01 06:00 [entrez]
AID - 10.1111/tmi.13082 [doi]
PST - ppublish
SO  - Trop Med Int Health. 2018 Aug;23(8):896-904. doi: 10.1111/tmi.13082. Epub 2018 Jun 
      19.

PMID- 29165512
OWN - NLM
STAT- MEDLINE
DCOM- 20180131
LR  - 20180131
IS  - 0717-6341 (Electronic)
IS  - 0716-1018 (Linking)
VI  - 34
IP  - 4
DP  - 2017 Aug
TI  - [Antiretroviral treatment adherence for HIV/AIDS in women: a sociocultural 
      perspective].
PG  - 352-358
LID - S0716-10182017000400352 [pii]
LID - 10.4067/s0716-10182017000400352 [doi]
AB  - BACKGROUND: Adequate adherence to HAART has a high impact on survival of AIDA 
      patients. There is little consensus on the causes of low adherence to treatment in 
      women, who are in a situation of inequality in terms of prevention and related care. 
      OBJECTIVES: To explore and describe the socio-cultural aspects related to the 
      adherence of women to antiretroviral treatment for HIV / AIDS. MATERIAL AND METHODS: 
      Qualitative, exploratory-descriptive study. The study population was focused on 
      Chilean women, who are 18 years of age or older, living with HIV/AIDS. The sample 
      size was defined by information saturation. In-depth interviews were conducted with 
      16 women contacted in seven public care centers for people living with HIV (PLHIV) 
      in 4 regions of the country, and it was take into account the saturation of the 
      information. RESULTS: There are several sociocultural factors that determine the 
      level of adherence that women adopt in relation to HAART. The most relevant ones are 
      the vital satisfaction, the imaginary about HIV, the availability of their networks 
      in front of diagnosis and the availability of information are fundamental. 
      DISCUSSION: It is necessary to enter into specific interventions considering the 
      sociocultural aspects and satisfying the psychosocial needs of women. It is 
      imperative that public policies and health teams consider these aspects to improve 
      adherence to HAART.
FAU - Belmar, Julieta
AU  - Belmar J
AD  - Escuela de Salud Pública, Facultad de Medicina, Universidad de Chile, Chile.
FAU - Stuardo, Valeria
AU  - Stuardo V
AD  - Escuela de Salud Pública, Facultad de Medicina, Universidad de Chile, Chile.
LA  - spa
PT  - Journal Article
TT  - Adherencia al tratamiento anti-retroviral para el VIH/SIDA en mujeres: una mirada 
      socio-cultural.
PL  - Chile
TA  - Rev Chilena Infectol
JT  - Revista chilena de infectologia : organo oficial de la Sociedad Chilena de 
      Infectologia
JID - 9305754
RN  - 0 (Anti-HIV Agents)
SB  - IM
MH  - Adult
MH  - Anti-HIV Agents/*therapeutic use
MH  - Chile
MH  - *Cultural Characteristics
MH  - Female
MH  - HIV Infections/*drug therapy
MH  - Humans
MH  - Medication Adherence/psychology/*statistics & numerical data
MH  - Qualitative Research
MH  - Sex Factors
MH  - Socioeconomic Factors
EDAT- 2017/11/23 06:00
MHDA- 2018/02/01 06:00
CRDT- 2017/11/23 06:00
PHST- 2016/12/05 00:00 [received]
PHST- 2017/07/11 00:00 [accepted]
PHST- 2017/11/23 06:00 [entrez]
PHST- 2017/11/23 06:00 [pubmed]
PHST- 2018/02/01 06:00 [medline]
AID - S0716-10182017000400352 [pii]
AID - 10.4067/s0716-10182017000400352 [doi]
PST - ppublish
SO  - Rev Chilena Infectol. 2017 Aug;34(4):352-358. doi: 10.4067/s0716-10182017000400352.

PMID- 30841566
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Electronic)
IS  - 2077-0383 (Linking)
VI  - 8
IP  - 3
DP  - 2019 Mar 5
TI  - VDR rs2228570 Polymorphism Is Related to Non-Progression to AIDS in Antiretroviral 
      Therapy Naïve HIV-Infected Patients.
LID - 10.3390/jcm8030311 [doi]
LID - 311
AB  - BACKGROUND: Vitamin D is a fundamental regulator of host defenses by activating 
      genes related to innate and adaptive immunity. In this study, we analyzed the 
      association among single nucleotide polymorphisms (SNPs) in the vitamin D receptor 
      (VDR) gene, with clinical patterns of AIDS progression in antiretroviral treatment 
      (ART)-naïve HIV-infected patients. METHODS: We conducted a retrospective study in 
      667 HIV-infected patients, who were classified within three groups according to 
      their AIDS progression pattern (183 long-term non-progressors (LTNPs), 334 moderate 
      progressors (MPs), and 150 rapid progressors (RPs)). Five VDR SNPs (rs11568820, 
      rs4516035, rs2228570, rs1544410, and rs7975232) were genotyped using Agena 
      Bioscience's MassARRAY platform. RESULTS: Significant association results were found 
      for rs2228570. Within all HIV patients, the presence of T allele at VDR rs2228570 
      SNP was protective against AIDS progression (ordinal outcome) under additive 
      (adjusted odds ratio (aOR) = 0.75; p = 0.009), dominant (aOR = 0.69; p = 0.015), and 
      codominant (aOR = 0.56; p = 0.017) inheritance models. In addition, the same allele 
      was protective under additive and codominant inheritance models when we compared 
      with LTNPs vs. RPs [aOR = 0.64 (p = 0.019) and aOR = 0.37 (p = 0.018), respectively] 
      and when we compared MPs vs. RPs [aOR = 0.72 (p = 0.035) and aOR = 0.45 (p = 0.028), 
      respectively]. CONCLUSIONS: The VDR rs2228570 T allele was related to a lower AIDS 
      progression pattern in ART-naïve HIV-infected patients. These findings expand upon 
      the knowledge about HIV pathogenesis in untreated HIV-infected patients with 
      different clinical outcomes.
FAU - Jiménez-Sousa, María A
AU  - Jiménez-Sousa MA
AD  - Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto 
      de Salud Carlos III, Carretera Majadahonda-Pozuelo, Km 2.2, 28220 Madrid, Spain. 
      jimenezsousa@isciii.es.
FAU - Jiménez, José Luis
AU  - Jiménez JL
AD  - Plataforma de Laboratorio, Hospital General Universitario "Gregorio Marañón", 28007 
      Madrid, Spain. joseluis.jimenez@salud.madrid.org.
AD  - Fundación para la Investigación Biomédica, Hospital General Universitario Gregorio 
      Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), 28007 
      Madrid, Spain. joseluis.jimenez@salud.madrid.org.
FAU - Fernández-Rodríguez, Amanda
AU  - Fernández-Rodríguez A
AUID- ORCID: 0000-0002-5110-2213
AD  - Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto 
      de Salud Carlos III, Carretera Majadahonda-Pozuelo, Km 2.2, 28220 Madrid, Spain. 
      amandafr@isciii.es.
FAU - Brochado-Kith, Oscar
AU  - Brochado-Kith O
AD  - Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto 
      de Salud Carlos III, Carretera Majadahonda-Pozuelo, Km 2.2, 28220 Madrid, Spain. 
      brochado1993@gmail.com.
FAU - Bellón, José María
AU  - Bellón JM
AUID- ORCID: 0000-0002-8492-1565
AD  - Fundación para la Investigación Biomédica, Hospital General Universitario Gregorio 
      Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), 28007 
      Madrid, Spain. bellon23@gmail.com.
FAU - Gutierrez, Félix
AU  - Gutierrez F
AD  - Unidad de Enfermedades Infecciosas, Hospital General de Elche & Universidad Miguel 
      Hernández, 03202 Alicante, Spain. gutierrezfel@gmail.com.
FAU - Díez, Cristina
AU  - Díez C
AD  - Servicio Microbiología, Unidad de Enfermedades Infecciosas/VIH, Hospital General 
      Universitario Gregorio Marañon, 28007 Madrid, Spain. crispu82@gmail.com.
FAU - Bernal-Morell, Enrique
AU  - Bernal-Morell E
AUID- ORCID: 0000-0002-4041-0579
AD  - Servicio de Enfermedades Infecciosas, Hospital General Universitario Reina Sofia, 
      30003 Madrid, Spain. ebm.hgurs@gmail.com.
FAU - Viciana, Pompeyo
AU  - Viciana P
AD  - Servicio de Enfermedades Infecciosas, Hospital Virgen del Rocío, 41013 Seville, 
      Spain. pompeyo.viciana.sspa@juntadeandalucia.es.
FAU - Muñoz-Fernández, María A
AU  - Muñoz-Fernández MA
AD  - Sección Inmunología, Laboratorio Inmuno Biología Molecular, Hospital General 
      Universitario Gregorio Marañón, IiSGM, and Spanish HIV HGM BioBank, 28007 Madrid, 
      Spain. mmunoz.hgugm@gmail.com.
AD  - Networking Research Center on Bioengineering, Biomaterials and Nanomedicine 
      (CIBER-BBN), 28007 Madrid, Spain. mmunoz.hgugm@gmail.com.
FAU - Resino, Salvador
AU  - Resino S
AUID- ORCID: 0000-0001-8783-0450
AD  - Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto 
      de Salud Carlos III, Carretera Majadahonda-Pozuelo, Km 2.2, 28220 Madrid, Spain. 
      sresino@isciii.es.
LA  - eng
GR  - RD16/0025/0019/Instituto de Salud Carlos III/
GR  - RD16CIII/0002/0002/Instituto de Salud Carlos III/
PT  - Journal Article
DEP - 20190305
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC6463017
OTO - NOTNLM
OT  - AIDS
OT  - LTNPs
OT  - VDR
OT  - non-progression
OT  - single nucleotide polymorphisms
COIS- The authors declare no conflict of interest.
EDAT- 2019/03/08 06:00
MHDA- 2019/03/08 06:01
CRDT- 2019/03/08 06:00
PHST- 2019/02/08 00:00 [received]
PHST- 2019/02/26 00:00 [revised]
PHST- 2019/02/26 00:00 [accepted]
PHST- 2019/03/08 06:00 [entrez]
PHST- 2019/03/08 06:00 [pubmed]
PHST- 2019/03/08 06:01 [medline]
AID - jcm8030311 [pii]
AID - jcm-08-00311 [pii]
AID - 10.3390/jcm8030311 [doi]
PST - epublish
SO  - J Clin Med. 2019 Mar 5;8(3):311. doi: 10.3390/jcm8030311.

PMID- 32631665
OWN - NLM
STAT- MEDLINE
DCOM- 20201215
LR  - 20201215
IS  - 0398-7620 (Print)
IS  - 0398-7620 (Linking)
VI  - 68
IP  - 4
DP  - 2020 Aug
TI  - [Access to the management of HIV infected children: Overview of the healthcare 
      supply in Cameroon in 2014].
PG  - 243-251
LID - S0398-7620(20)30368-0 [pii]
LID - 10.1016/j.respe.2020.05.008 [doi]
AB  - BACKGROUND: In Cameroon in 2012, the proportion (15%) of children eligible for 
      antiretroviral treatment (ART) was one of the lowest among the 21 Global Fund 
      priority countries. The objective of this study was to carry out a situational 
      analysis of the existing care offer for pediatric HIV in Cameroon. METHODS: A 
      descriptive cross-sectional study was conducted over a 4-month period (April to 
      August 2014) in 12 healthcare facilities in 7 regions of Cameroon selected by 
      systematic sampling. The data were collected in a self-administered questionnaire 
      filled out by the caregiving and administrative personnel included in the study. 
      RESULTS: All in all, 142 persons in charge of pediatric HIV treatment were included 
      in the study, of whom 115 were working at the operational level: 59 (51.2%) health 
      personnel, 44 (38.3%) community agents and 12 (10.4%) department heads; the other 27 
      exercised responsibilities at the regional (19) and the local (8) levels. An 
      overwhelming majority of the caregivers involved in pediatric VIH treatment were 
      nurses, a factor necessitating the delegation of medical tasks institutionalized in 
      Cameroon. Few standardized nationwide documents take into account these treatment 
      modalities. Inadequate dissemination of the documents at all levels of the 
      healthcare pyramid may justify the non-compliance with the care protocols that has 
      been observed in the training programs dedicated to the subject. CONCLUSION: The 
      updating and large-scale dissemination of standardized nationwide documents taking 
      into account the specificities of HIV-infected children are required to improve 
      implementation at the operational level of the Cameroonian healthcare system of the 
      existing guidelines for pediatric HIV treatment.
CI  - Copyright © 2020 Elsevier Masson SAS. All rights reserved.
FAU - Penda, C I
AU  - Penda CI
AD  - Department of clinical sciences, Faculty of medicine and pharmaceutical sciences, 
      University de Douala, Douala, Cameroun; Laquintinie de Douala hospital, Douala, 
      Cameroun. Electronic address: Calix.penda@gmail.com.
FAU - Zoung Kanyi Bissek, A-C
AU  - Zoung Kanyi Bissek AC
AD  - Department of medicine et specialties, Faculty of biomedical sciences, University of 
      Yaoundé 1, Yaoundé, Cameroun; Operational research division, Cameroonian ministry of 
      public health, Yaoundé, Cameroun.
FAU - Téjiokem, M C
AU  - Téjiokem MC
AD  - Epidemiology and public health department, Pasteur center of Cameroon, Member of the 
      Institut Pasteur International Network, Yaoundé, Cameroun.
FAU - Sofeu, C L
AU  - Sofeu CL
AD  - Epidemiology and public health department, Pasteur center of Cameroon, Member of the 
      Institut Pasteur International Network, Yaoundé, Cameroun; University of Bordeaux, 
      Inserm Bordeaux Population health U1219 (Biostatistics), Bordeaux, France.
FAU - Eboumbou Moukoko, E C
AU  - Eboumbou Moukoko EC
AD  - Epidemiology and public health department, Pasteur center of Cameroon, Member of the 
      Institut Pasteur International Network, Yaoundé, Cameroun; Department of the 
      biological sciences, Faculty of medicine and the pharmaceutical sciences, University 
      of Douala, Cameroun.
FAU - Ateba Ndongo, F
AU  - Ateba Ndongo F
AD  - Operational research division, Cameroonian ministry of public health, Yaoundé, 
      Cameroun; Chantal Biya foundation, Mother-and-Child center of Yaoundé, Yaoundé, 
      Cameroun.
FAU - Njock, L R
AU  - Njock LR
AD  - Laquintinie de Douala hospital, Douala, Cameroun; Department of surgery and 
      specialties, Faculty of medicine and the pharmaceutical sciences, University of 
      Douala, Douala, Cameroun.
FAU - Koki Ndombo, P O
AU  - Koki Ndombo PO
AD  - Chantal Biya foundation, Mother-and-Child center of Yaoundé, Yaoundé, Cameroun; 
      Departement of pediatrics, Faculty of biomedical sciences, University of Yaoundé 1, 
      Yaoundé, Cameroun.
LA  - fre
PT  - Journal Article
TT  - Accès à la prise en charge de l’infection VIH pédiatrique – État des lieux de 
      l’offre des soins au Cameroun en 2014.
DEP - 20200704
PL  - France
TA  - Rev Epidemiol Sante Publique
JT  - Revue d'epidemiologie et de sante publique
JID - 7608039
RN  - 0 (Anti-HIV Agents)
RN  - 0 (Anti-Retroviral Agents)
SB  - IM
MH  - Adult
MH  - Anti-HIV Agents/supply & distribution/therapeutic use
MH  - Anti-Retroviral Agents/supply & distribution/therapeutic use
MH  - *Antiretroviral Therapy, Highly Active
MH  - Cameroon/epidemiology
MH  - Child
MH  - Cross-Sectional Studies
MH  - Delivery of Health Care/organization & administration/standards/statistics & 
      numerical data
MH  - Female
MH  - HIV
MH  - HIV Infections/epidemiology/*therapy
MH  - Health Services Accessibility/standards/*statistics & numerical data
MH  - Healthcare Disparities/standards/statistics & numerical data
MH  - Humans
MH  - Male
MH  - Medical Staff/statistics & numerical data
MH  - Middle Aged
MH  - *Pediatrics/organization & administration/statistics & numerical data
MH  - Socioeconomic Factors
OTO - NOTNLM
OT  - Antiretroviral therapy
OT  - Cameroon
OT  - Cameroun
OT  - Enfants infectés par le VIH
OT  - HIV-infected children
OT  - Pediatric care
OT  - Prise en charge
OT  - Traitements antirétroviraux
EDAT- 2020/07/08 06:00
MHDA- 2020/12/16 06:00
CRDT- 2020/07/08 06:00
PHST- 2018/11/26 00:00 [received]
PHST- 2020/03/20 00:00 [revised]
PHST- 2020/05/19 00:00 [accepted]
PHST- 2020/07/08 06:00 [pubmed]
PHST- 2020/12/16 06:00 [medline]
PHST- 2020/07/08 06:00 [entrez]
AID - S0398-7620(20)30368-0 [pii]
AID - 10.1016/j.respe.2020.05.008 [doi]
PST - ppublish
SO  - Rev Epidemiol Sante Publique. 2020 Aug;68(4):243-251. doi: 
      10.1016/j.respe.2020.05.008. Epub 2020 Jul 4.

PMID- 32511709
OWN - NLM
STAT- MEDLINE
DCOM- 20210526
LR  - 20210526
IS  - 1460-2709 (Electronic)
IS  - 1369-3786 (Linking)
VI  - 58
IP  - 7
DP  - 2020 Oct 1
TI  - New multilocus sequence typing primers to enable genotyping of AD hybrids within the 
      Cryptococcus neoformans species complex.
PG  - 1005-1009
LID - 10.1093/mmy/myaa047 [doi]
AB  -  : Although AD hybrids within the Cryptococcus neoformans species complex represent 
      about 20% of the isolates identified in Europe, phylogenetic and population genetic 
      studies are lacking due to the inability to use the standardized typing method. The 
      aim of the present study was to design new molecular type specific primers in order 
      to apply the standard ISHAM consensus multilocus sequence typing (MLST) scheme to AD 
      hybrids. The new primers are able to specifically amplify VNI and VNIV alleles of 
      the seven MLST loci in both haploid and diploid or aneuploid hybrid strains. This 
      study forms the basis for future molecular epidemiology studies of AD hybrids. LAY 
      ABSTRACT: We designed and tested new specific primers to amplify the two alleles of 
      each of the seven MLST loci in C. neoformans species complex hybrids. The sequences 
      obtained from hybrids can be compared with those present in the Cryptococcus global 
      MLST database for future molecular epidemiology studies.
CI  - © The Author(s) 2020. Published by Oxford University Press on behalf of The 
      International Society for Human and Animal Mycology.
FAU - Cogliati, Massimo
AU  - Cogliati M
AD  - Lab. Medical Mycology, Dip. Scienze Biomediche per la Salute, Università degli Studi 
      di Milano, Milano, Italy.
FAU - Roger, Frederic
AU  - Roger F
AD  - Unité Mixte Internationale "Recherches Translationnelles sur l'infection à VIH et 
      les Maladies Infectieuses", Université de Montpellier, Montpellier, France.
FAU - Meyer, Wieland
AU  - Meyer W
AD  - Molecular Mycology Research Laboratory, Centre for Infectious Diseases and 
      Microbiology, Faculty of Medicine and Health, Sydney Medical School, Westmead 
      Clinical School, Marie Bashir Institute for Infectious Diseases and Biosecurity, The 
      University of Sydney, Westmead Hospital (Research and Education Network), Westmead 
      Institute for Medical Research, Westmead, NSW, Australia.
FAU - Robert, Vincent
AU  - Robert V
AD  - Westerdijk Fungal Biodiversity Institute, Utrecht, the Netherlands.
FAU - Bertout, Sébastien
AU  - Bertout S
AD  - Unité Mixte Internationale "Recherches Translationnelles sur l'infection à VIH et 
      les Maladies Infectieuses", Université de Montpellier, Montpellier, France.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Med Mycol
JT  - Medical mycology
JID - 9815835
SB  - IM
MH  - Chimera/*genetics
MH  - Cryptococcus neoformans/*classification/*genetics
MH  - Europe
MH  - Genetic Variation
MH  - Genotype
MH  - *Genotyping Techniques
MH  - Humans
MH  - Multilocus Sequence Typing/*methods
MH  - *Mycological Typing Techniques
MH  - Phylogeny
OTO - NOTNLM
OT  - Cryptococcus neoformans
OT  - AD hybrids
OT  - MLST
OT  - MLST database
OT  - sequence type
EDAT- 2020/06/09 06:00
MHDA- 2021/05/27 06:00
CRDT- 2020/06/09 06:00
PHST- 2020/03/03 00:00 [received]
PHST- 2020/05/19 00:00 [accepted]
PHST- 2020/04/22 00:00 [revised]
PHST- 2020/06/09 06:00 [pubmed]
PHST- 2021/05/27 06:00 [medline]
PHST- 2020/06/09 06:00 [entrez]
AID - 5854689 [pii]
AID - 10.1093/mmy/myaa047 [doi]
PST - ppublish
SO  - Med Mycol. 2020 Oct 1;58(7):1005-1009. doi: 10.1093/mmy/myaa047.

PMID- 26821952
OWN - NLM
STAT- MEDLINE
DCOM- 20161104
LR  - 20181113
IS  - 1813-4424 (Electronic)
IS  - 1729-0376 (Print)
IS  - 1729-0376 (Linking)
VI  - 13
IP  - 1
DP  - 2016
TI  - Weak signal detection: A discrete window of opportunity for achieving 'Vision 
      90:90:90'?
PG  - 17-34
LID - 10.1080/17290376.2015.1123642 [doi]
AB  - INTRODUCTION: UNAIDS' Vision 90:90:90 is a call to 'end AIDS'. Developing predictive 
      foresight of the unpredictable changes that this journey will entail could 
      contribute to the ambition of 'ending AIDS'. There are few opportunities for 
      managing unpredictable changes. We introduce 'weak signal detection' as a potential 
      opportunity to fill this void. METHOD: Combining futures and complexity theory, we 
      reflect on two pilot case studies that involved the Archetype Extraction technique 
      and the SenseMaker(®) Collector(™) tool. RESULTS: Both the piloted techniques have 
      the potentials to surface weak signals--but there is room for improvement. 
      DISCUSSION: A management response to a complex weak signal requires pattern 
      management, rather than an exclusive focus on behaviour management. CONCLUSION: Weak 
      signal detection is a window of opportunity to improve resilience to unpredictable 
      changes in the HIV/AIDS landscape that can both reduce the risk that emerges from 
      the changes and increase the visibility of opportunities to exploit the 
      unpredictable changes that could contribute to 'ending AIDS'.
FAU - Burman, Christopher J
AU  - Burman CJ
AD  - a PhD, is affiliated to Rural Development and Innovation Hub , University of Limpopo 
      , Turfloop Campus, Polokwane , South Africa.
FAU - Aphane, Marota
AU  - Aphane M
AD  - b Masters in Development, is affiliated to Rural Development and Innovation Hub , 
      University of Limpopo , Turfloop Campus, Polokwane , South Africa.
FAU - Delobelle, Peter
AU  - Delobelle P
AD  - c MD, PhD is affiliated to School of Public Health , University of the Western Cape 
      , Robert Sobukwe Road, Belville , Cape Town 7535 , South Africa.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
TA  - SAHARA J
JT  - SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance
JID - 101226212
SB  - IM
MH  - Community Health Services/*organization & administration
MH  - *Community Networks/organization & administration
MH  - Evidence-Based Practice
MH  - HIV Infections/*prevention & control
MH  - Health Promotion/*organization & administration
MH  - Humans
MH  - Models, Theoretical
MH  - Organizational Innovation
MH  - Pilot Projects
MH  - South Africa/epidemiology
PMC - PMC5642432
OAB - Publisher: Abstract available from the publisher.
OABL- fre
OTO - NOTNLM
OT  - Cynefin framework
OT  - HIV/AIDS
OT  - VIH/SIDA
OT  - autopoiesis
OT  - complexity theory
OT  - futures science
OT  - sciences des futures
OT  - théorie de la complexité
EDAT- 2016/01/30 06:00
MHDA- 2016/11/05 06:00
CRDT- 2016/01/30 06:00
PHST- 2016/01/30 06:00 [entrez]
PHST- 2016/01/30 06:00 [pubmed]
PHST- 2016/11/05 06:00 [medline]
AID - 1123642 [pii]
AID - 10.1080/17290376.2015.1123642 [doi]
PST - ppublish
SO  - SAHARA J. 2016;13(1):17-34. doi: 10.1080/17290376.2015.1123642.

PMID- 15749333
OWN - NLM
STAT- MEDLINE
DCOM- 20050512
LR  - 20131121
IS  - 0306-4522 (Print)
IS  - 0306-4522 (Linking)
VI  - 131
IP  - 4
DP  - 2005
TI  - Neuro-overprotection? A functional evaluation of clomethiazole-induced 
      neuroprotection following hypoxic-ischemic injury.
PG  - 785-92
AB  - Hypoxic-ischemic (H-I) injury produces extensive damage to the hippocampus of young 
      rats. We have recently shown that administration of 125 mg kg-1 clomethiazole (CMZ), 
      a GABA(A)-agonist, provides complete histological protection against H-I injury if 
      administered 3 h post-H-I (Brain Res 1035 (2005) 194). However, whether that 
      histological protection translates into lasting functional preservation is unclear. 
      To determine whether hippocampal-based circuits remain functionally intact in 
      CMZ-protected H-I rats, we administered 125 mg kg-1 (high dose [CMZ-HD]) or 65 mg 
      kg-1 (low dose [CMZ-LD]) CMZ, 3 h post-H-I, and examined numerous kindling 
      parameters in the dorsal hippocampus 60 days following H-I. Kindling parameters 
      included afterdischarge (AD) thresholds (ADTs), AD durations and kindling rates. 
      Additional groups assessed included vehicle-injected H-I (VIH), hypoxic, ligated and 
      naive rats. VIH, CMZ-HD, CMZ-LD and hypoxic rats all exhibited significantly faster 
      kindling rates than naive rats. Thus, a previous traumatic event, even hypoxia 
      alone, facilitated subsequent seizure propagation. Still, a significantly slower 
      kindling rate was evident in CMZ-HD rats than in hypoxic, VIH or CMZ-LD rats. 
      Moreover, while longer pre-kindling AD durations were observed in the damaged 
      hippocampus of VIH compared with naive rats, this was not true for either 
      CMZ-treated groups, hypoxic or ligated rats. Collectively, these findings suggest 
      CMZ can suppress the epileptogenic effects of H-I. Surprisingly, however, both 
      groups of CMZ-treated rats exhibited a four to nine times greater ADT than any other 
      group and this effect was most profound in the CMZ-protected hippocampus. Thus, CMZ 
      administration protected local neurons against terminal insult and left network 
      excitability relatively normal with respect to seizure offset mechanisms but also 
      caused profound elevation of local ADTs, which suggests a local 
      hypoexcitability/increased inhibition. Finally, this study demonstrates, for the 
      first time, that the kindling model can serve as a sensitive measure of 
      function-related neuroprotective efficacy in animal models of ischemia.
FAU - Gilby, K L
AU  - Gilby KL
AD  - Laboratory of Molecular Neurobiology, Department of Pharmacology, Faculty of 
      Medicine, Dalhousie University, Halifax, Nova Scotia, Canada B3H 4H7. 
      gilbykrista@hotmail.com
FAU - Kelly, M E
AU  - Kelly ME
FAU - McIntyre, D C
AU  - McIntyre DC
FAU - Robertson, H A
AU  - Robertson HA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Neuroscience
JT  - Neuroscience
JID - 7605074
RN  - 0 (Neuroprotective Agents)
RN  - 0C5DBZ19HV (Chlormethiazole)
SB  - IM
MH  - Anesthesia
MH  - Animals
MH  - Chlormethiazole/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Histocytochemistry
MH  - Hypoxia-Ischemia, Brain/*drug therapy/pathology
MH  - Kindling, Neurologic/physiology
MH  - Male
MH  - Neurons/drug effects/physiology
MH  - Neuroprotective Agents/*pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Seizures/chemically induced/physiopathology
MH  - Tissue Fixation
EDAT- 2005/03/08 09:00
MHDA- 2005/05/13 09:00
CRDT- 2005/03/08 09:00
PHST- 2004/11/24 00:00 [accepted]
PHST- 2005/03/08 09:00 [pubmed]
PHST- 2005/05/13 09:00 [medline]
PHST- 2005/03/08 09:00 [entrez]
AID - S0306-4522(04)01120-0 [pii]
AID - 10.1016/j.neuroscience.2004.11.053 [doi]
PST - ppublish
SO  - Neuroscience. 2005;131(4):785-92. doi: 10.1016/j.neuroscience.2004.11.053.

PMID- 30099816
OWN - NLM
STAT- MEDLINE
DCOM- 20190417
LR  - 20190417
IS  - 1365-3156 (Electronic)
IS  - 1360-2276 (Linking)
VI  - 23
IP  - 10
DP  - 2018 Oct
TI  - Excessive mortality and loss to follow-up among HIV-infected children in 
      Guinea-Bissau, West Africa: a retrospective follow-up study.
PG  - 1148-1156
LID - 10.1111/tmi.13136 [doi]
AB  - OBJECTIVES: To estimate the magnitude of mortality and loss to follow-up and 
      describe predictors of mortality among HIV-infected children in Guinea-Bissau. 
      METHODS: Retrospective follow-up study among HIV-infected children under 15 years of 
      age at the largest HIV-clinic in Guinea-Bissau from 2006-2016. A multivariate Cox 
      proportional hazards model was used to identify predictors of mortality. RESULTS: Of 
      525 children were included in the analysis: 371 (70.7%) with HIV-1, 17 (3.2%) with 
      HIV-2, 25 (4.8%) with HIV-1/2, and 112 (21.3%) with HIV of unknown type. At 
      diagnosis, the median age was 3.5 years, 44.7% met the WHO criteria for severe 
      immunodeficiency by age based on CD4 cell count, and 59.4% were underweight. The 
      median follow-up time was 6 months. Despite the availability of antiretroviral 
      treatment, the mortality rate was 10.4 deaths per 100 person-years of follow-up. 
      Within the first year of follow-up, 11.0% died, 3.1% were transferred and 38.8% were 
      lost to follow-up, leaving 47.1% in follow-up. Severe immunodeficiency (adjusted 
      hazard ratio (aHR) = 2.52, 95% CI: 1.22-5.21) and underweight (aHR = 3.14, 95% CI: 
      1.40-7.02) were independent predictors of mortality. CONCLUSIONS: This study reveals 
      a high rate of early mortality and loss to follow-up among HIV-infected children in 
      Guinea-Bissau. Initiatives to improve patient retention are urgently needed.
CI  - © 2018 John Wiley & Sons Ltd.
FAU - Steiniche, Ditte
AU  - Steiniche D
AD  - Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau.
AD  - Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
FAU - Jespersen, Sanne
AU  - Jespersen S
AD  - Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau.
AD  - Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
FAU - Medina, Candida
AU  - Medina C
AD  - National HIV Programme, Ministry of Health, Bissau, Guinea-Bissau.
FAU - Sanha, Fatima Corona
AU  - Sanha FC
AD  - National HIV Programme, Ministry of Health, Bissau, Guinea-Bissau.
FAU - Wejse, Christian
AU  - Wejse C
AD  - Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
AD  - Center for Global Health AU, Department of Public Health, Aarhus University, Aarhus, 
      Denmark.
FAU - Hønge, Bo Langhoff
AU  - Hønge BL
AD  - Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau.
AD  - Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark.
CN  - Bissau HIV Cohort Study Group
LA  - eng
GR  - U01 AI069919/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20180829
PL  - England
TA  - Trop Med Int Health
JT  - Tropical medicine & international health : TM & IH
JID - 9610576
RN  - 0 (Anti-HIV Agents)
SB  - IM
MH  - Adolescent
MH  - Anti-HIV Agents/administration & dosage
MH  - Child
MH  - *Child Mortality
MH  - Child Welfare/*statistics & numerical data
MH  - Child, Preschool
MH  - Female
MH  - Follow-Up Studies
MH  - Guinea-Bissau
MH  - HIV Infections/*drug therapy/*mortality
MH  - Humans
MH  - Male
MH  - Retrospective Studies
OTO - NOTNLM
OT  - * HIV
OT  - * VIH
OT  - *Afrique subsaharienne
OT  - *Guinea-Bissau
OT  - *Guinée-Bissau
OT  - *HIV-2
OT  - *VIH-2
OT  - *children
OT  - *enfants
OT  - *mortality
OT  - *mortalité
OT  - *sub-Saharan Africa
FIR - Rodrigues, Amabelia
IR  - Rodrigues A
FIR - da Silva, David
IR  - da Silva D
FIR - da Silva, Zacarias
IR  - da Silva Z
FIR - Oliviera-Souto, Ines
IR  - Oliviera-Souto I
FIR - Østergaard, Lars
IR  - Østergaard L
FIR - Laursen, Alex
IR  - Laursen A
FIR - Aaby, Peter
IR  - Aaby P
FIR - Fomsgaard, Anders
IR  - Fomsgaard A
FIR - Erikstrup, Christian
IR  - Erikstrup C
EDAT- 2018/08/14 06:00
MHDA- 2019/04/18 06:00
CRDT- 2018/08/13 06:00
PHST- 2018/08/14 06:00 [pubmed]
PHST- 2019/04/18 06:00 [medline]
PHST- 2018/08/13 06:00 [entrez]
AID - 10.1111/tmi.13136 [doi]
PST - ppublish
SO  - Trop Med Int Health. 2018 Oct;23(10):1148-1156. doi: 10.1111/tmi.13136. Epub 2018 
      Aug 29.

PMID- 30030542
OWN - NLM
STAT- MEDLINE
DCOM- 20190211
LR  - 20200101
IS  - 1740-634X (Electronic)
IS  - 0893-133X (Print)
IS  - 0893-133X (Linking)
VI  - 44
IP  - 2
DP  - 2019 Jan
TI  - Dopamine in the oval bed nucleus of the stria terminalis contributes to compulsive 
      responding for sucrose in rats.
PG  - 381-389
LID - 10.1038/s41386-018-0149-y [doi]
AB  - Binge eating disorder (BED) is characterized by periods of excessive food intake 
      combined with subjective feelings of loss of control. We examined whether sucrose 
      bingeing itself leads to uncontrolled or compulsive responding and whether this 
      effect is magnified following a period of abstinence. We then assessed dopamine (DA) 
      modulation of inhibitory synaptic transmission in the oval bed nucleus of the stria 
      terminalis (ovBNST) as a neural correlate of compulsive responding and whether this 
      behavioral effect could be disrupted by DA blockade in the ovBNST. Over 28 days, 
      male Long-Evans rats (n = 8-16 per group) had access to 10% sucrose and food (12 or 
      24 h), 0.1% saccharin and food (12 h), or food alone (12 h). Compulsive responding 
      was assessed following 1 or 28 days of sucrose abstinence using a conditioned 
      suppression paradigm. Only rats given 12 h access to sucrose developed binge-like 
      intake, manifested as copious intake within the first hour; compulsive responding 
      was significantly elevated in this group following 28 days of abstinence. In 
      parallel, the effect of DA on ovBNST inhibitory transmission switched from a 
      reduction to a potentiation; the effect, although observable after 1 day, was more 
      pronounced and sustained following 28 days of abstinence. Intra-ovBNST infusions of 
      a DA D1 receptor antagonist (0.8 µg/µl SCH-23390) reversed the blockade of 
      conditioned suppression, thereby confirming the causal relationship between ovBNST 
      DA modulation of γ-aminobutyric acid transmission and alterations in conditioned 
      suppression following binge-like intake of sucrose.
FAU - Maracle, Amanda C
AU  - Maracle AC
AD  - Department of Psychology, Queen's University, Kingston, ON, K7L 3N6, Canada.
FAU - Normandeau, Catherine P
AU  - Normandeau CP
AD  - Center for Neuroscience Studies, Queen's University, Kingston, ON, K7L 3N6, Canada.
AD  - Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, 
      K7L 3N6, Canada.
FAU - Dumont, Éric C
AU  - Dumont ÉC
AD  - Center for Neuroscience Studies, Queen's University, Kingston, ON, K7L 3N6, Canada.
AD  - Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, 
      K7L 3N6, Canada.
FAU - Olmstead, Mary C
AU  - Olmstead MC
AD  - Department of Psychology, Queen's University, Kingston, ON, K7L 3N6, Canada. 
      olmstead@queensu.ca.
AD  - Center for Neuroscience Studies, Queen's University, Kingston, ON, K7L 3N6, Canada. 
      olmstead@queensu.ca.
AD  - Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, 
      K7L 3N6, Canada. olmstead@queensu.ca.
LA  - eng
GR  - Vanier Graduate Scholarship (338319)/Canadian HIV Trials Network, Canadian 
      Institutes of Health Research (Réseau canadien pour les essais VIH des 
      IRSC)/International
GR  - MOP-25953/Gouvernement du Canada | Canadian Institutes of Health Research (Instituts 
      de Recherche en Santé du Canada)/International
GR  - MOP-25953/Gouvernement du Canada | Canadian Institutes of Health Research (Instituts 
      de Recherche en Santé du Canada)/International
GR  - 203707/Gouvernement du Canada | Natural Sciences and Engineering Research Council of 
      Canada (Conseil de Recherches en Sciences Naturelles et en Génie du 
      Canada)/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180710
TA  - Neuropsychopharmacology
JT  - Neuropsychopharmacology : official publication of the American College of 
      Neuropsychopharmacology
JID - 8904907
RN  - 0 (Benzazepines)
RN  - 0 (Dopamine Antagonists)
RN  - 0 (Receptors, Dopamine D1)
RN  - 0 (SCH 23390)
RN  - 57-50-1 (Sucrose)
SB  - IM
MH  - Animals
MH  - Behavior, Animal/drug effects
MH  - Benzazepines/pharmacology
MH  - Compulsive Behavior
MH  - Conditioning, Operant/*drug effects
MH  - Dopamine Antagonists/*pharmacology
MH  - Male
MH  - Rats
MH  - Rats, Long-Evans
MH  - Receptors, Dopamine D1/*antagonists & inhibitors
MH  - Self Administration
MH  - Septal Nuclei/*drug effects
MH  - Sucrose/*administration & dosage
PMC - PMC6300551
COIS- The authors declare no competing interests.
EDAT- 2018/07/22 06:00
MHDA- 2019/02/12 06:00
CRDT- 2018/07/22 06:00
PHST- 2018/04/04 00:00 [received]
PHST- 2018/07/04 00:00 [accepted]
PHST- 2018/06/06 00:00 [revised]
PHST- 2018/07/22 06:00 [pubmed]
PHST- 2019/02/12 06:00 [medline]
PHST- 2018/07/22 06:00 [entrez]
AID - 10.1038/s41386-018-0149-y [pii]
AID - 149 [pii]
AID - 10.1038/s41386-018-0149-y [doi]
PST - ppublish
SO  - Neuropsychopharmacology. 2019 Jan;44(2):381-389. doi: 10.1038/s41386-018-0149-y. 
      Epub 2018 Jul 10.

PMID- 30953839
OWN - NLM
STAT- MEDLINE
DCOM- 20200521
LR  - 20200521
IS  - 1096-0937 (Electronic)
IS  - 1087-1845 (Linking)
VI  - 129
DP  - 2019 Aug
TI  - Genotypes and population genetics of cryptococcus neoformans and cryptococcus gattii 
      species complexes in Europe and the mediterranean area.
PG  - 16-29
LID - S1087-1845(19)30049-0 [pii]
LID - 10.1016/j.fgb.2019.04.001 [doi]
AB  - A total of 476 European isolates (310 Cryptococcus neoformans var. grubii, 150 C. 
      neoformans var. neoformans, and 16 C. gattii species complex) from both clinical and 
      environmental sources were analyzed by multi-locus sequence typing. Phylogenetic and 
      population genetic analyses were performed. Sequence analysis identified 74 sequence 
      types among C. neoformans var. neoformans (VNIV), 65 among C. neoformans var. grubii 
      (56 VNI, 8 VNII, 1 VNB), and 5 among the C. gattii species complex (4 VGI and 1 
      VGIV) isolates. ST23 was the most frequent genotype (22%) among VNI isolates which 
      were mostly grouped in a large clonal cluster including 50% of isolates. Among VNIV 
      isolates, a predominant genotype was not identified. A high percentage of 
      autochthonous STs were identified in both VNI (71%) and VNIV (96%) group of 
      isolates. The 16 European C. gattii species complex isolates analyzed in the present 
      study originated all from the environment and all belonged to a large cluster 
      endemic in the Mediterranean area. Population genetic analysis confirmed that VNI 
      group of isolates were characterized by low variability and clonal expansion while 
      VNIV by a higher variability and a number of recombination events. However, when VNI 
      and VNIV environmental isolates were compared, they showed a similar population 
      structure with a high percentage of shared mutations and the absence of fixed 
      mutations. Also linkage disequilibrium analysis reveals differences between clinical 
      and environmental isolates showing a key role of PLB1 allele combinations in host 
      infection as well as the key role of LAC1 allele combinations for survival of the 
      fungus in the environment. The present study shows that genetic comparison of 
      clinical and environmental isolates represents a first step to understand the 
      genetic characteristics that cause the shift of some genotypes from a saprophytic to 
      a parasitic life style.
CI  - Copyright © 2019 Elsevier Inc. All rights reserved.
FAU - Cogliati, Massimo
AU  - Cogliati M
AD  - Dip. Scienze Biomediche per la Salute, Università degli Studi di Milano, Milano, 
      Italy. Electronic address: massimo.cogliati@unimi.it.
FAU - Desnos-Ollivier, Marie
AU  - Desnos-Ollivier M
AD  - Institut Pasteur, Molecular Mycology Unit, National Reference Center for Invasive 
      Mycoses & Antifungal, CNRS UMR2000, Paris, France.
FAU - McCormick-Smith, Ilka
AU  - McCormick-Smith I
AD  - Robert-Koch Institute, Berlin, Germany.
FAU - Rickerts, Volker
AU  - Rickerts V
AD  - Robert-Koch Institute, Berlin, Germany.
FAU - Ferreira-Paim, Kennio
AU  - Ferreira-Paim K
AD  - Molecular Mycology Research Laboratory, Center for Infectious Diseases, Faculty of 
      Medicine and Health, Sydney Medical School, Westmead Clinical School, Marie Bashier 
      Institute for Emerging Infectious Diseases and Biosecurity, University of Sydney, 
      Westmead Hospital, (Research and Educational Network) Westmead Institute for Medical 
      Research, Westmead, NSW, Australia; Department of Microbiology, Federal University 
      of Triangulo Mineiro, Uberaba, Minas Gerais, Brazil.
FAU - Meyer, Wieland
AU  - Meyer W
AD  - Molecular Mycology Research Laboratory, Center for Infectious Diseases, Faculty of 
      Medicine and Health, Sydney Medical School, Westmead Clinical School, Marie Bashier 
      Institute for Emerging Infectious Diseases and Biosecurity, University of Sydney, 
      Westmead Hospital, (Research and Educational Network) Westmead Institute for Medical 
      Research, Westmead, NSW, Australia.
FAU - Boekhout, Teun
AU  - Boekhout T
AD  - Westerdijk Fungal Biodiversity Institute, Utrecht, the Netherlands; Institute of 
      Biodiversity and Ecosystem Dynamic (IBED), University of Amsterdam, Amsterdam, the 
      Netherlands.
FAU - Hagen, Ferry
AU  - Hagen F
AD  - Westerdijk Fungal Biodiversity Institute, Utrecht, the Netherlands.
FAU - Theelen, Bart
AU  - Theelen B
AD  - Westerdijk Fungal Biodiversity Institute, Utrecht, the Netherlands.
FAU - Inácio, Joäo
AU  - Inácio J
AD  - School of Pharmacy and Biomolecular Sciences, University of Brighton, Brighton, UK.
FAU - Alonso, Beatriz
AU  - Alonso B
AD  - School of Pharmacy and Biomolecular Sciences, University of Brighton, Brighton, UK; 
      Instituto de Investigación Sanitaria Gregorio Marañón (IisGM), Hospital Gegorio 
      Marañón, Madrid, Spain.
FAU - Colom, Maria F
AU  - Colom MF
AD  - Universidad Miguel Hernández, Alicante, Spain.
FAU - Trilles, Luciana
AU  - Trilles L
AD  - FIOCRUZ, Fundaçao Oswaldo Cruz, Rio de Janeiro, Brazil.
FAU - Montagna, Maria Teresa
AU  - Montagna MT
AD  - Università degli Studi di Bari "Aldo Moro", Bari, Italy.
FAU - De Donno, Antonella
AU  - De Donno A
AD  - DiSTeBA, Università del Salento, Lecce, Italy.
FAU - Susever, Serdar
AU  - Susever S
AD  - Cyprus Near East University, Nicosia, Cyprus.
FAU - Ergin, Cagri
AU  - Ergin C
AD  - Pamukkale University, Denizli, Turkey.
FAU - Velegraki, Aristea
AU  - Velegraki A
AD  - Medical School, National and Kapodistrian University of Athens, Athens, Greece.
FAU - Ellabib, Mohamed S
AU  - Ellabib MS
AD  - Medical College University of Tripoli, Tripoli, Libya.
FAU - Nardoni, Simona
AU  - Nardoni S
AD  - Università di Pisa, Pisa, Italy.
FAU - Macci, Cristina
AU  - Macci C
AD  - National Research Council, Research Institute on Terrestrial Ecosystems (IRET), 
      Pisa, Italy.
FAU - Trovato, Laura
AU  - Trovato L
AD  - Università degli Studi di Catania, Catania, Italy.
FAU - Dipineto, Ludovico
AU  - Dipineto L
AD  - University of Napoli Federico II, Napoli, Italy.
FAU - Akcaglar, Sevim
AU  - Akcaglar S
AD  - Uludag University, School of Medicine, Bursa, Turkey.
FAU - Mlinaric-Missoni, Emilija
AU  - Mlinaric-Missoni E
AD  - Croatian National Institute of Public Health, Zagreb, Croatia.
FAU - Bertout, Sebastien
AU  - Bertout S
AD  - Unité Mixte Internationale "Recherches Translationnelles sur l'infection à VIH et 
      les Maladies Infectieuses", Université de Montpellier, Montpellier, France.
FAU - Vencá, Ana C F
AU  - Vencá ACF
AD  - Instituto de Higiene e Medicina Tropical, Lisbon, Portugal.
FAU - Sampaio, Ana C
AU  - Sampaio AC
AD  - Universidade de Trás-os-Montes e Alto Douro, CITAB, Quinta dos Prados, Vila Real, 
      Portugal.
FAU - Criseo, Giuseppe
AU  - Criseo G
AD  - Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, 
      University of Messina, Italy.
FAU - Ranque, Stéphane
AU  - Ranque S
AD  - Aix-Marseille University, IRD, APHM, SSA, VITROME, IHU-Méditerranée Infection, 
      Marseille, France.
FAU - Çerikçioğlu, Nilgün
AU  - Çerikçioğlu N
AD  - Marmara University, School of Medicine, Istanbul, Turkey.
FAU - Marchese, Anna
AU  - Marchese A
AD  - Sezione di Microbiologia del DISC, Università di Genova-IRCCS Policlinico San 
      Martino Genova, Genova, Italy.
FAU - Vezzulli, Luigi
AU  - Vezzulli L
AD  - Dipartimento di Scienze della Terra, dell'Ambiente e della Vita (DISTAV), Università 
      di Genova, Genova, Italy.
FAU - Ilkit, Macit
AU  - Ilkit M
AD  - University of Çukurova Sarıçam, Adana, Turkey.
FAU - Pasquale, Vincenzo
AU  - Pasquale V
AD  - Università degli Studi di Napoli Parthenope, Napoli, Italy.
FAU - Polacheck, Itzhack
AU  - Polacheck I
AD  - Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
FAU - Lockhart, Shawn R
AU  - Lockhart SR
AD  - Centers for Disease Control and Prevention, Atlanta, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190403
PL  - United States
TA  - Fungal Genet Biol
JT  - Fungal genetics and biology : FG & B
JID - 9607601
SB  - IM
MH  - Animals
MH  - Cryptococcus gattii/*genetics
MH  - Cryptococcus neoformans/*genetics
MH  - Environmental Microbiology
MH  - Europe
MH  - Genetics, Population
MH  - *Genotype
MH  - Humans
MH  - Mediterranean Region
MH  - Multilocus Sequence Typing
MH  - Mycological Typing Techniques
MH  - *Phylogeny
OTO - NOTNLM
OT  - *Cryptococcus gattii
OT  - *Cryptococcus neoformans
OT  - *Europe
OT  - *MLST
OT  - *Population genetics
EDAT- 2019/04/07 06:00
MHDA- 2020/05/22 06:00
CRDT- 2019/04/07 06:00
PHST- 2019/02/05 00:00 [received]
PHST- 2019/03/29 00:00 [revised]
PHST- 2019/04/02 00:00 [accepted]
PHST- 2019/04/07 06:00 [pubmed]
PHST- 2020/05/22 06:00 [medline]
PHST- 2019/04/07 06:00 [entrez]
AID - S1087-1845(19)30049-0 [pii]
AID - 10.1016/j.fgb.2019.04.001 [doi]
PST - ppublish
SO  - Fungal Genet Biol. 2019 Aug;129:16-29. doi: 10.1016/j.fgb.2019.04.001. Epub 2019 Apr 
      3.

PMID- 25884149
OWN - NLM
STAT- MEDLINE
DCOM- 20151216
LR  - 20190609
IS  - 1560-7917 (Electronic)
IS  - 1025-496X (Linking)
VI  - 20
IP  - 14
DP  - 2015 Apr 9
TI  - Assessment of an outreach street-based HIV rapid testing programme as a strategy to 
      promote early diagnosis: a comparison with two surveillance systems in Spain, 
      2008-2011.
LID - 21089 [pii]
AB  - We assess the added value of a multisite, street-based HIV rapid testing programme 
      by comparing its results to pre-existing services and assessing its potential to 
      reduce ongoing transmission. Between 2008 and 2011, 8,923 individuals underwent 
      testing. We compare outcomes with those of a network of 20 sexually transmitted 
      infections (STI)/HIV clinics (EPI-VIH) and the Spanish National HIV Surveillance 
      System (SNHSS); evaluate whether good visibility prompts testing and assess whether 
      it reaches under-tested populations. 89.2% of the new infections were in men who 
      have sex with men (MSM) vs 78.0% in EPI-VIH and 56.0% in SNHSS. 83.6% of the MSM 
      were linked to care and 20.9% had <350 CD4 HIV prevalence was substantially lower 
      than in EPI-VIH. 56.5% of the HIV-positive MSM tested because they happened to see 
      the programme, 18.4% were previously untested and 26.3% had their last test ≥2 years 
      ago. The programme provided linkage to care and early diagnosis mainly to MSM but 
      attendees presented a lower HIV prevalence than EPI-VIH. From a cost perspective it 
      would benefit from being implemented in locations highly frequented by MSM. 
      Conversely, its good visibility led to reduced periods of undiagnosed infection in a 
      high proportion of MSM who were not testing with the recommended frequency.
FAU - Belza, M J
AU  - Belza MJ
AD  - Escuela Nacional de Sanidad, Instituto de Salud Carlos III, Madrid, Spain.
FAU - Hoyos, J
AU  - Hoyos J
FAU - Fernández-Balbuena, S
AU  - Fernández-Balbuena S
FAU - Diaz, A
AU  - Diaz A
FAU - Bravo, M J
AU  - Bravo MJ
FAU - de la Fuente, L
AU  - de la Fuente L
CN  - Madrid HIV rapid testing group
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150409
PL  - Sweden
TA  - Euro Surveill
JT  - Euro surveillance : bulletin Europeen sur les maladies transmissibles = European 
      communicable disease bulletin
JID - 100887452
SB  - IM
MH  - Adult
MH  - Early Diagnosis
MH  - Female
MH  - HIV Infections/*diagnosis/epidemiology/prevention & control
MH  - Homosexuality, Male/statistics & numerical data
MH  - Humans
MH  - Male
MH  - Mass Screening/*methods
MH  - *Mobile Health Units
MH  - Population Surveillance/*methods
MH  - Prevalence
MH  - Program Evaluation
MH  - Risk-Taking
MH  - Sexual Behavior/statistics & numerical data
MH  - Spain/epidemiology
FIR - Oliva, Jesús
IR  - Oliva J
FIR - Ruiz, Mónica
IR  - Ruiz M
FIR - Rosales-Statkus, María Elena
IR  - Rosales-Statkus ME
FIR - Gutiérrez, Jorge
IR  - Gutiérrez J
FIR - Sánchez, Rebeca
IR  - Sánchez R
FIR - Álvarez, Jorge
IR  - Álvarez J
EDAT- 2015/04/18 06:00
MHDA- 2015/12/19 06:00
CRDT- 2015/04/18 06:00
PHST- 2015/04/18 06:00 [entrez]
PHST- 2015/04/18 06:00 [pubmed]
PHST- 2015/12/19 06:00 [medline]
AID - 21089 [pii]
AID - 10.2807/1560-7917.es2015.20.14.21089 [doi]
PST - epublish
SO  - Euro Surveill. 2015 Apr 9;20(14):21089. doi: 10.2807/1560-7917.es2015.20.14.21089.

PMID- 30657940
OWN - NLM
STAT- MEDLINE
DCOM- 20200520
LR  - 20210225
IS  - 1537-6613 (Electronic)
IS  - 0022-1899 (Linking)
VI  - 220
IP  - 10
DP  - 2019 Oct 8
TI  - Extensive Serological Survey of Multiple African Nonhuman Primate Species Reveals 
      Low Prevalence of Immunoglobulin G Antibodies to 4 Ebola Virus Species.
PG  - 1599-1608
LID - 10.1093/infdis/jiz006 [doi]
AB  - Bats are considered a reservoir species for Ebola viruses, but nonhuman primates 
      (NHPs) have represented a source of infection in several outbreaks in humans. Here 
      we report serological screening of blood or fecal samples from monkeys (n = 2322) 
      and apes (n = 2327). Thirty-six NHP species from Cameroon, Democratic Republic of 
      the Congo, and Ivory Coast were tested with a sensitive and specific Luminex-based 
      assay for immunoglobulin G antibodies to 4 Ebola virus species. Using the 
      simultaneous presence of antibodies to nucleoproteins and glycoproteins to define 
      positivity, we showed that specific Ebola virus antibodies are not widespread among 
      NHPs. Only 1 mustached monkey (Cercopithecus cephus) from Cameroon was positive for 
      Sudan ebolavirus. These observations support that NHPs are most likely intermediate 
      hosts for Ebola viruses. With the increasing frequency of Ebola outbreaks, it is 
      crucial to identify the animal reservoir and understand the ecology of Ebola viruses 
      to inform disease control.
CI  - © The Author(s) 2019. Published by Oxford University Press for the Infectious 
      Diseases Society of America. All rights reserved. For permissions, e-mail: 
      journals.permissions@oup.com.
FAU - Ayouba, Ahidjo
AU  - Ayouba A
AD  - Recherches Translationelles sur VIH et Maladies Infectieuses/Institut national de la 
      santé et de la recherche médicale, Institut de Recherche pour le Développement and 
      University of Montpellier, France.
FAU - Ahuka-Mundeke, Steve
AU  - Ahuka-Mundeke S
AD  - Institut National de Recherche Biomédicales, Kinshasa, Democratic Republic of the 
      Congo (DRC).
AD  - Service de Microbiologie, Cliniques Universitaires de Kinshasa, DRC.
FAU - Butel, Christelle
AU  - Butel C
AD  - Recherches Translationelles sur VIH et Maladies Infectieuses/Institut national de la 
      santé et de la recherche médicale, Institut de Recherche pour le Développement and 
      University of Montpellier, France.
FAU - Mbala Kingebeni, Placide
AU  - Mbala Kingebeni P
AD  - Institut National de Recherche Biomédicales, Kinshasa, Democratic Republic of the 
      Congo (DRC).
FAU - Loul, Severin
AU  - Loul S
AD  - Ministry of Livestock, Fisheries and Animal Industries, Yaoundé, Cameroon.
FAU - Tagg, Nikki
AU  - Tagg N
AD  - Projet Grands Singes, Centre for Research and Conservation, Royal Zoological Society 
      of Antwerp, Belgium.
FAU - Villabona-Arenas, Christian-Julian
AU  - Villabona-Arenas CJ
AD  - Recherches Translationelles sur VIH et Maladies Infectieuses/Institut national de la 
      santé et de la recherche médicale, Institut de Recherche pour le Développement and 
      University of Montpellier, France.
FAU - Lacroix, Audrey
AU  - Lacroix A
AD  - Recherches Translationelles sur VIH et Maladies Infectieuses/Institut national de la 
      santé et de la recherche médicale, Institut de Recherche pour le Développement and 
      University of Montpellier, France.
FAU - Ndimbo-Kumugo, Simon-Pierre
AU  - Ndimbo-Kumugo SP
AD  - Institut National de Recherche Biomédicales, Kinshasa, Democratic Republic of the 
      Congo (DRC).
FAU - Keita, Alpha K
AU  - Keita AK
AD  - Recherches Translationelles sur VIH et Maladies Infectieuses/Institut national de la 
      santé et de la recherche médicale, Institut de Recherche pour le Développement and 
      University of Montpellier, France.
AD  - Centre de Recherche et de Formation en Infectiologie de Guinée.
FAU - Toure, Abdoulaye
AU  - Toure A
AD  - Centre de Recherche et de Formation en Infectiologie de Guinée.
AD  - Chaire de Santé Publique, Université Gamal Abdel Nasser de Conakry, Guinea.
FAU - Couacy-Hymann, Emmanuel
AU  - Couacy-Hymann E
AD  - Laboratoire National D'appui au Développement Agricole/Laboratoire Central de 
      Pathologie Animale, Bingerville, Ivory Coast.
FAU - Calvignac-Spencer, Sebastien
AU  - Calvignac-Spencer S
AD  - Epidemiology of Highly Pathogenic Microorganisms, Robert Koch Institute, Berlin, 
      Germany.
FAU - Leendertz, Fabian H
AU  - Leendertz FH
AD  - Epidemiology of Highly Pathogenic Microorganisms, Robert Koch Institute, Berlin, 
      Germany.
FAU - Formenty, Pierre
AU  - Formenty P
AD  - Emerging and Dangerous Pathogens Laboratory Network, World Health Organization, 
      Geneva, Switzerland.
FAU - Delaporte, Eric
AU  - Delaporte E
AD  - Recherches Translationelles sur VIH et Maladies Infectieuses/Institut national de la 
      santé et de la recherche médicale, Institut de Recherche pour le Développement and 
      University of Montpellier, France.
FAU - Muyembe-Tamfum, Jean-Jacques
AU  - Muyembe-Tamfum JJ
AD  - Institut National de Recherche Biomédicales, Kinshasa, Democratic Republic of the 
      Congo (DRC).
AD  - Service de Microbiologie, Cliniques Universitaires de Kinshasa, DRC.
FAU - Mpoudi Ngole, Eitel
AU  - Mpoudi Ngole E
AD  - Centre de Recherches sur les Maladies emergentes, ré-émergentes et la médecine 
      nucleaire/Institut de Recherches Médicales et d'études des plantes médecinales, 
      Yaoundé, Cameroon.
FAU - Peeters, Martine
AU  - Peeters M
AD  - Recherches Translationelles sur VIH et Maladies Infectieuses/Institut national de la 
      santé et de la recherche médicale, Institut de Recherche pour le Développement and 
      University of Montpellier, France.
LA  - eng
GR  - 001/WHO_/World Health Organization/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Infect Dis
JT  - The Journal of infectious diseases
JID - 0413675
RN  - 0 (Antibodies, Viral)
RN  - 0 (Immunoglobulin G)
SB  - IM
CIN - J Infect Dis. 2019 Oct 8;220(10):1547-1550. PMID: 30657949
CIN - J Infect Dis. 2020 Aug 17;222(6):1065-1066. PMID: 32073606
CIN - J Infect Dis. 2020 Aug 17;222(6):1064-1065. PMID: 32073609
MH  - Animals
MH  - Antibodies, Viral/*blood
MH  - Ape Diseases/*epidemiology/immunology
MH  - Cameroon
MH  - Cote d'Ivoire
MH  - Democratic Republic of the Congo
MH  - Ebolavirus/*immunology
MH  - Hemorrhagic Fever, Ebola/epidemiology/immunology/*veterinary
MH  - Hominidae
MH  - Immunoglobulin G/*blood
MH  - Monkey Diseases/*epidemiology/immunology
MH  - Primates
MH  - Seroepidemiologic Studies
OTO - NOTNLM
OT  - *Africa
OT  - *Ebola
OT  - *ape
OT  - *monkey
EDAT- 2019/01/19 06:00
MHDA- 2020/05/21 06:00
CRDT- 2019/01/19 06:00
PHST- 2018/10/30 00:00 [received]
PHST- 2019/01/04 00:00 [accepted]
PHST- 2019/01/19 06:00 [pubmed]
PHST- 2020/05/21 06:00 [medline]
PHST- 2019/01/19 06:00 [entrez]
AID - 5292618 [pii]
AID - 10.1093/infdis/jiz006 [doi]
PST - ppublish
SO  - J Infect Dis. 2019 Oct 8;220(10):1599-1608. doi: 10.1093/infdis/jiz006.

PMID- 26481661
OWN - NLM
STAT- MEDLINE
DCOM- 20180426
LR  - 20181202
IS  - 1578-1852 (Electronic)
IS  - 0213-005X (Linking)
VI  - 35
IP  - 1
DP  - 2017 Jan
TI  - Implementing and expanding HIV testing in immigrant populations in Europe: Comparing 
      guideline's recommendations and expert's opinions.
PG  - 47-51
LID - S0213-005X(15)00316-X [pii]
LID - 10.1016/j.eimc.2015.08.008 [doi]
AB  - Immigrant populations, especially those from endemic countries, living in the 
      European Union (EU) suffer a disproportionate burden of HIV, delayed diagnosis and 
      poorer access to antiretroviral treatment. While International Organisations are 
      developing recommendations aimed at increasing the uptake of HIV testing, the 
      feasibility and real outcomes of these measures remain unexplored. The aim of this 
      review was, firstly to identify the recommendations of the main International 
      Organisations (IO) on HIV testing in immigrants. Secondly, to describe the 
      challenges for implementing and expanding HIV testing and counselling interventions 
      targeting immigrants by interviewing key informants. The importance of HIV testing 
      in immigrants is discussed, along with the appropriateness of universal HIV testing 
      approaches vs most at risk targeted approaches. Also addressed is, pre- and post-HIV 
      test counselling characteristics and community initiatives suitable to reach this 
      population and, finally the legal issues regarding access to treatment for illegal 
      immigrants.
CI  - Copyright © 2015 Elsevier España, S.L.U. and Sociedad Española de Enfermedades 
      Infecciosas y Microbiología Clínica. All rights reserved.
FAU - Álvarez-Del Arco, Débora
AU  - Álvarez-Del Arco D
AD  - National Centre of Epidemiology, Instituto de Salud Carlos III (Madrid) and Division 
      of Environmental and Reproductive Epidemiology, Biomedical Research Network on 
      Epidemiology and Public Health (CIBERESP), Spain. Electronic address: 
      dalvarez@isciii.es.
FAU - Monge, Susana
AU  - Monge S
AD  - Department of Medical and Social Sciences, Alcalá University and CIBERESP, Spain.
FAU - Rivero-Montesdeoca, Yaiza
AU  - Rivero-Montesdeoca Y
AD  - National Centre of Epidemiology, Instituto de Salud Carlos III (Madrid) and 
      CIBERESP, Spain.
FAU - Burns, Fiona
AU  - Burns F
AD  - Centre for Sexual Health & HIV Research, University College London, United Kingdom.
FAU - Noori, Teymur
AU  - Noori T
AD  - European Centre for Disease Prevention and Control (ECDC), Sweden.
FAU - Del Amo, Julia
AU  - Del Amo J
AD  - National Centre of Epidemiology, Instituto de Salud Carlos III (Madrid) and 
      CIBERESP, Spain.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20151017
PL  - Spain
TA  - Enferm Infecc Microbiol Clin
JT  - Enfermedades infecciosas y microbiologia clinica
JID - 9104081
SB  - IM
MH  - AIDS Serodiagnosis/*statistics & numerical data
MH  - *Emigrants and Immigrants
MH  - Europe
MH  - Expert Testimony
MH  - HIV Infections/*diagnosis/*prevention & control
MH  - Humans
MH  - *Mass Screening
MH  - Practice Guidelines as Topic
OTO - NOTNLM
OT  - Acquired immunodeficiency syndrome
OT  - Ethnic groups
OT  - Europa
OT  - Europe
OT  - Grupos étnicos
OT  - HIV
OT  - Immigrants
OT  - Investigación cualitativa
OT  - Migrantes
OT  - Qualitative research
OT  - Síndrome de inmunodeficiencia adquirida
OT  - VIH
EDAT- 2015/10/21 06:00
MHDA- 2018/04/27 06:00
CRDT- 2015/10/21 06:00
PHST- 2015/07/02 00:00 [received]
PHST- 2015/08/24 00:00 [revised]
PHST- 2015/08/29 00:00 [accepted]
PHST- 2015/10/21 06:00 [pubmed]
PHST- 2018/04/27 06:00 [medline]
PHST- 2015/10/21 06:00 [entrez]
AID - S0213-005X(15)00316-X [pii]
AID - 10.1016/j.eimc.2015.08.008 [doi]
PST - ppublish
SO  - Enferm Infecc Microbiol Clin. 2017 Jan;35(1):47-51. doi: 10.1016/j.eimc.2015.08.008. 
      Epub 2015 Oct 17.

PMID- 28222757
OWN - NLM
STAT- MEDLINE
DCOM- 20170510
LR  - 20181113
IS  - 1742-4690 (Electronic)
IS  - 1742-4690 (Linking)
VI  - 14
IP  - 1
DP  - 2017 Feb 21
TI  - Spatiotemporal dynamics of HIV-1 transmission in France (1999-2014) and impact of 
      targeted prevention strategies.
PG  - 15
LID - 10.1186/s12977-017-0339-4 [doi]
LID - 15
AB  - BACKGROUND: Characterizing HIV-1 transmission networks can be important in 
      understanding the evolutionary patterns and geospatial spread of the epidemic. We 
      reconstructed the broad molecular epidemiology of HIV from individuals with primary 
      HIV-1 infection (PHI) enrolled in France in the ANRS PRIMO C06 cohort over 15 years. 
      RESULTS: Sociodemographic, geographic, clinical, biological and pol sequence data 
      from 1356 patients were collected between 1999 and 2014. Network analysis was 
      performed to infer genetic relationships, i.e. clusters of transmission, between 
      HIV-1 sequences. Bayesian coalescent-based methods were used to examine the temporal 
      and spatial dynamics of identified clusters from different regions in France. We 
      also evaluated the use of network information to target prevention efforts. 
      Participants were mostly Caucasian (85.9%) and men (86.7%) who reported sex with men 
      (MSM, 71.4%). Overall, 387 individuals (28.5%) were involved in clusters: 156 
      patients (11.5%) in 78 dyads and 231 participants (17%) in 42 larger clusters 
      (median size: 4, range 3-41). Compared to individuals with single PHI (n = 969), 
      those in clusters were more frequently men (95.9 vs 83%, p < 0.01), MSM (85.8 vs 
      65.6%, p < 0.01) and infected with CRF02_AG (20.4 vs 13.4%, p < 0.01). 
      Reconstruction of viral migrations across time suggests that Paris area was the 
      major hub of dissemination of both subtype B and CRF02_AG epidemics. By targeting 
      clustering individuals belonging to the identified active transmission network 
      before 2010, 60 of the 143 onward transmissions could have been prevented. 
      CONCLUSION: These analyses support the hypothesis of a recent and rapid rise of 
      CRF02_AG within the French HIV-1 epidemic among MSM. Combined with a short 
      turnaround time for sample processing, targeting prevention efforts based on 
      phylogenetic monitoring may be an efficient way to deliver prevention interventions 
      but would require near real time targeted interventions on the identified index 
      cases and their partners.
FAU - Chaillon, Antoine
AU  - Chaillon A
AD  - University of California, San Diego, 9500 Gilman Drive, Stein Clinical Research 
      Building #325, La Jolla, CA, 92093-0697, USA. achaillon@ucsd.edu.
FAU - Essat, Asma
AU  - Essat A
AD  - INSERM CESP U1018, University Paris Sud, Hôpital Bicêtre, Assistance 
      Publique-Hôpitaux de Paris (APHP), Le Kremlin-Bicêtre, France.
FAU - Frange, Pierre
AU  - Frange P
AD  - EA7327, Université Paris Descartes, Paris, France.
AD  - Laboratoire de Microbiologie Clinique, Hôpital Necker - Enfants Malades, APHP, 
      Paris, France.
FAU - Smith, Davey M
AU  - Smith DM
AD  - University of California, San Diego, 9500 Gilman Drive, Stein Clinical Research 
      Building #325, La Jolla, CA, 92093-0697, USA.
AD  - Veterans Affairs San Diego Healthcare System, San Diego, CA, USA.
FAU - Delaugerre, Constance
AU  - Delaugerre C
AD  - INSERM U941, Laboratoire de Virologie, Université Paris Diderot, Hôpital 
      Saint-Louis, AP-HP, CNR VIH associé Primo infection, Paris, France.
FAU - Barin, Francis
AU  - Barin F
AD  - INSERM U966 and National Reference Center for HIV, CHU Bretonneau and Université 
      François Rabelais, Tours, France.
FAU - Ghosn, Jade
AU  - Ghosn J
AD  - EA7327, Université Paris Descartes, Paris, France.
AD  - UF de Thérapeutique en Immuno-Infectiologie, Hôpital Hôtel Dieu, APHP, Paris, 
      France.
FAU - Pialoux, Gilles
AU  - Pialoux G
AD  - Service des Maladies Infectieuses et Tropicales, Hôpital Tenon, APHP, Paris, France.
FAU - Robineau, Olivier
AU  - Robineau O
AD  - Service Universitaire des Maladies infectieuses et du Voyageur, Centre Hospitalier 
      de Tourcoing, Tourcoing, France.
FAU - Rouzioux, Christine
AU  - Rouzioux C
AD  - EA7327, Université Paris Descartes, Paris, France.
FAU - Goujard, Cécile
AU  - Goujard C
AD  - INSERM CESP U1018, University Paris Sud, Hôpital Bicêtre, Assistance 
      Publique-Hôpitaux de Paris (APHP), Le Kremlin-Bicêtre, France.
AD  - Service de Médecine interne et Immunologie clinique, Hôpital Bicêtre, APHP, Le 
      Kremlin-Bicêtre, France.
FAU - Meyer, Laurence
AU  - Meyer L
AD  - INSERM CESP U1018, University Paris Sud, Hôpital Bicêtre, Assistance 
      Publique-Hôpitaux de Paris (APHP), Le Kremlin-Bicêtre, France.
FAU - Chaix, Marie-Laure
AU  - Chaix ML
AD  - INSERM U941, Laboratoire de Virologie, Université Paris Diderot, Hôpital 
      Saint-Louis, AP-HP, CNR VIH associé Primo infection, Paris, France.
CN  - on behalf the ANRS PRIMO Cohort Study
LA  - eng
GR  - K24 AI100665/AI/NIAID NIH HHS/United States
GR  - R01 MH101012/MH/NIMH NIH HHS/United States
GR  - R21 DA041007/DA/NIDA NIH HHS/United States
GR  - R25 MH081482/MH/NIMH NIH HHS/United States
GR  - K23 AI093163/AI/NIAID NIH HHS/United States
GR  - R01 AI120009/AI/NIAID NIH HHS/United States
GR  - U01 AI068636/AI/NIAID NIH HHS/United States
GR  - DP1 DA034978/DA/NIDA NIH HHS/United States
GR  - P30 AI027763/AI/NIAID NIH HHS/United States
GR  - P30 MH062512/MH/NIMH NIH HHS/United States
GR  - P30 AI036214/AI/NIAID NIH HHS/United States
GR  - R01 MH097520/MH/NIMH NIH HHS/United States
GR  - UM1 AI068636/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
DEP - 20170221
TA  - Retrovirology
JT  - Retrovirology
JID - 101216893
RN  - 0 (pol Gene Products, Human Immunodeficiency Virus)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Cluster Analysis
MH  - Female
MH  - France/epidemiology
MH  - *Genotype
MH  - HIV Infections/*epidemiology/*prevention & control/transmission/virology
MH  - HIV-1/*classification/*genetics/isolation & purification
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Molecular Epidemiology
MH  - Sequence Analysis, DNA
MH  - Spatio-Temporal Analysis
MH  - Young Adult
MH  - pol Gene Products, Human Immunodeficiency Virus/genetics
PMC - PMC5322782
OTO - NOTNLM
OT  - *HIV-1
OT  - *Phylogeography
OT  - *Primary infection
OT  - *Transmission network
OT  - *Treatment as prevention
EDAT- 2017/02/23 06:00
MHDA- 2017/05/11 06:00
CRDT- 2017/02/23 06:00
PHST- 2016/09/07 00:00 [received]
PHST- 2017/02/07 00:00 [accepted]
PHST- 2017/02/23 06:00 [entrez]
PHST- 2017/02/23 06:00 [pubmed]
PHST- 2017/05/11 06:00 [medline]
AID - 10.1186/s12977-017-0339-4 [pii]
AID - 339 [pii]
AID - 10.1186/s12977-017-0339-4 [doi]
PST - epublish
SO  - Retrovirology. 2017 Feb 21;14(1):15. doi: 10.1186/s12977-017-0339-4.

PMID- 25707605
OWN - NLM
STAT- MEDLINE
DCOM- 20170213
LR  - 20170213
IS  - 1578-1283 (Electronic)
IS  - 0213-9111 (Linking)
VI  - 29
IP  - 3
DP  - 2015 May-Jun
TI  - Use of new technologies to notify possible contagion of sexually-transmitted 
      infections among men.
PG  - 190-7
LID - S0213-9111(15)00006-0 [pii]
LID - 10.1016/j.gaceta.2015.01.003 [doi]
AB  - BACKGROUND: Among men who have sex with men (MSM), the association between searching 
      for sexual partners' on the Internet and increased risk of sexually transmitted 
      infections (STIs)/HIV infection, together with current low levels of partner 
      notification (PN), justifies a study to explore the intention to use new 
      communication technologies for PN in Spain. METHODS: Two cross-sectional surveys 
      were performed: the first was administered online to visitors to web pages where the 
      survey was advertised; the second was administered on paper to patients attending an 
      STI Unit and centres similar to Community-Based Voluntary Counselling and Testing 
      centres. RESULTS: The study population comprised 1578 Spanish residents (median age, 
      34 years [range: 18 to 74]); 84% lived in urban areas, and 69% reported searching 
      for sexual partners on the Internet. Thirty-seven per cent would be willing to use a 
      website for PN, 26% did not know if they would use one, and 37% would not want to 
      use one. The main reasons for not intending to notify STI/HIV were "shame or fear" 
      (stable partner) and "not knowing how to contact them" (casual partner). The 
      preferred method of notification was face to face (73%) for both stable and casual 
      partners, although using new technologies (Short Messaging System, e-mail, web page, 
      phone applications) was widely accepted for notifying casual partners. CONCLUSIONS: 
      Fighting stigma and promoting alternative methods of PN among MSM and health 
      professionals through new technologies could increase the frequency of PN. This 
      approach will improve early detection and reduce transmission in Spain.
CI  - Copyright © 2014 SESPAS. Published by Elsevier Espana. All rights reserved.
FAU - Carnicer-Pont, Dolors
AU  - Carnicer-Pont D
AD  - Centre of Epidemiological Studies of HIV/AIDS and STI of Catalonia (CEEISCAT) 
      Catalan Institut of Oncology (ICO) -Public Health Agency of Catalonia (ASPCAT), 
      Spain; Department of Paediatrics, Obstetrics and Gynaecology of the Autonomous 
      University of Barcelona (UAB), Bellaterra, Spain; CIBER, Epidemiology and Public 
      Health (CIBERESP), Spain. Electronic address: dcarnice@gmail.com.
FAU - Barbera-Gracia, María Jesús
AU  - Barbera-Gracia MJ
AD  - STI Unit, Special Programme Infectious Diseases Vall d'Hebron-Drassanes University 
      Hospital Vall d'Hebrón, Barcelona, Spain.
FAU - Fernández-Dávila, Percy
AU  - Fernández-Dávila P
AD  - Centre of Epidemiological Studies of HIV/AIDS and STI of Catalonia (CEEISCAT) 
      Catalan Institut of Oncology (ICO) -Public Health Agency of Catalonia (ASPCAT), 
      Spain; Stop Sida, Barcelona, Spain.
FAU - García de Olalla, Patricia
AU  - García de Olalla P
AD  - Agència de Salut Pública de Barcelona (ASPB), Spain; CIBER, Epidemiology and Public 
      Health (CIBERESP), Spain.
FAU - Muñoz, Rafael
AU  - Muñoz R
AD  - Centre of Epidemiological Studies of HIV/AIDS and STI of Catalonia (CEEISCAT) 
      Catalan Institut of Oncology (ICO) -Public Health Agency of Catalonia (ASPCAT), 
      Spain; Stop Sida, Barcelona, Spain.
FAU - Jacques-Aviñó, Constanza
AU  - Jacques-Aviñó C
AD  - Agència de Salut Pública de Barcelona (ASPB), Spain.
FAU - Saladié-Martí, María Pilar
AU  - Saladié-Martí MP
AD  - STI Unit, Special Programme Infectious Diseases Vall d'Hebron-Drassanes University 
      Hospital Vall d'Hebrón, Barcelona, Spain.
FAU - Gosch-Elcoso, Mercè
AU  - Gosch-Elcoso M
AD  - STI Unit, Special Programme Infectious Diseases Vall d'Hebron-Drassanes University 
      Hospital Vall d'Hebrón, Barcelona, Spain.
FAU - Arellano Muñoz, Encarna
AU  - Arellano Muñoz E
AD  - STI Unit, Special Programme Infectious Diseases Vall d'Hebron-Drassanes University 
      Hospital Vall d'Hebrón, Barcelona, Spain.
FAU - Casabona, Jordi
AU  - Casabona J
AD  - Centre of Epidemiological Studies of HIV/AIDS and STI of Catalonia (CEEISCAT) 
      Catalan Institut of Oncology (ICO) -Public Health Agency of Catalonia (ASPCAT), 
      Spain; Department of Paediatrics, Obstetrics and Gynaecology of the Autonomous 
      University of Barcelona (UAB), Bellaterra, Spain; CIBER, Epidemiology and Public 
      Health (CIBERESP), Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150221
PL  - Spain
TA  - Gac Sanit
JT  - Gaceta sanitaria
JID - 8901623
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Community Health Centers
MH  - Contact Tracing/*methods
MH  - Cross-Sectional Studies
MH  - Emotions
MH  - Humans
MH  - *Internet
MH  - Male
MH  - Middle Aged
MH  - Sexual Behavior
MH  - *Sexual Partners
MH  - Sexually Transmitted Diseases/epidemiology/*prevention & 
      control/psychology/transmission
MH  - Social Media
MH  - Social Stigma
MH  - Socioeconomic Factors
MH  - Spain/epidemiology
MH  - Telephone
MH  - Urban Population
MH  - Young Adult
OTO - NOTNLM
OT  - Communication networks
OT  - Infección de transmisión sexual/VIH
OT  - Internet
OT  - Notificación a las parejas sexuales
OT  - Partner notification
OT  - Redes de comunicación
OT  - Sexually Transmitted Infection/HIV
EDAT- 2015/02/25 06:00
MHDA- 2017/02/14 06:00
CRDT- 2015/02/25 06:00
PHST- 2014/10/14 00:00 [received]
PHST- 2015/01/14 00:00 [revised]
PHST- 2015/01/14 00:00 [accepted]
PHST- 2015/02/25 06:00 [entrez]
PHST- 2015/02/25 06:00 [pubmed]
PHST- 2017/02/14 06:00 [medline]
AID - S0213-9111(15)00006-0 [pii]
AID - 10.1016/j.gaceta.2015.01.003 [doi]
PST - ppublish
SO  - Gac Sanit. 2015 May-Jun;29(3):190-7. doi: 10.1016/j.gaceta.2015.01.003. Epub 2015 
      Feb 21.

PMID- 11958747
OWN - NLM
STAT- MEDLINE
DCOM- 20150820
LR  - 20190922
IS  - 1578-1283 (Electronic)
IS  - 0213-9111 (Linking)
VI  - 16
IP  - 2
DP  - 2002 Mar-Apr
TI  - [Requests for HIV tests and their performance in primary health care. Study of the 
      Sentinel Physician Network of Castilla y León in Spain, 1990-1996].
PG  - 114-20
AB  - AIM: To describe the patterns of requests for and the carrying out of the HIV test 
      in Primary Health Care and the epidemological characteristics of the individuals who 
      have undergone the test. METHOD: A retrospective descriptive study of requests for 
      the HIV test in Primary Health Care, in the area covered by the Sentinel Network of 
      Castile and Leon between 1991 and 1996. The validity of the results was assured 
      through an initial study of geographical representativity and populational 
      diversity, with periodical adjustments. The information was obtained through weekly 
      reports from Sentinel doctors. RESULTS: The request rate per 100.000 inhabitants 
      showed a tendency to increase until 1993, levelling off in 1995 and 1996. There were 
      significant differences between percentage of test requested by doctors (55.9%) and 
      patients (40%), as well as between males/females and average for age of these. Of 
      the 63.1% of patients with known risk factor: 17.5% were injected drug users (IDUs) 
      and 11.2% were through unsafe heterosexual contact; these factors being modified 
      over time. The predominant risk factors among males were: heterosexual contact 
      (31.1%) and the use of injected drugs (27.9%). The case was similar for females: 
      22.7% and 6.9% respectively. The results were positive in 3.2% of the HIV tests. 
      CONCLUSIONS: An increase in requests and tests carried out between 1991 and 1993 was 
      detected. The figures later stabilized and, in general, they were lower than in 
      other studies. The doctor was predominantly the origin of the request. A decrease in 
      IDUs and an increase in the percentage of unsafe heterosexual contact, were 
      detected, both in line with data from other research. Primary Health Care had a 
      predominant place in early detection of risk practice and in the areas of 
      prevention, education and information.
FAU - Redondo Martín, S
AU  - Redondo Martín S
AD  - Red de Médicos Centinelas de Castilla y León. Servicio Territorial de Sanidad y 
      Bienestar Social de Valladolid. Junta de Castilla y León. Spain.
FAU - Morquecho Gil, M
AU  - Morquecho Gil M
FAU - Berbel Hernández, C
AU  - Berbel Hernández C
FAU - Viña Simón, M C
AU  - Viña Simón MC
LA  - spa
PT  - Journal Article
TT  - Solicitud y realización del test del VIH en atención primaria. Estudio de la Red de 
      Médicos Centinelas de Castilla y León 1990-1996.
PL  - Spain
TA  - Gac Sanit
JT  - Gaceta sanitaria
JID - 8901623
SB  - IM
MH  - AIDS Serodiagnosis/*statistics & numerical data
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Female
MH  - HIV Infections/*diagnosis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Primary Health Care
MH  - Retrospective Studies
MH  - Sentinel Surveillance
MH  - Spain
MH  - Time Factors
MH  - Young Adult
EDAT- 2002/04/18 10:00
MHDA- 2015/08/21 06:00
CRDT- 2002/04/18 10:00
PHST- 2002/04/18 10:00 [pubmed]
PHST- 2015/08/21 06:00 [medline]
PHST- 2002/04/18 10:00 [entrez]
AID - 13029335 [pii]
AID - 10.1016/s0213-9111(02)71642-7 [doi]
PST - ppublish
SO  - Gac Sanit. 2002 Mar-Apr;16(2):114-20. doi: 10.1016/s0213-9111(02)71642-7.

PMID- 26765073
OWN - NLM
STAT- MEDLINE
DCOM- 20161010
LR  - 20181202
IS  - 1521-0391 (Electronic)
IS  - 1055-0496 (Print)
IS  - 1055-0496 (Linking)
VI  - 25
IP  - 2
DP  - 2016 Mar
TI  - Predictors of needle exchange program utilization during its implementation and 
      expansion in Tijuana, Mexico.
PG  - 118-24
LID - 10.1111/ajad.12326 [doi]
AB  - OBJECTIVE: Until the early 2000s, there was only one needle exchange program (NEP) 
      offered in Mexico. In 2004, the second Mexican NEP opened in Tijuana, but its 
      utilization has not been studied. We studied predictors of initiating NEP during its 
      early expansion in Tijuana, Mexico. METHODS: From April 2006 to April 2007, people 
      who inject drugs (PWID) residing in Tijuana who had injected within the last month 
      were recruited using respondent-driven sampling. Weighted Poisson regression 
      incorporating generalized estimating equations was used to identify predictors of 
      initiating NEP, while accounting for correlation between recruiter and recruits. 
      RESULTS: NEP uptake increased from 20% at baseline to 59% after 6 months. Among a 
      subsample of PWID not accessing NEP at baseline (n = 480), 83% were male and median 
      age was 37 years (Interquartile Range: 32-43). At baseline, 4.4% were HIV-infected 
      and 5.9% had syphilis titers >1:8. In multivariate models, factors associated with 
      NEP initiation (p < .05) were attending shooting galleries (Adjusted Relative Risk 
      [ARR]: 1.54); arrest for track-marks (ARR: 1.38); having a family member that ever 
      used drugs (ARR: 1.37); and having a larger PWID network (ARR: 1.01 per 10 persons). 
      NEP initiation was inversely associated with obtaining syringes at pharmacies (ARR: 
      .56); earning >2500 pesos/month (ARR: .66); and reporting needle sharing (ARR: .71). 
      CONCLUSIONS: Uptake of NEP expansion in Tijuana was vigorous among PWID. We 
      identified a range of factors that influenced the likelihood of NEP initiation, 
      including police interaction. These findings have important implications for the 
      scale-up of NEP in Mexico.
CI  - © American Academy of Addiction Psychiatry.
FAU - Smith, Danielle M
AU  - Smith DM
AD  - Division of Global Public Health, Department of Medicine, University of California, 
      San Diego.
AD  - Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, 
      Canada.
FAU - Werb, Dan
AU  - Werb D
AD  - Division of Global Public Health, Department of Medicine, University of California, 
      San Diego.
FAU - Abramovitz, Daniela
AU  - Abramovitz D
AD  - Division of Global Public Health, Department of Medicine, University of California, 
      San Diego.
FAU - Magis-Rodriguez, Carlos
AU  - Magis-Rodriguez C
AD  - Centro Nacional parala Prevencion y Control del VIH/SIDA e ITS (CENSIDA), Mexico 
      City, Mexico.
FAU - Vera, Alicia
AU  - Vera A
AD  - Division of Global Public Health, Department of Medicine, University of California, 
      San Diego.
FAU - Patterson, Thomas L
AU  - Patterson TL
AD  - Division of Global Public Health, Department of Medicine, University of California, 
      San Diego.
FAU - Strathdee, Steffanie A
AU  - Strathdee SA
AD  - Division of Global Public Health, Department of Medicine, University of California, 
      San Diego.
CN  - for Proyecto El Cuete
LA  - eng
GR  - DP2 DA040256-01/DA/NIDA NIH HHS/United States
GR  - R01 DA039073/DA/NIDA NIH HHS/United States
GR  - DP2 DA040256/DA/NIDA NIH HHS/United States
GR  - R01 DA019829/DA/NIDA NIH HHS/United States
GR  - R37 DA019829/DA/NIDA NIH HHS/United States
GR  - MOP-79297/Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20160114
TA  - Am J Addict
JT  - The American journal on addictions
JID - 9208821
SB  - IM
MH  - Adult
MH  - Female
MH  - Humans
MH  - Male
MH  - Mexico
MH  - Middle Aged
MH  - Needle-Exchange Programs/*statistics & numerical data
MH  - Patient Acceptance of Health Care/*statistics & numerical data
MH  - Police/statistics & numerical data
MH  - Substance Abuse, Intravenous/*prevention & control
PMC - PMC5470727
MID - NIHMS863804
COIS- Declaration of Interest The authors report no conflicts of interest. The authors 
      alone are responsible for the content and writing of this paper
EDAT- 2016/01/15 06:00
MHDA- 2016/10/11 06:00
CRDT- 2016/01/15 06:00
PHST- 2015/08/24 00:00 [received]
PHST- 2015/11/18 00:00 [revised]
PHST- 2015/12/10 00:00 [accepted]
PHST- 2016/01/15 06:00 [entrez]
PHST- 2016/01/15 06:00 [pubmed]
PHST- 2016/10/11 06:00 [medline]
AID - 10.1111/ajad.12326 [doi]
PST - ppublish
SO  - Am J Addict. 2016 Mar;25(2):118-24. doi: 10.1111/ajad.12326. Epub 2016 Jan 14.

PMID- 33324493
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201217
IS  - 2057-1577 (Print)
IS  - 2057-1577 (Electronic)
IS  - 2057-1577 (Linking)
VI  - 6
IP  - 2
DP  - 2020 Jul
TI  - Increasing prevalence and local transmission of non-B HIV-1 subtypes in the French 
      Antilles and French Guiana between 1995 and 2018.
PG  - veaa081
LID - 10.1093/ve/veaa081 [doi]
LID - veaa081
AB  - The Caribbean and South American French Overseas Territories (CSAFOT) are the 
      regions most heavily affected by the Human Immunodeficiency Virus type 1 (HIV-1) 
      epidemic in France. Although dominated by HIV-1 subtype B, the detection of non-B 
      subtypes and the great proportion of HIV-positive persons born abroad demonstrated 
      the potential for local spread of non-B subtype strains in CSAFOT. To reconstruct 
      the epidemiologic dynamics of major non-B subtype clusters spreading in CSAFOT, we 
      conducted phylogenetic and evolutionary analyses of 2,523 HIV-1 pol sequences 
      collected from patients living in Martinique, Guadeloupe, and French Guiana from 
      1995 to 2018. A large variety of HIV-1 non-B subtype strains (eight subtypes, twelve 
      CRFs, and multiple URFs) have been introduced in CSAFOT and their prevalence 
      significantly increases over time in Martinique and Guadeloupe. We identified twelve 
      major transmission networks of non-B subtypes (CRF02_AG and subtypes A3, C, D, and 
      F1) that probably arose in Guadeloupe, Martinique, French Guiana, and mainland 
      France between the late 1970s and the middle 2000s. Phylogeographic analyses support 
      frequent non-B subtype viral transmissions within CSAFOT as well as transatlantic 
      transmission between CSAFOT and mainland France. Domestic transmission networks of 
      non-B subtype variants in CSAFOT comprise both men having sex with men and 
      heterosexual individuals from different age groups. Different HIV-1 non-B subtype 
      variants were sequentially introduced in CSAFOT between the late 1970s and the 
      middle 2000s and are currently spreading through domestic, regional, and/or 
      transatlantic networks of individuals from different age and risk groups.
CI  - © The Author(s) 2020. Published by Oxford University Press.
FAU - Bello, Gonzalo
AU  - Bello G
AD  - Laboratório de AIDS e Imunologia Molecular, Instituto Oswaldo Cruz, FIOCRUZ, Rio de 
      Janeiro, Brazil.
FAU - Delatorre, Edson
AU  - Delatorre E
AD  - Departamento de Biologia, Centro de Ciências Exatas, Naturais e da Saúde, 
      Universidade Federal do Espírito Santo, Alegre, Brazil.
FAU - Lacoste, Vincent
AU  - Lacoste V
AD  - Laboratoire des Interactions Virus-Hôtes, Institut Pasteur de la Guyane, Cayenne, 
      Guyane Française.
FAU - Darcissac, Edith
AU  - Darcissac E
AD  - Laboratoire des Interactions Virus-Hôtes, Institut Pasteur de la Guyane, Cayenne, 
      Guyane Française.
FAU - Herrmann-Storck, Cécile
AU  - Herrmann-Storck C
AD  - Laboratory of Microbiology, University Hospital, Pointe-à-Pitre, Guadeloupe.
FAU - Tressières, Benoit
AU  - Tressières B
AD  - INSERM Centre d'Investigation Clinique 1424, Centre Hospitalier Universitaire de 
      Pointe-à-Pitre, Pointe-à-Pitre, Guadeloupe.
FAU - Cabras, Ornella
AU  - Cabras O
AD  - Service de Maladies Infectieuses et Tropicales, Martinique University Hospital, 
      Université des Antilles, Fort-de-France EA 7524, Martinique.
FAU - Lamaury, Isabelle
AU  - Lamaury I
AD  - Department of Infectious and Tropical Diseases, Dermatology, Internal Medicine, 
      University Hospital Guadeloupe, Pointe-à-Pitre, Guadeloupe.
FAU - Cabié, André
AU  - Cabié A
AD  - Service de Maladies Infectieuses et Tropicales, Martinique University Hospital, 
      Université des Antilles, Fort-de-France EA 7524, Martinique.
FAU - Visseaux, Benoit
AU  - Visseaux B
AUID- ORCID: 0000-0002-9279-5538
AD  - Université de Paris, INSERM UMR 1137 IAME, Laboratoire de Virologie, AP-HP, Hôpital 
      Bichat-Claude Bernard, Paris, France.
FAU - Chaix, Marie-Laure
AU  - Chaix ML
AD  - Université de Paris, INSERM U944, Laboratoire de Virologie, AP-HP, Hôpital 
      Saint-Louis, Paris, France.
FAU - Descamps, Diane
AU  - Descamps D
AD  - Université de Paris, INSERM UMR 1137 IAME, Laboratoire de Virologie, AP-HP, Hôpital 
      Bichat-Claude Bernard, Paris, France.
FAU - Césaire, Raymond
AU  - Césaire R
AD  - Service de Virologie, Martinique University Hospital, Université des Antilles, 
      Fort-de-France EA 7524, Martinique.
FAU - Nacher, Mathieu
AU  - Nacher M
AUID- ORCID: 0000-0001-9397-3204
AD  - Coordination Régionale de la lutte contre le VIH (COREVIH) and Centre 
      d'Investigation Clinique - CIC INSERM 1424, Centre Hospitalier de Cayenne "Andrée 
      Rosemon", Cayenne, Guyane Française.
FAU - Dos Santos, Georges
AU  - Dos Santos G
AD  - Service de Virologie, Martinique University Hospital, Université des Antilles, 
      Fort-de-France EA 7524, Martinique.
LA  - eng
PT  - Journal Article
DEP - 20201127
TA  - Virus Evol
JT  - Virus evolution
JID - 101664675
PMC - PMC7724245
OTO - NOTNLM
OT  - French Guiana
OT  - Guadeloupe
OT  - HIV cluster
OT  - HIV-1
OT  - Martinique
OT  - Phylodynamics
OT  - non-B subtype
EDAT- 2020/12/17 06:00
MHDA- 2020/12/17 06:01
CRDT- 2020/12/16 05:37
PHST- 2020/12/16 05:37 [entrez]
PHST- 2020/12/17 06:00 [pubmed]
PHST- 2020/12/17 06:01 [medline]
AID - veaa081 [pii]
AID - 10.1093/ve/veaa081 [doi]
PST - epublish
SO  - Virus Evol. 2020 Nov 27;6(2):veaa081. doi: 10.1093/ve/veaa081. eCollection 2020 Jul.

PMID- 30722780
OWN - NLM
STAT- MEDLINE
DCOM- 20200220
LR  - 20200309
IS  - 1471-2431 (Electronic)
IS  - 1471-2431 (Linking)
VI  - 19
IP  - 1
DP  - 2019 Feb 5
TI  - High level of treatment failure and drug resistance to first-line antiretroviral 
      therapies among HIV-infected children receiving decentralized care in Senegal.
PG  - 47
LID - 10.1186/s12887-019-1420-z [doi]
LID - 47
AB  - BACKGROUND: In Senegal in 2015, an estimated 4800 children were living with HIV, 
      with 1200 receiving ARV treatment, of whom half had follow-up care in decentralized 
      sites outside Dakar. However, until now no studies have determined the efficacy of 
      pediatric treatment in decentralized settings, even though the emergence of viral 
      resistance, particularly among children in Africa, is a well-known phenomenon. This 
      study aimed to assess the virological status of HIV-infected children in all 
      decentralized facilities to help improve access to quality care. METHODS: A 
      cross-sectional epidemiological and virological study was conducted in all of 
      Senegal's regions, except Dakar, between March and June 2015 and sought to include 
      all HIV-infected children and adolescents (0-19 years), treated or not with ARVs. 
      Socio-demographic and clinical data and a blood sample on blotting paper were 
      collected for children from treatment sites. Samples were routed on public 
      transportation, assisted by a network of community health workers. A viral load (VL) 
      assay was performed for each child, followed by genotyping when it exceeded 1000 
      copies/mL (3 log(10)). RESULTS: Of the 851 identified children, 666 (78%) were 
      enrolled in the study. Half of the children were girls, and the average age was 
      8 years (6 months-19 years). Most of the children (96.7%) were infected with HIV-1, 
      and 90% were treated with ART, primarily with AZT + 3TC + NVP/EFV therapeutic 
      regimen. The median duration of time on ART was 21 months (1-129). VL was measured 
      for 2% of children before this study. Almost two-thirds (64%) of the children are 
      experiencing virological failure. Among them, there was resistance to at least one 
      drug for 86.5% of cases. Also, 25% children presented resistance to one drug and 40% 
      to two out of three. For nearly one-third of the children presenting resistance, 
      none of the three drugs of the treatment was active. Factors associated with 
      virological failure were male sex, follow-up by a generalist rather than a 
      specialist, and treatment interruptions. CONCLUSIONS: We observed a high level of 
      virological failure and a high percentage of viral resistance among children 
      receiving health care in decentralized facilities in Senegal.
FAU - Cissé, Abdoul-Magib
AU  - Cissé AM
AD  - Service de pédiatrie Établissement Public de Santé (EPS) de Mbour, UFR Sciences de 
      la Santé, Thiès University, Thiès, Senegal.
FAU - Laborde-Balen, Gabrièle
AU  - Laborde-Balen G
AD  - Expertise France, Paris, France.
AD  - ANRS-Senegal site, Dakar, Senegal.
AD  - Centre régional de recherche et de formation à la prise en charge clinique de Fann 
      (CRCF), Dakar, Senegal.
FAU - Kébé-Fall, Khady
AU  - Kébé-Fall K
AD  - Bacteriology-Virology Laboratory, A. Le Dantec CHU, Cheikh Anta Diop University, 
      Dakar, Senegal.
FAU - Dramé, Aboubacry
AU  - Dramé A
AD  - Bacteriology-Virology Laboratory, A. Le Dantec CHU, Cheikh Anta Diop University, 
      Dakar, Senegal.
FAU - Diop, Halimatou
AU  - Diop H
AD  - Bacteriology-Virology Laboratory, A. Le Dantec CHU, Cheikh Anta Diop University, 
      Dakar, Senegal.
FAU - Diop, Karim
AU  - Diop K
AD  - Expertise France, Paris, France.
AD  - Centre régional de recherche et de formation à la prise en charge clinique de Fann 
      (CRCF), Dakar, Senegal.
AD  - Division de lutte contre le sidxa et les IST (DLSI), Ministry of Health and Social 
      Action (MSAS), Dakar, Senegal.
FAU - FatouNiasse-Traoré
AU  - FatouNiasse-Traoré
AD  - Conseil national de lutte contre le sida (CNLS), Dakar, Senegal.
FAU - Coulibaly, Mohamed
AU  - Coulibaly M
AD  - Division de lutte contre le sidxa et les IST (DLSI), Ministry of Health and Social 
      Action (MSAS), Dakar, Senegal.
FAU - Have, Ndeye-Ngone
AU  - Have NN
AD  - Réseau national des associations de personnes vivant avec le VIH au (RNP+), Dakar, 
      Senegal.
FAU - Vidal, Nicole
AU  - Vidal N
AD  - Institut de Recherche pour le Développement (IRD), Montpellier, France.
FAU - Thiam, Safiatou
AU  - Thiam S
AD  - Conseil national de lutte contre le sida (CNLS), Dakar, Senegal.
FAU - Wade, Abdoulaye S
AU  - Wade AS
AD  - Division de lutte contre le sidxa et les IST (DLSI), Ministry of Health and Social 
      Action (MSAS), Dakar, Senegal.
FAU - Peeters, Martine
AU  - Peeters M
AD  - Institut de Recherche pour le Développement (IRD), Montpellier, France.
FAU - Taverne, Bernard
AU  - Taverne B
AD  - Centre régional de recherche et de formation à la prise en charge clinique de Fann 
      (CRCF), Dakar, Senegal.
AD  - Institut de Recherche pour le Développement (IRD), Montpellier, France.
FAU - Msellati, Philippe
AU  - Msellati P
AUID- ORCID: 0000-0003-2568-1626
AD  - Institut de Recherche pour le Développement (IRD), Montpellier, France. 
      philippe.msellati@ird.fr.
AD  - TransVIHMI, IRD, PACCI, 18 BP 1954, Abidjan 18, Abidjan, Côte d'Ivoire. 
      philippe.msellati@ird.fr.
FAU - Touré-Kane, Coumba
AU  - Touré-Kane C
AD  - Bacteriology-Virology Laboratory, A. Le Dantec CHU, Cheikh Anta Diop University, 
      Dakar, Senegal.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190205
TA  - BMC Pediatr
JT  - BMC pediatrics
JID - 100967804
RN  - 0 (Anti-Retroviral Agents)
SB  - IM
MH  - Adolescent
MH  - Anti-Retroviral Agents/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Cross-Sectional Studies
MH  - Delivery of Health Care/organization & administration
MH  - *Drug Resistance, Viral
MH  - Female
MH  - HIV Infections/*drug therapy/epidemiology
MH  - Humans
MH  - Infant
MH  - Male
MH  - Senegal/epidemiology
MH  - *Treatment Failure
MH  - Young Adult
PMC - PMC6362577
OTO - NOTNLM
OT  - *Antiretroviral
OT  - *Decentralization
OT  - *Pediatric HIV
OT  - *Senegal
OT  - *Viral resistance
COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: The protocol was approved by the 
      National Ethics Committee for Research in Health in Senegal on 16 December 2014 
      under no. 377/MSAS/DPRS/CNERS. All parents or guardians provided written informed 
      consent. CONSENT FOR PUBLICATION: “Not applicable”. COMPETING INTERESTS: The authors 
      declare that they have no competing interests. PUBLISHER’S NOTE: Springer Nature 
      remains neutral with regard to jurisdictional claims in published maps and 
      institutional affiliations.
EDAT- 2019/02/07 06:00
MHDA- 2020/02/23 06:00
CRDT- 2019/02/07 06:00
PHST- 2018/10/12 00:00 [received]
PHST- 2019/01/29 00:00 [accepted]
PHST- 2019/02/07 06:00 [entrez]
PHST- 2019/02/07 06:00 [pubmed]
PHST- 2020/02/23 06:00 [medline]
AID - 10.1186/s12887-019-1420-z [pii]
AID - 1420 [pii]
AID - 10.1186/s12887-019-1420-z [doi]
PST - epublish
SO  - BMC Pediatr. 2019 Feb 5;19(1):47. doi: 10.1186/s12887-019-1420-z.

PMID- 30377979
OWN - NLM
STAT- MEDLINE
DCOM- 20190711
LR  - 20200225
IS  - 1573-3254 (Electronic)
IS  - 1090-7165 (Print)
IS  - 1090-7165 (Linking)
VI  - 23
IP  - 4
DP  - 2019 Apr
TI  - Making the Link: A Pilot Health Navigation Intervention to Improve Timely Linkage to 
      Care for Men Who have Sex with Men and Transgender Women Recently Diagnosed with HIV 
      in Guatemala City.
PG  - 900-907
LID - 10.1007/s10461-018-2328-6 [doi]
AB  - We piloted a health navigation strategy to promote timely linkage to care among men 
      who have sex with men (MSM) and transgender women (TW) recently diagnosed with HIV 
      in Guatemala City. We used a mixed-methods approach, integrating quantitative data 
      collected during clinic visits and qualitative data from in-depth interviews, to 
      characterize acceptability of navigation and time to linkage, defined as having the 
      first clinical care visit. Out of 54 participants who enrolled in the pilot (n = 52 
      MSM; n = 2 TW), 50 (92.6%) accepted navigation and all were linked to care. Median 
      time to linkage was 3 days (Interquartile Range 2-5 days). In qualitative 
      interviews, participants expressed feeling scared and alone following their 
      diagnosis and appreciated the support of a navigator, especially when they did not 
      feel they could access their existing support networks. Future research and 
      evaluation should continue to assess how to best use health navigation to support 
      key populations recently diagnosed with HIV.
FAU - Loya-Montiel, M Itzel
AU  - Loya-Montiel MI
AD  - HIV Central America Regional Program, Center for Health Studies, Universidad del 
      Valle de Guatemala, Guatemala City, Guatemala.
FAU - Davis, Dirk A
AU  - Davis DA
AD  - Department of Health Behavior, Gillings School of Global Public Health, University 
      of North Carolina, Chapel Hill, NC, USA.
FAU - Aguilar-Martínez, Jose Manuel
AU  - Aguilar-Martínez JM
AD  - HIV Central America Regional Program, Center for Health Studies, Universidad del 
      Valle de Guatemala, Guatemala City, Guatemala.
FAU - Paz Bailey, Olga Alicia
AU  - Paz Bailey OA
AD  - Center for Conflict, Power and Violence Studies - CENDES, Guatemala City, Guatemala.
FAU - Morales-Miranda, Sonia
AU  - Morales-Miranda S
AD  - Consorcio de Investigación sobre VIH, SIDA y TB (CISIDAT), Cuernavaca, Mexico.
FAU - Alvis-Estrada, Juan Pablo
AU  - Alvis-Estrada JP
AD  - HIV Central America Regional Program, Center for Health Studies, Universidad del 
      Valle de Guatemala, Guatemala City, Guatemala.
FAU - Northbrook, Sanny
AU  - Northbrook S
AD  - U.S. Centers for Disease Control and Prevention (CDC) Central America Region, 
      Guatemala City, Guatemala.
FAU - Barrington, Clare
AU  - Barrington C
AD  - Department of Health Behavior, Gillings School of Global Public Health, University 
      of North Carolina, Chapel Hill, NC, USA. cbarring@email.unc.edu.
LA  - eng
GR  - CC999999/Intramural CDC HHS/United States
GR  - GH0000575/U.S. President's Emergency Plan for AIDS Relief/
PT  - Journal Article
TA  - AIDS Behav
JT  - AIDS and behavior
JID - 9712133
SB  - IM
MH  - Adult
MH  - *Continuity of Patient Care
MH  - Female
MH  - Guatemala/epidemiology
MH  - HIV Infections/diagnosis/*drug therapy/epidemiology
MH  - *Health Services Accessibility/statistics & numerical data
MH  - Homosexuality, Male/*psychology
MH  - Humans
MH  - Interviews as Topic
MH  - Male
MH  - *Patient Navigation
MH  - Pilot Projects
MH  - Qualitative Research
MH  - Sexual and Gender Minorities
MH  - Transgender Persons/psychology
MH  - Transsexualism/*psychology
PMC - PMC6691504
MID - NIHMS1045779
OTO - NOTNLM
OT  - Guatemala
OT  - HIV
OT  - Health navigation
OT  - Linkage to care
OT  - MSM
COIS- Disclosure Statement: No potential conflict of interest was reported by the authors.
EDAT- 2018/11/01 06:00
MHDA- 2019/07/12 06:00
CRDT- 2018/11/01 06:00
PHST- 2018/11/01 06:00 [pubmed]
PHST- 2019/07/12 06:00 [medline]
PHST- 2018/11/01 06:00 [entrez]
AID - 10.1007/s10461-018-2328-6 [pii]
AID - 10.1007/s10461-018-2328-6 [doi]
PST - ppublish
SO  - AIDS Behav. 2019 Apr;23(4):900-907. doi: 10.1007/s10461-018-2328-6.

PMID- 31333594
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1664-302X (Print)
IS  - 1664-302X (Electronic)
IS  - 1664-302X (Linking)
VI  - 10
DP  - 2019
TI  - Phylogeographic Analyses Reveal the Early Expansion and Frequent Bidirectional 
      Cross-Border Transmissions of Non-pandemic HIV-1 Subtype B Strains in Hispaniola.
PG  - 1340
LID - 10.3389/fmicb.2019.01340 [doi]
LID - 1340
AB  - The human immunodeficiency virus-type 1 (HIV-1) subtype B has probably been 
      circulating on the island of Hispaniola since the 1960s, but information about the 
      early viral history on this Caribbean island is scarce. In this study, we 
      reconstruct the dissemination dynamics of early divergent non-pandemic subtype B 
      lineages (designated B(CAR)) on Hispaniola by analyzing a country-balanced dataset 
      of HIV-1 B(CAR) pol sequences from Haiti (n = 103) and the Dominican Republic (n = 
      123). Phylogenetic analyses supported that B(CAR) strains from Haiti and the 
      Dominican Republic were highly intermixed between each other, although the null 
      hypothesis of completely random mixing was rejected. Bayesian phylogeographic 
      analyses placed the ancestral B(CAR) virus in Haiti and the Dominican Republic with 
      the same posterior probability support. These analyses estimate frequent viral 
      transmissions between Haiti and the Dominican Republic since the early 1970s 
      onwards, and the presence of local B(CAR) transmission networks in both countries 
      before first AIDS cases was officially recognized. Demographic reconstructions point 
      that the B(CAR) epidemic in Hispaniola grew exponentially until the 1990s. These 
      findings support that the HIV-1 epidemics in Haiti and the Dominican Republic have 
      been connected by a recurrent bidirectional viral flux since the initial phase, 
      which poses a great challenge in tracing the geographic origin of the B(CAR) 
      epidemic within Hispaniola using only genetic data. These data also reinforce the 
      notion that prevention programs have successfully reduced the rate of new HIV-1 
      transmissions in Hispaniola since the end of the 1990s.
FAU - Bello, Gonzalo
AU  - Bello G
AD  - Laboratório de AIDS e Imunologia Molecular, Instituto Oswaldo Cruz, FIOCRUZ, Rio de 
      Janeiro, Brazil.
FAU - Arantes, Ighor
AU  - Arantes I
AD  - Laboratório de AIDS e Imunologia Molecular, Instituto Oswaldo Cruz, FIOCRUZ, Rio de 
      Janeiro, Brazil.
FAU - Lacoste, Vincent
AU  - Lacoste V
AD  - Laboratoire des Interactions Virus-Hôtes, Institut Pasteur de la Guyane, Cayenne, 
      French Guiana.
FAU - Ouka, Marlene
AU  - Ouka M
AD  - Virology Laboratory, EA 4537, Martinique University Hospital, Fort de France, 
      Martinique.
FAU - Boncy, Jacques
AU  - Boncy J
AD  - Laboratoire National de Santé Publique, Ministère de la Santé Publique et de la 
      Population, Port-au-Prince, Haiti.
FAU - Césaire, Raymond
AU  - Césaire R
AD  - Virology Laboratory, EA 4537, Martinique University Hospital, Fort de France, 
      Martinique.
FAU - Liautaud, Bernard
AU  - Liautaud B
AD  - Training Unit, GHESKIO Centers, Port-au-Prince, Haiti.
FAU - Nacher, Mathieu
AU  - Nacher M
AD  - Coordination Régionale de la lutte contre le VIH (COREVIH) and Centre 
      d'Investigation Clinique-CIC INSERM 1424, Centre Hospitalier de Cayenne "Andrée 
      Rosemon", Cayenne, French Guiana.
FAU - Dos Santos, Georges
AU  - Dos Santos G
AD  - Virology Laboratory, EA 4537, Martinique University Hospital, Fort de France, 
      Martinique.
LA  - eng
PT  - Journal Article
DEP - 20190626
TA  - Front Microbiol
JT  - Frontiers in microbiology
JID - 101548977
PMC - PMC6622406
OTO - NOTNLM
OT  - Dominican Republic
OT  - HIV-1
OT  - Haiti
OT  - non-pandemic
OT  - origin
OT  - phylodynamics
OT  - subtype B
EDAT- 2019/07/25 06:00
MHDA- 2019/07/25 06:01
CRDT- 2019/07/24 06:00
PHST- 2018/09/27 00:00 [received]
PHST- 2019/05/29 00:00 [accepted]
PHST- 2019/07/24 06:00 [entrez]
PHST- 2019/07/25 06:00 [pubmed]
PHST- 2019/07/25 06:01 [medline]
AID - 10.3389/fmicb.2019.01340 [doi]
PST - epublish
SO  - Front Microbiol. 2019 Jun 26;10:1340. doi: 10.3389/fmicb.2019.01340. eCollection 
      2019.

PMID- 30899768
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210211
IS  - 2328-8957 (Print)
IS  - 2328-8957 (Electronic)
IS  - 2328-8957 (Linking)
VI  - 6
IP  - 3
DP  - 2019 Mar
TI  - In-depth Sampling of High-risk Populations to Characterize HIV Transmission 
      Epidemics Among Young MSM Using PrEP in France and Quebec.
PG  - ofz080
LID - 10.1093/ofid/ofz080 [doi]
LID - ofz080
AB  - BACKGROUND: A better understanding of HIV transmission dynamics among populations at 
      high risk is important for development of prevention strategies. We determined HIV 
      transmission networks from infected individuals enrolled in the pre-exposure 
      prophylaxis (PrEP) IPERGAY trial in combination with the ANRS PRIMO and Montreal PHI 
      cohorts to identify and characterize active clusters of transmission in this 
      high-risk population. METHODS: Genotypic resistance tests were performed on plasma 
      samples from 31 IPERGAY participants. Reverse transcriptase sequences were analyzed 
      in combination with unique HIV pol sequences from 1351 individuals enrolled in the 
      PRIMO ANRS cohort (1999-2014) and 511 individuals enrolled in the Montreal PHI 
      cohort (1996-2016). Network analyses were performed to infer putative relationships 
      between all participants. RESULTS: Overall, 1893 participants were included. 
      Transmission network analyses revealed that 14 individuals (45.2%) from the IPERGAY 
      trial were involved in 13 clusters sampled over a median period (interquartile 
      range) of 2 (0.3-7.8) years, including 7 dyads and 6 larger clusters ranging from 4 
      to 28 individuals. When comparing characteristics between clustering individuals 
      enrolled in the PRIMO cohort (n = 377) and in IPERGAY (n = 14), we found that 
      IPERGAY participants had a higher viral load (5.93 vs 5.20 log(10) copies/mL, P = 
      .032) and reported a higher number of partners in the last 2 months (P < .01). 
      CONCLUSIONS: These results demonstrate high rates of HIV transmission clustering 
      among young high-risk MSM enrolled in the IPERGAY trial. In-depth sampling of 
      high-risk populations may help to uncover unobserved transmission intermediaries and 
      improve prevention efforts that could be targeted to the most active clusters.
FAU - Chaillon, Antoine
AU  - Chaillon A
AD  - Department of Medicine, University of California, San Diego, San Diego, California.
FAU - Delaugerre, Constance
AU  - Delaugerre C
AD  - Virologie, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, CNR VIH, 
      Paris, France.
AD  - INSERM U944, CNRS UMR 7212, Institut Universitaire d'Hématologie, Sorbonne Paris 
      Cité, Université Paris Diderot, Hôpital Saint Louis, Paris, France.
FAU - Brenner, Bluma
AU  - Brenner B
AD  - BB, Lady Davis Institute, Departments of Medicine, McGill University, Montreal, 
      Canada.
FAU - Armero, Alix
AU  - Armero A
AD  - Virologie, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, CNR VIH, 
      Paris, France.
FAU - Capitant, Catherine
AU  - Capitant C
AD  - INSERM SC10 US19, Villejuif, France.
FAU - Nere, Marie Laure
AU  - Nere ML
AD  - Virologie, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, CNR VIH, 
      Paris, France.
FAU - Leturque, Nicolas
AU  - Leturque N
AD  - INSERM SC10 US19, Villejuif, France.
FAU - Pialoux, Gilles
AU  - Pialoux G
AD  - Maladies Infectieuses, Hôpital Tenon, Assistance Publique Hôpitaux de Paris, Paris, 
      France.
FAU - Cua, Eric
AU  - Cua E
AD  - Maladies Infectieuses, Hôpital de l'Archet, Centre Hospitalier de Nice, Nice, 
      France.
FAU - Tremblay, Cecile
AU  - Tremblay C
AD  - Centre Hospitalier de l'Université de Montréal, Montréal, Canada.
FAU - Smith, Davey M
AU  - Smith DM
AD  - Department of Medicine, University of California, San Diego, San Diego, California.
FAU - Goujard, Cecile
AU  - Goujard C
AD  - Assistance Publique Hôpitaux de Paris, Hôpital de Bicêtre, Le Kremlin-Bicêtre, 
      France.
AD  - INSERM CESP U1018, Université Paris Sud, Université Paris Saclay, Saint-Aubin, 
      France.
FAU - Meyer, Laurence
AU  - Meyer L
AD  - INSERM SC10 US19, Villejuif, France.
AD  - Assistance Publique Hôpitaux de Paris, Hôpital de Bicêtre, Le Kremlin-Bicêtre, 
      France.
AD  - INSERM CESP U1018, Université Paris Sud, Université Paris Saclay, Saint-Aubin, 
      France.
FAU - Molina, Jean Michel
AU  - Molina JM
AD  - INSERM U944, CNRS UMR 7212, Institut Universitaire d'Hématologie, Sorbonne Paris 
      Cité, Université Paris Diderot, Hôpital Saint Louis, Paris, France.
AD  - Maladies Infectieuses, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, 
      Paris, France.
FAU - Chaix, Marie Laure
AU  - Chaix ML
AD  - Virologie, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, CNR VIH, 
      Paris, France.
AD  - INSERM U944, CNRS UMR 7212, Institut Universitaire d'Hématologie, Sorbonne Paris 
      Cité, Université Paris Diderot, Hôpital Saint Louis, Paris, France.
LA  - eng
GR  - P30 MH062512/MH/NIMH NIH HHS/United States
GR  - R21 AI131971/AI/NIAID NIH HHS/United States
PT  - Journal Article
DEP - 20190215
TA  - Open Forum Infect Dis
JT  - Open forum infectious diseases
JID - 101637045
PMC - PMC6422434
OTO - NOTNLM
OT  - HIV
OT  - MSM
OT  - PrEP
OT  - clustering
OT  - network
EDAT- 2019/03/23 06:00
MHDA- 2019/03/23 06:01
CRDT- 2019/03/23 06:00
PHST- 2019/02/14 00:00 [received]
PHST- 2019/02/14 00:00 [accepted]
PHST- 2019/03/23 06:00 [entrez]
PHST- 2019/03/23 06:00 [pubmed]
PHST- 2019/03/23 06:01 [medline]
AID - ofz080 [pii]
AID - 10.1093/ofid/ofz080 [doi]
PST - epublish
SO  - Open Forum Infect Dis. 2019 Feb 15;6(3):ofz080. doi: 10.1093/ofid/ofz080. 
      eCollection 2019 Mar.

PMID- 23377915
OWN - NLM
STAT- MEDLINE
DCOM- 20130708
LR  - 20190722
IS  - 1896-1851 (Electronic)
IS  - 1230-2821 (Linking)
VI  - 58
IP  - 1
DP  - 2013 Mar
TI  - Cell phenotypic change due to Cryptosporidium parvum infection in immunocompetent 
      mice.
PG  - 70-9
LID - 10.2478/s11686-013-0113-2 [doi]
AB  - Cryptosporidium parvum is an intracellular parasite causing enteritis which can 
      become life-threatening in immunocompromised host. Immunoregulatory T cells play a 
      central role in the regulatory network of the host. Here, we proposed to 
      characterize the populations of immune cells during infection and reinfection with 
      C. parvum. Four-week-old BALB/C mice were inoculated with oocysts of C. parvum at 
      days 0 and 22. Fecal and blood samples, spleens, and small intestines were collected 
      for analysis. Peripheral blood and spleen cell populations were characterized by 
      flow cytometry. After infection (days 0 to 21), mice presented higher values of 
      neutrophils, eosinophils, NK cells and CD4(+)CD25(high) T cells in peripheral blood. 
      After reinfection, this upward trend continued in the following days for all four 
      populations in infected mice. At day 35, infected mice presented similar values to 
      the control group, except for CD4(+)CD25(high) T cells, which remained higher in 
      infected mice. A possible correlation between alterations in blood and spleen cell 
      populations was also studied, but no consistent association could be established. 
      Small intestine sections were screened for intracellular stages of the parasite but 
      no evidence of pathology was observed. Here, we report information which may be 
      important for the understanding of the specific cell-mediated response in 
      immunocompetent mice to C. parvum infection. Although some questions remain 
      unanswered and complementary studies are needed, our results are expected to 
      contribute to a better understanding of innate and Treg cells role in the clearance 
      process of this parasite.
FAU - Codices, Vera
AU  - Codices V
AD  - Unidade de Parasitologia Médica, Grupo de Protozoários Oportunistas/VIH e Outros 
      Protozoários, CMDT, Instituto de Higiene e Medicina Tropical, Universidade Nova de 
      Lisboa, Lisboa, Portugal.
FAU - Martins, Catarina
AU  - Martins C
FAU - Novo, Carlos
AU  - Novo C
FAU - Pinho, Mário
AU  - Pinho M
FAU - de Sousa, Bruno
AU  - de Sousa B
FAU - Lopes, Angela
AU  - Lopes A
FAU - Borrego, Miguel
AU  - Borrego M
FAU - Matos, Olga
AU  - Matos O
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130202
PL  - Switzerland
TA  - Acta Parasitol
JT  - Acta parasitologica
JID - 9301947
SB  - IM
MH  - Animals
MH  - Cryptosporidiosis/*immunology
MH  - Cryptosporidium parvum/*immunology
MH  - Eosinophils
MH  - Female
MH  - Immunity, Cellular
MH  - Immunocompetence
MH  - Immunocompromised Host
MH  - Lymphocytes
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Monocytes
MH  - Neutrophils
MH  - Spleen/cytology/immunology
MH  - T-Lymphocyte Subsets
EDAT- 2013/02/05 06:00
MHDA- 2013/07/09 06:00
CRDT- 2013/02/05 06:00
PHST- 2012/10/30 00:00 [accepted]
PHST- 2013/02/05 06:00 [entrez]
PHST- 2013/02/05 06:00 [pubmed]
PHST- 2013/07/09 06:00 [medline]
AID - 10.2478/s11686-013-0113-2 [doi]
PST - ppublish
SO  - Acta Parasitol. 2013 Mar;58(1):70-9. doi: 10.2478/s11686-013-0113-2. Epub 2013 Feb 
      2.

PMID- 20003899
OWN - NLM
STAT- MEDLINE
DCOM- 20100225
LR  - 20190608
IS  - 1560-7917 (Electronic)
IS  - 1025-496X (Linking)
VI  - 14
IP  - 48
DP  - 2009 Dec 3
TI  - HIV/STI co-infection among men who have sex with men in Spain.
LID - 19426 [pii]
AB  - In Spain, neither the HIV nor the STI national surveillance systems collect 
      information on HIV/STI co-infection. However, there are two networks based on 
      HIV/STI clinics which gather this data. We describe HIV prevalence in men who have 
      sex with men (MSM) diagnosed with infectious syphilis and/or gonorrhoea in 15 STI 
      clinics; and concurrent diagnoses of STI in MSM newly diagnosed with HIV in 19 
      HIV/STI clinics. In total, 572 MSM were diagnosed with infectious syphilis and 580 
      with gonorrhoea during 2005-2007. HIV prevalence among syphilis and gonorrhoea cases 
      was 29.8% and 15.2% respectively. In the multivariate analysis, HIV/syphilis 
      co-infection was associated with being Latin American; having a history of STI; 
      reporting exclusively anal intercourse; and having sex with casual or several types 
      of partners. HIV and gonorrhoea co-infection was associated with age older than 45 
      years; having no education or only primary education completed; and having a history 
      of STI. In total, 1,462 HIV infections were newly diagnosed among MSM during 
      2003-2007. Of these, 31.0% were diagnosed with other STI at the same time. Factors 
      associated with STI co-infection among new HIV cases in MSM were being Latin 
      American; and having sex with casual partners or with both steady and casual 
      partners. In Spain, a considerable proportion of MSM are co-infected with HIV and 
      STI.
FAU - Diaz, A
AU  - Diaz A
AD  - Area de Epidemiologia del VIH, Centro Nacional de Epidemiologia, Instituto de Salud 
      Carlos III, Madrid, Spain. adiaz@isciii.es
FAU - Junquera, M L
AU  - Junquera ML
FAU - Esteban, V
AU  - Esteban V
FAU - Martínez, B
AU  - Martínez B
FAU - Pueyo, I
AU  - Pueyo I
FAU - Suarez, J
AU  - Suarez J
FAU - Ureña, J M
AU  - Ureña JM
FAU - Varela, J A
AU  - Varela JA
FAU - Vall, M
AU  - Vall M
FAU - del Romero, J
AU  - del Romero J
FAU - Sanz, I
AU  - Sanz I
FAU - Belda, J
AU  - Belda J
FAU - Boronat, J
AU  - Boronat J
FAU - Gomez, P
AU  - Gomez P
FAU - Gual, F
AU  - Gual F
FAU - Colomo, C
AU  - Colomo C
FAU - López de Munain, J
AU  - López de Munain J
FAU - Balaguer, J
AU  - Balaguer J
FAU - Landa, M C
AU  - Landa MC
FAU - Lezaun, M E
AU  - Lezaun ME
FAU - Cámara, M C
AU  - Cámara MC
FAU - Fernández, E
AU  - Fernández E
FAU - Bru, F J
AU  - Bru FJ
FAU - Alastrue, I
AU  - Alastrue I
FAU - Ordoñana, J R
AU  - Ordoñana JR
FAU - de Armas, C
AU  - de Armas C
FAU - Azpiri, M A
AU  - Azpiri MA
FAU - Gomez, L
AU  - Gomez L
FAU - Trullén, J
AU  - Trullén J
FAU - Diez, M
AU  - Diez M
CN  - STI Study Group and EPI-VIH Group
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20091203
PL  - Sweden
TA  - Euro Surveill
JT  - Euro surveillance : bulletin Europeen sur les maladies transmissibles = European 
      communicable disease bulletin
JID - 100887452
SB  - IM
MH  - Adult
MH  - Disease Outbreaks/*statistics & numerical data
MH  - HIV Infections/*epidemiology
MH  - Homosexuality, Male/*statistics & numerical data
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Population Surveillance
MH  - Risk Assessment
MH  - Risk Factors
MH  - Spain/epidemiology
FIR - Diaz, A
IR  - Diaz A
FIR - Diez, M
IR  - Diez M
FIR - Garriga, C
IR  - Garriga C
FIR - Suarez, J
IR  - Suarez J
FIR - Ureña, J M
IR  - Ureña JM
FIR - Castro, E
IR  - Castro E
FIR - Benavides, V
IR  - Benavides V
FIR - Gómez, M
IR  - Gómez M
FIR - Martínez, B
IR  - Martínez B
FIR - Pueyo, I
IR  - Pueyo I
FIR - Ruiz, E
IR  - Ruiz E
FIR - Redondo, C
IR  - Redondo C
FIR - Martinez, C
IR  - Martinez C
FIR - Sanchez, D
IR  - Sanchez D
FIR - Varela, J A
IR  - Varela JA
FIR - López, C
IR  - López C
FIR - Junquera, M L
IR  - Junquera ML
FIR - Cuesta, M
IR  - Cuesta M
FIR - Valls, M
IR  - Valls M
FIR - Arellano, E
IR  - Arellano E
FIR - Saladié, P
IR  - Saladié P
FIR - Armengol, P
IR  - Armengol P
FIR - Sanz, B
IR  - Sanz B
FIR - Alcalde, M J
IR  - Alcalde MJ
FIR - Loureiro, E
IR  - Loureiro E
FIR - Boronat, J
IR  - Boronat J
FIR - Bru, F J
IR  - Bru FJ
FIR - Colomo, C
IR  - Colomo C
FIR - Comunión, A
IR  - Comunión A
FIR - Martín, R
IR  - Martín R
FIR - Marinero, S
IR  - Marinero S
FIR - Belda, J
IR  - Belda J
FIR - Fernández, E
IR  - Fernández E
FIR - Zafra, T
IR  - Zafra T
FIR - Muñoz, C
IR  - Muñoz C
FIR - Martínez, R
IR  - Martínez R
FIR - Galán, E
IR  - Galán E
FIR - Balaguer, J
IR  - Balaguer J
FIR - Cámara, M
IR  - Cámara M
FIR - López de Munain, J
IR  - López de Munain J
FIR - Larrañaga, G
IR  - Larrañaga G
FIR - Oiarzabal, M J
IR  - Oiarzabal MJ
FIR - Esteban, V
IR  - Esteban V
FIR - Ezpeleta, G
IR  - Ezpeleta G
FIR - Sanz, I
IR  - Sanz I
FIR - Camino, X
IR  - Camino X
FIR - Gual, F
IR  - Gual F
FIR - Gómez, P
IR  - Gómez P
FIR - Diaz, A
IR  - Diaz A
FIR - Diez, M
IR  - Diez M
FIR - Garriga, C
IR  - Garriga C
FIR - Sanchez, F
IR  - Sanchez F
FIR - Galindo, S
IR  - Galindo S
FIR - Bleda, M J
IR  - Bleda MJ
FIR - Ureña, J M
IR  - Ureña JM
FIR - Castro, E
IR  - Castro E
FIR - Benavides, V
IR  - Benavides V
FIR - Gómez, M
IR  - Gómez M
FIR - Pueyo, I
IR  - Pueyo I
FIR - Ruiz, E
IR  - Ruiz E
FIR - Redondo, C
IR  - Redondo C
FIR - Martinez, C
IR  - Martinez C
FIR - Sanchez, D
IR  - Sanchez D
FIR - Varela, J A
IR  - Varela JA
FIR - López, C
IR  - López C
FIR - Junquera, M
IR  - Junquera M
FIR - Cuesta, M
IR  - Cuesta M
FIR - Valls, M
IR  - Valls M
FIR - Arellano, E
IR  - Arellano E
FIR - Saladié, P
IR  - Saladié P
FIR - Armengol, P
IR  - Armengol P
FIR - Sanz, B
IR  - Sanz B
FIR - Alcalde, M J
IR  - Alcalde MJ
FIR - Loureiro, E
IR  - Loureiro E
FIR - Bru, F J
IR  - Bru FJ
FIR - Colomo, C
IR  - Colomo C
FIR - Comunión, A
IR  - Comunión A
FIR - Martín, R
IR  - Martín R
FIR - Marinero, S
IR  - Marinero S
FIR - Belda, J
IR  - Belda J
FIR - Fernández, E
IR  - Fernández E
FIR - Zafra, T
IR  - Zafra T
FIR - Muñoz, C
IR  - Muñoz C
FIR - Martínez, R
IR  - Martínez R
FIR - Galán, E
IR  - Galán E
FIR - Alastrué, J I
IR  - Alastrué JI
FIR - Santos, C
IR  - Santos C
FIR - Tasa, T
IR  - Tasa T
FIR - Juan, A
IR  - Juan A
FIR - Trullén, J
IR  - Trullén J
FIR - Fenosa, A
IR  - Fenosa A
FIR - Altava, C
IR  - Altava C
FIR - Polo, A
IR  - Polo A
FIR - Balaguer, J
IR  - Balaguer J
FIR - Cámara, M
IR  - Cámara M
FIR - López de Munain, J
IR  - López de Munain J
FIR - Larrañaga, G
IR  - Larrañaga G
FIR - Oiarzabal, M J
IR  - Oiarzabal MJ
FIR - Sanz, I
IR  - Sanz I
FIR - Camino, X
IR  - Camino X
FIR - De Armas, C
IR  - De Armas C
FIR - García-Ramos, E
IR  - García-Ramos E
FIR - Rodríguez-Franco, J
IR  - Rodríguez-Franco J
FIR - Capote, L
IR  - Capote L
FIR - Nuñez, D
IR  - Nuñez D
FIR - Viloria, L J
IR  - Viloria LJ
FIR - Gómez, L
IR  - Gómez L
FIR - Fernández-Oruña, C
IR  - Fernández-Oruña C
FIR - Fernández, M C
IR  - Fernández MC
FIR - de Vierna, M
IR  - de Vierna M
FIR - Estébanez, A
IR  - Estébanez A
FIR - Del Rio, F
IR  - Del Rio F
FIR - del Romero, J
IR  - del Romero J
FIR - Rodríguez, C
IR  - Rodríguez C
FIR - Puerta, T
IR  - Puerta T
FIR - Ballesteros, J
IR  - Ballesteros J
FIR - Clavo, P
IR  - Clavo P
FIR - García, S
IR  - García S
FIR - del Corral, S
IR  - del Corral S
FIR - Neila, M A
IR  - Neila MA
FIR - Jerez, N
IR  - Jerez N
FIR - Belmar, J M
IR  - Belmar JM
FIR - Ordoñana, J R
IR  - Ordoñana JR
FIR - Landa, M C
IR  - Landa MC
FIR - Sánchez, P
IR  - Sánchez P
FIR - Gaztambide, A
IR  - Gaztambide A
FIR - Huarte, I
IR  - Huarte I
FIR - Sesma, E
IR  - Sesma E
FIR - Yagüe, H
IR  - Yagüe H
FIR - Azpiri, M A
IR  - Azpiri MA
FIR - Lezaun, M E
IR  - Lezaun ME
FIR - Ramalle, E
IR  - Ramalle E
FIR - Quiñones, C
IR  - Quiñones C
FIR - Metola, L
IR  - Metola L
FIR - Metola, M
IR  - Metola M
EDAT- 2009/12/17 06:00
MHDA- 2010/02/26 06:00
CRDT- 2009/12/17 06:00
PHST- 2009/12/17 06:00 [entrez]
PHST- 2009/12/17 06:00 [pubmed]
PHST- 2010/02/26 06:00 [medline]
AID - 19426 [pii]
AID - 10.2807/ese.14.48.19426-en [doi]
PST - epublish
SO  - Euro Surveill. 2009 Dec 3;14(48):19426. doi: 10.2807/ese.14.48.19426-en.

PMID- 31576801
OWN - NLM
STAT- MEDLINE
DCOM- 20200831
LR  - 20200831
IS  - 1560-7917 (Electronic)
IS  - 1025-496X (Print)
IS  - 1025-496X (Linking)
VI  - 24
IP  - 39
DP  - 2019 Sep
TI  - New HIV-1 circulating recombinant form 94: from phylogenetic detection of a large 
      transmission cluster to prevention in the age of geosocial-networking apps in 
      France, 2013 to 2017.
LID - 10.2807/1560-7917.ES.2019.24.39.1800658 [doi]
LID - 1800658
AB  - BackgroundEnding the HIV pandemic must involve new tools to rapidly identify and 
      control local outbreaks and prevent the emergence of recombinant strains with 
      epidemiological advantages.AimThis observational study aimed to investigate in 
      France a cluster of HIV-1 cases related to a new circulating recombinant form (CRF). 
      The confirmation this CRF's novelty as well as measures to control its spread are 
      presented.MethodsPhylogenetic analyses of HIV sequences routinely generated for drug 
      resistance genotyping before 2018 in French laboratories were employed to detect the 
      transmission chain. The CRF involved was characterised by almost full-length viral 
      sequencing for six cases. Cases' clinical data were reviewed. Where possible, 
      epidemiological information was collected with a questionnaire.ResultsThe 
      transmission cluster comprised 49 cases, mostly diagnosed in 2016-2017 (n = 37). All 
      were infected with a new CRF, CRF94_cpx. The molecular proximity of this CRF to X4 
      strains and the high median viraemia, exceeding 5.0 log(10) copies/mL, at diagnosis, 
      even in chronic infection, raise concerns of enhanced virulence. Overall, 41 cases 
      were diagnosed in the Ile-de-France region and 45 were men who have sex with men. 
      Among 24 cases with available information, 20 reported finding partners through a 
      geosocial networking app. Prevention activities in the area and population affected 
      were undertaken.ConclusionWe advocate the systematic use of routinely generated HIV 
      molecular data by a dedicated reactive network, to improve and accelerate targeted 
      prevention interventions. Geosocial networking apps can play a role in the spread of 
      outbreaks, but could also deliver local targeted preventive alerts.
FAU - Wirden, Marc
AU  - Wirden M
AD  - Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé 
      Publique IPLESP, AP-HP, Hôpital Pitié Salpêtrière, Laboratoire de virologie, Paris, 
      France.
FAU - De Oliveira, Fabienne
AU  - De Oliveira F
AD  - Normandie Université, UNIROUEN, EA2656 GRAM, CHU de Rouen, Laboratoire de virologie 
      associé au CNR VIH, Rouen, France.
FAU - Bouvier-Alias, Magali
AU  - Bouvier-Alias M
AD  - HU Henri Mondor, Laboratoire de virologie, Créteil, France.
FAU - Lambert-Niclot, Sidonie
AU  - Lambert-Niclot S
AD  - AP-HP, Hopital Saint-Antoine, Laboratoire de virologie, Paris, France.
FAU - Chaix, Marie-Laure
AU  - Chaix ML
AD  - AP-HP, Hôpital Saint-Louis, Laboratoire de virologie, INSERM U944, Paris, France.
FAU - Raymond, Stéphanie
AU  - Raymond S
AD  - Laboratoire de virologie, CHU Purpan de Toulouse, Toulouse, France.
FAU - Si-Mohammed, Ali
AU  - Si-Mohammed A
AD  - Laboratoire de virologie CHU de Dijon, Dijon, France.
FAU - Alloui, Chakib
AU  - Alloui C
AD  - Laboratoire de virologie, Hôpital Avicenne, Bobigny, France.
FAU - André-Garnier, Elisabeth
AU  - André-Garnier E
AD  - Laboratoire de virologie, CHU Hôtel Dieu, Nantes, France.
FAU - Bellecave, Pantxika
AU  - Bellecave P
AD  - Laboratoire de virologie CHU de Bordeaux, Bordeaux, France.
FAU - Malve, Brice
AU  - Malve B
AD  - Laboratoire de virologie CHU de Nancy, Nancy, France.
FAU - Mirand, Audrey
AU  - Mirand A
AD  - Laboratoire de virologie CHU de Clermont-Ferrand, Clermont-Ferrand, France.
FAU - Pallier, Coralie
AU  - Pallier C
AD  - Laboratoire de virologie, Hôpital P. Brousse, Villejuif, France.
FAU - Poveda, Jean-Dominique
AU  - Poveda JD
AD  - Laboratoire CERBA, Saint-Ouen-l'Aumône, France.
FAU - Rabenja, Theresa
AU  - Rabenja T
AD  - Laboratoire du Grand Hôpital de l'Est Francilien, Jossigny, France.
FAU - Schneider, Veronique
AU  - Schneider V
AD  - Laboratoire de virologie, Hôpital Tenon, Paris, France.
FAU - Signori-Schmuck, Anne
AU  - Signori-Schmuck A
AD  - Laboratoire de virologie CHU de Grenoble, Grenoble, France.
FAU - Stefic, Karl
AU  - Stefic K
AD  - Laboratoire de virologie CHU de Tours, Tours, France.
FAU - Calvez, Vincent
AU  - Calvez V
AD  - Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé 
      Publique IPLESP, AP-HP, Hôpital Pitié Salpêtrière, Laboratoire de virologie, Paris, 
      France.
FAU - Descamps, Diane
AU  - Descamps D
AD  - Laboratoire de virologie, AP-HP, Hopital Bichat Claude Bernard, Univ Paris-Diderot, 
      INSERM, IAME, CNR VIH, Paris, France.
FAU - Plantier, Jean-Christophe
AU  - Plantier JC
AD  - Normandie Université, UNIROUEN, EA2656 GRAM, CHU de Rouen, Laboratoire de virologie 
      associé au CNR VIH, Rouen, France.
FAU - Marcelin, Anne-Genevieve
AU  - Marcelin AG
AD  - Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé 
      Publique IPLESP, AP-HP, Hôpital Pitié Salpêtrière, Laboratoire de virologie, Paris, 
      France.
FAU - Visseaux, Benoit
AU  - Visseaux B
AD  - Laboratoire de virologie, AP-HP, Hopital Bichat Claude Bernard, Univ Paris-Diderot, 
      INSERM, IAME, CNR VIH, Paris, France.
FAU - On Behalf Of The French National Agency For Research On Aids And Viral Hepatitis 
      Anrs Ac Study Group
AU  - On Behalf Of The French National Agency For Research On Aids And Viral Hepatitis 
      Anrs Ac Study Group
AD  - Members are listed in the acknowledgements.
LA  - eng
PT  - Journal Article
PT  - Observational Study
TA  - Euro Surveill
JT  - Euro surveillance : bulletin Europeen sur les maladies transmissibles = European 
      communicable disease bulletin
JID - 100887452
RN  - 0 (DNA, Viral)
SB  - IM
MH  - Adult
MH  - Cluster Analysis
MH  - DNA, Viral/genetics
MH  - Disease Outbreaks/prevention & control
MH  - Drug Resistance, Viral/genetics
MH  - France/epidemiology
MH  - HIV Infections/epidemiology/prevention & control/*transmission/virology
MH  - HIV-1/*classification/*genetics/pathogenicity
MH  - Humans
MH  - Male
MH  - Online Social Networking
MH  - *Phylogeny
MH  - Phylogeography
MH  - *Recombination, Genetic
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Sequence Alignment
MH  - Sexual and Gender Minorities/statistics & numerical data
MH  - Viral Load
MH  - Viremia/virology
MH  - Virulence
MH  - Whole Genome Sequencing
PMC - PMC6774227
OTO - NOTNLM
OT  - HIV CRF94
OT  - HIV Outbreak
OT  - HIV Prevention
OT  - HIV cluster
OT  - phylogenetic analysis
COIS- Conflict of interest: None declared.
EDAT- 2019/10/03 06:00
MHDA- 2020/09/01 06:00
CRDT- 2019/10/03 06:00
PHST- 2019/10/03 06:00 [entrez]
PHST- 2019/10/03 06:00 [pubmed]
PHST- 2020/09/01 06:00 [medline]
AID - 1800658 [pii]
AID - 10.2807/1560-7917.ES.2019.24.39.1800658 [doi]
PST - ppublish
SO  - Euro Surveill. 2019 Sep;24(39):1800658. doi: 
      10.2807/1560-7917.ES.2019.24.39.1800658.

PMID- 27831948
OWN - NLM
STAT- MEDLINE
DCOM- 20180102
LR  - 20180523
IS  - 1473-5571 (Electronic)
IS  - 0269-9370 (Linking)
VI  - 31
IP  - 3
DP  - 2017 Jan 28
TI  - HIV surveillance combining an assay for identification of very recent infection and 
      phylogenetic analyses on dried spots.
PG  - 407-416
LID - 10.1097/QAD.0000000000001325 [doi]
AB  - BACKGROUND: Transmitted/founder viruses isolated at the early stage of infection are 
      indicators of the variants that are spreading within a population. The French 
      reporting system for new HIV diagnoses is linked to a virological surveillance using 
      dried serum spots. METHODS: We combined an immunoassay for very recent infection 
      (less than 31 days) to a phylogenetic analysis of transmitted/founder viruses and 
      sociodemographic information to analyze the dynamics of the HIV-1 epidemic during a 
      3-year period. Bayesian coalescent-based methods were used to explore the temporal 
      and spatial dynamics of the identified clusters. RESULTS: Of 17 010 dried serum 
      spots collected, 549 very recent infections were identified for which both env 
      sequences and sociodemographic data were available. Non-B transmitted/founder 
      viruses were found in 196 cases (35.7%), belonging to six subtypes and seven 
      circulating recombinant forms. Forty-three dyads/clusters were identified (range 
      2-11 cases), including 107 individuals (19.5%), mainly MSM. The largest cluster 
      involved MSM infected by a CRF02_AG variant. Reconstruction of viral migrations 
      across time suggests that Paris was the major hub of dissemination. CONCLUSION: The 
      study shows the feasibility of the surveillance of the HIV epidemic using this 
      methodology. The observation of actively growing spatiotemporal clusters allows 
      identification of specific networks that may be targets for intervention.
FAU - Brand, Denys
AU  - Brand D
AD  - aCentre National de Référence du VIH, Laboratoire de Virologie, CHRU de Tours 
      bInserm U966, Université François-Rabelais cDepartment of Medical Information, 
      Epidemiology and Medical Economy, CHRU de Tours, Tours, France dDivision of 
      Infectious Diseases, San Diego Veterans Affairs Medical Center, University of 
      California San Diego, San Diego, California, USA eInstitut de Veille Sanitaire, 
      Paris, France.
FAU - Capsec, Jean
AU  - Capsec J
FAU - Chaillon, Antoine
AU  - Chaillon A
FAU - Cazein, Françoise
AU  - Cazein F
FAU - Le Vu, Stéphane
AU  - Le Vu S
FAU - Moreau, Alain
AU  - Moreau A
FAU - Pillonel, Josiane
AU  - Pillonel J
FAU - Brunet, Sylvie
AU  - Brunet S
FAU - Thierry, Damien
AU  - Thierry D
FAU - Guillon-Grammatico, Leslie
AU  - Guillon-Grammatico L
FAU - Lot, Florence
AU  - Lot F
FAU - Barin, Francis
AU  - Barin F
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - AIDS
JT  - AIDS (London, England)
JID - 8710219
SB  - IM
MH  - Adult
MH  - Blood/*virology
MH  - *Cluster Analysis
MH  - Disease Transmission, Infectious
MH  - *Epidemiological Monitoring
MH  - France/epidemiology
MH  - Genotype
MH  - HIV Infections/*epidemiology/*transmission
MH  - HIV-1/*classification/genetics/isolation & purification
MH  - Humans
MH  - Male
MH  - Molecular Epidemiology
MH  - *Phylogeny
MH  - Sexual and Gender Minorities
MH  - Spatio-Temporal Analysis
EDAT- 2016/11/11 06:00
MHDA- 2018/01/03 06:00
CRDT- 2016/11/11 06:00
PHST- 2016/11/11 06:00 [pubmed]
PHST- 2018/01/03 06:00 [medline]
PHST- 2016/11/11 06:00 [entrez]
AID - 10.1097/QAD.0000000000001325 [doi]
PST - ppublish
SO  - AIDS. 2017 Jan 28;31(3):407-416. doi: 10.1097/QAD.0000000000001325.

PMID- 26427798
OWN - NLM
STAT- MEDLINE
DCOM- 20160704
LR  - 20181113
IS  - 1756-0500 (Electronic)
IS  - 1756-0500 (Linking)
VI  - 8
DP  - 2015 Oct 1
TI  - Predictors of non-adherence to antihypertensive medication in Kinshasa, Democratic 
      Republic of Congo: a cross-sectional study.
PG  - 526
LID - 10.1186/s13104-015-1519-8 [doi]
LID - 526
AB  - BACKGROUND: Hypertension remains a public health challenge worldwide. In the 
      Democratic Republic of Congo, its prevalence has increased in the past three 
      decades. Higher prevalence of poor blood pressure control and an increasing number 
      of reported cases of complications due to hypertension have also been observed. It 
      is well established that non-adherence to antihypertensive medication contributes to 
      poor control of blood pressure. The aim of this study is to measure non-adherence to 
      antihypertensive medication and to identify its predictors. METHODS: A 
      cross-sectional study was conducted at Kinshasa Primary Health-care network 
      facilities from October to November 2013. A total of 395 hypertensive patients were 
      included in the study. A structured interview was used to collect data. Adherence to 
      medication was assessed using the Morisky Medication Scale. Covariates were defined 
      according to the framework of the World Health Organization. Logistic regression was 
      used to identify predictors of non-adherence. RESULTS: A total of 395 patients 
      participated in this study. The prevalence of non-adherence to antihypertensive 
      medication and blood pressure control was 54.2 % (95 % CI 47.3-61.8) and 15.6 % (95 
      % CI 12.1-20.0), respectively. Poor knowledge of complications of hypertension (OR = 
      2.4; 95 % CI 1.4-4.4), unavailability of antihypertensive drugs in the healthcare 
      facilities (OR = 2.8; 95 % CI 1.4-5.5), lack of hypertensive patients education in 
      the healthcare facilities (OR = 1.7; 95 % CI 1.1-2.7), prior experience of 
      medication side effects (OR = 2.2; 95 % CI 1.4-3.3), uncontrolled blood pressure (OR 
      = 2.0; 95 % CI 1.1-3.9), and taking non-prescribed medications (OR = 2.2; 95 % CI 
      1.2-3.8) were associated with non-adherence to antihypertensive medication. 
      CONCLUSION: This study identified predictors of non-adherence to antihypertensive 
      medication. All predictors identified were modifiable. Interventional studies 
      targeting these predictors for improving adherence are needed.
FAU - Lulebo, Aimée M
AU  - Lulebo AM
AD  - Department of Epidemiology and Bio-statistics, Faculty of Medicine, Kinshasa School 
      of Public Health, University of Kinshasa, PO Box 11850, Kinshasa, DR Congo. 
      aimelulebo@yahoo.fr.
FAU - Mutombo, Paulin B
AU  - Mutombo PB
AD  - Department of Epidemiology and Bio-statistics, Faculty of Medicine, Kinshasa School 
      of Public Health, University of Kinshasa, PO Box 11850, Kinshasa, DR Congo. 
      paulinmutombo2004@yahoo.fr.
FAU - Mapatano, Mala A
AU  - Mapatano MA
AD  - Department of Epidemiology and Bio-statistics, Faculty of Medicine, Kinshasa School 
      of Public Health, University of Kinshasa, PO Box 11850, Kinshasa, DR Congo. 
      mapatanow@espkinshasa.net.
FAU - Mafuta, Eric M
AU  - Mafuta EM
AD  - Department of Epidemiology and Bio-statistics, Faculty of Medicine, Kinshasa School 
      of Public Health, University of Kinshasa, PO Box 11850, Kinshasa, DR Congo. 
      ericmafuta2@gmail.com.
FAU - Kayembe, Patrick K
AU  - Kayembe PK
AD  - Department of Epidemiology and Bio-statistics, Faculty of Medicine, Kinshasa School 
      of Public Health, University of Kinshasa, PO Box 11850, Kinshasa, DR Congo. 
      patkayembe@yahoo.fr.
FAU - Ntumba, Lisa T
AU  - Ntumba LT
AD  - Programme National Multisectoriel de Lutte contre le VIH, Ministère de la Santé, 
      Kinshasa, DR Congo. ntshisau@yahoo.fr.
FAU - Mayindu, Alain N
AU  - Mayindu AN
AD  - Department of Epidemiology, Bio-statistics and Occupational Health, Mc Gill 
      University, Montreal, QC, Canada. doc_mayindu@yahoo.fr.
FAU - Coppieters, Yves
AU  - Coppieters Y
AD  - Ecole de Santé Publique, Université libre de Bruxelles, Brussels, Belgium. 
      yves.coppieters@ulb.ac.be.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20151001
TA  - BMC Res Notes
JT  - BMC research notes
JID - 101462768
RN  - 0 (Antihypertensive Agents)
SB  - IM
MH  - Antihypertensive Agents/*therapeutic use
MH  - Cross-Sectional Studies
MH  - Culture
MH  - Democratic Republic of the Congo
MH  - Female
MH  - Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Hypertension/*drug therapy
MH  - Male
MH  - *Medication Adherence
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Socioeconomic Factors
PMC - PMC4591704
EDAT- 2015/10/03 06:00
MHDA- 2016/07/05 06:00
CRDT- 2015/10/03 06:00
PHST- 2015/05/07 00:00 [received]
PHST- 2015/09/21 00:00 [accepted]
PHST- 2015/10/03 06:00 [entrez]
PHST- 2015/10/03 06:00 [pubmed]
PHST- 2016/07/05 06:00 [medline]
AID - 10.1186/s13104-015-1519-8 [pii]
AID - 1519 [pii]
AID - 10.1186/s13104-015-1519-8 [doi]
PST - epublish
SO  - BMC Res Notes. 2015 Oct 1;8:526. doi: 10.1186/s13104-015-1519-8.

PMID- 26482266
OWN - NLM
STAT- MEDLINE
DCOM- 20161031
LR  - 20170916
IS  - 1469-0691 (Electronic)
IS  - 1198-743X (Linking)
VI  - 22
IP  - 2
DP  - 2016 Feb
TI  - Contribution of APOBEC3G/F activity to the development of low-abundance 
      drug-resistant human immunodeficiency virus type 1 variants.
PG  - 191-200
LID - S1198-743X(15)00903-9 [pii]
LID - 10.1016/j.cmi.2015.10.004 [doi]
AB  - Plasma drug-resistant minority human immunodeficiency virus type 1 variants (DRMVs) 
      increase the risk of virological failure to first-line non-nucleoside reverse 
      transcriptase inhibitor antiretroviral therapy (ART). The origin of DRMVs in 
      ART-naive patients, however, remains unclear. In a large pan-European case-control 
      study investigating the clinical relevance of pre-existing DRMVs using 454 
      pyrosequencing, the six most prevalent plasma DRMVs detected corresponded to G-to-A 
      nucleotide mutations (V90I, V106I, V108I, E138K, M184I and M230I). Here, we 
      evaluated if such DRMVs could have emerged from apolipoprotein B mRNA editing 
      enzyme, catalytic polypeptide 3G/F (APOBEC3G/F) activity. Out of 236 ART-naive 
      subjects evaluated, APOBEC3G/F hypermutation signatures were detected in plasma 
      viruses of 14 (5.9%) individuals. Samples with minority E138K, M184I, and M230I 
      mutations, but not those with V90I, V106I or V108I, were significantly associated 
      with APOBEC3G/F activity (Fisher's P < 0.005), defined as the presence of > 0.5% of 
      sample sequences with an APOBEC3G/F signature. Mutations E138K, M184I and M230I 
      co-occurred in the same sequence as APOBEC3G/F signatures in 3/9 (33%), 5/11 (45%) 
      and 4/8 (50%) of samples, respectively; such linkage was not found for V90I, V106I 
      or V108I. In-frame STOP codons were observed in 1.5% of all clonal sequences; 14.8% 
      of them co-occurred with APOBEC3G/F signatures. APOBEC3G/F-associated E138K, M184I 
      and M230I appeared within clonal sequences containing in-frame STOP codons in 2/3 
      (66%), 5/5 (100%) and 4/4 (100%) of the samples. In a re-analysis of the parent case 
      control study, the presence of APOBEC3G/F signatures was not associated with 
      virological failure. In conclusion, the contribution of APOBEC3G/F editing to the 
      development of DRMVs is very limited and does not affect the efficacy of 
      non-nucleoside reverse transcriptase inhibitor ART.
CI  - Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases. 
      Published by Elsevier Ltd. All rights reserved.
FAU - Noguera-Julian, M
AU  - Noguera-Julian M
AD  - Institut de Recerca de la SIDA IrsiCaixa i Unitat VIH, Universitat Autònoma de 
      Barcelona, Universitat de Vic, Catalonia, Spain. Electronic address: 
      mnoguera@irsicaixa.es.
FAU - Cozzi-Lepri, A
AU  - Cozzi-Lepri A
AD  - University College London, London, UK.
FAU - Di Giallonardo, F
AU  - Di Giallonardo F
AD  - Division of Infectious Diseases and Hospital Epidemiology, University Hospital 
      Zurich, University of Zurich, Zurich, Switzerland.
FAU - Schuurman, R
AU  - Schuurman R
AD  - Department of Virology, University Medical Centre, Utrecht, The Netherlands.
FAU - Däumer, M
AU  - Däumer M
AD  - Institut für Immunologie und Genetik, Kaiserslautern, Germany.
FAU - Aitken, S
AU  - Aitken S
AD  - Department of Virology, University Medical Centre, Utrecht, The Netherlands.
FAU - Ceccherini-Silberstein, F
AU  - Ceccherini-Silberstein F
AD  - Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, 
      Rome, Italy.
FAU - D'Arminio Monforte, A
AU  - D'Arminio Monforte A
AD  - Department of Health Sciences, Clinic of Infectious Diseases, 'San Paolo' Hospital, 
      University of Milan, Milan, Italy.
FAU - Geretti, A M
AU  - Geretti AM
AD  - Institute of Infection & Global Health, University of Liverpool, Liverpool, UK.
FAU - Booth, C L
AU  - Booth CL
AD  - Department of Virology, Royal Free London NHS Foundation Trust, London, UK.
FAU - Kaiser, R
AU  - Kaiser R
AD  - Institute of Virology, University of Cologne, Cologne, Germany.
FAU - Michalik, C
AU  - Michalik C
AD  - Competence Network for HIV/AIDS, Bochum, Germany; Clinic for Dermatology, 
      Venereology and Allergology of the Ruhr-Universität, Bochum, Germany; Clinical Trial 
      Centre (ZKS), University Cologne, Germany.
FAU - Jansen, K
AU  - Jansen K
AD  - Competence Network for HIV/AIDS, Bochum, Germany; Clinic for Dermatology, 
      Venereology and Allergology of the Ruhr-Universität, Bochum, Germany.
FAU - Masquelier, B
AU  - Masquelier B
AD  - Laboratoire de Virologie, CHU de Bordeaux and MFP-UMR5234, Universite Bordeaux 2, 
      Bordeaux, France.
FAU - Bellecave, P
AU  - Bellecave P
AD  - Laboratoire de Virologie, CHU de Bordeaux and MFP-UMR5234, Universite Bordeaux 2, 
      Bordeaux, France.
FAU - Kouyos, R D
AU  - Kouyos RD
AD  - Division of Infectious Diseases and Hospital Epidemiology, University Hospital 
      Zurich, University of Zurich, Zurich, Switzerland.
FAU - Castro, E
AU  - Castro E
AD  - Addiction Medicine, Service of Community Psychiatry, Centre Hospitalier 
      Universitaire Vaudois, Lausanne, Switzerland.
FAU - Furrer, H
AU  - Furrer H
AD  - Department of Infectious Diseases, Bern University Hospital and University of Bern, 
      Bern, Switzerland.
FAU - Schultze, A
AU  - Schultze A
AD  - University College London, London, UK.
FAU - Günthard, H F
AU  - Günthard HF
AD  - Division of Infectious Diseases and Hospital Epidemiology, University Hospital 
      Zurich, University of Zurich, Zurich, Switzerland; Institute of Medical Virology, 
      University of Zurich, Zurich, Switzerland.
FAU - Brun-Vezinet, F
AU  - Brun-Vezinet F
AD  - Department of Virology, Bichat University Hospital, Paris7, France.
FAU - Metzner, K J
AU  - Metzner KJ
AD  - Division of Infectious Diseases and Hospital Epidemiology, University Hospital 
      Zurich, University of Zurich, Zurich, Switzerland; Institute of Medical Virology, 
      University of Zurich, Zurich, Switzerland.
FAU - Paredes, R
AU  - Paredes R
AD  - Institut de Recerca de la SIDA IrsiCaixa i Unitat VIH, Universitat Autònoma de 
      Barcelona, Universitat de Vic, Catalonia, Spain.
CN  - CHAIN Minority HIV-1 Variants Working group
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20151023
PL  - England
TA  - Clin Microbiol Infect
JT  - Clinical microbiology and infection : the official publication of the European 
      Society of Clinical Microbiology and Infectious Diseases
JID - 9516420
RN  - 0 (RNA, Viral)
RN  - 0 (Reverse Transcriptase Inhibitors)
RN  - EC 3.5.4.1 (APOBEC3F protein, human)
RN  - EC 3.5.4.1 (Cytosine Deaminase)
RN  - EC 3.5.4.5 (APOBEC-3G Deaminase)
RN  - EC 3.5.4.5 (APOBEC3G protein, human)
RN  - EC 3.5.4.5 (Cytidine Deaminase)
SB  - IM
MH  - APOBEC-3G Deaminase
MH  - Antiretroviral Therapy, Highly Active
MH  - Case-Control Studies
MH  - Cytidine Deaminase/*genetics
MH  - Cytosine Deaminase/*genetics
MH  - *Drug Resistance, Viral
MH  - Female
MH  - HIV Infections/drug therapy/metabolism/*virology
MH  - HIV-1/*genetics
MH  - Humans
MH  - Male
MH  - *Mutation
MH  - RNA Editing
MH  - RNA, Viral/genetics/metabolism
MH  - Reverse Transcriptase Inhibitors/therapeutic use
OTO - NOTNLM
OT  - APOBEC3
OT  - NNRTI resistance
OT  - human immunodeficiency virus type 1
OT  - minority variants
OT  - resistance
FIR - Paredes, Roger
IR  - Paredes R
FIR - Metzner, Karin J
IR  - Metzner KJ
FIR - Cozzi-Lepri, Alessandro
IR  - Cozzi-Lepri A
FIR - Schuurman, Rob
IR  - Schuurman R
FIR - Brun-Vezinet, Francoise
IR  - Brun-Vezinet F
FIR - Günthard, Huldrych
IR  - Günthard H
FIR - Ceccherini-Silberstein, Francesca
IR  - Ceccherini-Silberstein F
FIR - Kaiser, Rolf
IR  - Kaiser R
FIR - Geretti, Anna Maria
IR  - Geretti AM
FIR - Brockmeyer, Norbert
IR  - Brockmeyer N
FIR - Masquelier, Bernard
IR  - Masquelier B
EDAT- 2015/10/21 06:00
MHDA- 2016/11/01 06:00
CRDT- 2015/10/21 06:00
PHST- 2015/05/13 00:00 [received]
PHST- 2015/09/07 00:00 [revised]
PHST- 2015/10/03 00:00 [accepted]
PHST- 2015/10/21 06:00 [entrez]
PHST- 2015/10/21 06:00 [pubmed]
PHST- 2016/11/01 06:00 [medline]
AID - S1198-743X(15)00903-9 [pii]
AID - 10.1016/j.cmi.2015.10.004 [doi]
PST - ppublish
SO  - Clin Microbiol Infect. 2016 Feb;22(2):191-200. doi: 10.1016/j.cmi.2015.10.004. Epub 
      2015 Oct 23.

PMID- 27753681
OWN - NLM
STAT- MEDLINE
DCOM- 20180913
LR  - 20181202
IS  - 1473-5571 (Electronic)
IS  - 0269-9370 (Linking)
VI  - 30
IP  - 16
DP  - 2016 Oct 23
TI  - First report of transmission of a highly resistant strain of HIV-1 group O.
PG  - 2565-2568
FAU - Unal, Guillemette
AU  - Unal G
AD  - aLaboratoire de Virologie, associé au Centre National de Référence du VIH, CHU 
      Charles Nicolle, Rouen bFaculté de Médecine Paris Sud; INSERM U1018, Centre de 
      recherche en Epidémiologie et Santé des Populations, Université Paris Sud, Le 
      Kremlin Bicêtre cGroupe de Recherche sur les Antimicrobiens et les Micro-organismes 
      (GRAM), Institut pour la Recherche et l'Innovation en Biome'decine (IRIB), 
      Université de Rouen Normandie, Rouen dLaboratoire de Virologie et de Bactériologie 
      eServices des maladies infectieuses, CHU Angers, Angers, France fDépartement de 
      Microbiologie et Infectiologie, Faculté de médecine de l'Université de Montréal, 
      Montréal, Québec, Canada.
FAU - Mourez, Thomas
AU  - Mourez T
FAU - Leoz, Marie
AU  - Leoz M
FAU - Alessandri-Gradt, Elodie
AU  - Alessandri-Gradt E
FAU - Le Guillou-Guillemette, Hélène
AU  - Le Guillou-Guillemette H
FAU - Chennebault, Jean-Marie
AU  - Chennebault JM
FAU - Depatureaux, Agnès
AU  - Depatureaux A
FAU - Meyer, Laurence
AU  - Meyer L
FAU - Plantier, Jean-Christophe
AU  - Plantier JC
CN  - RES-O Surveillance Network
LA  - eng
PT  - Case Reports
PT  - Letter
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - AIDS
JT  - AIDS (London, England)
JID - 8710219
RN  - 0 (Anti-HIV Agents)
RN  - EC 2.7.7.- (reverse transcriptase, Human immunodeficiency virus 1)
RN  - EC 2.7.7.49 (HIV Reverse Transcriptase)
RN  - EC 3.4.- (Peptide Hydrolases)
SB  - IM
MH  - Anti-HIV Agents/*therapeutic use
MH  - Drug Resistance, Multiple, Viral/*genetics
MH  - Fatal Outcome
MH  - Female
MH  - Genetic Association Studies
MH  - HIV Infections/drug therapy/*transmission/*virology
MH  - HIV Reverse Transcriptase/genetics
MH  - HIV-1/*classification/drug effects/genetics
MH  - Humans
MH  - Male
MH  - Peptide Hydrolases/genetics
MH  - Phylogeny
MH  - Spouses
EDAT- 2016/10/19 06:00
MHDA- 2018/09/14 06:00
CRDT- 2016/10/19 06:00
PHST- 2016/10/19 06:00 [pubmed]
PHST- 2018/09/14 06:00 [medline]
PHST- 2016/10/19 06:00 [entrez]
AID - 00002030-201610230-00020 [pii]
AID - 10.1097/QAD.0000000000001253 [doi]
PST - ppublish
SO  - AIDS. 2016 Oct 23;30(16):2565-2568. doi: 10.1097/QAD.0000000000001253.

PMID- 23578527
OWN - NLM
STAT- MEDLINE
DCOM- 20140519
LR  - 20161020
IS  - 1578-1283 (Electronic)
IS  - 0213-9111 (Linking)
VI  - 27
IP  - 4
DP  - 2013 Jul-Aug
TI  - Gender differences in HIV risk behaviours among intravenous drug users in Catalonia, 
      Spain.
PG  - 338-43
LID - S0213-9111(13)00048-4 [pii]
LID - 10.1016/j.gaceta.2013.02.006 [doi]
AB  - OBJECTIVE: To describe gender differences in injection and sexual risks behaviours, 
      and human immunodeficiency virus (HIV) and hepatitis C (HCV) prevalence among 
      injecting drug users (IDU) in Catalonia, Spain. METHODS: Cross-sectional studies in 
      2008-2009 (n=748) and 2010-2011 (n=597) in the network of harm reduction centres. 
      Face to face interviews were conducted and oral fluid samples were collected to 
      estimate HIV/HCV prevalence. RESULTS: Female were more likely than male IDU to have 
      had a steady sexual partner (68.2% versus 44.9%), to have had an IDU steady sexual 
      partner (46.6% versus 15.1%) and to have exchanged sex for money or drugs in the 
      last 6 months (25.5% versus 2.3%). There were no gender differences in injecting 
      risk behaviours. HIV prevalence was 38.7% (91/235) in women and 31.5% (347/1103) in 
      men (p=0.031). HIV prevalence among female IDU who reported having exchange sex for 
      money or drugs was 53.3% (32/60). The prevalence of HCV was 67.4% (159/236) and 
      73.6% (810/1101) in female and male IDU, respectively (p=0.053). After adjustment by 
      immigrant status, age and years of injection, differences among HIV/HCV prevalence 
      by gender were not significant. CONCLUSIONS: This study demonstrated differences in 
      sexual risk behaviours between male and female IDU, but failed to find gender 
      differences in injecting risk behaviours. Apart from that, the higher prevalence of 
      HIV among women than among men, together with a lower prevalence of HCV, provides 
      evidence that sexual transmission of HIV is important among female IDU. Additional 
      studies are needed to analyze in-depth these specific risk factors for women in 
      order to develop appropriate prevention and health education programs.
CI  - Copyright © 2012 SESPAS. Published by Elsevier Espana. All rights reserved.
FAU - Folch, Cinta
AU  - Folch C
AD  - Centre d'Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de 
      Catalunya CEEISCAT, Institut català d'Oncologia ICO, Agència de Salut Pública de 
      Catalunya ASPC, Generalitat de Catalunya, Badalona, Barcelona, Spain. 
      cfolch@iconcologia.net
FAU - Casabona, Jordi
AU  - Casabona J
FAU - Espelt, Albert
AU  - Espelt A
FAU - Majó, Xavier
AU  - Majó X
FAU - Meroño, Mercè
AU  - Meroño M
FAU - Gonzalez, Victoria
AU  - Gonzalez V
FAU - Brugal, Maria Teresa
AU  - Brugal MT
CN  - REDAN Study Group
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130408
PL  - Spain
TA  - Gac Sanit
JT  - Gaceta sanitaria
JID - 8901623
SB  - IM
MH  - Adult
MH  - Cross-Sectional Studies
MH  - Drug Users
MH  - Female
MH  - *HIV Infections/epidemiology
MH  - *Hepatitis C/epidemiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prevalence
MH  - *Risk-Taking
MH  - Sex Factors
MH  - *Sexual Behavior
MH  - Spain
MH  - Substance Abuse, Intravenous/epidemiology/*psychology
OTO - NOTNLM
OT  - Abuso de sustancias
OT  - Conductas de riesgo
OT  - Gender
OT  - Género
OT  - HIV
OT  - Hepatitis C
OT  - Intravenous injection
OT  - Risk behaviours
OT  - Substance abuse
OT  - Usuarios de drogas por vía parenteral
OT  - VIH
EDAT- 2013/04/13 06:00
MHDA- 2014/05/20 06:00
CRDT- 2013/04/13 06:00
PHST- 2012/12/03 00:00 [received]
PHST- 2013/02/14 00:00 [revised]
PHST- 2013/02/20 00:00 [accepted]
PHST- 2013/04/13 06:00 [entrez]
PHST- 2013/04/13 06:00 [pubmed]
PHST- 2014/05/20 06:00 [medline]
AID - S0213-9111(13)00048-4 [pii]
AID - 10.1016/j.gaceta.2013.02.006 [doi]
PST - ppublish
SO  - Gac Sanit. 2013 Jul-Aug;27(4):338-43. doi: 10.1016/j.gaceta.2013.02.006. Epub 2013 
      Apr 8.

PMID- 20381210
OWN - NLM
STAT- MEDLINE
DCOM- 20110224
LR  - 20191210
IS  - 1578-1852 (Electronic)
IS  - 0213-005X (Linking)
VI  - 28
IP  - 8
DP  - 2010 Oct
TI  - [Scientific productivity, collaboration and research areas in Enfermedades 
      Infecciosas y Microbiología Clínica (2003-2007)].
PG  - 509-16
LID - 10.1016/j.eimc.2009.12.011 [doi]
AB  - INTRODUCTION: Collaboration is essential for biomedical research. The Carlos III 
      Health Institute (the Spanish national public organization responsible for promoting 
      biomedical research) has encouraged scientific collaboration by promoting Thematic 
      Networks and Cooperative Research Centres. Scientific collaboration in Enfermedades 
      Infecciosas y Microbiología Clinica journal is investigated. METHODS: Papers 
      published in Enfermedades Infecciosas y Microbiología Clinica in the period 
      2002-2007 have been identified. Bibliometrics and Social Network Analysis methods 
      have been carried out in order to quantify and characterise scientific collaboration 
      and research areas. RESULTS: A total of 805 papers generated by 2,289 authors and 
      326 institutions have been analysed. There were 36 research groups involving 138 
      authors identified. The Collaboration Index for articles was 5.5. Institutional 
      collaboration was determined in 75% of articles. The collaboration between 
      departments or units of the same institution prevails (43%), followed by 
      intra-regional domestic collaboration (41%) and inter-regional domestic 
      collaboration (14%). Hospital centres were the main institutional sector responsible 
      of research (88% of papers), with 68% of articles cited. Sida/VIH (AIDS/HIV) is the 
      main research area (n=114), followed by Staphylococcal Infections (n=33). 
      CONCLUSIONS: Notable collaboration and citation rates have been observed. Research 
      is focused on diseases with the highest mortality rates caused by infectious 
      diseases in Spain.
CI  - Copyright © 2009 Elsevier España, S.L. All rights reserved.
FAU - González-Alcaide, Gregorio
AU  - González-Alcaide G
AD  - Instituto de Historia de la Medicina y de la Ciencia López Piñero, Departamento de 
      Historia de la Ciencia y Documentación, Universitat de València-Consejo Superior de 
      Investigaciones Científicas, Valencia, España. gregorio.gonzalez@uv.es
FAU - Valderrama-Zurián, Juan Carlos
AU  - Valderrama-Zurián JC
FAU - Ramos-Rincón, José Manuel
AU  - Ramos-Rincón JM
LA  - spa
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
TT  - Producción científica, colaboración y ámbitos de investigación en Enfermedades 
      Infecciosas y Microbiología Clínica (2003-2007).
DEP - 20100408
PL  - Spain
TA  - Enferm Infecc Microbiol Clin
JT  - Enfermedades infecciosas y microbiologia clinica
JID - 9104081
SB  - IM
MH  - *Bibliometrics
MH  - *Biomedical Research
MH  - Humans
MH  - *Infections
MH  - *Microbiology
MH  - Periodicals as Topic/*statistics & numerical data
MH  - Publishing/*statistics & numerical data
EDAT- 2010/04/13 06:00
MHDA- 2011/02/25 06:00
CRDT- 2010/04/13 06:00
PHST- 2009/09/24 00:00 [received]
PHST- 2009/11/25 00:00 [revised]
PHST- 2009/12/04 00:00 [accepted]
PHST- 2010/04/13 06:00 [entrez]
PHST- 2010/04/13 06:00 [pubmed]
PHST- 2011/02/25 06:00 [medline]
AID - S0213-005X(10)00080-7 [pii]
AID - 10.1016/j.eimc.2009.12.011 [doi]
PST - ppublish
SO  - Enferm Infecc Microbiol Clin. 2010 Oct;28(8):509-16. doi: 
      10.1016/j.eimc.2009.12.011. Epub 2010 Apr 8.

PMID- 20646884
OWN - NLM
STAT- MEDLINE
DCOM- 20110516
LR  - 20181201
IS  - 1769-6690 (Electronic)
IS  - 0399-077X (Linking)
VI  - 40
IP  - 12
DP  - 2010 Dec
TI  - [Specific diagnosis and follow-up of HIV-1 group O infection: RES-O data].
PG  - 669-76
LID - 10.1016/j.medmal.2010.04.011 [doi]
AB  - INTRODUCTION: HIV-1 group O (HIV-O), mainly found in Cameroon, has a very high 
      genetic diversity with consequences on the diagnosis and treatment of patients, 
      requiring the development of specific tools. OBJECTIVE: We present the currently 
      available tools for the specific detection of HIV-O and its therapeutic monitoring, 
      and the first RES-O data, a French network for the identification and monitoring of 
      patients infected by HIV-O. METHOD: The diagnosis of infection was confirmed by 
      group-specific envelope serotyping. The viral load was assessed by a specific 
      technique, LTR-O, developed in the laboratory and compared to the nonspecific kit 
      RealTime HIV-1 (Abbott). The sequencing of antiretroviral target regions (Protease, 
      Reverse Transcriptase (RT), Integrase and Gp41), was performed by specific primers. 
      The analysis of resistance mutations was performed with the ANRS algorithm used for 
      HIV-M. RESULTS: HIV-O infection was confirmed for 117 patients. Measuring viral load 
      showed the two techniques were equivalent, but with a tendency to 
      under-quantification for the Abbott technique greater than 1 log for 5% of samples. 
      70 to 100% of the studied strains had at least 10 mutations in the Protease, four 4 
      in the RT, and one in Gp41, resulting in a natural genotypic resistance to some 
      anti-retroviral molecules. DISCUSSION: The diagnosis and monitoring of HIV-O 
      infection is now possible. However, the impact of this variant's natural 
      polymorphism on response to treatment remains undocumented.
CI  - Copyright © 2010 Elsevier Masson SAS. All rights reserved.
FAU - Depatureaux, A
AU  - Depatureaux A
AD  - Laboratoire associé au CNR du VIH, EA 2656, CHU Charles-Nicolle, 76031 Rouen, 
      France.
FAU - Leoz, M
AU  - Leoz M
FAU - De Oliveira, F
AU  - De Oliveira F
FAU - Gueudin, M
AU  - Gueudin M
FAU - Damond, F
AU  - Damond F
FAU - Descamps, D
AU  - Descamps D
FAU - Brun-Vézinet, F
AU  - Brun-Vézinet F
FAU - Lemée, V
AU  - Lemée V
FAU - Simon, F
AU  - Simon F
FAU - Barin, F
AU  - Barin F
FAU - Plantier, J-C
AU  - Plantier JC
LA  - fre
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
TT  - Diagnostic spécifique et prise en charge des infections par un VIH-1 groupe O: 
      données de RES-O.
DEP - 20100619
PL  - France
TA  - Med Mal Infect
JT  - Medecine et maladies infectieuses
JID - 0311416
RN  - 0 (Anti-HIV Agents)
RN  - 0 (HIV Envelope Protein gp41)
RN  - 0 (Reagent Kits, Diagnostic)
RN  - 0 (gp41 protein, Human immunodeficiency virus 1)
RN  - EC 2.7.7.- (HIV Integrase)
RN  - EC 2.7.7.- (reverse transcriptase, Human immunodeficiency virus 1)
RN  - EC 2.7.7.49 (HIV Reverse Transcriptase)
RN  - EC 3.4.23.- (HIV Protease)
RN  - EC 3.4.23.- (p16 protease, Human immunodeficiency virus 1)
RN  - YY6481J2FF (p31 integrase protein, Human immunodeficiency virus 1)
SB  - IM
MH  - Africa, Western/ethnology
MH  - Anti-HIV Agents/pharmacology/therapeutic use
MH  - Computer Systems
MH  - Databases, Factual/*statistics & numerical data
MH  - Drug Resistance, Multiple, Viral/genetics
MH  - France/epidemiology
MH  - *Genes, env
MH  - *Genes, pol
MH  - Genetic Variation
MH  - Genotype
MH  - HIV Envelope Protein gp41/genetics
MH  - HIV Infections/*diagnosis/drug therapy/epidemiology/virology
MH  - HIV Integrase/genetics
MH  - HIV Protease/genetics
MH  - HIV Reverse Transcriptase/genetics
MH  - HIV-1/*classification/genetics/isolation & purification
MH  - Humans
MH  - Mutation
MH  - Phylogeny
MH  - Polymorphism, Genetic
MH  - Reagent Kits, Diagnostic
MH  - Sequence Analysis, RNA
MH  - Serotyping
EDAT- 2010/07/22 06:00
MHDA- 2011/05/17 06:00
CRDT- 2010/07/22 06:00
PHST- 2009/10/31 00:00 [received]
PHST- 2010/01/04 00:00 [revised]
PHST- 2010/04/21 00:00 [accepted]
PHST- 2010/07/22 06:00 [entrez]
PHST- 2010/07/22 06:00 [pubmed]
PHST- 2011/05/17 06:00 [medline]
AID - S0399-077X(10)00113-7 [pii]
AID - 10.1016/j.medmal.2010.04.011 [doi]
PST - ppublish
SO  - Med Mal Infect. 2010 Dec;40(12):669-76. doi: 10.1016/j.medmal.2010.04.011. Epub 2010 
      Jun 19.

PMID- 25145557
OWN - NLM
STAT- MEDLINE
DCOM- 20141204
LR  - 20141008
IS  - 1365-3156 (Electronic)
IS  - 1360-2276 (Linking)
VI  - 19
IP  - 11
DP  - 2014 Nov
TI  - Decline in overall, smear-negative and HIV-positive TB incidence while 
      smear-positive incidence stays stable in Guinea-Bissau 2004-2011.
PG  - 1367-76
LID - 10.1111/tmi.12378 [doi]
AB  - OBJECTIVE: To calculate Tuberculosis (TB) incidence rates in Guinea-Bissau over an 
      8-year period. METHODS: Since 2003, a surveillance system has registered all TB 
      cases in six suburban districts of Bissau. In this population-based prospective 
      follow-up study, 1205 cases of pulmonary TB were identified between January 2004 and 
      December 2011. Incidence rates were calculated using census data from the Bandim 
      Health and Demographic Surveillance System (HDSS). RESULTS: The overall incidence of 
      pulmonary TB was 279 per 100,000 person-years of observation; the male incidence 
      being 385, and the female 191. TB incidence rates increased significantly with age 
      in both sexes, regardless of smear or HIV status. Despite a peak with unknown cause 
      of 352 per 100,000 in 2007, the overall incidence of pulmonary TB declined over the 
      period. The incidence of HIV infected TB cases declined significantly from 108 to 39 
      per 100,000, while the incidence of smear-positive TB cases remained stable; the 
      overall figure was 188 per 100,000. CONCLUSIONS: Overall incidence of pulmonary TB 
      in Guinea-Bissau has declined from 2004 to 2011. The decline was also seen in the 
      subgroups of smear-negative and HIV-positive TB cases, probably due to 
      antiretroviral treatment. Smear-positive TB incidence remains stable over the 
      period.
CI  - © 2014 John Wiley & Sons Ltd.
FAU - Lemvik, G
AU  - Lemvik G
AD  - Bandim Health Project, INDEPTH network, Bissau, Guinea-Bissau; Bandim Health 
      Project, Statens Serum Institut, Copenhagen, Denmark; Department of Infectious 
      Diseases, Aarhus University Hospital, Aarhus, Denmark.
FAU - Rudolf, F
AU  - Rudolf F
FAU - Vieira, F
AU  - Vieira F
FAU - Sodemann, M
AU  - Sodemann M
FAU - Østergaard, L
AU  - Østergaard L
FAU - Rodrigues, A
AU  - Rodrigues A
FAU - Gomes, V
AU  - Gomes V
FAU - Aaby, P
AU  - Aaby P
FAU - Wejse, C
AU  - Wejse C
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140822
PL  - England
TA  - Trop Med Int Health
JT  - Tropical medicine & international health : TM & IH
JID - 9610576
RN  - 0 (Antitubercular Agents)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age Distribution
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Antitubercular Agents/*therapeutic use
MH  - Comorbidity
MH  - Female
MH  - Follow-Up Studies
MH  - Guinea-Bissau/epidemiology
MH  - HIV Seropositivity/*epidemiology
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Mycobacterium tuberculosis/drug effects
MH  - Prospective Studies
MH  - Sex Distribution
MH  - Tuberculosis, Pulmonary/diagnosis/*drug therapy/*epidemiology
MH  - Young Adult
OTO - NOTNLM
OT  - Africa South of the Sahara
OT  - Afrique subsaharienne
OT  - Guinea-Bissau
OT  - Guinée-Bissau
OT  - HIV
OT  - Incidencia
OT  - Tuberculosis
OT  - VIH
OT  - crachat
OT  - esputo
OT  - incidence
OT  - sputum
OT  - tuberculose
OT  - tuberculosis
OT  - África al Sur del Sahara
EDAT- 2014/08/26 06:00
MHDA- 2014/12/15 06:00
CRDT- 2014/08/23 06:00
PHST- 2014/08/23 06:00 [entrez]
PHST- 2014/08/26 06:00 [pubmed]
PHST- 2014/12/15 06:00 [medline]
AID - 10.1111/tmi.12378 [doi]
PST - ppublish
SO  - Trop Med Int Health. 2014 Nov;19(11):1367-76. doi: 10.1111/tmi.12378. Epub 2014 Aug 
      22.

PMID- 29283272
OWN - NLM
STAT- MEDLINE
DCOM- 20190605
LR  - 20190605
IS  - 1943-2755 (Electronic)
IS  - 0899-9546 (Linking)
VI  - 29
IP  - 6
DP  - 2017 Dec
TI  - "Oh, I'm Not Alone": Experiences of HIV-Positive Men Who Have Sex With Men in a 
      Health Navigation Program to Promote Timely Linkage to Care in Guatemala City.
PG  - 554-566
LID - 10.1521/aeap.2017.29.6.554 [doi]
AB  - Men who have sex with men (MSM) are disproportionately affected by HIV in Guatemala 
      and may benefit from health navigation programs designed to support timely linkage 
      to HIV care. We conducted qualitative in-depth interviews with MSM (n = 19) linked 
      to care within days of their diagnosis with the support of a health navigator. We 
      used narrative analysis and systematic coding to identify themes related to HIV 
      diagnosis and experiences with navigators. Participants experienced strong feelings 
      of fear upon receiving a positive HIV test result. This fear led to social isolation 
      and limited reliance on family and friend networks for support. Health navigators 
      developed strong relationships with participants by providing the emotional support 
      they were lacking and supporting them to overcome their fear and other structural 
      barriers to HIV care, including stigma. Findings support the important role of 
      navigation for MSM in Guatemala and could be transferable to other settings in Latin 
      America.
FAU - Davis, Dirk A
AU  - Davis DA
AD  - Department of Health Behavior, Gillings School of Global Public Health, University 
      of North Carolina, Chapel Hill.
FAU - Aguilar, Jose Manuel
AU  - Aguilar JM
AD  - HIV Unit, Centre for Health Studies, Del Valle University of Guatemala, Guatemala 
      City, Guatemala.
AD  - Colectivo Amigos Contra el SIDS (CAS), Guatemala City, Guatemala.
FAU - Arandi, Cesar Galindo
AU  - Arandi CG
AD  - HIV Unit, Centre for Health Studies, Del Valle University of Guatemala, Guatemala 
      City, Guatemala.
AD  - Colectivo Amigos Contra el SIDS (CAS), Guatemala City, Guatemala.
FAU - Northbrook, Sanny
AU  - Northbrook S
AD  - U.S. Centers for Disease Control and Prevention (CDC) Central America Region, 
      Guatemala City, Guatemala.
FAU - Loya-Montiel, M Itzel
AU  - Loya-Montiel MI
AD  - HIV Unit, Centre for Health Studies, Del Valle University of Guatemala, Guatemala 
      City, Guatemala.
FAU - Morales-Miranda, Sonia
AU  - Morales-Miranda S
AD  - Consorcio de Investigación sobre VIH SIDA TB (CISIDAT), Cuernavaca, Mexico.
FAU - Barrington, Clare
AU  - Barrington C
AD  - Department of Health Behavior, Gillings School of Global Public Health, University 
      of North Carolina, Chapel Hill.
LA  - eng
GR  - PEPFAR/PEPFAR/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - AIDS Educ Prev
JT  - AIDS education and prevention : official publication of the International Society 
      for AIDS Education
JID - 9002873
SB  - IM
MH  - Adult
MH  - Fear
MH  - Guatemala
MH  - HIV Infections/diagnosis/*drug therapy/prevention & control/*psychology
MH  - *Health Services Accessibility
MH  - Homosexuality, Male/*psychology/statistics & numerical data
MH  - Humans
MH  - Interviews as Topic
MH  - Male
MH  - Patient Acceptance of Health Care
MH  - *Patient Navigation
MH  - Qualitative Research
MH  - Social Isolation
MH  - *Social Stigma
EDAT- 2017/12/29 06:00
MHDA- 2019/06/06 06:00
CRDT- 2017/12/29 06:00
PHST- 2017/12/29 06:00 [entrez]
PHST- 2017/12/29 06:00 [pubmed]
PHST- 2019/06/06 06:00 [medline]
AID - 10.1521/aeap.2017.29.6.554 [doi]
PST - ppublish
SO  - AIDS Educ Prev. 2017 Dec;29(6):554-566. doi: 10.1521/aeap.2017.29.6.554.

PMID- 24903942
OWN - NLM
STAT- MEDLINE
DCOM- 20150202
LR  - 20140606
IS  - 1815-7920 (Electronic)
IS  - 1027-3719 (Linking)
VI  - 18
IP  - 6
DP  - 2014 Jun
TI  - Tuberculosis in a cohort of HIV-positive patients: epidemiology, clinical practice 
      and treatment outcomes.
PG  - 700-8
LID - 10.5588/ijtld.13.0778 [doi]
AB  - OBJECTIVE: To describe tuberculosis (TB) incidence, risk factors, clinical 
      presentation, disease management and outcomes in human immunodeficiency virus (HIV) 
      infected patients from the CoRIS cohort, Spain, 2004-2010. DESIGN: Open multicentre 
      cohort of antiretroviral treatment (ART) naïve patients at entry. Incidence and risk 
      factors were evaluated using multivariate Poisson regression. RESULTS: Among 6811 
      patients, 271 were eligible for the study and 198 for the estimation of the 
      incidence rate; TB incidence ranged from 12.1 to 14.1/1000 person-years. TB was 
      associated with low education level (rate ratio [RR] 2.65, 95%CI 1.73-4.07), being 
      sub-Saharan African (RR 3.14, 95%CI 1.81-5.45), heterosexual (RR 2.01, 95%CI 
      1.22-3.29) or an injecting drug user (RR 2.11, 95%CI 1.20-3.69), not undergoing ART 
      (RR 3.33, 95%CI 2.22-4.76), CD4 <200 cells/mm(3) (RR 5.20, 95%CI 3.25-8.33) and 
      log-viral load of 4-5 (RR 5.44, 95%CI 3.28-9.02) or >5 (RR 13.10, 95%CI 8.27-20.76). 
      Overall, 87% were new cases and 13% were previously treated cases; 175 (65%) were 
      bacteriologically confirmed. Drug susceptibility testing was performed in 146 (83%) 
      patients: resistance to first-line drugs was 11.1% in new and 36.4% in previously 
      treated cases. Standard anti-tuberculosis treatment with four or three drugs was 
      prescribed in respectively 55% and 36% of cases. Treatment default was 11%, and was 
      higher among previously treated cases; 80% received ART during anti-tuberculosis 
      treatment, 80% of new and 50% of previously treated cases were cured or completed 
      treatment, and 18 (6.6%) died. CONCLUSION: TB incidence in HIV-infected patients 
      remains high. Interventions should include early HIV diagnosis and access to ART, 
      enhanced bacteriological confirmation, wider use of four-drug regimens and reduction 
      in treatment default.
FAU - Monge, S
AU  - Monge S
AD  - Red de Investigación en Sida, Centro Nacional de Epidemiología, CIBER de 
      Epidemiología y Salud Pública (CIBERESP), Spain.
FAU - Diez, M
AU  - Diez M
AD  - Aacute;rea de Vigilancia Epidemiológica del VIH/SIDA y Comportamientos de Riesgo, 
      Plan Nacional sobre el SIDA, Ministerio de Sanidad, Servicios Sociales e 
      Igualdad/Centro Nacional de Epidemiología, Instituto de Salud Carlos III and 
      CIBERESP Madrid, Spain.
FAU - Pulido, F
AU  - Pulido F
AD  - Hospital Universitario 12 de Octubre, Madrid, Spain.
FAU - Iribarren, J A
AU  - Iribarren JA
AD  - Hospital Universitario de Donostia, San Sebastián, Spain.
FAU - Campins, A A
AU  - Campins AA
AD  - Hospital Universitari Son Espases, Palma de Mallorca, Spain.
FAU - Arazo, P
AU  - Arazo P
AD  - Hospital Universitario Miguel Servet, Zaragoza, Spain.
FAU - Montero, M
AU  - Montero M
AD  - El Hospital Universitari i Politècnic La Fe, Valencia, Spain.
FAU - Miro, J M
AU  - Miro JM
AD  - Hospital Clinic Institut d'Investigacions Biomèdiques August Pi i Sunyer, University 
      of Barcelona, Barcelona, Spain.
FAU - Moreno, S
AU  - Moreno S
AD  - Hospital Universitario Ramón y Cajal, Madrid, Spain.
FAU - Del Amo, J
AU  - Del Amo J
AD  - Red de Investigación en Sida, Centro Nacional de Epidemiología, CIBER de 
      Epidemiología y Salud Pública (CIBERESP), Spain.
CN  - Spanish AIDS Research Network Cohort (CoRIS)
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - France
TA  - Int J Tuberc Lung Dis
JT  - The international journal of tuberculosis and lung disease : the official journal of 
      the International Union against Tuberculosis and Lung Disease
JID - 9706389
RN  - 0 (Anti-HIV Agents)
RN  - 0 (Antitubercular Agents)
SB  - IM
MH  - Adult
MH  - Anti-HIV Agents/therapeutic use
MH  - Antitubercular Agents/therapeutic use
MH  - Chi-Square Distribution
MH  - *Coinfection
MH  - Drug Resistance, Multiple, Bacterial
MH  - Drug Therapy, Combination
MH  - Female
MH  - HIV Infections/diagnosis/drug therapy/*epidemiology
MH  - Humans
MH  - Incidence
MH  - Latent Tuberculosis/diagnosis/drug therapy/epidemiology
MH  - Male
MH  - Microbial Sensitivity Tests
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Predictive Value of Tests
MH  - Prospective Studies
MH  - Risk Factors
MH  - Spain/epidemiology
MH  - Time Factors
MH  - Treatment Outcome
MH  - Tuberculosis/diagnosis/drug therapy/*epidemiology
MH  - Tuberculosis, Multidrug-Resistant/diagnosis/drug therapy/epidemiology
FIR - Berenguer, J
IR  - Berenguer J
FIR - del Amo, J
IR  - del Amo J
FIR - García, F
IR  - García F
FIR - Gutiérrez, F
IR  - Gutiérrez F
FIR - Labarga, P
IR  - Labarga P
FIR - Moreno, S
IR  - Moreno S
FIR - Muñoz, M A
IR  - Muñoz MA
FIR - Sobrino, P
IR  - Sobrino P
FIR - Alejos, B
IR  - Alejos B
FIR - Hernando, V
IR  - Hernando V
FIR - Alvarez, D
IR  - Alvarez D
FIR - Monge, S
IR  - Monge S
FIR - Jarrin, I
IR  - Jarrin I
FIR - Muñoz, M A
IR  - Muñoz MA
FIR - García-Merino, I
IR  - García-Merino I
FIR - Gómez, C
IR  - Gómez C
FIR - Gallego, J
IR  - Gallego J
FIR - García, A
IR  - García A
FIR - Sogorb, J P
IR  - Sogorb JP
FIR - Merino de Lucas, E
IR  - Merino de Lucas E
FIR - Reus Bañuls, S
IR  - Reus Bañuls S
FIR - Martínez, V B
IR  - Martínez VB
FIR - Oncina, L G
IR  - Oncina LG
FIR - Pastor, C G
IR  - Pastor CG
FIR - Tamarit, I P
IR  - Tamarit IP
FIR - Toledo, P A
IR  - Toledo PA
FIR - Gómez Sirvent, J L
IR  - Gómez Sirvent JL
FIR - Rodríguez Fortùnez, P
IR  - Rodríguez Fortùnez P
FIR - Alemán Valls, M R
IR  - Alemán Valls MR
FIR - del Mar Alonso Socas, M
IR  - del Mar Alonso Socas M
FIR - López Lirola, A M
IR  - López Lirola AM
FIR - Hernández Hernández, M I
IR  - Hernández Hernández MI
FIR - Díaz-Flores, F
IR  - Díaz-Flores F
FIR - Soriano, V
IR  - Soriano V
FIR - Labarga, P
IR  - Labarga P
FIR - Barreiro, P
IR  - Barreiro P
FIR - Rivas, P
IR  - Rivas P
FIR - Blanco, F
IR  - Blanco F
FIR - Carbonero, L M
IR  - Carbonero LM
FIR - Vispo, E
IR  - Vispo E
FIR - Solera, C
IR  - Solera C
FIR - Asensi, V
IR  - Asensi V
FIR - Valle, E
IR  - Valle E
FIR - Cartóon, J A
IR  - Cartóon JA
FIR - Miró, J M
IR  - Miró JM
FIR - López-Dieguez, M
IR  - López-Dieguez M
FIR - Manzardo, C
IR  - Manzardo C
FIR - Zamora, L
IR  - Zamora L
FIR - Pérez, I
IR  - Pérez I
FIR - García, M T
IR  - García MT
FIR - Ligero, C
IR  - Ligero C
FIR - Blanco, J L
IR  - Blanco JL
FIR - García-Alcaide, F
IR  - García-Alcaide F
FIR - Martínez, E
IR  - Martínez E
FIR - Mallolas, J
IR  - Mallolas J
FIR - Gatell, J M
IR  - Gatell JM
FIR - Rubio, R
IR  - Rubio R
FIR - Pulido, F
IR  - Pulido F
FIR - Fiorante, S
IR  - Fiorante S
FIR - Llenas, J
IR  - Llenas J
FIR - Rodríguez, V
IR  - Rodríguez V
FIR - Matarranz, M
IR  - Matarranz M
FIR - Iribarren, J A
IR  - Iribarren JA
FIR - Arrizabalaga, J
IR  - Arrizabalaga J
FIR - Aramburu, M J
IR  - Aramburu MJ
FIR - Camino, X
IR  - Camino X
FIR - Rodríguez-Arrondo, F
IR  - Rodríguez-Arrondo F
FIR - Ángel von Wichmann, M
IR  - Ángel von Wichmann M
FIR - Tomé, L P
IR  - Tomé LP
FIR - Goenaga, M A
IR  - Goenaga MA
FIR - Bustinduy, M J
IR  - Bustinduy MJ
FIR - Galparsoro, H A
IR  - Galparsoro HA
FIR - Gutiérrez, F
IR  - Gutiérrez F
FIR - Masiá, M
IR  - Masiá M
FIR - Ramos, J M
IR  - Ramos JM
FIR - Padilla, S
IR  - Padilla S
FIR - Navarro, A
IR  - Navarro A
FIR - Montolio, F
IR  - Montolio F
FIR - Peral, Y
IR  - Peral Y
FIR - Robledano García, C
IR  - Robledano García C
FIR - Clotet, B
IR  - Clotet B
FIR - Tural, C
IR  - Tural C
FIR - Ruiz, L
IR  - Ruiz L
FIR - Miranda, C
IR  - Miranda C
FIR - Muga, R
IR  - Muga R
FIR - Tor, J
IR  - Tor J
FIR - Sanvisens, A
IR  - Sanvisens A
FIR - Berenguer, J
IR  - Berenguer J
FIR - López Bernaldo de Quirós, J C
IR  - López Bernaldo de Quirós JC
FIR - Miralles, P
IR  - Miralles P
FIR - Cosín Ochaíta, J
IR  - Cosín Ochaíta J
FIR - Sánchez Conde, M
IR  - Sánchez Conde M
FIR - Gutiérrez Cuellar, I
IR  - Gutiérrez Cuellar I
FIR - Ramírez Schacke, M
IR  - Ramírez Schacke M
FIR - Padilla Ortega, B
IR  - Padilla Ortega B
FIR - Gijón Vidaurreta, P
IR  - Gijón Vidaurreta P
FIR - Vidal, F
IR  - Vidal F
FIR - Peraire, J
IR  - Peraire J
FIR - Viladés, C
IR  - Viladés C
FIR - Veloso, S
IR  - Veloso S
FIR - Vargas, M
IR  - Vargas M
FIR - López-Dupla, M
IR  - López-Dupla M
FIR - Olona, M
IR  - Olona M
FIR - Aguilar, A
IR  - Aguilar A
FIR - Sirvent, J J
IR  - Sirvent JJ
FIR - Soriano, A
IR  - Soriano A
FIR - Qaneta, R A A
IR  - Qaneta RA
FIR - López Aldeguer, J
IR  - López Aldeguer J
FIR - Blanes Juliá, M
IR  - Blanes Juliá M
FIR - Lacruz Rodrigo, J
IR  - Lacruz Rodrigo J
FIR - Salavert, M
IR  - Salavert M
FIR - Montero, M
IR  - Montero M
FIR - Calabuig, E
IR  - Calabuig E
FIR - Cuéllar, S
IR  - Cuéllar S
FIR - González García, J
IR  - González García J
FIR - Bernardino de la Serna, I
IR  - Bernardino de la Serna I
FIR - Peña Sánchez de Rivera, J M
IR  - Peña Sánchez de Rivera JM
FIR - Arribas López, J R
IR  - Arribas López JR
FIR - Montes Ramírez, M L
IR  - Montes Ramírez ML
FIR - Pareja, J F P
IR  - Pareja JF
FIR - Arribas, B
IR  - Arribas B
FIR - Castro, J M
IR  - Castro JM
FIR - Zamora Vargas, E J
IR  - Zamora Vargas EJ
FIR - Pérez Valero, I
IR  - Pérez Valero I
FIR - Estebanez, M
IR  - Estebanez M
FIR - Mohr, R
IR  - Mohr R
FIR - Arnalich Fernández, F
IR  - Arnalich Fernández F
FIR - de los Santos, I
IR  - de los Santos I
FIR - Sanz Sanz, J
IR  - Sanz Sanz J
FIR - Rodríguez, J
IR  - Rodríguez J
FIR - Salas Aparicio, A
IR  - Salas Aparicio A
FIR - Sarriá Cepeda, C
IR  - Sarriá Cepeda C
FIR - Oteo, J A
IR  - Oteo JA
FIR - Blanco, J R
IR  - Blanco JR
FIR - Ibarra, V
IR  - Ibarra V
FIR - Metola, L
IR  - Metola L
FIR - Sanz, M
IR  - Sanz M
FIR - Pérez-Martínez, L
IR  - Pérez-Martínez L
FIR - Pinilla Moraza, J
IR  - Pinilla Moraza J
FIR - Dalmau, D
IR  - Dalmau D
FIR - Jaén Manzanera, A
IR  - Jaén Manzanera A
FIR - Cairó Llobell, M
IR  - Cairó Llobell M
FIR - Puig, D I
IR  - Puig DI
FIR - Ibáñez, L
IR  - Ibáñez L
FIR - Montañez, Q J
IR  - Montañez QJ
FIR - Xercavins Valls, M
IR  - Xercavins Valls M
FIR - Martinez-Lacasa, J
IR  - Martinez-Lacasa J
FIR - Velli, P
IR  - Velli P
FIR - Font, R
IR  - Font R
FIR - Boneta, J S
IR  - Boneta JS
FIR - Uriz, J
IR  - Uriz J
FIR - Castiello, J
IR  - Castiello J
FIR - Reparaz, J
IR  - Reparaz J
FIR - Arraiza, M J
IR  - Arraiza MJ
FIR - Irigoyen, C
IR  - Irigoyen C
FIR - Mozas, D
IR  - Mozas D
FIR - Segura, F
IR  - Segura F
FIR - Amengual, M J
IR  - Amengual MJ
FIR - Penelo, E
IR  - Penelo E
FIR - Navarro, G
IR  - Navarro G
FIR - Sala, M
IR  - Sala M
FIR - Cervantes, M
IR  - Cervantes M
FIR - Pineda, V
IR  - Pineda V
FIR - Moreno, S
IR  - Moreno S
FIR - Casado, J L
IR  - Casado JL
FIR - Dronda, F
IR  - Dronda F
FIR - Moreno, A
IR  - Moreno A
FIR - Pérez Elías, M J
IR  - Pérez Elías MJ
FIR - López, D
IR  - López D
FIR - Gutiérrez, C
IR  - Gutiérrez C
FIR - Hernández, B
IR  - Hernández B
FIR - Pumares, M
IR  - Pumares M
FIR - Martí, P
IR  - Martí P
FIR - Cano Sánchez, A
IR  - Cano Sánchez A
FIR - Bernal Morell, E
IR  - Bernal Morell E
FIR - Muñoz Pérez, A
IR  - Muñoz Pérez A
FIR - García García, F
IR  - García García F
FIR - Quero, J H
IR  - Quero JH
FIR - Peña Monje, A
IR  - Peña Monje A
FIR - Muñoz Medina, L
IR  - Muñoz Medina L
FIR - Parra Ruiz, J
IR  - Parra Ruiz J
FIR - Del Romero Guerrero, J
IR  - Del Romero Guerrero J
FIR - Rodríguez Martín, C
IR  - Rodríguez Martín C
FIR - Puerta López, T
IR  - Puerta López T
FIR - Carrió Montiel, J C
IR  - Carrió Montiel JC
FIR - González, C
IR  - González C
FIR - Vera, M
IR  - Vera M
FIR - Antela, A
IR  - Antela A
FIR - Prieto, A
IR  - Prieto A
FIR - Losada, E
IR  - Losada E
FIR - Riera, M
IR  - Riera M
FIR - Murillas, J
IR  - Murillas J
FIR - Peñaranda, M
IR  - Peñaranda M
FIR - Leyes, M
IR  - Leyes M
FIR - Ribas, M A
IR  - Ribas MA
FIR - Campins, A
IR  - Campins A
FIR - Villalonga, C
IR  - Villalonga C
FIR - Vidal, C
IR  - Vidal C
FIR - Pineda, J A
IR  - Pineda JA
FIR - Recio Sánchez, E
IR  - Recio Sánchez E
FIR - Lozano de León, F
IR  - Lozano de León F
FIR - Macías, J
IR  - Macías J
FIR - del Valle, J
IR  - del Valle J
FIR - Gómez-Mateos, J
IR  - Gómez-Mateos J
FIR - Mata, R
IR  - Mata R
FIR - Santos González, J
IR  - Santos González J
FIR - Solero, M M
IR  - Solero MM
FIR - Viciana Ramos, I
IR  - Viciana Ramos I
FIR - Palacios Muñoz, R
IR  - Palacios Muñoz R
FIR - Viciana, P
IR  - Viciana P
FIR - Leal, M
IR  - Leal M
FIR - López-Cortés, L F
IR  - López-Cortés LF
FIR - Trastoy, M
IR  - Trastoy M
EDAT- 2014/06/07 06:00
MHDA- 2015/02/03 06:00
CRDT- 2014/06/07 06:00
PHST- 2014/06/07 06:00 [entrez]
PHST- 2014/06/07 06:00 [pubmed]
PHST- 2015/02/03 06:00 [medline]
AID - 10.5588/ijtld.13.0778 [doi]
PST - ppublish
SO  - Int J Tuberc Lung Dis. 2014 Jun;18(6):700-8. doi: 10.5588/ijtld.13.0778.

PMID- 28112336
OWN - NLM
STAT- MEDLINE
DCOM- 20170608
LR  - 20170817
IS  - 0717-6341 (Electronic)
IS  - 0716-1018 (Linking)
VI  - 33
IP  - 5
DP  - 2016 Oct
TI  - Virological and immunological outcomes to antiretroviral therapy in HIV-infected 
      patients of an academic medical center in Chile.
PG  - 531-536
LID - S0716-10182016000500007 [pii]
LID - 10.4067/S0716-10182016000500007 [doi]
AB  - INTRODUCTION: Red Salud UC is an Academic health network where HIV-infected patients 
      from the public and private health system are followed by a multidisplinary team. 
      AIM: To determine virologic and immunologic response after 144 weeks of starting 
      first antiretroviral therapy in these patients. METHODS: A retrospective analysis of 
      adult HIV patients attended between 1992 and 2011 was performed. Demographic and 
      clinical characteristics, antiretroviral therapies data and immunologic and 
      virologic outcomes were collected. CD4 count and HIV viral load changes up to 144 
      weeks after initiation of antiretroviral therapy were analyzed. RESULTS: 860 
      patients were included in the analyses. Median age was 42 years, 93% were men. 
      Median CD4+ count at baseline was 202 cells/mm³. The most used ART regimen was 
      zidovudine/lamivudine plus efavirenz. First line anti-retroviral therapy was changed 
      in 42% patients, being the most common cause, drug toxicity. At week 144, median 
      CD4+ lymphocyte cell count was 449 cells/mm³. Ninety percent and 96% had 
      undetectable viral load measured as < 50 copies/mL or < 400 copies/mL respectively. 
      DISCUSSION: First report of a university cohort, with CD4 and viral load follow up 
      for 144 weeks, including Chilean patients from public and private system. After 
      initiation of ART, an excellent immunologic and virologic response was observed in 
      this cohort.
FAU - Ceballos, M Elena
AU  - Ceballos ME
AD  - Escuela de Medicina, Departamento de Enfermedades Infecciosas del Adulto, Pontificia 
      Universidad Católica de Chile, Santiago, Chile.
FAU - Rojas, Álvaro
AU  - Rojas Á
AD  - Escuela de Medicina, Departamento de Enfermedades Infecciosas del Adulto, Pontificia 
      Universidad Católica de Chile, Santiago, Chile.
FAU - Donato, Paulina
AU  - Donato P
AD  - Escuela de Medicina, Departamento de Enfermedades Infecciosas del Adulto, Pontificia 
      Universidad Católica de Chile, Santiago, Chile.
FAU - Huilcamán, Marcos
AU  - Huilcamán M
AD  - Escuela de Medicina, Departamento de Enfermedades Infecciosas del Adulto, Pontificia 
      Universidad Católica de Chile, Santiago, Chile.
FAU - Rivera, Gonzalo
AU  - Rivera G
AD  - Escuela de Medicina, Departamento de Enfermedades Infecciosas del Adulto, Pontificia 
      Universidad Católica de Chile, Santiago, Chile.
FAU - López, Tania
AU  - López T
AD  - Escuela de Medicina, Departamento de Enfermedades Infecciosas del Adulto, Pontificia 
      Universidad Católica de Chile, Santiago, Chile.
FAU - Gutiérrez, Catalina
AU  - Gutiérrez C
AD  - Escuela de Medicina, Departamento de Enfermedades Infecciosas del Adulto, Pontificia 
      Universidad Católica de Chile, Santiago, Chile.
FAU - Labarca, Jaime
AU  - Labarca J
AD  - Escuela de Medicina, Departamento de Enfermedades Infecciosas del Adulto, Pontificia 
      Universidad Católica de Chile, Santiago, Chile.
FAU - Pérez, Carlos
AU  - Pérez C
AD  - Escuela de Medicina, Departamento de Enfermedades Infecciosas del Adulto, Pontificia 
      Universidad Católica de Chile, Santiago, Chile.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
TT  - Respuesta virológica e inmunológica a la terapia anti-retroviral en pacientes 
      portadores de infección por VIH atendidos en una red de salud académica de Chile.
PL  - Chile
TA  - Rev Chilena Infectol
JT  - Revista chilena de infectologia : organo oficial de la Sociedad Chilena de 
      Infectologia
JID - 9305754
RN  - 0 (Anti-HIV Agents)
RN  - 0 (RNA, Viral)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-HIV Agents/*therapeutic use
MH  - *Antiretroviral Therapy, Highly Active
MH  - CD4 Lymphocyte Count
MH  - Chile
MH  - Female
MH  - HIV Infections/*drug therapy/immunology/virology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - RNA, Viral
MH  - Retrospective Studies
MH  - Time Factors
MH  - Viral Load
MH  - Young Adult
EDAT- 2017/01/24 06:00
MHDA- 2017/06/09 06:00
CRDT- 2017/01/24 06:00
PHST- 2015/09/07 00:00 [received]
PHST- 2016/08/08 00:00 [accepted]
PHST- 2017/01/24 06:00 [entrez]
PHST- 2017/01/24 06:00 [pubmed]
PHST- 2017/06/09 06:00 [medline]
AID - S0716-10182016000500007 [pii]
AID - 10.4067/S0716-10182016000500007 [doi]
PST - ppublish
SO  - Rev Chilena Infectol. 2016 Oct;33(5):531-536. doi: 10.4067/S0716-10182016000500007.

PMID- 29190784
OWN - NLM
STAT- MEDLINE
DCOM- 20180101
LR  - 20190118
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 12
IP  - 11
DP  - 2017
TI  - HIV transmission and pre-exposure prophylaxis in a high risk MSM population: A 
      simulation study of location-based selection of sexual partners.
PG  - e0189002
LID - 10.1371/journal.pone.0189002 [doi]
LID - e0189002
AB  - OBJECTIVE: In France, indications for pre-exposure prophylaxis (PrEP) for HIV 
      prevention are based on individual-level risk factors for HIV infection. However, 
      the risk of HIV infection may also depend on characteristics of sexual partnerships. 
      Here we study how place-based selection of partners change transmission and the 
      overall efficiency of PrEP. METHODS: We used the PREVAGAY survey of sexual behavior 
      and HIV serostatus in men who have sex with men (MSM) in a Parisian district to look 
      for associations between sexual network characteristics and HIV infection. We then 
      simulated HIV transmission in a high-risk MSM population. We used information about 
      venues visited to meet casual sexual partners (clubs, backrooms or saunas) to define 
      sexual networks. We then simulated HIV transmission in these networks and assessed 
      the impact of PrEP in this population. RESULTS: In the PREVAGAY study, we found that 
      HIV serostatus changed with the type of venues visited, in addition to other 
      individual risk factors. In simulations, we found similar differences in HIV 
      incidence when the choice of venues visited was not random. The use of PrEP allowed 
      reducing incidence, irrespective of the venues visited by PrEP users. However, with 
      the same amount of PrEP, the number of infections adverted could almost double 
      depending on network structure and venues visited by PrEP users. CONCLUSION: This 
      study shows that characteristics of the sexual network structure can strongly impact 
      the effectiveness of PrEP interventions. These should be considered further to 
      refine individual risk assessment and maximize the effect of individual-based 
      prevention policies.
FAU - Robineau, Olivier
AU  - Robineau O
AUID- ORCID: 0000-0001-8196-5442
AD  - Sorbonne Universités - Univ Paris 06, INSERM, Institut Pierre Louis d'Epidémiologie 
      et de Santé Publique, INSERM U1136, Paris, France.
AD  - Service Universitaire des Maladies Infectieuses et du Voyageur, Centre Hospitalier 
      Gustave Dron, Tourcoing, France.
AD  - Département des maladies infectieuses, Univ Lille 2, Lille, France.
FAU - Velter, Annie
AU  - Velter A
AD  - Santé Publique France, Saint Maurice, France.
FAU - Barin, Francis
AU  - Barin F
AD  - Université François-Rabelais, INSERM UMR966, Tours, France.
AD  - Centre Hospitalier Régional Universitaire, Centre National de Référence du VIH, 
      Tours, France.
FAU - Boelle, Pierre-Yves
AU  - Boelle PY
AD  - Sorbonne Universités - Univ Paris 06, INSERM, Institut Pierre Louis d'Epidémiologie 
      et de Santé Publique, INSERM U1136, Paris, France.
LA  - eng
PT  - Journal Article
DEP - 20171130
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Anti-HIV Agents)
SB  - IM
MH  - Anti-HIV Agents/*therapeutic use
MH  - HIV Infections/prevention & control/*transmission
MH  - *Homosexuality, Male
MH  - Humans
MH  - Male
MH  - *Pre-Exposure Prophylaxis
PMC - PMC5708822
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2017/12/01 06:00
MHDA- 2018/01/02 06:00
CRDT- 2017/12/01 06:00
PHST- 2017/07/30 00:00 [received]
PHST- 2017/11/16 00:00 [accepted]
PHST- 2017/12/01 06:00 [entrez]
PHST- 2017/12/01 06:00 [pubmed]
PHST- 2018/01/02 06:00 [medline]
AID - PONE-D-17-28378 [pii]
AID - 10.1371/journal.pone.0189002 [doi]
PST - epublish
SO  - PLoS One. 2017 Nov 30;12(11):e0189002. doi: 10.1371/journal.pone.0189002. 
      eCollection 2017.

PMID- 26616349
OWN - NLM
STAT- MEDLINE
DCOM- 20160609
LR  - 20160202
IS  - 1365-3156 (Electronic)
IS  - 1360-2276 (Linking)
VI  - 21
IP  - 2
DP  - 2016 Feb
TI  - Differential effects of sex in a West African cohort of HIV-1, HIV-2 and HIV-1/2 
      dually infected patients: men are worse off.
PG  - 253-62
LID - 10.1111/tmi.12646 [doi]
AB  - OBJECTIVES: Several studies have reported conflicting effects of sex on HIV-1 
      infection. We describe differences in baseline characteristics and assess the impact 
      of sex on HIV progression among patients at a clinic with many HIV-2 and HIV-1/2 
      dually infected patients. METHODS: This study utilised a retrospective cohort of 
      treatment-naïve adults at the largest HIV clinic in Guinea-Bissau from 6 June 2005 
      to 1 December 2013. Baseline characteristics were assessed and the patients followed 
      until death, transfer, loss to follow-up, or 1 June 2014. We estimated the time from 
      the first clinic visit until initiation of ART, death or loss to follow-up using Cox 
      proportional hazard models. RESULTS: A total of 5694 patients were included in the 
      study, 3702 women (65%) and 1992 men (35%). Women were more likely than men to be 
      infected with HIV-2 (19% vs. 15%, P < 0.01) or dually infected with HIV-1/2 (11% vs. 
      9%, P = 0.02). For all HIV types, women were younger (median 35 vs. 40 years), less 
      likely to have schooling (55% vs. 77%) or to be married (46% vs. 67%), and had 
      higher baseline CD4 cell counts (median 214 vs. 178 cells/μl). Men had a higher 
      age-adjusted mortality rate (hazard rate ratio (HRR) 1.29, 95% confidence interval 
      (CI) 1.09-1.52) and were more often lost to follow-up (HRR 1.27, 95% CI 1.17-1.39). 
      CONCLUSION: Significant differences exist between HIV-infected men and women 
      regardless of HIV type. Men seek treatment at a later stage and, despite better 
      socio-economic status, have higher mortality and loss to follow-up than women.
CI  - © 2015 John Wiley & Sons Ltd.
FAU - Jespersen, Sanne
AU  - Jespersen S
AD  - Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau.
AD  - Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
FAU - Hønge, Bo Langhoff
AU  - Hønge BL
AD  - Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau.
AD  - Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
AD  - Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark.
FAU - Esbjörnsson, Joakim
AU  - Esbjörnsson J
AD  - Department of Experimental Medical Science, Section of Molecular Virology, Lund 
      University, Lund, Sweden.
AD  - Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
FAU - Medina, Candida
AU  - Medina C
AD  - National HIV Programme, Ministry of Health, Bissau, Guinea-Bissau.
FAU - da Silva Té, David
AU  - da Silva Té D
AD  - National HIV Programme, Ministry of Health, Bissau, Guinea-Bissau.
FAU - Correira, Faustino Gomes
AU  - Correira FG
AD  - National HIV Programme, Ministry of Health, Bissau, Guinea-Bissau.
FAU - Laursen, Alex Lund
AU  - Laursen AL
AD  - Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
FAU - Østergaard, Lars
AU  - Østergaard L
AD  - Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
FAU - Andersen, Andreas
AU  - Andersen A
AD  - Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau.
FAU - Aaby, Peter
AU  - Aaby P
AD  - Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau.
AD  - Research Center for Vitamins and Vaccines (CVIVA), Bandim Health Project, Statens 
      Serum Institut, Copenhagen, Denmark.
FAU - Erikstrup, Christian
AU  - Erikstrup C
AD  - Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark.
FAU - Wejse, Christian
AU  - Wejse C
AD  - Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau.
AD  - Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.
AD  - GloHAU, Center for Global Health, School of Public Health, Aarhus University, 
      Aarhus, Denmark.
CN  - Bissau HIV Cohort study group
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20151221
PL  - England
TA  - Trop Med Int Health
JT  - Tropical medicine & international health : TM & IH
JID - 9610576
RN  - 0 (Anti-HIV Agents)
SB  - IM
MH  - Adult
MH  - Anti-HIV Agents/*therapeutic use
MH  - CD4 Lymphocyte Count
MH  - Female
MH  - Guinea-Bissau/epidemiology
MH  - HIV Infections/*drug therapy/mortality/virology
MH  - *HIV-1
MH  - *HIV-2
MH  - Humans
MH  - Lost to Follow-Up
MH  - Male
MH  - Men
MH  - *Men's Health
MH  - Middle Aged
MH  - *Patient Acceptance of Health Care
MH  - Proportional Hazards Models
MH  - Retrospective Studies
MH  - Sex Factors
MH  - Socioeconomic Factors
OTO - NOTNLM
OT  - Africa
OT  - Afrique
OT  - Guinea-Bissau
OT  - Guinée-Bissau
OT  - HIV
OT  - HIV-2
OT  - Sex
OT  - Sexo
OT  - VIH
OT  - VIH-2
OT  - sexe
OT  - África
FIR - Rodrigues, Amabelia
IR  - Rodrigues A
FIR - da Silva, David
IR  - da Silva D
FIR - da Silva, Zacarias
IR  - da Silva Z
FIR - Oliviera-Souto, Ines
IR  - Oliviera-Souto I
FIR - Laursen, Alex
IR  - Laursen A
FIR - Sodemann, Morten
IR  - Sodemann M
FIR - Fomsgaard, Anders
IR  - Fomsgaard A
FIR - Eugen-Olsen, Jesper
IR  - Eugen-Olsen J
EDAT- 2015/12/01 06:00
MHDA- 2016/06/10 06:00
CRDT- 2015/12/01 06:00
PHST- 2015/12/01 06:00 [entrez]
PHST- 2015/12/01 06:00 [pubmed]
PHST- 2016/06/10 06:00 [medline]
AID - 10.1111/tmi.12646 [doi]
PST - ppublish
SO  - Trop Med Int Health. 2016 Feb;21(2):253-62. doi: 10.1111/tmi.12646. Epub 2015 Dec 
      21.

PMID- 26847504
OWN - NLM
STAT- Publisher
LR  - 20191120
IS  - 1873-4758 (Electronic)
IS  - 0955-3959 (Linking)
DP  - 2015 Nov 28
TI  - Recommandations pour la prise en charge de l'infection par le virus de l'hépatite C 
      chez les usagers de drogues par injection.
LID - S0955-3959(15)00351-5 [pii]
LID - 10.1016/j.drugpo.2015.11.009 [doi]
FAU - Grebely, Jason
AU  - Grebely J
AD  - Kirby Institute, UNSW Australia, Sydney, Australia. Electronic address: 
      jgrebely@kirby.unsw.edu.au.
FAU - Robaeys, Geert
AU  - Robaeys G
AD  - Department of Gastroenterology and Hepatology, Ziekenhuis Oost Limburg, Genk, 
      Belgium; Department of Hepatology, UZ Leuven, Leuven, Belgium; Faculty of Medicine 
      and Life Sciences, Limburg Clinical Research Program, Hasselt University, Hasselt, 
      Belgium.
FAU - Bruggmann, Philip
AU  - Bruggmann P
AD  - Arud Centres of Addiction Medicine, Zurich, Switzerland.
FAU - Aghemo, Alessio
AU  - Aghemo A
AD  - A.M. Migliavacca Center for Liver Disease, Division of Gastroenterology and 
      Hepatology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Università 
      degli Studi di Milano, Milan, Italy.
FAU - Backmund, Markus
AU  - Backmund M
AD  - Ludwig-Maximilians-University, Munich, Germany; Praxiszentrum im Tal Munich, Munich, 
      Germany.
FAU - Bruneau, Julie
AU  - Bruneau J
AD  - CRCHUM, Université de Montréal, Montreal, Canada.
FAU - Byrne, Jude
AU  - Byrne J
AD  - International Network of People who Use Drugs, Canberra, Australia.
FAU - Dalgard, Olav
AU  - Dalgard O
AD  - Department of Infectious Diseases, Akershus University Hospital, Lørenskog, Norway.
FAU - Feld, Jordan J
AU  - Feld JJ
AD  - University of Toronto, Toronto, Canada.
FAU - Hellard, Margaret
AU  - Hellard M
AD  - Burnet Institute, Melbourne, Australia; Department of Epidemiology and Preventive 
      Medicine, Monash University, Melbourne, Australia.
FAU - Hickman, Matthew
AU  - Hickman M
AD  - School of Social & Community Medicine, University of Bristol, Bristol, United 
      Kingdom.
FAU - Kautz, Achim
AU  - Kautz A
AD  - European Liver Patients Association, Cologne, Germany.
FAU - Litwin, Alain
AU  - Litwin A
AD  - Division of General Internal Medicine, Department of Medicine, Albert Einstein 
      College of Medicine and Montefiore Medical Center, Bronx, NY, United States.
FAU - Lloyd, Andrew R
AU  - Lloyd AR
AD  - Inflammation and Infection Research Centre, School of Medical Sciences, UNSW 
      Australia, Sydney, Australia.
FAU - Mauss, Stefan
AU  - Mauss S
AD  - Center for HIV and Hepatogastroenterology, Düsseldorf, Germany.
FAU - Prins, Maria
AU  - Prins M
AD  - Department of Research, Cluster Infectious Diseases, Public Health Service of 
      Amsterdam, Amsterdam, The Netherlands; Department of Internal Medicine, CINIMA, 
      Academic Medical Centre, Amsterdam, The Netherlands.
FAU - Swan, Tracy
AU  - Swan T
AD  - Treatment Action Group, New York, United States.
FAU - Schaefer, Martin
AU  - Schaefer M
AD  - Department of Psychiatry, Psychotherapy and Addiction Medicine, Kliniken 
      Essen-Mitte, Essen, Germany; Department of Psychiatry and Psychotherapy-CCM, Charité 
      - Universitätsmedizin Berlin, Berlin, Germany.
FAU - Taylor, Lynn E
AU  - Taylor LE
AD  - Department of Medicine, Brown University, Providence, RI, United States.
FAU - Dore, Gregory J
AU  - Dore GJ
AD  - Kirby Institute, UNSW Australia, Sydney, Australia.
CN  - l’International Network on Hepatitis among Substance Users (Réseau international sur 
      l’hépatite chez les consommateurs de drogues)
LA  - eng
PT  - Journal Article
DEP - 20151128
PL  - Netherlands
TA  - Int J Drug Policy
JT  - The International journal on drug policy
JID - 9014759
OTO - NOTNLM
OT  - Consommateurs de drogues
OT  - Injection
OT  - Lignes directrices
OT  - UDI
OT  - VHC
OT  - VIH
EDAT- 2016/02/06 06:00
MHDA- 2016/02/06 06:00
CRDT- 2016/02/06 06:00
PHST- 2016/02/06 06:00 [entrez]
PHST- 2016/02/06 06:00 [pubmed]
PHST- 2016/02/06 06:00 [medline]
AID - S0955-3959(15)00351-5 [pii]
AID - 10.1016/j.drugpo.2015.11.009 [doi]
PST - aheadofprint
SO  - Int J Drug Policy. 2015 Nov 28:S0955-3959(15)00351-5. doi: 
      10.1016/j.drugpo.2015.11.009.

PMID- 26890155
OWN - NLM
STAT- MEDLINE
DCOM- 20180119
LR  - 20180911
IS  - 1360-0443 (Electronic)
IS  - 0965-2140 (Linking)
VI  - 111
IP  - 7
DP  - 2016 Jul
TI  - Clinical outcomes of patients infected with HIV through use of injected drugs 
      compared to patients infected through sexual transmission: late presentation, 
      delayed anti-retroviral treatment and higher mortality.
PG  - 1235-45
LID - 10.1111/add.13348 [doi]
AB  - AIMS: To compare patients who acquired HIV infection through use of injected drugs 
      (HIV-IDU) with patients who acquired HIV by sexual transmission (HIV-ST) in terms of 
      late presentation (LP), delay in anti-retroviral treatment (ART) initiation, 
      virological and immunological response to ART, mortality and progression to AIDS. 
      DESIGN: Prospective multi-centre cohort study of HIV-infected subjects naive to ART 
      at entry (Cohort of the Spanish HIV Research Network: CoRIS). SETTING: Thirty-one 
      centres from the Spanish public health-care system. PARTICIPANTS: A total of 9355 
      patients were included (1064 HIV-IDU and 8291 HIV-ST) during 2004-13. MEASUREMENTS: 
      We compared LP (defined as presentation for care with a CD4 cell count < 350/μl 
      and/or AIDS-defining illness), delayed ART initiation (defined as initiating 
      treatment more than 6 months after the date when treatment was indicated by the 
      guidelines, or not initiating treatment at all when it was indicated), virological 
      and immunological response to ART (defined as viral load < 50 HIV-1 RNA copies/ml 
      and a CD4 count increase of at least 100 cells/μl, respectively, after 1 year of 
      treatment), mortality and progression to AIDS in HIV-IDU and HIV-ST. FINDINGS: 
      Compared with HIV-ST, HIV-IDU had higher risk of LP [odds ratio (OR) = 1.76; 95% 
      confidence interval (CI) = 1.41-2.18], delayed ART initiation (OR 1.87; 95% 
      CI = 1.46-2.40) and higher mortality [hazard ratio (HR) = 1.43; 95% CI = 1.03-2.01] 
      and risk of progression to AIDS [subhazard ratio (SHR) = 1.68; 95% CI = 1.29-2.18]. 
      Virological suppression due to ART was lower in HIV-IDU than in patients with HIV-ST 
      only among patients without hepatitis C virus (HCV) infection [adjusted OR 
      (aOR) = 0.59; 95% CI = 0.36-0.95]; among patients with HCV infection, virological 
      suppression due to ART did not show significant differences between HIV-IDU and 
      HIV-ST. There were no significant differences in immunological response after 
      adjusting by HCV (aOR = 0.74; 95% CI = 0.52-1.06). CONCLUSIONS: In Spain, patients 
      who acquire HIV infection through use of injected drugs appear to have a higher risk 
      of late presentation, delayed initiation of anti-retroviral treatment and 
      progression to AIDS and death than patients who acquire HIV by sexual transmission.
CI  - © 2016 Society for the Study of Addiction.
FAU - Suárez-García, Inés
AU  - Suárez-García I
AD  - Infectious Diseases Unit, Department of Internal Medicine, Hospital Universitario 
      Infanta Sofía, Madrid, Spain.
FAU - Sobrino-Vegas, Paz
AU  - Sobrino-Vegas P
AD  - Centro Nacional de Epidemiología, Instituto de Salud Carlos III, Madrid, Spain.
FAU - Dalmau, David
AU  - Dalmau D
AD  - Hospital Universitari Mutua Terrassa, Terrassa, Spain.
FAU - Rubio, Rafael
AU  - Rubio R
AD  - Unidad Infección VIH, Hospital Universitario Doce de Octubre, Madrid, Spain.
FAU - Iribarren, José Antonio
AU  - Iribarren JA
AD  - Department of Infectious Diseases, Hospital Universitario Donostia, Gipuzkoa, Spain.
FAU - Blanco, José Ramón
AU  - Blanco JR
AD  - Department of Infectious Diseases, Hospital San Pedro-CIBIR, Logroño, Spain.
FAU - Gutierrez, Félix
AU  - Gutierrez F
AD  - Infectious Diseases Unit, Hospital General de Elche and Universidad Miguel 
      Hernández, Alicante, Spain.
FAU - Montero Alonso, Marta
AU  - Montero Alonso M
AD  - Department of Infectious Diseases, Hospital Universitario La Fe, Valencia, Spain.
FAU - Bernal, Enrique
AU  - Bernal E
AD  - Hospital Reina Sofía, Murcia, Spain.
FAU - Vinuesa García, David
AU  - Vinuesa García D
AD  - Unidad de Gestion Clínica de Microbiología y Enfermedades Infecciosas, Hospital 
      Clínico San Cecilio, Granada, Spain.
FAU - Del Amo, Julia
AU  - Del Amo J
AD  - Centro Nacional de Epidemiología, Instituto de Salud Carlos III, Madrid, Spain.
CN  - Cohort of the Spanish HIV Research Network (CoRIS)
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160414
PL  - England
TA  - Addiction
JT  - Addiction (Abingdon, England)
JID - 9304118
RN  - 0 (Anti-HIV Agents)
SB  - IM
MH  - Adult
MH  - Anti-HIV Agents/therapeutic use
MH  - Antiretroviral Therapy, Highly Active
MH  - CD4 Lymphocyte Count
MH  - Delayed Diagnosis
MH  - Disease Progression
MH  - Female
MH  - HIV Infections/diagnosis/drug therapy/mortality/*transmission
MH  - Humans
MH  - Male
MH  - Odds Ratio
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - *Sexually Transmitted Diseases, Viral
MH  - Spain
MH  - *Substance Abuse, Intravenous
MH  - Time-to-Treatment
MH  - Treatment Outcome
MH  - Viral Load
OTO - NOTNLM
OT  - *Cohort studies
OT  - *HIV infections
OT  - *drug users
OT  - *mortality
EDAT- 2016/02/19 06:00
MHDA- 2018/01/20 06:00
CRDT- 2016/02/19 06:00
PHST- 2015/06/13 00:00 [received]
PHST- 2015/11/30 00:00 [revised]
PHST- 2016/02/08 00:00 [accepted]
PHST- 2016/02/19 06:00 [entrez]
PHST- 2016/02/19 06:00 [pubmed]
PHST- 2018/01/20 06:00 [medline]
AID - 10.1111/add.13348 [doi]
PST - ppublish
SO  - Addiction. 2016 Jul;111(7):1235-45. doi: 10.1111/add.13348. Epub 2016 Apr 14.

PMID- 24641669
OWN - NLM
STAT- MEDLINE
DCOM- 20150125
LR  - 20211021
IS  - 1813-4424 (Electronic)
IS  - 1729-0376 (Print)
IS  - 1729-0376 (Linking)
VI  - 10
IP  - 3-4
DP  - 2013
TI  - The association between social networks and self-rated risk of HIV infection among 
      secondary school students in Moshi Municipality, Tanzania.
PG  - 131-9
LID - 10.1080/17290376.2014.888676 [doi]
AB  - This study describes the social networks of secondary school students in Moshi 
      Municipality, and their association with self-rated risk of human immunodeficiency 
      virus (HIV) infection. A cross-sectional analytical study was conducted among 300 
      students aged 15-24 years in 5 secondary schools in Moshi, Tanzania. Bonding 
      networks were defined as social groupings of students participating in activities 
      within the school, while bridging networks were groups that included students 
      participating in social groupings from outside of the school environs. A structured 
      questionnaire was used to ask about participation in bonding and bridging social 
      networks and self-rated HIV risk behavior. More participants participated in bonding 
      networks (72%) than in bridging networks (29%). Participation in bridging networks 
      was greater among females (25%) than males (12%, p<.005). Of 300 participants, 88 
      (29%) were sexually experienced, and of these 62 (70%) considered themselves to be 
      at low risk of HIV infection. Factors associated with self-rated risk of HIV 
      included: type of school (p<.003), family structure (p<.008), being sexually 
      experienced (p<.004), having had sex in the past three months (p<.009), having an 
      extra sexual partner (p<.054) and non-condom use in last sexual intercourse 
      (p<.001), but not the presence or type of social capital. The study found no 
      association between bonding and bridging social networks on self-rated risk of HIV 
      among study participants. However, sexually experienced participants rated 
      themselves at low risk of HIV infection despite practicing unsafe sex. Efforts to 
      raise adolescents' self-awareness of risk of HIV infection through life skills 
      education and HIV/acquired immunodeficiency syndrome risk reduction strategies may 
      be beneficial to students in this at-risk group.
FAU - Lyimo, Elizabeth J
AU  - Lyimo EJ
AD  - a MPH, Kilimanjaro Christian Medical University College, Tumaini University , Moshi 
      , Tanzania.
FAU - Todd, Jim
AU  - Todd J
FAU - Richey, Lisa Ann
AU  - Richey LA
FAU - Njau, Bernard
AU  - Njau B
LA  - eng
GR  - 087540/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20140318
TA  - SAHARA J
JT  - SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance
JID - 101226212
SB  - IM
MH  - Adolescent
MH  - Adolescent Behavior
MH  - Cross-Sectional Studies
MH  - Female
MH  - HIV Infections/epidemiology/prevention & control/*psychology
MH  - Health Education
MH  - Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Male
MH  - School Health Services/*organization & administration
MH  - *Schools
MH  - Self Report
MH  - *Sexual Behavior/psychology
MH  - Sexual Partners
MH  - *Social Support
MH  - Students/*psychology/statistics & numerical data
MH  - Surveys and Questionnaires
MH  - Tanzania
MH  - Young Adult
PMC - PMC4039191
OAB - Publisher: Abstract available from the publisher.
OABL- fre
OTO - NOTNLM
OT  - HIV
OT  - VIH
OT  - bonding
OT  - bridging
OT  - comportements à risque
OT  - reseaux sociaux
OT  - risk behaviors
OT  - school students
OT  - social network
OT  - étudiants
EDAT- 2014/03/20 06:00
MHDA- 2015/01/27 06:00
CRDT- 2014/03/20 06:00
PHST- 2014/03/20 06:00 [entrez]
PHST- 2014/03/20 06:00 [pubmed]
PHST- 2015/01/27 06:00 [medline]
AID - 10.1080/17290376.2014.888676 [doi]
PST - ppublish
SO  - SAHARA J. 2013;10(3-4):131-9. doi: 10.1080/17290376.2014.888676. Epub 2014 Mar 18.

PMID- 28335737
OWN - NLM
STAT- MEDLINE
DCOM- 20170630
LR  - 20181202
IS  - 1471-2334 (Electronic)
IS  - 1471-2334 (Linking)
VI  - 17
IP  - 1
DP  - 2017 Mar 23
TI  - Cytomegalovirus infection in HIV-infected versus non-infected infants and HIV 
      disease progression in Cytomegalovirus infected versus non infected infants early 
      treated with cART in the ANRS 12140-Pediacam study in Cameroon.
PG  - 224
LID - 10.1186/s12879-017-2308-x [doi]
LID - 224
AB  - BACKGROUND: The outcome of CMV/HIV co-infection in infants treated early with 
      combined antiretroviral therapy (cART) in resource-limited settings has not been 
      described. We aimed to estimate the prevalence and identify factors associated with 
      early CMV infection in HIV-infected and non-infected infants included in a study in 
      Cameroon, and to compare HIV disease progression and survival after 1 year of early 
      cART, following infants' CMV status. METHODS: HIV-infected infants followed from 
      birth or from HIV diagnosis before 7 months old and HIV-uninfected infants born to 
      HIV-infected or uninfected mothers were tested for CMV at a median age of 4.0 months 
      [Interquartile range (IQR): 3.4-4.9]. Multivariable logistic regression was 
      performed to identify factors associated with CMV infection. Early cART was offered 
      to HIV-infected infants: mortality, immunological and virological outcomes were 
      assessed. RESULTS: Three hundred and sixty-nine infants were tested. The proportion 
      of infants infected with CMV at baseline was significantly higher in HIV-infected 
      than in HIV-uninfected groups (58.9% (86/146) vs 30.0% (67/223), p < 0.001). At 
      baseline, median CMV viral load was higher in HIV-infected (3.7 log copies/ml [IQR; 
      3.1-4.3]) than in HIV-uninfected infants (2.8 log copies [IQR; 2.1-3.4], p < 0.001). 
      cART was initiated in 90% of HIV-infected infants (132/146) at a median age of 
      4.0 months (IQR; 3.2-5.9); in this sub-group CMV infection was independently 
      associated with being followed from the time of HIV diagnosis rather than from birth 
      (aOR = 3.1, 95%CI [1.2-8.0]), born to a non-single mother (aOR = 3.4[1.4-8.1]), and 
      breastfeeding (aOR = 7.3 [2.7-19.4]). HIV-infected infants were retested after a 
      median of 7.1 months [4.8-9.5]: CMV was undetectable in 37 of the 61 (60.7%) 
      initially CMV-infected cases and became detectable in 8 of the 38 (21.1%) initially 
      CMV-negative cases. After 1 year of cART, the probability of death (0.185 vs 0.203; 
      p = 0.75), the proportion of cases with HIV RNA viral load <400 copies/ml (75.5% vs 
      61.5%; p = 0.17) and the mean CD4 percentage increase (10.97% vs 6.88%; p = 0.15) 
      did not differ between CMV+ and CMV- infants. CONCLUSIONS: We observed a high 
      prevalence of CMV infection among HIV-infected infants. Early initiation of cART may 
      have limited the negative impact of CMV even in the absence of specific anti-CMV 
      treatment.
FAU - Kfutwah, Anfumbom K W
AU  - Kfutwah AK
AD  - Virology Service, Centre Pasteur of Cameroon, Member of the International Network of 
      Pasteur Institutes, P.O. Box 31076, Yaounde, Cameroon. anfumbom25@yahoo.com.
FAU - Ngoupo, Paul Alain T
AU  - Ngoupo PA
AD  - Virology Service, Centre Pasteur of Cameroon, Member of the International Network of 
      Pasteur Institutes, P.O. Box 31076, Yaounde, Cameroon.
FAU - Sofeu, Casimir Ledoux
AU  - Sofeu CL
AD  - Epidemiology and Public Health Service, Centre Pasteur of Cameroon, Member of the 
      International Network of Pasteur Institutes, Yaounde, Cameroon.
FAU - Ndongo, Francis Ateba
AU  - Ndongo FA
AD  - Pediatric Day Clinic, Mother and Child Center of the Chantal Biya Foundation, 
      Yaounde, Cameroon.
FAU - Guemkam, Georgette
AU  - Guemkam G
AD  - Pediatric Day Clinic, Mother and Child Center of the Chantal Biya Foundation, 
      Yaounde, Cameroon.
FAU - Ndiang, Suzie Tetang
AU  - Ndiang ST
AD  - Pediatric Service, Hospital Center Essos, Yaounde, Cameroon.
FAU - Owona, Félicité
AU  - Owona F
AD  - Epidemiology and Public Health Service, Centre Pasteur of Cameroon, Member of the 
      International Network of Pasteur Institutes, Yaounde, Cameroon.
FAU - Penda, Ida Calixte
AU  - Penda IC
AD  - Day Clinic, Laquintinie Hospital, Douala, Cameroon.
AD  - Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Douala, 
      Cameroon.
FAU - Tchendjou, Patrice
AU  - Tchendjou P
AD  - Epidemiology and Public Health Service, Centre Pasteur of Cameroon, Member of the 
      International Network of Pasteur Institutes, Yaounde, Cameroon.
FAU - Rouzioux, Christine
AU  - Rouzioux C
AD  - Assistance Publique des Hôpitaux de Paris, Laboratoire de Virologie, Hôpital Necker, 
      Paris, France.
AD  - Université Paris 5 René Descartes, URF de Médecine, Paris, France.
FAU - Warszawski, Josiane
AU  - Warszawski J
AD  - Equipe 4 (VIH et IST)-INSERM U1018 (CESP), Le Kremlin Bicêtre, France.
AD  - Assistance Publique des Hôpitaux de Paris, Service d'Epidémiologie et de Santé 
      Publique, Hôpital de Bicêtre, Le Kremlin Bicêtre, France.
AD  - Université de Paris Sud 11, Paris, France.
FAU - Faye, Albert
AU  - Faye A
AD  - Assistance Publique des Hôpitaux de Paris, Pédiatrie Générale, Hôpital Robert Debré, 
      Paris, France.
AD  - Université Paris 7 Denis Diderot, Paris Sorbonne Cité, Paris, France.
AD  - INSERM UMR 1123, ECEVE, Paris, France.
FAU - Tejiokem, Mathurin Cyrille
AU  - Tejiokem MC
AD  - Epidemiology and Public Health Service, Centre Pasteur of Cameroon, Member of the 
      International Network of Pasteur Institutes, Yaounde, Cameroon. 
      tejiokem@pasteur-yaounde.org.
AD  - Equipe 4 (VIH et IST)-INSERM U1018 (CESP), Le Kremlin Bicêtre, France. 
      tejiokem@pasteur-yaounde.org.
AD  - , P.O. Box 1274, Yaounde, Cameroon. tejiokem@pasteur-yaounde.org.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20170323
TA  - BMC Infect Dis
JT  - BMC infectious diseases
JID - 100968551
RN  - 0 (Anti-Retroviral Agents)
SB  - IM
MH  - Anti-Retroviral Agents/*therapeutic use
MH  - Cameroon/epidemiology
MH  - Case-Control Studies
MH  - Coinfection/diagnosis/drug therapy/*epidemiology
MH  - Cytomegalovirus Infections/complications/diagnosis/*epidemiology
MH  - Developing Countries
MH  - Disease Progression
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - HIV Infections/complications/*drug therapy/*epidemiology
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Logistic Models
MH  - Male
MH  - Prevalence
MH  - Prospective Studies
MH  - Risk Factors
MH  - Treatment Outcome
PMC - PMC5364639
OTO - NOTNLM
OT  - *Co-infection
OT  - *Cytomegalovirus
OT  - *Early treated HIV-infected infants
OT  - *Human Immunodeficiency Virus
EDAT- 2017/03/25 06:00
MHDA- 2017/07/01 06:00
CRDT- 2017/03/25 06:00
PHST- 2016/08/09 00:00 [received]
PHST- 2017/03/07 00:00 [accepted]
PHST- 2017/03/25 06:00 [entrez]
PHST- 2017/03/25 06:00 [pubmed]
PHST- 2017/07/01 06:00 [medline]
AID - 10.1186/s12879-017-2308-x [pii]
AID - 2308 [pii]
AID - 10.1186/s12879-017-2308-x [doi]
PST - epublish
SO  - BMC Infect Dis. 2017 Mar 23;17(1):224. doi: 10.1186/s12879-017-2308-x.

PMID- 25723991
OWN - NLM
STAT- MEDLINE
DCOM- 20150427
LR  - 20200930
IS  - 1944-7884 (Electronic)
IS  - 1525-4135 (Linking)
VI  - 68 Suppl 2
DP  - 2015 Mar 1
TI  - Applying innovative approaches for reaching men who have sex with men and female sex 
      workers in the Democratic Republic of Congo.
PG  - S248-51
LID - 10.1097/QAI.0000000000000449 [doi]
AB  - BACKGROUND: In the Democratic Republic of Congo (DRC), men who have sex with men 
      (MSM) and female sex workers (FSW) have the highest HIV prevalence but have the 
      least access to services due to their marginalization within Congolese society. 
      METHODS: The Projet Intégré de VIH/SIDA au Congo (ProVIC) aims to reduce the risk 
      and impact of HIV in the DRC through community- and facility-based prevention, 
      counseling and testing, and treatment strategies aimed at high-risk populations, 
      including MSM and FSW. To more effectively meet the needs of key populations, ProVIC 
      tailored the existing interventions to better suit MSM and FSW by offering mobile 
      counseling and rapid HIV testing services at night in MSM and FSW "hotspots," 
      targeting outreach to and mobilizing key populations through social networks of MSM 
      and FSW peer educators and recruiters, and referring MSM and FSW who test HIV 
      positive to "friendly" clinics. RESULTS: Through these approaches, ProVIC was able 
      to reach 2,621 MSM and 12,746 FSW with targeted prevention messaging in 2013 and 
      provide testing and counseling services to 4,366 MSM and 21,033 FSW from October 
      2012 to June 2014. CONCLUSIONS: By applying innovative adaptations geared toward key 
      populations, ProVIC has been able to better reach MSM and FSW in the DRC. ProVIC's 
      targeted interventions for MSM and FSW provide promising examples of programming 
      that can be used to meet the HIV prevention and testing needs of key populations and 
      improve referrals for care and treatment, particularly in complex and unstable 
      settings similar to the DRC.
FAU - Mulongo, Salva
AU  - Mulongo S
AD  - *PATH, Kinshasa, Democratic Republic of Congo; and †PATH, Washington, DC.
FAU - Kapila, Gilbert
AU  - Kapila G
FAU - Hatton, Trad
AU  - Hatton T
FAU - Canagasabey, Davina
AU  - Canagasabey D
FAU - Arney, Jennifer
AU  - Arney J
FAU - Kazadi, Tifa
AU  - Kazadi T
FAU - Scott, Lisa M
AU  - Scott LM
FAU - Colfax, Grant
AU  - Colfax G
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - J Acquir Immune Defic Syndr
JT  - Journal of acquired immune deficiency syndromes (1999)
JID - 100892005
SB  - IM
MH  - Ambulatory Care Facilities
MH  - Democratic Republic of the Congo/epidemiology
MH  - Female
MH  - HIV Infections/epidemiology/*prevention & control
MH  - Health Services
MH  - Health Services Accessibility
MH  - *Homosexuality, Male
MH  - Humans
MH  - Male
MH  - *Sex Workers
EDAT- 2015/02/28 06:00
MHDA- 2015/04/29 06:00
CRDT- 2015/02/28 06:00
PHST- 2015/02/28 06:00 [entrez]
PHST- 2015/02/28 06:00 [pubmed]
PHST- 2015/04/29 06:00 [medline]
AID - 00126334-201503011-00023 [pii]
AID - 10.1097/QAI.0000000000000449 [doi]
PST - ppublish
SO  - J Acquir Immune Defic Syndr. 2015 Mar 1;68 Suppl 2:S248-51. doi: 
      10.1097/QAI.0000000000000449.

PMID- 26416439
OWN - NLM
STAT- MEDLINE
DCOM- 20170130
LR  - 20170130
IS  - 1552-5732 (Electronic)
IS  - 0890-3344 (Linking)
VI  - 32
IP  - 1
DP  - 2016 Feb
TI  - Enforcing the International Code of Marketing of Breast-milk Substitutes for Better 
      Promotion of Exclusive Breastfeeding: Can Lessons Be Learned?
PG  - 20-7
LID - 10.1177/0890334415607816 [doi]
AB  - Exclusive breastfeeding, one of the best natural resources, needs protection and 
      promotion. The International Code of Marketing of Breast-milk Substitutes (the 
      Code), which aims to prevent the undermining of breastfeeding by formula 
      advertising, faces implementation challenges. We reviewed frequently overlooked 
      challenges and obstacles that the Code is facing worldwide, but particularly in 
      Southeast Asia. Drawing lessons from various countries where we work, and following 
      the example of successful public health interventions, we discussed legislation, 
      enforcement, and experiences that are needed to successfully implement the Code. 
      Successful holistic approaches that have strengthened the Code need to be scaled up. 
      Community-based actions and peer-to-peer promotions have proved successful. 
      Legislation without stringent enforcement and sufficient penalties is ineffective. 
      The public needs education about the benefits and ways and means to support 
      breastfeeding. It is crucial to combine strong political commitment and leadership 
      with strict national regulations, definitions, and enforcement. National 
      breastfeeding committees, with the authority to improve regulations, investigate 
      violations, and enforce the laws, must be established. Systematic monitoring and 
      reporting are needed to identify companies, individuals, intermediaries, and 
      practices that infringe on the Code. Penalizing violators is crucial. Managers of 
      multinational companies must be held accountable for international violations, and 
      international legislative enforcement needs to be established. Further measures 
      should include improved regulations to protect the breastfeeding mother: large-scale 
      education campaigns; strong penalties for Code violators; exclusion of the formula 
      industry from nutrition, education, and policy roles; supportive legal networks; and 
      independent research of interventions supporting breastfeeding.
CI  - © The Author(s) 2015.
FAU - Barennes, Hubert
AU  - Barennes H
AD  - Agence Nationale de Recherche sur le VIH et les Hepatites (ANRS), Phnom Penh, 
      Cambodia ISPED, Centre INSERM U897-Epidemiologie-Biostatistique, Université de 
      Bordeaux, Bordeaux, France Epidemiology Unit, Pasteur Institute, Phnom Penh, 
      Cambodia barenneshub@yahoo.fr.
FAU - Slesak, Guenther
AU  - Slesak G
AD  - Tropenklinik Paul-Lechler-Krankenhaus, Tübingen, Germany.
FAU - Goyet, Sophie
AU  - Goyet S
AD  - Epidemiology Unit, Pasteur Institute, Phnom Penh, Cambodia.
FAU - Aaron, Percy
AU  - Aaron P
AD  - Vientiane College, Vientiane, Laos.
FAU - Srour, Leila M
AU  - Srour LM
AD  - Health Frontiers, Vientiane, Laos.
LA  - eng
PT  - Journal Article
DEP - 20150928
PL  - United States
TA  - J Hum Lact
JT  - Journal of human lactation : official journal of International Lactation Consultant 
      Association
JID - 8709498
MH  - Asia, Southeastern
MH  - *Breast Feeding
MH  - Developing Countries
MH  - Female
MH  - Global Health
MH  - Health Education
MH  - *Health Policy
MH  - *Health Promotion
MH  - Humans
MH  - Infant
MH  - *Infant Formula/economics/legislation & jurisprudence
MH  - Infant, Newborn
MH  - International Cooperation
MH  - Law Enforcement
MH  - Marketing/*legislation & jurisprudence/*standards
OTO - NOTNLM
OT  - Asia
OT  - Code
OT  - Laos
OT  - advance
OT  - ban
OT  - boycott
OT  - breast-milk substitute
OT  - breastfeeding
OT  - enforcements
OT  - follow up
OT  - formula
OT  - infant feeding
OT  - laws
OT  - malnutrition
OT  - policy
OT  - regulations
OT  - violations
EDAT- 2015/09/30 06:00
MHDA- 2017/01/31 06:00
CRDT- 2015/09/30 06:00
PHST- 2015/02/17 00:00 [received]
PHST- 2015/08/25 00:00 [accepted]
PHST- 2015/09/30 06:00 [entrez]
PHST- 2015/09/30 06:00 [pubmed]
PHST- 2017/01/31 06:00 [medline]
AID - 0890334415607816 [pii]
AID - 10.1177/0890334415607816 [doi]
PST - ppublish
SO  - J Hum Lact. 2016 Feb;32(1):20-7. doi: 10.1177/0890334415607816. Epub 2015 Sep 28.

PMID- 26010948
OWN - NLM
STAT- MEDLINE
DCOM- 20160204
LR  - 20181113
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 10
IP  - 5
DP  - 2015
TI  - Epidemiological Surveillance of HIV-1 Transmitted Drug Resistance in Spain in 
      2004-2012: Relevance of Transmission Clusters in the Propagation of Resistance 
      Mutations.
PG  - e0125699
LID - 10.1371/journal.pone.0125699 [doi]
LID - e0125699
AB  - Our objectives were to carry out an epidemiological surveillance study on 
      transmitted drug resistance (TDR) among individuals newly diagnosed of HIV-1 
      infection during a nine year period in Spain and to assess the role of transmission 
      clusters (TC) in the propagation of resistant strains. An overall of 1614 newly 
      diagnosed individuals were included in the study from January 2004 through December 
      2012. Individuals come from two different Spanish regions: Galicia and the Basque 
      Country. Resistance mutations to reverse transcriptase inhibitors (RTI) and protease 
      inhibitors (PI) were analyzed according to mutations included in the surveillance 
      drug-resistance mutations list updated in 2009. TC were defined as those comprising 
      viruses from five or more individuals whose sequences clustered in maximum 
      likelihood phylogenetic trees with a bootstrap value ≥90%. The overall prevalence of 
      TDR to any drug was 9.9%: 4.9% to nucleoside RTIs (NRTIs), 3.6% to non-nucleoside 
      RTIs (NNRTIs), and 2.7% to PIs. A significant decrease of TDR to NRTIs over time was 
      observed [from 10% in 2004 to 2% in 2012 (p=0.01)]. Sixty eight (42.2%) of 161 
      sequences with TDR were included in 25 TC composed of 5 or more individuals. Of 
      them, 9 clusters harbored TDR associated with high level resistance to 
      antiretroviral drugs. T215D revertant mutation was transmitted in a large cluster 
      comprising 25 individuals. The impact of epidemiological networks on TDR frequency 
      may explain its persistence in newly diagnosed individuals. The knowledge of the 
      populations involved in TC would facilitate the design of prevention programs and 
      public health interventions.
FAU - Vega, Yolanda
AU  - Vega Y
AD  - Unidad de Biología y Variabilidad de VIH, Centro Nacional de Microbiología, 
      Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.
FAU - Delgado, Elena
AU  - Delgado E
AD  - Unidad de Biología y Variabilidad de VIH, Centro Nacional de Microbiología, 
      Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.
FAU - Fernández-García, Aurora
AU  - Fernández-García A
AD  - Unidad de Biología y Variabilidad de VIH, Centro Nacional de Microbiología, 
      Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.
FAU - Cuevas, Maria Teresa
AU  - Cuevas MT
AD  - Unidad de Biología y Variabilidad de VIH, Centro Nacional de Microbiología, 
      Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.
FAU - Thomson, Michael M
AU  - Thomson MM
AD  - Unidad de Biología y Variabilidad de VIH, Centro Nacional de Microbiología, 
      Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.
FAU - Montero, Vanessa
AU  - Montero V
AD  - Unidad de Biología y Variabilidad de VIH, Centro Nacional de Microbiología, 
      Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.
FAU - Sánchez, Monica
AU  - Sánchez M
AD  - Unidad de Biología y Variabilidad de VIH, Centro Nacional de Microbiología, 
      Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.
FAU - Sánchez, Ana Maria
AU  - Sánchez AM
AD  - Unidad de Biología y Variabilidad de VIH, Centro Nacional de Microbiología, 
      Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.
FAU - Pérez-Álvarez, Lucia
AU  - Pérez-Álvarez L
AD  - Unidad de Biología y Variabilidad de VIH, Centro Nacional de Microbiología, 
      Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.
CN  - Spanish Group for the Study of New HIV-1 Diagnoses in Galicia and Basque Country
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150526
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (HIV Protease Inhibitors)
RN  - 0 (Reverse Transcriptase Inhibitors)
RN  - EC 2.7.7.49 (HIV Reverse Transcriptase)
RN  - EC 3.4.23.- (HIV Protease)
SB  - IM
MH  - Adult
MH  - Cluster Analysis
MH  - Drug Resistance, Viral/drug effects/genetics
MH  - *Epidemiological Monitoring
MH  - Female
MH  - Genotype
MH  - HIV Infections/drug therapy/*epidemiology/transmission/virology
MH  - HIV Protease/*genetics/metabolism
MH  - HIV Protease Inhibitors/therapeutic use
MH  - HIV Reverse Transcriptase/antagonists & inhibitors/*genetics/metabolism
MH  - HIV-1/*classification/drug effects/enzymology/*genetics
MH  - Humans
MH  - Male
MH  - *Mutation
MH  - Phylogeny
MH  - Prevalence
MH  - Reverse Transcriptase Inhibitors/therapeutic use
MH  - Spain/epidemiology
PMC - PMC4444345
COIS- Competing Interests: The authors have declared that no competing interests exist.
FIR - Alvarez, H
IR  - Alvarez H
FIR - Mariño, A
IR  - Mariño A
FIR - Ordoñez, P
IR  - Ordoñez P
FIR - Castro, M A
IR  - Castro MA
FIR - Alonso, P
IR  - Alonso P
FIR - Coira, M A
IR  - Coira MA
FIR - Corredoira, J
IR  - Corredoira J
FIR - López-Álvarez, M J
IR  - López-Álvarez MJ
FIR - Velasco, D
IR  - Velasco D
FIR - Casado Bustillo, M
IR  - Casado Bustillo M
FIR - García-Costa, J
IR  - García-Costa J
FIR - Fernández-Rodríguez, R
IR  - Fernández-Rodríguez R
FIR - Naval, G
IR  - Naval G
FIR - López-Díaz, D
IR  - López-Díaz D
FIR - Rodriguez, R
IR  - Rodriguez R
FIR - Miralles, C
IR  - Miralles C
FIR - Ocampo, A
IR  - Ocampo A
FIR - Pérez-Castro, S
IR  - Pérez-Castro S
FIR - Díz, Arén
IR  - Díz A
FIR - Ojea de Castro, R
IR  - Ojea de Castro R
FIR - Rodríguez, R
IR  - Rodríguez R
FIR - Trigo, M
IR  - Trigo M
FIR - Agud, J M
IR  - Agud JM
FIR - Aldamiz, M
IR  - Aldamiz M
FIR - Ayensa, C
IR  - Ayensa C
FIR - Barroso, J
IR  - Barroso J
FIR - Lezaun, M J
IR  - Lezaun MJ
FIR - Michaus, L
IR  - Michaus L
FIR - Pérez-Ortolá, R
IR  - Pérez-Ortolá R
FIR - Portu, J J
IR  - Portu JJ
FIR - Andia, A
IR  - Andia A
FIR - Canut, A
IR  - Canut A
FIR - Arrizabalaga, J
IR  - Arrizabalaga J
FIR - Cilla, G
IR  - Cilla G
FIR - Echeverría, J
IR  - Echeverría J
FIR - Echeverría, M J
IR  - Echeverría MJ
FIR - Iribarren, J A
IR  - Iribarren JA
FIR - Von Wichmann, M A
IR  - Von Wichmann MA
FIR - Bustillo, M A
IR  - Bustillo MA
FIR - Baraia, J B
IR  - Baraia JB
FIR - Cisterna, R
IR  - Cisterna R
FIR - Ferrero, O
IR  - Ferrero O
FIR - Hernáez-Crespo, S
IR  - Hernáez-Crespo S
FIR - Ibarra, S
IR  - Ibarra S
FIR - Muñoz-Sánchez, J
IR  - Muñoz-Sánchez J
FIR - Santamaría, J M
IR  - Santamaría JM
FIR - Sota, M
IR  - Sota M
FIR - Suarez, D
IR  - Suarez D
FIR - Zubero, Z
IR  - Zubero Z
FIR - Aguirrebengoa, K
IR  - Aguirrebengoa K
FIR - Bereciartura, E
IR  - Bereciartura E
FIR - Goikoetxea, J
IR  - Goikoetxea J
FIR - López Soria, L
IR  - López Soria L
FIR - Montejo, J M
IR  - Montejo JM
FIR - Lizarraga, M
IR  - Lizarraga M
FIR - Silvariño, R
IR  - Silvariño R
FIR - López de Goicoechea, M J
IR  - López de Goicoechea MJ
FIR - Mayo, J
IR  - Mayo J
EDAT- 2015/05/27 06:00
MHDA- 2016/02/05 06:00
CRDT- 2015/05/27 06:00
PHST- 2015/01/08 00:00 [received]
PHST- 2015/03/21 00:00 [accepted]
PHST- 2015/05/27 06:00 [entrez]
PHST- 2015/05/27 06:00 [pubmed]
PHST- 2016/02/05 06:00 [medline]
AID - PONE-D-15-00939 [pii]
AID - 10.1371/journal.pone.0125699 [doi]
PST - epublish
SO  - PLoS One. 2015 May 26;10(5):e0125699. doi: 10.1371/journal.pone.0125699. eCollection 
      2015.

PMID- 26267615
OWN - NLM
STAT- MEDLINE
DCOM- 20160526
LR  - 20181113
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 10
IP  - 8
DP  - 2015
TI  - Combining the Estimated Date of HIV Infection with a Phylogenetic Cluster Study to 
      Better Understand HIV Spread: Application in a Paris Neighbourhood.
PG  - e0135367
LID - 10.1371/journal.pone.0135367 [doi]
LID - e0135367
AB  - OBJECTIVES: To relate socio-demographic and virological information to phylogenetic 
      clustering in HIV infected patients in a limited geographical area and to evaluate 
      the role of recently infected individuals in the spread of HIV. METHODS: HIV-1 pol 
      sequences from newly diagnosed and treatment-naive patients receiving follow-up 
      between 2008 and 2011 by physicians belonging to a health network in Paris were used 
      to build a phylogenetic tree using neighbour-joining analysis. Time since infection 
      was estimated by immunoassay to define recently infected patients (very early 
      infected presenters, VEP). Data on socio-demographic, clinical and biological 
      features in clustered and non-clustered patients were compared. Chains of infection 
      structure was also analysed. RESULTS: 547 patients were included, 49 chains of 
      infection containing 108 (20%) patients were identified by phylogenetic analysis. 
      analysis. Eighty individuals formed pairs and 28 individuals were belonging to 
      larger clusters. The median time between two successive HIV diagnoses in the same 
      chain of infection was 248 days [CI = 176-320]. 34.7% of individuals were considered 
      as VEP, and 27% of them were included in chains of infection. Multivariable analysis 
      showed that belonging to a cluster was more frequent in VEP and those under 30 years 
      old (OR: 3.65, 95 CI 1.49-8.95, p = 0.005 and OR: 2.42, 95% CI 1.05-5.85, p = 0.04 
      respectively). The prevalence of drug resistance was not associated with belonging 
      to a pair or a cluster. Within chains, VEP were not grouped together more than 
      chance predicted (p = 0.97). CONCLUSIONS: Most newly diagnosed patients did not 
      belong to a chain of infection, confirming the importance of undiagnosed or 
      untreated HIV infected individuals in transmission. Furthermore, clusters involving 
      both recently infected individuals and longstanding infected individuals support a 
      substantial role in transmission of the latter before diagnosis.
FAU - Robineau, Olivier
AU  - Robineau O
AD  - Service Universitaire Régional de Maladies Infectieuses et Tropicales, Centre 
      Hospitalier de Tourcoing, Tourcoing, France; INSERM, UMR_S 1136, Institut Pierre 
      Louis d'Epidémiologie et de Santé Publique, Paris, France.
FAU - Frange, Pierre
AU  - Frange P
AD  - EA 3620, Université Paris Descartes, Sorbonne Paris-Cité, Paris, France; Laboratoire 
      de Microbiologie & Unité d'Immunologie, Hématologie et Rhumatologie Pédiatriques, 
      AP-HP, Hôpital Necker, Enfants Malades, Paris, France.
FAU - Barin, Francis
AU  - Barin F
AD  - Centre National de Référence du VIH & INSERM U966, CHU Bretonneau & Université 
      Francois Rabelais, Tours, France.
FAU - Cazein, Françoise
AU  - Cazein F
AD  - Institut de Veille Sanitaire, Saint-Maurice, France.
FAU - Girard, Pierre-Marie
AU  - Girard PM
AD  - INSERM, UMR_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, 
      Paris, France; Service des Maladies Infectieuses et Tropicales, Hôpital Saint 
      Antoine, APHP, Paris, France.
FAU - Chaix, Marie-Laure
AU  - Chaix ML
AD  - EA 3620, Université Paris Descartes, Sorbonne Paris-Cité, Paris, France; Laboratoire 
      de Virologie, AP-HP, Hôpital Saint-Louis, Paris, France.
FAU - Kreplak, Georges
AU  - Kreplak G
AD  - Laboratoire du Chemin Vert, Paris, France.
FAU - Boelle, Pierre-Yves
AU  - Boelle PY
AD  - INSERM, UMR_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, 
      Paris, France; Sorbonne Universités, UPMC Univ Paris 06, UMR_S 943, Paris, France; 
      Service de Santé Publique, AP-HP, Hôpital Saint-Antoine, Paris, France.
FAU - Morand-Joubert, Laurence
AU  - Morand-Joubert L
AD  - INSERM, UMR_S 943, Paris, France; Laboratoire de Virologie, Hôpital Saint-Antoine, 
      AP-HP, Paris, France.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150812
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - AIDS Serodiagnosis
MH  - Adult
MH  - Female
MH  - Genotype
MH  - HIV Infections/diagnosis/*epidemiology/virology
MH  - HIV-1/*genetics/isolation & purification
MH  - Humans
MH  - Male
MH  - Paris
MH  - *Phylogeny
PMC - PMC4534393
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2015/08/13 06:00
MHDA- 2016/05/27 06:00
CRDT- 2015/08/13 06:00
PHST- 2015/01/03 00:00 [received]
PHST- 2015/07/21 00:00 [accepted]
PHST- 2015/08/13 06:00 [entrez]
PHST- 2015/08/13 06:00 [pubmed]
PHST- 2016/05/27 06:00 [medline]
AID - PONE-D-14-49224 [pii]
AID - 10.1371/journal.pone.0135367 [doi]
PST - epublish
SO  - PLoS One. 2015 Aug 12;10(8):e0135367. doi: 10.1371/journal.pone.0135367. eCollection 
      2015.

PMID- 22263357
OWN - NLM
STAT- MEDLINE
DCOM- 20120403
LR  - 20181201
IS  - 0034-0634 (Print)
IS  - 0034-0634 (Linking)
VI  - 127
IP  - 4
DP  - 2010
TI  - [Clinical indications for resistance testing HIV infection].
PG  - 749-58; discussion 758-62
AB  - Treatment of HIV infection currently presents a number of problems such as: a) 
      Capacity choice of antiretrovirals used (classic and new), b) study of the emergence 
      of resistance to them (molecular mechanisms of emergence of mutations agains 
      treverse transcriptase, protease, integrase and CCR5 antagonists), c) high cost of 
      drugs, as well as analytical testing or hospital incarnation, so palpable that 
      expensive treatment; d) Information clinical application of tests of resistance, ie 
      to whom and when tobe performed; e) Interpretation of genotype resistance, good 
      clinical type (internal, external and cross), the fuzzy rules and fuzzy rules 
      mathematics, neural networks (net neurat Works) or the different cohorts of 
      resistance based on the development of databases.
FAU - Maroto Vela, M del Carmen
AU  - Maroto Vela Mdel C
LA  - spa
PT  - Lecture
TT  - Indicaciones clínicas de las pruebas de resistencia en la infección VIH.
PL  - Spain
TA  - An R Acad Nac Med (Madr)
JT  - Anales de la Real Academia Nacional de Medicina
JID - 7505188
RN  - 0 (Anti-Retroviral Agents)
SB  - IM
MH  - Anti-Retroviral Agents/therapeutic use
MH  - *Drug Resistance, Viral
MH  - HIV Infections/*drug therapy
MH  - Humans
EDAT- 2010/01/01 00:00
MHDA- 2012/04/04 06:00
CRDT- 2012/01/24 06:00
PHST- 2012/01/24 06:00 [entrez]
PHST- 2010/01/01 00:00 [pubmed]
PHST- 2012/04/04 06:00 [medline]
PST - ppublish
SO  - An R Acad Nac Med (Madr). 2010;127(4):749-58; discussion 758-62.

PMID- 25143025
OWN - NLM
STAT- MEDLINE
DCOM- 20140918
LR  - 20181202
IS  - 1528-4336 (Print)
IS  - 1528-4336 (Linking)
VI  - 15
IP  - 4
DP  - 2014 Jul-Aug
TI  - Citalopram for the prevention of depression and its consequences in HIV-hepatitis C 
      coinfected individuals initiating pegylated interferon/ribavirin therapy: a 
      multicenter randomized double-blind placebo-controlled trial.
PG  - 161-75
LID - 10.1310/hct1504-161 [doi]
AB  - BACKGROUND: Depression related to interferon-alpha (IFN-α) is common, may reduce 
      adherence, and can be treatment limiting. HIV-HCV coinfected persons experience 
      lower sustained virologic response rates and commonly have psychiatric 
      comorbidities, thus they may benefit from prevention of depression. OBJECTIVE: The 
      aim of the study was to determine whether prophylactic citalopram can increase HCV 
      treatment adherence and reduce the incidence of moderate depression in HIV-HCV 
      coinfected patients initiating PEG-IFN-α/ribavirin therapy. METHODS: This was an 
      investigator-initiated Canadian multicenter randomized, double-blind 
      placebo-controlled trial. HIV-HCV coinfected patients were randomized in a 1:1 ratio 
      to receive citalopram or placebo 3 weeks prior to starting PEG-IFN-α2b/ribavirin, 
      stratified by study center and HCV genotype. The protocol design permitted the 
      comparison of prophylaxis with the treatment of emergent depression. The primary 
      outcomes were adherence (assessed through questionnaire and returned medication) and 
      time to moderate depression measured by Beck Depression Inventory-II (BDI- II) score 
      greater than 15, confirmed 2 weeks apart. RESULTS: Seventy-six patients (36 
      citalopram/40 placebo) were randomized. Overall adherence was high, ranging from 95% 
      (week 12) to 91% (week 48). There was no difference between arms with respect to 
      mean or median adherence at any study time point. Cumulative incidence of moderate 
      depression did not differ significantly by group (log rank P = .32). The hazard 
      ratio for moderate depression was 0.81 (95% CI, 0.26 to 2.54) for citalopram 
      compared with placebo when adjusted for baseline BDI-II score. CONCLUSIONS: A 
      strategy of prophylactic citalopram compared to treatment of emergent depression was 
      not associated with higher adherence or a reduction in treatment-limiting depression 
      nor did it significantly reduce depressive symptoms among HIV-HCV coinfected persons 
      during treatment for HCV.
FAU - Klein, Marina B
AU  - Klein MB
AD  - Division of Infectious Diseases/Chronic Viral Illness Service, Department of 
      Medicine, Royal Victoria Hospital, McGill University Health Centre, Montréal, 
      Québec, Canada Canadian HIV Trials Network, Vancouver, British Columbia, Canada.
FAU - Lee, Terry
AU  - Lee T
AD  - Canadian HIV Trials Network, Vancouver, British Columbia, Canada.
FAU - Brouillette, Marie-Josée
AU  - Brouillette MJ
AD  - Division of Infectious Diseases/Chronic Viral Illness Service, Department of 
      Medicine, Royal Victoria Hospital, McGill University Health Centre, Montréal, 
      Québec, Canada Department of Psychiatry, McGill University, Montréal, Québec, Canada 
      Royal Victoria Hospital, McGill University Health Centre, Montréal, Québec, Canada.
FAU - Sheehan, Nancy L
AU  - Sheehan NL
AD  - Division of Infectious Diseases/Chronic Viral Illness Service, Department of 
      Medicine, Royal Victoria Hospital, McGill University Health Centre, Montréal, 
      Québec, Canada Department of Pharmacy, McGill University Health Centre, Montréal, 
      Québec, Canada Faculté de Pharmacie, Université de Montréal, Montréal, Québec, 
      Canada.
FAU - Walmsley, Sharon
AU  - Walmsley S
AD  - Canadian HIV Trials Network, Vancouver, British Columbia, Canada University Health 
      Network, University of Toronto, Toronto, Ontario, Canada.
FAU - Wong, David K
AU  - Wong DK
AD  - University Health Network, University of Toronto, Toronto, Ontario, Canada.
FAU - Conway, Brian
AU  - Conway B
AD  - Vancouver Infectious Diseases Research and Care Centre, Vancouver, British Columbia, 
      Canada.
FAU - Hull, Mark
AU  - Hull M
AD  - BC Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
FAU - Cooper, Curtis
AU  - Cooper C
AD  - Canadian HIV Trials Network, Vancouver, British Columbia, Canada The Ottawa Hospital 
      Research Institute, Ottawa, Ontario, Canada.
FAU - Haidar, Shariq
AU  - Haidar S
AD  - McMaster Health Science Centre, Hamilton, Ontario, Canada.
FAU - Vezina, Sylvie
AU  - Vezina S
AD  - Clinique médicale l'Actuel (VIH ITS Hépatites), Montréal, Québec, Canada Centre 
      hospitalier de l'université de Montréal, Montréal, Québec, Canada.
FAU - Annable, Lawrence
AU  - Annable L
AD  - Department of Psychiatry, McGill University, Montréal, Québec, Canada.
FAU - Young, Simon
AU  - Young S
AD  - Department of Psychiatry, McGill University, Montréal, Québec, Canada Royal Victoria 
      Hospital, McGill University Health Centre, Montréal, Québec, Canada.
FAU - Zubyk, Wendy
AU  - Zubyk W
AD  - Canadian HIV Trials Network, Vancouver, British Columbia, Canada.
FAU - Singer, Joel
AU  - Singer J
AD  - Canadian HIV Trials Network, Vancouver, British Columbia, Canada.
LA  - eng
SI  - ClinicalTrials.gov/NCT00317746
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - HIV Clin Trials
JT  - HIV clinical trials
JID - 100936377
RN  - 0 (Antidepressive Agents, Second-Generation)
RN  - 0 (Antiviral Agents)
RN  - 0 (Interferon alpha-2)
RN  - 0 (Interferon-alpha)
RN  - 0 (Recombinant Proteins)
RN  - 0DHU5B8D6V (Citalopram)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - 49717AWG6K (Ribavirin)
RN  - G8RGG88B68 (peginterferon alfa-2b)
SB  - IM
MH  - Adult
MH  - Antidepressive Agents, Second-Generation/*therapeutic use
MH  - Antiviral Agents/*therapeutic use
MH  - Citalopram/adverse effects/*therapeutic use
MH  - Coinfection
MH  - Depression/*prevention & control
MH  - Double-Blind Method
MH  - Female
MH  - HIV Infections/*complications
MH  - Hepatitis C/*complications
MH  - Humans
MH  - Interferon alpha-2
MH  - Interferon-alpha/administration & dosage/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Polyethylene Glycols/administration & dosage/therapeutic use
MH  - Recombinant Proteins/administration & dosage/therapeutic use
MH  - Ribavirin/administration & dosage/therapeutic use
OTO - NOTNLM
OT  - HIV
OT  - citalopram
OT  - coinfection
OT  - depression
OT  - hepatitis C virus
OT  - interferon-alpha
EDAT- 2014/08/22 06:00
MHDA- 2014/09/19 06:00
CRDT- 2014/08/22 06:00
PHST- 2014/08/22 06:00 [entrez]
PHST- 2014/08/22 06:00 [pubmed]
PHST- 2014/09/19 06:00 [medline]
AID - K7X0H87061228078 [pii]
AID - 10.1310/hct1504-161 [doi]
PST - ppublish
SO  - HIV Clin Trials. 2014 Jul-Aug;15(4):161-75. doi: 10.1310/hct1504-161.

PMID- 21522007
OWN - NLM
STAT- MEDLINE
DCOM- 20110914
LR  - 20110629
IS  - 1473-5571 (Electronic)
IS  - 0269-9370 (Linking)
VI  - 25
IP  - 11
DP  - 2011 Jul 17
TI  - Circulation of multiple patterns of unique recombinant forms B/CRF02_AG in France: 
      precursor signs of the emergence of an upcoming CRF B/02.
PG  - 1371-7
LID - 10.1097/QAD.0b013e328347c060 [doi]
AB  - BACKGROUND: HIV-1 group M is characterized by substantial genetic diversity, and 
      includes nine subtypes, more than 45 circulating recombinant forms (CRFs), and 
      numerous unique recombinant forms (URFs). In France, the epidemic is characterized 
      by predominance of subtype B strains, increasing prevalence of non-B subtypes 
      (CRF02_AG being the most prevalent) and increasing at-risk behaviour in the MSM 
      population. The high prevalence and co-circulation of B and CRF02_AG strains in this 
      population raise the possibility that recombinant forms might emerge and spread. 
      METHODS: Samples from seven patients (five being MSM) were selected on the basis of 
      subtyping discordances in different regions. The pattern of each near full-length 
      genome of the viruses was characterized. The relationships between the newly and 
      previously described B/CRF02_AG URFs were analysed using phylogenetic networks. 
      Single genome amplification was used to search for the parental strains and 
      confirmation of the breakpoints. RESULTS: Seven unique recombination patterns were 
      identified, breakpoints being found throughout the genomes, with hotspots in pol and 
      accessory genes. No link was observed with the previous forms, but the CRF02 regions 
      of two new viruses indicated that they are phylogenetically associated, suggesting a 
      common ancestral strain. No evidence of circulating parental strains was found. 
      CONCLUSION: This description of seven URFs involving subtype B and CRF02_AG 
      highlights the growing complexity of HIV molecular epidemiology in France. These 
      multiple patterns, found mostly in MSM, and the hypothesis of a better fitness of 
      some recombinant strains, argue for a context that could lead to the genesis of 
      CRFB/02_AG strains in France.
FAU - Leoz, Marie
AU  - Leoz M
AD  - Laboratoire associé au CNR du VIH, hôpital Ch. Nicolle, CHU de Rouen, France.
FAU - Chaix, Marie-Laure
AU  - Chaix ML
FAU - Delaugerre, Constance
AU  - Delaugerre C
FAU - Rivoisy, Claire
AU  - Rivoisy C
FAU - Meyer, Laurence
AU  - Meyer L
FAU - Rouzioux, Christine
AU  - Rouzioux C
FAU - Simon, François
AU  - Simon F
FAU - Plantier, Jean-Christophe
AU  - Plantier JC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - AIDS
JT  - AIDS (London, England)
JID - 8710219
RN  - 0 (DNA, Recombinant)
RN  - 0 (RNA, Viral)
SB  - IM
MH  - Adult
MH  - Aged
MH  - DNA, Recombinant/*genetics/immunology
MH  - Female
MH  - France/epidemiology
MH  - Gene Amplification/physiology
MH  - Genetic Variation
MH  - HIV Infections/epidemiology/*genetics/immunology
MH  - HIV-1/*genetics/isolation & purification
MH  - Homosexuality, Male
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Phylogeny
MH  - RNA, Viral/*genetics
MH  - Reverse Transcriptase Polymerase Chain Reaction
EDAT- 2011/04/28 06:00
MHDA- 2011/09/15 06:00
CRDT- 2011/04/28 06:00
PHST- 2011/04/28 06:00 [entrez]
PHST- 2011/04/28 06:00 [pubmed]
PHST- 2011/09/15 06:00 [medline]
AID - 10.1097/QAD.0b013e328347c060 [doi]
PST - ppublish
SO  - AIDS. 2011 Jul 17;25(11):1371-7. doi: 10.1097/QAD.0b013e328347c060.

PMID- 25336166
OWN - NLM
STAT- MEDLINE
DCOM- 20151016
LR  - 20211021
IS  - 1460-2091 (Electronic)
IS  - 0305-7453 (Print)
IS  - 0305-7453 (Linking)
VI  - 70
IP  - 3
DP  - 2015 Mar
TI  - Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line 
      NNRTI-based ART: a multicohort European case-control study using centralized 
      ultrasensitive 454 pyrosequencing.
PG  - 930-40
LID - 10.1093/jac/dku426 [doi]
AB  - OBJECTIVES: It is still debated if pre-existing minority drug-resistant HIV-1 
      variants (MVs) affect the virological outcomes of first-line NNRTI-containing ART. 
      METHODS: This Europe-wide case-control study included ART-naive subjects infected 
      with drug-susceptible HIV-1 as revealed by population sequencing, who achieved 
      virological suppression on first-line ART including one NNRTI. Cases experienced 
      virological failure and controls were subjects from the same cohort whose viraemia 
      remained suppressed at a matched time since initiation of ART. Blinded, centralized 
      454 pyrosequencing with parallel bioinformatic analysis in two laboratories was used 
      to identify MVs in the 1%-25% frequency range. ORs of virological failure according 
      to MV detection were estimated by logistic regression. RESULTS: Two hundred and 
      sixty samples (76 cases and 184 controls), mostly subtype B (73.5%), were used for 
      the analysis. Identical MVs were detected in the two laboratories. 31.6% of cases 
      and 16.8% of controls harboured pre-existing MVs. Detection of at least one MV 
      versus no MVs was associated with an increased risk of virological failure 
      (OR = 2.75, 95% CI = 1.35-5.60, P = 0.005); similar associations were observed for 
      at least one MV versus no NRTI MVs (OR = 2.27, 95% CI = 0.76-6.77, P = 0.140) and at 
      least one MV versus no NNRTI MVs (OR = 2.41, 95% CI = 1.12-5.18, P = 0.024). A 
      dose-effect relationship between virological failure and mutational load was found. 
      CONCLUSIONS: Pre-existing MVs more than double the risk of virological failure to 
      first-line NNRTI-based ART.
CI  - © The Author 2014. Published by Oxford University Press on behalf of the British 
      Society for Antimicrobial Chemotherapy.
FAU - Cozzi-Lepri, Alessandro
AU  - Cozzi-Lepri A
AD  - University College London, London, UK.
FAU - Noguera-Julian, Marc
AU  - Noguera-Julian M
AD  - Institut de Recerca de la SIDA IrsiCaixa i Unitat VIH, Universitat Autònoma de 
      Barcelona, Universitat de Vic, Catalonia, Spain.
FAU - Di Giallonardo, Francesca
AU  - Di Giallonardo F
AD  - Division of Infectious Diseases and Hospital Epidemiology, University Hospital 
      Zurich, University of Zurich, Zurich, Switzerland.
FAU - Schuurman, Rob
AU  - Schuurman R
AD  - Department of Virology, University Medical Centre, Utrecht, The Netherlands.
FAU - Däumer, Martin
AU  - Däumer M
AD  - Institut für Immunologie und Genetik, Kaiserslautern, Germany.
FAU - Aitken, Sue
AU  - Aitken S
AD  - Department of Virology, University Medical Centre, Utrecht, The Netherlands.
FAU - Ceccherini-Silberstein, Francesca
AU  - Ceccherini-Silberstein F
AD  - Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, 
      Rome, Italy.
FAU - D'Arminio Monforte, Antonella
AU  - D'Arminio Monforte A
AD  - Department of Health Sciences, Clinic of Infectious Diseases, 'San Paolo' Hospital, 
      University of Milan, Milan, Italy.
FAU - Geretti, Anna Maria
AU  - Geretti AM
AD  - Institute of Infection & Global Health, University of Liverpool, Liverpool, UK.
FAU - Booth, Clare L
AU  - Booth CL
AD  - Department of Virology, Royal Free London NHS Foundation Trust, London, UK.
FAU - Kaiser, Rolf
AU  - Kaiser R
AD  - Institute of Virology, University of Cologne, Cologne, Germany.
FAU - Michalik, Claudia
AU  - Michalik C
AD  - Competence Network for HIV/AIDS, Bochum, Germany and Clinic for Dermatology, 
      Venerology and Allergology of the Ruhr-Universität, Bochum, Germany Clinical Trial 
      Centre (ZKS), University of Cologne, Cologne, Germany.
FAU - Jansen, Klaus
AU  - Jansen K
AD  - Competence Network for HIV/AIDS, Bochum, Germany and Clinic for Dermatology, 
      Venerology and Allergology of the Ruhr-Universität, Bochum, Germany.
FAU - Masquelier, Bernard
AU  - Masquelier B
AD  - Laboratoire de Virologie, CHU de Bordeaux and MFP-UMR5234, Université Bordeaux 2, 
      Bordeaux, France.
FAU - Bellecave, Pantxika
AU  - Bellecave P
AD  - Laboratoire de Virologie, CHU de Bordeaux and MFP-UMR5234, Université Bordeaux 2, 
      Bordeaux, France.
FAU - Kouyos, Roger D
AU  - Kouyos RD
AD  - Division of Infectious Diseases and Hospital Epidemiology, University Hospital 
      Zurich, University of Zurich, Zurich, Switzerland.
FAU - Castro, Erika
AU  - Castro E
AD  - Addiction Medicine, Service of Community Psychiatry, Centre Hospitalier 
      Universitaire Vaudois, Lausanne, Switzerland.
FAU - Furrer, Hansjakob
AU  - Furrer H
AD  - Department of Infectious Diseases, Bern University Hospital and University of Bern, 
      Bern, Switzerland.
FAU - Schultze, Anna
AU  - Schultze A
AD  - University College London, London, UK.
FAU - Günthard, Huldrych F
AU  - Günthard HF
AD  - Division of Infectious Diseases and Hospital Epidemiology, University Hospital 
      Zurich, University of Zurich, Zurich, Switzerland.
FAU - Brun-Vezinet, Francoise
AU  - Brun-Vezinet F
AD  - Department of Virology, Bichat University Hospital, Paris, France.
FAU - Paredes, Roger
AU  - Paredes R
AD  - Institut de Recerca de la SIDA IrsiCaixa i Unitat VIH, Universitat Autònoma de 
      Barcelona, Universitat de Vic, Catalonia, Spain.
FAU - Metzner, Karin J
AU  - Metzner KJ
AD  - Division of Infectious Diseases and Hospital Epidemiology, University Hospital 
      Zurich, University of Zurich, Zurich, Switzerland karin.metzner@usz.ch.
CN  - CHAIN Minority HIV-1 Variants Working Group
LA  - eng
PT  - Journal Article
DEP - 20141021
TA  - J Antimicrob Chemother
JT  - The Journal of antimicrobial chemotherapy
JID - 7513617
RN  - 0 (Reverse Transcriptase Inhibitors)
SB  - IM
MH  - Adult
MH  - Antiretroviral Therapy, Highly Active/*methods
MH  - Case-Control Studies
MH  - Cohort Studies
MH  - Computational Biology
MH  - *Drug Resistance, Viral
MH  - Europe
MH  - Female
MH  - Genotype
MH  - HIV Infections/*drug therapy/*virology
MH  - HIV-1/*drug effects/genetics/isolation & purification
MH  - High-Throughput Nucleotide Sequencing
MH  - Humans
MH  - Male
MH  - Reverse Transcriptase Inhibitors/*therapeutic use
MH  - Risk Assessment
MH  - Sequence Analysis, DNA
MH  - Treatment Failure
MH  - Young Adult
PMC - PMC4319483
OTO - NOTNLM
OT  - CHAIN
OT  - European multicentre study
OT  - antiretroviral therapy
OT  - minority drug-resistant HIV-1 variants
FIR - Paredes, Roger
IR  - Paredes R
FIR - Metzner, Karin J
IR  - Metzner KJ
FIR - Cozzi-Lepri, Alessandro
IR  - Cozzi-Lepri A
FIR - Schuurman, Rob
IR  - Schuurman R
FIR - Brun-Vezinet, Francoise
IR  - Brun-Vezinet F
FIR - Günthard, Huldrych
IR  - Günthard H
FIR - Ceccherini-Silberstein, Francesca
IR  - Ceccherini-Silberstein F
FIR - Kaiser, Rolf
IR  - Kaiser R
FIR - Geretti, Anna Maria
IR  - Geretti AM
FIR - Brockmeyer, Norbert
IR  - Brockmeyer N
FIR - Masquelier, Bernard
IR  - Masquelier B
EDAT- 2014/10/23 06:00
MHDA- 2015/10/17 06:00
CRDT- 2014/10/23 06:00
PHST- 2014/10/23 06:00 [entrez]
PHST- 2014/10/23 06:00 [pubmed]
PHST- 2015/10/17 06:00 [medline]
AID - dku426 [pii]
AID - 10.1093/jac/dku426 [doi]
PST - ppublish
SO  - J Antimicrob Chemother. 2015 Mar;70(3):930-40. doi: 10.1093/jac/dku426. Epub 2014 
      Oct 21.

PMID- 10224878
OWN - NLM
STAT- MEDLINE
DCOM- 19990517
LR  - 20161124
IS  - 1135-5727 (Print)
IS  - 1135-5727 (Linking)
VI  - 73
IP  - 1
DP  - 1999 Jan-Feb
TI  - [HIV seroprevalence in patients seen at sexually-transmitted disease and family 
      planning centers in Spain, 1995-1996. AIDS Programs of the Autonomic Communities and 
      Network of sexually-transmitted disease, HIV and family planning centers].
PG  - 25-34
AB  - BACKGROUND: The sexually-transmitted diseases (STD's) centers are good sentinels for 
      monitoring the sexual transmitting of HIV. This study analyzes the results of 
      voluntary HIV tests run in 1995 and 1996 within a network of STD, HIV and family 
      planning centers in Spain. METHODS: Starting as of 1995, a questionnaire was sent 
      out yearly to said centers for recording the number of individuals found to have HIV 
      the previous year and the number of those who are proven to be HIV positive. A 
      calculation of HIV incidence was based as a function of sex and the main HIV 
      transmission categories. RESULTS: Eighty-one centers answered the survey in 1995, 78 
      having done so in 1996. Ninety-five percent of these centers ran the HIV test at the 
      request of the interested parties. At the 39 centers which provided data regarding 
      the HIV tests conducted in 1996, a total of 15,964 individuals had been tested. 
      Positive: 4.8% (n = 760) (CI: 4.4%-5.1%). The HIV seroprevalence was higher for 
      males (5.9%) than for females (2.6%; p, 0001). The highest HIV seroprevalence was 
      found among injecting drug users (IDU's) (18.7%). On comparing HIV seroprevalence in 
      1995 with that of 1996, drops were detected in the number of homosexual/bisexual men 
      from 7.4% to 6.1% (p = 0.049) and in women prostitutes, from 2.0% to 1.3% (p = 
      0.034). The Sexual partners of IDUs went from 3.4% to 4.6% (p = 0.267). CONCLUSIONS: 
      These results provide a nationwide reference regarding HIV incidence among 
      populations having high-risk sexual relations. The trend therein is favorable among 
      homosexual/bisexual men and female prostitutes.
LA  - spa
PT  - Comparative Study
PT  - Journal Article
TT  - Seroprevalencia de VIH en las personas que acuden a consultas de enfermedades de 
      transmisión sexual y planificación familiar. España, 1995-1996. Programas de SIDA de 
      las Comunidades Autónomas y Red de centros de enfermedades de transmisión sexual, 
      VIH y planificación familiar.
PL  - Spain
TA  - Rev Esp Salud Publica
JT  - Revista espanola de salud publica
JID - 9600212
SB  - IM
MH  - Adult
MH  - Female
MH  - HIV Infections/*epidemiology/transmission
MH  - HIV Seropositivity/epidemiology
MH  - *HIV Seroprevalence
MH  - Health Surveys
MH  - Homosexuality, Male
MH  - Humans
MH  - Male
MH  - Risk Factors
MH  - Sex Factors
MH  - Sex Work
MH  - Spain/epidemiology
MH  - Substance Abuse, Intravenous/complications
MH  - Surveys and Questionnaires
EDAT- 1999/05/04 00:00
MHDA- 1999/05/04 00:01
CRDT- 1999/05/04 00:00
PHST- 1999/05/04 00:00 [pubmed]
PHST- 1999/05/04 00:01 [medline]
PHST- 1999/05/04 00:00 [entrez]
PST - ppublish
SO  - Rev Esp Salud Publica. 1999 Jan-Feb;73(1):25-34.

PMID- 21360861
OWN - NLM
STAT- MEDLINE
DCOM- 20110421
LR  - 20110301
IS  - 0995-3914 (Print)
IS  - 0995-3914 (Linking)
VI  - 22
IP  - 5
DP  - 2010 Sep-Oct
TI  - [Knowledge, attitudes and practices regarding HIV/AIDS among disabled youth in 
      Maputo (Mozambique)].
PG  - 517-28
AB  - This study deals with knowledge, attitudes and practices regarding HIV/AIDS amongst 
      disabled youth (motor disabilities, visually or hearing impaired) aged 15 to 29 
      years in Maputo (Mozambique) where the prevalence rate of HIV is 20.7%. The study is 
      the first of its kind in Mozambique on this subject. The NGO Handicap International 
      would like to improve and adapt the activities carried out under its project "HIV 
      and Disability" that targets this vulnerable group within the population. Data 
      collection was done using an interview guide. The study sought to present a 
      comparison of knowledge, attitudes and practices among the disabled youth who 
      participated in the study and with non-disabled youth in Maputo, and a comparison 
      between the three kinds of disability among the disabled youth who participated in 
      the study. The results showed that the level of knowledge about HIV/AIDS in the 
      group of disabled youth is lower than that of youth without disabilities. The 
      comparison between the three types of disabilities showed that those who are 
      hearing-impaired are not reached by the usual HIV/AIDS awareness-raising or 
      prevention campaigns, as they are not a part of these communication networks. The 
      study analyzed reasons for these differences and showed that there is a need to 
      improve access to HIV/AIDS information, counseling and screening for young people 
      with disabilities. A series of recommendations have been proposed based on our 
      results.
FAU - Lefèvre-Chaponnière, Céline
AU  - Lefèvre-Chaponnière C
LA  - fre
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
TT  - Connaissances, attitudes et pratiques de jeunes handicapés sur le VIH/sida à Maputo 
      (Mozambique).
PL  - France
TA  - Sante Publique
JT  - Sante publique (Vandoeuvre-les-Nancy, France)
JID - 9216153
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - *Disabled Persons
MH  - Female
MH  - HIV Infections/*prevention & control/*transmission
MH  - *Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Male
MH  - Mozambique
MH  - Young Adult
EDAT- 2011/03/03 06:00
MHDA- 2011/04/22 06:00
CRDT- 2011/03/03 06:00
PHST- 2011/03/03 06:00 [entrez]
PHST- 2011/03/03 06:00 [pubmed]
PHST- 2011/04/22 06:00 [medline]
PST - ppublish
SO  - Sante Publique. 2010 Sep-Oct;22(5):517-28.

PMID- 20045273
OWN - NLM
STAT- MEDLINE
DCOM- 20110106
LR  - 20211020
IS  - 1769-6690 (Electronic)
IS  - 0399-077X (Print)
IS  - 0399-077X (Linking)
VI  - 40
IP  - 8
DP  - 2010 Aug
TI  - [Time trends in demographic and clinical characteristics of adult patients on HAART 
      initiation in West Africa].
PG  - 449-55
LID - 10.1016/j.medmal.2009.11.003 [doi]
AB  - OBJECTIVE: We studied the evolution of drug combinations used, as well as the 
      clinical and immunological profile of patients at initiation of highly active 
      antiretroviral therapy (HAART) between 1996 and 2006 in West Africa. SETTINGS AND 
      METHOD: IeDEA West Africa is a network of HIV care programs established in 2006. We 
      analyzed data from 12 clinical centers treating adults in five countries: Benin, 
      Cote d'Ivoire, Senegal, Gambia, and Mali. Patients 16 years of age or over were 
      included in the study and the following was documented: sex, date of birth and date 
      of initiation of HAART. RESULTS: We included 14,496 adult patients having started 
      HAART, among these 55 % had started HAART between 2005-2006. The proportion of 
      HIV-infected women increased from 46 % in 1996-2000 to 63 % in 2005-2006. The median 
      age at HAART initiation remained constant: 35 years for women and 40 years for men. 
      The proportion of patients having started HAART with a CD4 count<200 cells/microl 
      was 54 % in 1996-2000, and 64 % in 2005-2006. The most frequently prescribed HAART 
      was: AZT/3TC (or d4T/DDI)/IDV (27 %) in 1996-2000; d4T (or AZT)/3TC/EFV (49 %) in 
      2003-2004, and d4T/3TC/NVP (49 %) in 2005-2006. CONCLUSION: The first line HAART 
      regimen recommended by WHO was initiated in 83 % of cases in 2005-2006. New 
      approaches to an earlier initiation of ART should be explored to reduce mortality in 
      HIV-infected patients on HAART.
CI  - (c) 2009 Elsevier Masson SAS. All rights reserved.
FAU - Bashi, J
AU  - Bashi J
AD  - Centre de prise en charge des personnes vivant avec le VIH, CHNU, Cotonou, Bénin.
FAU - Balestre, E
AU  - Balestre E
FAU - Messou, E
AU  - Messou E
FAU - Maiga, M
AU  - Maiga M
FAU - Coffie, P A
AU  - Coffie PA
FAU - Zannou, D M
AU  - Zannou DM
FAU - Ba-Gomis, O
AU  - Ba-Gomis O
FAU - Traore, H A
AU  - Traore HA
FAU - Eholie, S
AU  - Eholie S
FAU - Minga, A
AU  - Minga A
FAU - Sow, P S
AU  - Sow PS
FAU - Bissagnene, E
AU  - Bissagnene E
FAU - Dabis, F
AU  - Dabis F
FAU - Ekouevi, D K
AU  - Ekouevi DK
CN  - Collaboration IeDEA West Africa
LA  - fre
GR  - U01 AI069919/AI/NIAID NIH HHS/United States
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
TT  - Evolution des conditions d'initiation du traitement antirétroviral des patients 
      infectés par le VIH en Afrique de l'Ouest.
DEP - 20091231
TA  - Med Mal Infect
JT  - Medecine et maladies infectieuses
JID - 0311416
SB  - IM
MH  - Adult
MH  - Africa, Western
MH  - Antiretroviral Therapy, Highly Active/*trends
MH  - Female
MH  - HIV Infections/*drug therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Time Factors
PMC - PMC3722501
MID - NIHMS490576
OAB - Publisher: Abstract available from the publisher.
OABL- fre
FIR - Dabis, François
IR  - Dabis F
FIR - Amani-Bosse, Clarisse
IR  - Amani-Bosse C
FIR - Bissagnene, Franck Olivier Ba-Gomis Emmanuel
IR  - Bissagnene FO
FIR - Delaporte, Eric
IR  - Delaporte E
FIR - Kanga-Koffi, Constace
IR  - Kanga-Koffi C
FIR - Maiga, Moussa
IR  - Maiga M
FIR - Messou, Eugène
IR  - Messou E
FIR - Minga, Albert
IR  - Minga A
FIR - Peterson, Kevin
IR  - Peterson K
FIR - Sow, Papa Salif
IR  - Sow PS
FIR - Traoré, Hamar
IR  - Traoré H
FIR - Zannou, Marcel D
IR  - Zannou MD
FIR - Allou, Gérard
IR  - Allou G
FIR - Anglaret, Xavier
IR  - Anglaret X
FIR - Azondékon, Alain
IR  - Azondékon A
FIR - Balestre, Eric
IR  - Balestre E
FIR - Bashi, Jules
IR  - Bashi J
FIR - Drabo, Joseph
IR  - Drabo J
FIR - Ye-Diarra
IR  - Ye-Diarra
FIR - Jacquet, Antoine
IR  - Jacquet A
FIR - Ekouévi, Didier K
IR  - Ekouévi DK
FIR - Eytard, Jean-François
IR  - Eytard JF
FIR - Kouakoussui, Alain
IR  - Kouakoussui A
FIR - Leroy, Valériane
IR  - Leroy V
FIR - Lewden, Charlotte
IR  - Lewden C
FIR - Malateste, Karen
IR  - Malateste K
FIR - Renner, Lorna
IR  - Renner L
FIR - Sasco, Annnie
IR  - Sasco A
FIR - Sy, Haby Signaté
IR  - Sy HS
FIR - Thiebault, Rodolphe
IR  - Thiebault R
FIR - Timité-Konan, Marguerite
IR  - Timité-Konan M
FIR - Touré, Hapsatou
IR  - Touré H
EDAT- 2010/01/05 06:00
MHDA- 2011/01/07 06:00
CRDT- 2010/01/05 06:00
PHST- 2009/01/22 00:00 [received]
PHST- 2009/09/18 00:00 [revised]
PHST- 2009/11/13 00:00 [accepted]
PHST- 2010/01/05 06:00 [entrez]
PHST- 2010/01/05 06:00 [pubmed]
PHST- 2011/01/07 06:00 [medline]
AID - S0399-077X(09)00371-0 [pii]
AID - 10.1016/j.medmal.2009.11.003 [doi]
PST - ppublish
SO  - Med Mal Infect. 2010 Aug;40(8):449-55. doi: 10.1016/j.medmal.2009.11.003. Epub 2009 
      Dec 31.

PMID- 16266636
OWN - NLM
STAT- MEDLINE
DCOM- 20060227
LR  - 20190823
IS  - 0025-7753 (Print)
IS  - 0025-7753 (Linking)
VI  - 125
IP  - 14
DP  - 2005 Oct 22
TI  - [Epidemiological surveillance of sexually-transmitted diseases. Spain 1995-2003].
PG  - 529-30
AB  - BACKGROUND AND OBJECTIVE: Sexually transmitted infections (STIs) are a major public 
      health problem due to their morbidity, complications and sequels, and also by their 
      relationships with human immunodeficiency virus infection. Several countries have 
      been described a resurgence of STIs since the mid-1990's. MATERIAL AND METHOD: 
      Descriptive study of the STIs monitored by epidemiological surveillance, using as 
      source of information the Spanish National Network of Epidemiological Surveillance 
      data, from 1995 to 2003. RESULTS: In 2003, 1069 new cases of gonorrhoea (rate: 2.55 
      per 100,000 population) and 917 new cases of syphilis (rate: 2.19 per 100,000 
      population) were notified to the Spanish Compulsory Disease Reporting System. 
      Between 1995 and 2003, gonorrhoea incidence rates decreased in a 78% and syphilis 
      rates diminish in a 15%. Nevertheless, between 2001 and 2003, both gonorrhoea and 
      syphilis incidence rates have increased in a 29% and 27% respectively. CONCLUSIONS: 
      The data analyzed in this period show an evident change in the trend of the 
      incidence of these STIs. This fact has to be confirmed in the future.
FAU - Díaz-Franco, Asunción
AU  - Díaz-Franco A
AD  - Area de Vigilancia Epidemiológica de VIH/sida, Centro Nacional de Epidemiología, 
      Instituto de Salud Carlos III, Madrid, Spain. adiaz@isciii.es
FAU - Noguer-Zambrano, Isabel
AU  - Noguer-Zambrano I
FAU - Cano-Portero, Rosa
AU  - Cano-Portero R
LA  - spa
PT  - English Abstract
PT  - Journal Article
TT  - Vigilancia epidemiológica de las infecciones de transmisión sexual. España, 
      1995-2003.
PL  - Spain
TA  - Med Clin (Barc)
JT  - Medicina clinica
JID - 0376377
SB  - IM
MH  - Gonorrhea/*epidemiology
MH  - Humans
MH  - Population Surveillance/methods
MH  - Sexually Transmitted Diseases/*epidemiology
MH  - Spain/epidemiology
MH  - Syphilis/*epidemiology
EDAT- 2005/11/04 09:00
MHDA- 2006/02/28 09:00
CRDT- 2005/11/04 09:00
PHST- 2005/11/04 09:00 [pubmed]
PHST- 2006/02/28 09:00 [medline]
PHST- 2005/11/04 09:00 [entrez]
AID - S0025-7753(05)72103-5 [pii]
AID - 10.1157/13080449 [doi]
PST - ppublish
SO  - Med Clin (Barc). 2005 Oct 22;125(14):529-30. doi: 10.1157/13080449.

PMID- 20185388
OWN - NLM
STAT- MEDLINE
DCOM- 20100409
LR  - 20100226
IS  - 1157-5999 (Print)
IS  - 1157-5999 (Linking)
VI  - 19
IP  - 3
DP  - 2009 Jul-Sep
TI  - [HIV/AIDS in South Africa and Haiti: the failure of epidemic governance and 
      achievement of the MDGs].
PG  - 121-32
LID - 10.1684/san.2009.0170 [doi]
AB  - Since their adoption in 2000 by the United Nations, the Millennium Development Goals 
      set for 2015 appear to have become a part of the policy agenda of all of the member 
      states. Three of these eight objectives deal with health issues. "Combat HIV/AIDS, 
      malaria and other diseases": this is the formulation of the sixth MDG. Observing 
      that in many countries strongly affected by poverty and inequalities, the epidemic 
      continues to spread, without really reversing at all, and that access to 
      antiretrovirals is possible for only a small proportion of the patient who need 
      them, we consider the problems of global governance in the field of health. Our 
      intention is to explain that the failure to deal with the HIV/AIDS epidemic may 
      constitute an obstacle to the achievement of the MDGs by 2015. Proposing a 
      comprehensive sociology of HIV/AIDS, this article pays special attention to the 
      dimension of the meaning of the disease, simultaneously as a policy issue, a social 
      construction, and an object of study in the social sciences. Looking at the two 
      countries most affected by the epidemic in Africa and in the Caribbean, we examine 
      the different aspects that have determined the failure of governance and the effects 
      of this failure on the populations concerned. The excessive conflictuality in South 
      Africa and the biopolitics of "let them die" and the fragmentation of the networks 
      involved in the combat in Haiti are considered to have contributed to a crisis in 
      the epidemic's governance. In both cases, the consequences have been expressed by a 
      reduced life expectancy, insufficient access to antiretroviral drugs, reinforcement 
      of the socioeconomic inequalities of health, the production of new pockets of 
      poverty, more fragile household and national economies, an increase in maternal and 
      child mortality ... The failure of the governance of the HIV/AIDS epidemic in 
      countries such as Haiti and South Africa appears to foretell the impossibility of 
      achieving the MDGs by 2015.
FAU - Thelot, Fils-Lien Ely
AU  - Thelot FL
AD  - Centre d'enseignement et de recherche en action humanitaire (CERAH), Institut de 
      hautes études internationales et du développement (IHEID), Université de Genève 24, 
      rue du Général-Dufour CH-1211 Genève 4, Suisse. Fils.Thelot@graduateinstitute.ch
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Le VIH/sida en Afrique du Sud et en Haïti : de l'échec de la gouvernance de 
      l'épidémie aux difficultés d'atteindre les OMD.
PL  - France
TA  - Sante
JT  - Sante (Montrouge, France)
JID - 9212437
SB  - IM
MH  - Acquired Immunodeficiency Syndrome/drug therapy/*epidemiology/prevention & 
      control/transmission
MH  - Adult
MH  - Africa, Southern
MH  - Female
MH  - HIV Infections/drug therapy/*epidemiology/prevention & control/transmission
MH  - HIV Seropositivity
MH  - Haiti
MH  - Health Services Accessibility
MH  - Humans
MH  - Infant, Newborn
MH  - Infectious Disease Transmission, Vertical
MH  - Male
MH  - Risk Factors
MH  - Socioeconomic Factors
EDAT- 2010/02/27 06:00
MHDA- 2010/04/10 06:00
CRDT- 2010/02/27 06:00
PHST- 2010/02/27 06:00 [entrez]
PHST- 2010/02/27 06:00 [pubmed]
PHST- 2010/04/10 06:00 [medline]
AID - san.2009.0170 [pii]
AID - 10.1684/san.2009.0170 [doi]
PST - ppublish
SO  - Sante. 2009 Jul-Sep;19(3):121-32. doi: 10.1684/san.2009.0170.

PMID- 19810612
OWN - NLM
STAT- MEDLINE
DCOM- 20091116
LR  - 20091008
IS  - 1157-5999 (Print)
IS  - 1157-5999 (Linking)
VI  - 18
IP  - 4
DP  - 2008 Oct-Dec
TI  - [From economic difficulties to social suffering of people living with HIV in Burkina 
      Faso].
PG  - 187-91
AB  - A qualitative study conducted in 2006 shows that many people in Burkina Faso, living 
      with HIV and receiving antiretroviral treatment (ART), have difficulties in meeting 
      the expenses related to care. This anthropological analysis considers their 
      perceptions, the causes and the social impact of these economic problems. This 
      research is based on semi-structured interviews with 35 people living with HIV 
      (PLWHIV) infection, contacted through HIV care programs in Ouagadougou, 
      Bobo-Dioulasso and Ouahigouya. After recording, transcribing and indexing the 
      interviews, we analysed them. Even when they did not have to pay for treatment, most 
      of the subjects faced economic problems dealing with follow-up care and monitoring, 
      transportation, and other expenses, and these problems occur when PLWHIV have 
      already faced the long, complex and expensive therapeutic itinerary before the test 
      that diagnosed HIV infection. The new diet required by the treatment is also 
      mentioned. Moreover, work problems often due to the disease (low output at work, 
      inability to work, job loss) have already decreased patients' income by the time 
      they get treatment. It is not easy for them to return to the level of resources they 
      had before their disease, even if they can find a job. This financial exhaustion 
      frequently leads to the exclusion of PLWHIV from their former solidarity networks, 
      mostly because they can no longer participate in collective contributions or return 
      what they were given when they were totally dependent. The analysis of these 
      conversations shows the relevance of the concept of "social suffering" in describing 
      the social effects of the economic problems that face many PLWHIV on ART, even when 
      treatment is subsidized.
FAU - Bila, Blandine
AU  - Bila B
AD  - Institut de recherche en sciences de la santé, Centre national de recherche 
      scientifique et technologique (IRSS-CNRST), 03 BP 7192 Ouagadougou, Burkina Faso. 
      blandinebila@yahoo.com
FAU - Kouanda, Seni
AU  - Kouanda S
FAU - Desclaux, Alice
AU  - Desclaux A
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Des difficultés économiques à la souffrance sociale des personnes vivant avec le VIH 
      au Burkina Faso.
PL  - France
TA  - Sante
JT  - Sante (Montrouge, France)
JID - 9212437
SB  - IM
MH  - Adult
MH  - Burkina Faso
MH  - Cost of Illness
MH  - Female
MH  - *HIV Infections
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Poverty
MH  - *Social Isolation
EDAT- 2009/10/09 06:00
MHDA- 2009/11/17 06:00
CRDT- 2009/10/09 06:00
PHST- 2009/10/09 06:00 [entrez]
PHST- 2009/10/09 06:00 [pubmed]
PHST- 2009/11/17 06:00 [medline]
PST - ppublish
SO  - Sante. 2008 Oct-Dec;18(4):187-91.

PMID- 16999043
OWN - NLM
STAT- MEDLINE
DCOM- 20061103
LR  - 20081121
IS  - 0025-682X (Print)
IS  - 0025-682X (Linking)
VI  - 66
IP  - 4
DP  - 2006 Aug
TI  - [The French Red Cross: a network of care centers dedicated to HIV-AIDS].
PG  - 346-7
AB  - The commitment of the French Red Cross Society to the fight against HIV/AIDS in 
      Africa and Asia is based on day care centers (DCC) set up and operated within public 
      hospitals. These outpatient facilities offer global care including clinical and 
      biologic follow-up for patients undergoing anti-retroviral treatment. In most 
      countries these DCC have become reference centers providing support for national 
      decentralization policies. To reinforce the impact of their activities, centers 
      offer regular educational programs and provide extensive training for medical 
      personnel.
FAU - Tran-Minh, T
AU  - Tran-Minh T
AD  - La Croix-Rouge française, Paris, France. t.tm@wanadoo.fr
FAU - Adam, G
AU  - Adam G
FAU - Simon, B
AU  - Simon B
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Croix-Rouge française: un réseau de soins dédié au VIH-sida.
PL  - France
TA  - Med Trop (Mars)
JT  - Medecine tropicale : revue du Corps de sante colonial
JID - 8710146
SB  - IM
MH  - Acquired Immunodeficiency Syndrome/prevention & control/*therapy/transmission
MH  - Adolescent
MH  - Africa
MH  - Asia
MH  - Child
MH  - Female
MH  - France
MH  - Humans
MH  - Infant, Newborn
MH  - Infectious Disease Transmission, Vertical/prevention & control
MH  - Pregnancy
MH  - *Red Cross
EDAT- 2006/09/27 09:00
MHDA- 2006/11/04 09:00
CRDT- 2006/09/27 09:00
PHST- 2006/09/27 09:00 [pubmed]
PHST- 2006/11/04 09:00 [medline]
PHST- 2006/09/27 09:00 [entrez]
PST - ppublish
SO  - Med Trop (Mars). 2006 Aug;66(4):346-7.

PMID- 19068977
OWN - NLM
STAT- MEDLINE
DCOM- 20090305
LR  - 20081212
IS  - 0025-682X (Print)
IS  - 0025-682X (Linking)
VI  - 68
IP  - 5
DP  - 2008 Oct
TI  - [Experience of a pharmacist/activist in Cayenne in 2007: fighting HIV/AIDS through 
      prevention and care. A look at women].
PG  - 471-7
AB  - The author relates her experience as a pharmacist/activist involved in the fight 
      against HIV. She has worked as a health care professional in French Guiana, as an 
      instructor for NGO, and as an activist working with squatters and street people in 
      cooperation with prevention teams. The goal of her action has been to enhance 
      prevention and to enhance social services for the poor and precarious people in 
      particular for women with regard to reproductive health including HIV/AIDS. A record 
      of these activities was kept as a basis for future planning. The data obtained was 
      used to design and implement information, prevention, and risk control measures to 
      assist infected groups with the least access to health care. Based on her experience 
      in the field, the author concludes that effective management of the epidemic crisis 
      in French Guiana will require a radically different strategy from that used in 
      mainland France not only with regard to financial and human resources but also, and 
      above all, to innovative ideas. The author stresses the need to make maximum use of 
      link (network) the city and hospital services taking full advantage of all players 
      involved in patient management and always ensuring that care providers understand 
      the importance of maintaining contact with associations that provide the only direct 
      link with patients in their everyday lives.
FAU - Chiron, S
AU  - Chiron S
AD  - Act-Up Toulouse, 10 bis Rue du Colonel Driant, 31400, Toulouse. 
      sylviechiron@hotmail.com
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Pharmacien et activiste à Cayenne en 2007: face au VIH/SIDA accès à la prévention et 
      aux soins, un regard sur les femmes.
PL  - France
TA  - Med Trop (Mars)
JT  - Medecine tropicale : revue du Corps de sante colonial
JID - 8710146
SB  - IM
MH  - Acquired Immunodeficiency Syndrome/*drug therapy/*prevention & control
MH  - Female
MH  - French Guiana
MH  - HIV Infections/prevention & control
MH  - Humans
MH  - Male
MH  - *Pharmacists
EDAT- 2008/12/17 09:00
MHDA- 2009/03/06 09:00
CRDT- 2008/12/17 09:00
PHST- 2008/12/17 09:00 [entrez]
PHST- 2008/12/17 09:00 [pubmed]
PHST- 2009/03/06 09:00 [medline]
PST - ppublish
SO  - Med Trop (Mars). 2008 Oct;68(5):471-7.

PMID- 17261243
OWN - NLM
STAT- MEDLINE
DCOM- 20070424
LR  - 20190922
IS  - 0213-005X (Print)
IS  - 0213-005X (Linking)
VI  - 25
IP  - 1
DP  - 2007 Jan
TI  - [Spanish cohort of naïve HIV-infected patients (CoRIS): rationale, organization and 
      initial results].
PG  - 23-31
AB  - OBJECTIVE: To describe the methodology and baseline results of the Spanish cohort of 
      naïve HIV-infected patients included in the Research Network on HIV/AIDS (CoRIS). 
      METHODS: CoRIS is a multicenter, hospital-based prospective cohort of HIV 
      sero-prevalent, retroviral-naïve subjects, over 13 years old, and seen at 17 
      hospitals in 8 of the 17 Autonomous Regions in Spain from January 2004 to October 
      2005. The socio-demographic characteristics, as well as epidemiological, clinical, 
      laboratory and treatment data were recorded, and biological samples were collected 
      at baseline and during follow-up. RESULTS: A total of 1,591 subjects have been 
      included in CoRIS; 24% are women, median age at cohort entry is 36 years, and 74% 
      were diagnosed during 2004 or 2005. Twenty-seven percent came from countries other 
      than Spain, mainly Latin-America (16%) and sub-Saharan Africa (5%). Thirty-two 
      percent had completed secondary education and 16% university studies. The most 
      frequent categories of transmission were men having sex with men (37%) and 
      heterosexual sex (36%); only 21% were injection drug users. At cohort entry, median 
      CD4 count was 317 cells/mm 3 and median viral load was 52,300 copies/mL; 18% were 
      diagnosed with AIDS. Main AIDS-defining illnesses were Pneumocystis jiroveci 
      pneumonia (6.1%), esophageal candidiasis (3.3%) and tuberculosis (extrapulmonary, 
      3.0% and pulmonary 2.7%). There were 35 deaths (2.2%). Thirty-three percent of 
      patients gave a baseline sample to the BioBank. CONCLUSIONS: CoRIS offers relevant 
      information about the current epidemiological profile of HIV infection in Spain, 
      where sexual transmission has become predominant. The type and amount of information 
      obtained from clinical and epidemiological data collection together with biological 
      samples demonstrate the viability of the project, which offers many possibilities 
      for future research.
FAU - Caro-Murillo, Ana María
AU  - Caro-Murillo AM
AD  - Centro Nacional de Epidemiología, Instituto de Salud Carlos III, Madrid, Spain. 
      amcaro@isciii.es
FAU - Castilla, Jesús
AU  - Castilla J
FAU - Pérez-Hoyos, Santiago
AU  - Pérez-Hoyos S
FAU - Miró, José M
AU  - Miró JM
FAU - Podzamczer, Daniel
AU  - Podzamczer D
FAU - Rubio, Rafael
AU  - Rubio R
FAU - Riera, Melchor
AU  - Riera M
FAU - Viciana, Pompeyo
AU  - Viciana P
FAU - López Aldeguer, José
AU  - López Aldeguer J
FAU - Iribarren, José Antonio
AU  - Iribarren JA
FAU - de los Santos-Gil, Ignacio
AU  - de los Santos-Gil I
FAU - Gómez-Sirvent, Juan Luis
AU  - Gómez-Sirvent JL
FAU - Berenguer, Juan
AU  - Berenguer J
FAU - Gutiérrez, Félix
AU  - Gutiérrez F
FAU - Saumoy, María
AU  - Saumoy M
FAU - Segura, Ferrán
AU  - Segura F
FAU - Soriano, Vicente
AU  - Soriano V
FAU - Peña, Alejandro
AU  - Peña A
FAU - Pulido, Federico
AU  - Pulido F
FAU - Oteo, José Antonio
AU  - Oteo JA
FAU - Leal, Manuel
AU  - Leal M
FAU - Casabona, Jordi
AU  - Casabona J
FAU - del Amo, Julia
AU  - del Amo J
FAU - Moreno, Santiago
AU  - Moreno S
CN  - Grupo de trabajo de la Cohorte de la Red de Investigación en Sida (CoRIS)
LA  - spa
PT  - English Abstract
PT  - Journal Article
PT  - Multicenter Study
TT  - Cohorte RIS de pacientes con infección por VIH sin tratamiento antirretroviral 
      previo (CoRIS): metodología y primeros resultados.
PL  - Spain
TA  - Enferm Infecc Microbiol Clin
JT  - Enfermedades infecciosas y microbiologia clinica
JID - 9104081
SB  - IM
CIN - Enferm Infecc Microbiol Clin. 2007 Jan;25(1):3-4. PMID: 17261239
MH  - AIDS-Related Opportunistic Infections/epidemiology
MH  - Adolescent
MH  - Adult
MH  - Africa South of the Sahara/epidemiology
MH  - Aged
MH  - CD4 Lymphocyte Count
MH  - Candidiasis/epidemiology
MH  - Cohort Studies
MH  - Educational Status
MH  - Female
MH  - HIV Infections/*epidemiology/transmission
MH  - Humans
MH  - Latin America/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Pneumonia, Pneumocystis/epidemiology
MH  - Prospective Studies
MH  - Risk Factors
MH  - Sexual Behavior/statistics & numerical data
MH  - Spain/epidemiology
MH  - Substance Abuse, Intravenous/epidemiology
MH  - Tuberculosis/epidemiology
EDAT- 2007/01/31 09:00
MHDA- 2007/04/25 09:00
CRDT- 2007/01/31 09:00
PHST- 2007/01/31 09:00 [pubmed]
PHST- 2007/04/25 09:00 [medline]
PHST- 2007/01/31 09:00 [entrez]
AID - 13096749 [pii]
AID - 10.1157/13096749 [doi]
PST - ppublish
SO  - Enferm Infecc Microbiol Clin. 2007 Jan;25(1):23-31. doi: 10.1157/13096749.

PMID- 17296087
OWN - NLM
STAT- MEDLINE
DCOM- 20070323
LR  - 20191210
IS  - 0214-9915 (Print)
IS  - 0214-9915 (Linking)
VI  - 18
IP  - 3
DP  - 2006 Aug
TI  - [Questionnaire to assess advertising campaigns impact about HIV/AIDS prevention].
PG  - 557-64
AB  - Present work is concerned with a questionnaire aimed to the impact evaluation of a 
      selection of Spanish advertising campaigns about HIV/AIDS prevention. The work 
      objective is to determine reliability and factorial structure of the instrument. It 
      is described the designed questionnaire and its three scales (affective impact 
      scale, cognitive impact scale and behavioural intention impact scale). The sample 
      was composed by 405 high school teenagers to who were projected the advertising 
      campaigns. So, teenagers filled the designed questionnaire. From a theoretical and 
      psychometric point of view, data show the instrument is appropriate about internal 
      consistency and factorial structure. The final goal of the questionnaire is to 
      become useful tool to assess the persuasive effectiveness of the advertising 
      campaigns within the HIV/AIDS network, as an intervention of primary prevention to 
      reduce the expansion of epidemic.
FAU - Bretón-López, Juana
AU  - Bretón-López J
AD  - Universidad de Granada, Spain. jbreton@ugr.es
FAU - Buela-Casal, Gualberto
AU  - Buela-Casal G
LA  - spa
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
TT  - Cuestionario para la evaluación del impacto de campañas publicitarias sobre 
      prevención del VIH/SIDA.
PL  - Spain
TA  - Psicothema
JT  - Psicothema
JID - 101189384
SB  - IM
MH  - Acquired Immunodeficiency Syndrome/*prevention & control
MH  - Adolescent
MH  - *Advertising
MH  - Factor Analysis, Statistical
MH  - Female
MH  - HIV Infections/*prevention & control
MH  - Humans
MH  - Male
MH  - Preventive Health Services/*organization & administration
MH  - *Surveys and Questionnaires
EDAT- 2007/02/14 09:00
MHDA- 2007/03/24 09:00
CRDT- 2007/02/14 09:00
PHST- 2007/02/14 09:00 [pubmed]
PHST- 2007/03/24 09:00 [medline]
PHST- 2007/02/14 09:00 [entrez]
PST - ppublish
SO  - Psicothema. 2006 Aug;18(3):557-64.

PMID- 17334568
OWN - NLM
STAT- MEDLINE
DCOM- 20080131
LR  - 20190823
IS  - 0102-311X (Print)
IS  - 0102-311X (Linking)
VI  - 23
IP  - 3
DP  - 2007 Mar
TI  - [Social actors in HIV/AIDS prevention: opposition and interests in educational 
      policy in Mexico, 1994-2000].
PG  - 535-44
AB  - Studies and recommendations by health agencies have emphasized the importance of 
      education in HIV-AIDS prevention. Mexico has included topics on sexuality and 
      HIV-AIDS in school programs, triggering resistance by some social actors. The 
      current study seeks to clarify the various positions and interests and their 
      influence on the textbook content. A literature search was conducted on the period 
      during which the last educational reform was implemented in Mexico. The discourse 
      analysis focused on the ethnography of communication, which identified: the various 
      actors' positions, arguments, actions, economic and political power, and relations 
      to others. The results show that those who oppose the inclusion of these themes in 
      the school curriculum base their position on tradition, contrary to modernization 
      and secularization of social life, and that their positions range from refusal to 
      raising conditions. Networks have been formed that provide such groups with 
      significant economic and political power. Government has given in to some demands by 
      partially modifying the textbook contents. The current analysis proposes to reflect 
      on the potential repercussions of such actions on the control of the epidemic.
FAU - Granados-Cosme, José Arturo
AU  - Granados-Cosme JA
AD  - Universidad Autónoma Metropolitana, Calzada del Hueso 1100, Col. Villa Quietud 
      04960, Coyoacán, México DF, México. jcosme@correo.xoc.uam.mx
FAU - Nasaiya, Kittipong
AU  - Nasaiya K
FAU - Brambila, Alberto Torres
AU  - Brambila AT
LA  - spa
PT  - Journal Article
TT  - Actores sociales en la prevención del VIH/SIDA: oposiciones e intereses en la 
      política educativa en México, 1994-2000.
PL  - Brazil
TA  - Cad Saude Publica
JT  - Cadernos de saude publica
JID - 8901573
SB  - IM
MH  - Acquired Immunodeficiency Syndrome/*prevention & control
MH  - Catholicism
MH  - *Community Participation
MH  - Condoms/statistics & numerical data
MH  - Contraception Behavior
MH  - Curriculum
MH  - Female
MH  - HIV Infections/prevention & control
MH  - *Health Education
MH  - Health Knowledge, Attitudes, Practice
MH  - Humans
MH  - Male
MH  - Mexico
MH  - Organizational Objectives
MH  - Preventive Health Services
MH  - *Public Policy
MH  - Religion and Sex
MH  - School Health Services
MH  - *Sexuality
MH  - Societies
EDAT- 2007/03/06 09:00
MHDA- 2008/02/01 09:00
CRDT- 2007/03/06 09:00
PHST- 2005/12/13 00:00 [received]
PHST- 2005/08/01 00:00 [accepted]
PHST- 2007/03/06 09:00 [pubmed]
PHST- 2008/02/01 09:00 [medline]
PHST- 2007/03/06 09:00 [entrez]
AID - S0102-311X2007000300012 [pii]
AID - 10.1590/s0102-311x2007000300012 [doi]
PST - ppublish
SO  - Cad Saude Publica. 2007 Mar;23(3):535-44. doi: 10.1590/s0102-311x2007000300012.

PMID- 24451429
OWN - NLM
STAT- MEDLINE
DCOM- 20140403
LR  - 20161128
IS  - 0995-3914 (Print)
IS  - 0995-3914 (Linking)
VI  - 25
IP  - 6
DP  - 2013 Nov-Dec
TI  - [The Burkinabe experience of the creation of a Community Advisory Committee to 
      improve the support of HIV research projects].
PG  - 829-37
AB  - INTRODUCTION: Community Advisory Committees (CAC) have become indicators of good 
      community involvement in health research all over the world. CACs have been 
      developed only recently in several Sub-Saharan African countries. Many countries 
      wonder about how to create and ensure good functioning of a community advisory 
      committee. The objective of this article is to describe the creation of two CACs in 
      Burkina Faso. METHODS: This qualitative study comprised a literature review phase, a 
      data collection phase conducted on a sample of 27 subjects (research scientists, 
      representatives of AIDS associations or networks and the local technical and/or 
      financial partners of these associations) and an implementation phase. Study 
      participants were selected on a rational basis, the study complied with the ethical 
      principles of research and data were transcribed and analysed manually. RESULTS: 
      Scientists and/or community workers may initiate the creation of a CAC based on the 
      following main elements: the profile of individuals and/or structures, the dynamism 
      of CAC members, reinforcement of their skills and capacities. The CAC must be 
      independent of research scientists and must be designed to be sustainable. 
      DISCUSSION: The difficulties of sustainability and the poor perception of CACs 
      remain major challenges. Continuing collaboration between CAC members and research 
      scientists improves their knowledge in the field of research ethics, allowing the 
      community to perceive CACs as supporters of research.
FAU - Berthé, Abdramane
AU  - Berthé A
FAU - Traoré, Isidore
AU  - Traoré I
FAU - Somé, Josiane
AU  - Somé J
FAU - Berthé-Sanou, Lalla
AU  - Berthé-Sanou L
FAU - Salouka, Souleymane
AU  - Salouka S
FAU - Rouamba, Jérémi
AU  - Rouamba J
FAU - Mayaud, Philippe
AU  - Mayaud P
FAU - Nagot, Nicolas
AU  - Nagot N
FAU - Méda, Nicolas
AU  - Méda N
LA  - fre
PT  - Journal Article
TT  - L'expérience burkinabè de constitution d'un Comité Consultatif Communautaire pour un 
      meilleur accompagnement des projets de recherche sur le VIH.
PL  - France
TA  - Sante Publique
JT  - Sante publique (Vandoeuvre-les-Nancy, France)
JID - 9216153
SB  - IM
MH  - *Advisory Committees
MH  - Burkina Faso
MH  - *Community Participation
MH  - *Community-Based Participatory Research
MH  - HIV Infections/*prevention & control
MH  - Humans
EDAT- 2014/01/24 06:00
MHDA- 2014/04/04 06:00
CRDT- 2014/01/24 06:00
PHST- 2014/01/24 06:00 [entrez]
PHST- 2014/01/24 06:00 [pubmed]
PHST- 2014/04/04 06:00 [medline]
PST - ppublish
SO  - Sante Publique. 2013 Nov-Dec;25(6):829-37.

PMID- 9424118
OWN - NLM
STAT- MEDLINE
DCOM- 19980105
LR  - 20061115
IS  - 0213-005X (Print)
IS  - 0213-005X (Linking)
VI  - 15
IP  - 8
DP  - 1997 Oct
TI  - [Analysis of the microbiological information derived from the sentinel laboratory 
      network for the monitoring of the human immunodeficiency virus infection in 
      Catalonia (1989-1995)].
PG  - 401-6
AB  - BACKGROUND: The epidemiologic information on AIDS derived exclusively from the AIDS 
      case registry presents a series of limitations. To solve some of these epidemiologic 
      surveillance systems of HIV infection have been designed. The information of the 
      microbiology laboratories in which anti-HIV antibody detection tests are performed 
      has been one of the most commonly used sources of information. MATERIAL AND METHOD: 
      The detection activity of the anti-HIV antibodies from a surveillance laboratory 
      network in Catalonia from 1989 to 1995 was collected. RESULTS: A continuous increase 
      was observed in the number of tests performed in the network laboratories (30012 in 
      1989 up to 63323 in 1995) as was a significant decrease in the number of tests which 
      were reactive (20.7% in 1989 to 6.1% in 1995). Great variability was found in the 
      results among the different laboratories as well as in the diagnostic algorythms 
      used. CONCLUSIONS: Laboratories are an important source to take into account to 
      perform epidemiologic surveillance of HIV infection. The collaboration among the 
      laboratories and public health care officials allows information to be obtained that 
      aids in better defining the characteristics of people who currently have HIV 
      infection and in designing preventive activities directed at the needs of each 
      community. This collaboration also allows homogeneous diagnostic algorythmns and 
      common criteria to be established to ensure quality control.
FAU - Blanch, C
AU  - Blanch C
AD  - Centre d'Estudis Epidemiològics sobre la VIH/sida a Catalunya (CEESCAT), Hospital 
      Universitari Germans Trias i Pujol, Badalona, Barcelona.
FAU - Vall, M
AU  - Vall M
FAU - Casabona, J
AU  - Casabona J
LA  - spa
PT  - English Abstract
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
TT  - Análisis de la información microbiológica derivada de la red de laboratorios 
      centinela para la monitorización de la infección por el virus de la 
      inmunodeficiencia humana en Cataluña (1989-1995). Colaboradores del proyecto VIHLAB.
PL  - Spain
TA  - Enferm Infecc Microbiol Clin
JT  - Enfermedades infecciosas y microbiologia clinica
JID - 9104081
RN  - 0 (HIV Antibodies)
SB  - IM
MH  - Acquired Immunodeficiency Syndrome/diagnosis/*epidemiology
MH  - HIV Antibodies/*analysis
MH  - Humans
MH  - Laboratories/statistics & numerical data
MH  - Population Surveillance/methods
MH  - Spain/epidemiology
EDAT- 1998/01/10 00:00
MHDA- 1998/01/10 00:01
CRDT- 1998/01/10 00:00
PHST- 1998/01/10 00:00 [pubmed]
PHST- 1998/01/10 00:01 [medline]
PHST- 1998/01/10 00:00 [entrez]
PST - ppublish
SO  - Enferm Infecc Microbiol Clin. 1997 Oct;15(8):401-6.

PMID- 19188133
OWN - NLM
STAT- MEDLINE
DCOM- 20090409
LR  - 20191210
IS  - 1157-5999 (Print)
IS  - 1157-5999 (Linking)
VI  - 18
IP  - 2
DP  - 2008 Apr-Jun
TI  - [National coordination of the ambulatory treatment centers (ATC) in Gabon: a new 
      process to conduct the scaling up of care for people living with HIV-AIDS].
PG  - 97-102
LID - 10.1684/san.2008.0116 [doi]
AB  - Gabonese authorities are strongly mobilized in the fight against AIDS. With a 
      national seroprevalence of 5.9%, 54,000 people are living with HIV-AIDS. Starting 
      from the experience conducted on three ambulatory treatment centers (ATC) 
      [Libreville, Franceville, Port-Gentil] in collaboration with the French Red Cross, 
      Gabonese authorities decided the scaling up of HIV patients' care to seven new ATC 
      at a national level. The increasing number of structures conducted to standardize 
      treatment's guidelines, training of caregivers, quality of care, coordination, 
      monitoring and evaluation. Technical and medical supervision of the ten ATC were 
      attributed to the French Red Cross by Gabonese authorities with the financial 
      support of the French Agency for Development. The ten ATC, founded by the ministry 
      of public health, were then organized within a network under the responsibility of a 
      national coordination. This structure created in September 2007 represents the main 
      organism to conduct, evaluate and follow-up activities and functioning of the ten 
      ATC. All these activities are conducted in agreement with the national program of 
      fight against AIDS. Within one year this structure of coordination allowed to 
      organize the training of 208 caregivers, to elaborate a team of national and 
      international experts, to start a process of national guidelines, to elaborate 
      technical procedures and indicators for monitoring, follow-up and evaluation. In 
      June 2007, 5 ATC were in function taking care of 7,062 PLWA. In November 2008, 9 ATC 
      were in function taking care of 8,174 PLWA. This project is planned for four years. 
      It might allow to structure and organize a national network of care for PLWA 
      according to the national strategy. This procedure of scaling up under the 
      responsibility of a national team of technical and operational coordination is a new 
      process. It completes and strengthens the national organization process.
FAU - Ndong, G-P Obiang
AU  - Ndong GP
AD  - Coordination nationale des CTA Ministère de la Santé et de l'Hygiène publique, 
      Libreville, Gabon.
FAU - Adam, G
AU  - Adam G
FAU - Mouala, C
AU  - Mouala C
FAU - Faucherre, V
AU  - Faucherre V
FAU - Kouely, Pe Nfoubou
AU  - Kouely PN
FAU - Sibeoni, J
AU  - Sibeoni J
FAU - Courpotin, C
AU  - Courpotin C
LA  - fre
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
TT  - La coordination nationale des centres de traitement ambulatoire au Gabon : une 
      expérience novatrice de décentralisation opérationnelle de la prise en charge du 
      VIH-sida.
PL  - France
TA  - Sante
JT  - Sante (Montrouge, France)
JID - 9212437
RN  - 0 (Anti-Retroviral Agents)
SB  - IM
MH  - Acquired Immunodeficiency Syndrome/drug therapy/*therapy
MH  - *Ambulatory Care/standards
MH  - Anti-Retroviral Agents/therapeutic use
MH  - France
MH  - Gabon
MH  - HIV Infections/drug therapy/*therapy
MH  - Humans
MH  - *Quality of Health Care
MH  - Quality of Life
MH  - *Red Cross
MH  - Workforce
EDAT- 2009/02/04 09:00
MHDA- 2009/04/10 09:00
CRDT- 2009/02/04 09:00
PHST- 2009/02/04 09:00 [entrez]
PHST- 2009/02/04 09:00 [pubmed]
PHST- 2009/04/10 09:00 [medline]
AID - san.2008.0116 [pii]
AID - 10.1684/san.2008.0116 [doi]
PST - ppublish
SO  - Sante. 2008 Apr-Jun;18(2):97-102. doi: 10.1684/san.2008.0116.

PMID- 12219364
OWN - NLM
STAT- MEDLINE
DCOM- 20021001
LR  - 20041117
IS  - 1195-2695 (Print)
IS  - 1195-2695 (Linking)
VI  - 9
IP  - 6
DP  - 2002 Jul-Aug
TI  - [Towards an integrated network for substance abusers with HIV/AIDS].
PG  - 27-31, 37-8
FAU - Lahaie, Claire
AU  - Lahaie C
AD  - UHRESS de l'Hôspital Saint-Luc du CHUM.
LA  - fre
PT  - Case Reports
PT  - Journal Article
TT  - Vers un réseau de soins intégrés pour la clientèle toxicomane atteinte du VIH/SIDA.
PL  - Canada
TA  - Infirm Que
JT  - L'Infirmiere du Quebec : revue officielle de l'Ordre des infirmieres et infirmiers 
      du Quebec
JID - 9430795
MH  - Acquired Immunodeficiency Syndrome/complications/*therapy
MH  - Adult
MH  - *Community Networks
MH  - Delivery of Health Care, Integrated/*organization & administration
MH  - Female
MH  - Hospitals, Urban
MH  - Humans
MH  - Substance-Related Disorders/*complications
EDAT- 2002/09/11 10:00
MHDA- 2002/10/03 04:00
CRDT- 2002/09/11 10:00
PHST- 2002/09/11 10:00 [pubmed]
PHST- 2002/10/03 04:00 [medline]
PHST- 2002/09/11 10:00 [entrez]
PST - ppublish
SO  - Infirm Que. 2002 Jul-Aug;9(6):27-31, 37-8.

PMID- 23427467
OWN - NLM
STAT- MEDLINE
DCOM- 20130405
LR  - 20161124
IS  - 0375-0760 (Print)
IS  - 0375-0760 (Linking)
VI  - 59
IP  - 3
DP  - 2007 Sep-Dec
TI  - [AIDS Prevention Group: 15 years of sustained efforts for the prevention of 
      HIV/AIDS].
PG  - 261-9
AB  - An AIDS epidemic is an important challenge to human survival. Although the 
      prevalence in Cuba is below 0.1% in adult people, this disease is a priority 
      problem. The AIDS Prevention Group (known as GPSIDA in Cuba) was created to 
      contribute to the response of the Ministry of Public Health to this slow but growing 
      epidemic. GPSIDA, made up of HIV seropositive and seronegative people, carry out 
      actions aimed at educating the population. avoiding new infections and supporting 
      the infected people and their relatives. This paper was intended to document the 
      development of the group since its inception in 1991 up to 2006, that is, its first 
      15 years of existence. An infrastructure for GPSIDA at provincial level has been 
      built in addition to the strengthening of the communication and exchange network. 
      There are at present 16 AIDS prevention groups in the country that group over 300 
      members and 500 collaborators working for the prevention of STI and HIV/AIDS.
FAU - Aragonés López, Carlos
AU  - Aragonés López C
AD  - Departamento de Bioestadistica y Computación, Instituto de Medicina Tropical Pedro 
      Kouri, Ciudad de La Habana, Cuba. aragones@ipk.sld.cu
FAU - Campos Díaz, Jorge Raúl
AU  - Campos Díaz JR
FAU - Sánchez Valdés, Lizet
AU  - Sánchez Valdés L
FAU - Pérez Avila, Lorenzo Jorge
AU  - Pérez Avila LJ
LA  - spa
PT  - Journal Article
TT  - Grupos de Prevención del SIDA (GPSIDA): 15 años de trabajo sostenido en la 
      prevención del VIH/sida.
PL  - Cuba
TA  - Rev Cubana Med Trop
JT  - Revista cubana de medicina tropical
JID - 0074364
RN  - 0 (Anti-HIV Agents)
SB  - IM
MH  - Acquired Immunodeficiency Syndrome/epidemiology/*prevention & control
MH  - Anti-HIV Agents/supply & distribution/therapeutic use
MH  - Community Participation
MH  - Cuba/epidemiology
MH  - Female
MH  - HIV Seronegativity
MH  - HIV Seropositivity
MH  - Health Promotion
MH  - Health Services Accessibility
MH  - Hospitals, Chronic Disease/organization & administration
MH  - Humans
MH  - Interdisciplinary Communication
MH  - Male
MH  - Mass Media
MH  - National Health Programs/*organization & administration
MH  - Program Evaluation
MH  - Public Health Administration
EDAT- 2007/09/01 00:00
MHDA- 2013/04/06 06:00
CRDT- 2013/02/23 06:00
PHST- 2013/02/23 06:00 [entrez]
PHST- 2007/09/01 00:00 [pubmed]
PHST- 2013/04/06 06:00 [medline]
PST - ppublish
SO  - Rev Cubana Med Trop. 2007 Sep-Dec;59(3):261-9.

PMID- 17947084
OWN - NLM
STAT- MEDLINE
DCOM- 20080402
LR  - 20200306
IS  - 1557-170X (Print)
IS  - 1557-170X (Linking)
VI  - 2006
DP  - 2006
TI  - A cascade control approach for a class of biomedical systems.
PG  - 4420-3
AB  - An approach for the robust feedback control of a class of biomedical systems in 
      chained form is presented. The control approach is based on modeling error 
      compensation techniques and a recursive cascade scheme. Numerical simulations on 
      three biomedical models of VIH-1, cancer and glucose systems are provided to 
      illustrate our findings.
FAU - Ortiz-Vargas, Moisés
AU  - Ortiz-Vargas M
AD  - Escuela de Ingeniería, Univ. of Panamericana, México DF. ing_moisesortiz@hotmail.com
FAU - Puebla, Hector
AU  - Puebla H
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Conf Proc IEEE Eng Med Biol Soc
JT  - Conference proceedings : ... Annual International Conference of the IEEE Engineering 
      in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. 
      Annual Conference
JID - 101243413
RN  - 0 (Insulin)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Acquired Immunodeficiency Syndrome/pathology
MH  - Algorithms
MH  - *Artificial Intelligence
MH  - Computer Simulation
MH  - *Feedback
MH  - Glucose/metabolism
MH  - HIV-1/metabolism
MH  - Humans
MH  - Insulin/metabolism
MH  - Models, Biological
MH  - Models, Statistical
MH  - Neoplasms/pathology
MH  - Neural Networks, Computer
MH  - Nonlinear Dynamics
MH  - *Systems Biology
EDAT- 2007/10/20 09:00
MHDA- 2008/04/03 09:00
CRDT- 2007/10/20 09:00
PHST- 2007/10/20 09:00 [pubmed]
PHST- 2008/04/03 09:00 [medline]
PHST- 2007/10/20 09:00 [entrez]
AID - 10.1109/IEMBS.2006.260841 [doi]
PST - ppublish
SO  - Conf Proc IEEE Eng Med Biol Soc. 2006;2006:4420-3. doi: 10.1109/IEMBS.2006.260841.

PMID- 15581471
OWN - NLM
STAT- MEDLINE
DCOM- 20050517
LR  - 20070413
IS  - 0767-0974 (Print)
IS  - 0767-0974 (Linking)
VI  - 20
IP  - 12
DP  - 2004 Dec
TI  - [Free anonymous screening consultation and clinical management of HIV infection].
PG  - 1145-8
AB  - In France, since 1988, anonymous and free consultations (called CDAG) have been 
      settled in the country to facilitate an individual and volunteer approach for HIV 
      screening. At the time, there are more than 380 CDAG with newly defined objectives. 
      CDAG are supposed to encourage early screening, facilitate access to precarious 
      persons and persons at risk for sexually transmitted diseases, and reinforce 
      prevention, helping consultants to define a personal preventive strategy. CDAG are 
      also supposed to play a role in prevention of both hepatitis B and C, and syphilis. 
      They may help to link screening and healthcare. Their activity is increasing and the 
      rate of positive test is twice that of private laboratories. Patients consulting 
      those facilities are younger and more at risk than general population. Between 1000 
      and 2000 HIV positive tests are detected in CDAG each year (11 % of positive tests 
      in the country). The real impact on prevention and screening at the national level 
      is unknown, in part because of anonymity. To improve the characterization of 
      consultants, data collection will be modified in 2004, and a network of selected and 
      volunteer centres will collect continuously more accurate data.
FAU - Bouvet, Elisabeth
AU  - Bouvet E
AD  - Service des Maladies infectieuses et tropicales A, Hôpital Bichat, 46, rue Henri 
      Huchard, 75018 Paris, France. elisabeth.bouvet@bch.ap-hop-paris.fr
FAU - Le Vu, Stéphane
AU  - Le Vu S
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Les CDAG et la prise en charge de l'infection par le VIH.
PL  - France
TA  - Med Sci (Paris)
JT  - Medecine sciences : M/S
JID - 8710980
SB  - IM
MH  - *Anonymous Testing
MH  - France
MH  - HIV Infections/*diagnosis/therapy
MH  - Humans
MH  - *Mass Screening
EDAT- 2004/12/08 09:00
MHDA- 2005/05/18 09:00
CRDT- 2004/12/08 09:00
PHST- 2004/12/08 09:00 [pubmed]
PHST- 2005/05/18 09:00 [medline]
PHST- 2004/12/08 09:00 [entrez]
AID - 00/00/06/74/ [pii]
AID - 10.1051/medsci/200420121145 [doi]
PST - ppublish
SO  - Med Sci (Paris). 2004 Dec;20(12):1145-8. doi: 10.1051/medsci/200420121145.

PMID- 9092096
OWN - NLM
STAT- MEDLINE
DCOM- 19970408
LR  - 20131106
IS  - 0036-3634 (Print)
IS  - 0036-3634 (Linking)
VI  - 39
IP  - 1
DP  - 1997 Jan-Feb
TI  - [Management strategies in HIV/AIDS at the family level].
PG  - 32-43
AB  - OBJECTIVE: To identify the critical points of the trajectories of the families of 
      persons with AIDS which may serve as a basis to develop educational and support 
      programs. THEORY AND METHODS: A qualitative investigation was conducted in 1995 in 
      Ciudad Netzahualcóyotl, State of Mexico, Mexico. Rapid Assessment Procedures (RAP) 
      were applied to determine the social, economic, demographic and cultural context of 
      persons with HIV/AIDS in the community. Forty-six in-depth interviews were applied 
      to persons with AIDS, their families and people from their social networks. RESULTS: 
      The main aspects of the family response to the HIV/ AIDS are characterized, and it 
      is demonstrated that it is possible to identify critical points in such a response 
      which can be targeted through specific interventions. In Ciudad Netzahualcóyotl, a 
      context of poverty, a migrating tradition, and gender social relations are the basis 
      of the acceptance or rejection of persons with AIDS. The main finding refers to the 
      ambiguos attitude, ranging from rejection to support, displayed by family members of 
      persons with AIDS. This pattern varies according to the history and specific 
      conditions of each family. CONCLUSIONS: Specific health interventions are proposed 
      to support families with one or more persons with AIDS.
FAU - Castro, R
AU  - Castro R
AD  - Centro de Investigación en Sistemas de Salud, Instituto Nacional de Salud Pública, 
      México.
FAU - Eroza, E
AU  - Eroza E
FAU - Orozco, E
AU  - Orozco E
FAU - Manca, M C
AU  - Manca MC
FAU - Hernández, J J
AU  - Hernández JJ
LA  - spa
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
TT  - Estrategias de manejo en torno al VIH/SIDA a nivel familiar.
PL  - Mexico
TA  - Salud Publica Mex
JT  - Salud publica de Mexico
JID - 0404371
SB  - IM
MH  - *Acquired Immunodeficiency Syndrome/mortality
MH  - *Attitude to Health
MH  - Emigration and Immigration
MH  - *Family
MH  - *HIV Infections/mortality
MH  - Humans
MH  - Interpersonal Relations
MH  - Mexico
MH  - Poverty
MH  - Social Support
EDAT- 1997/01/01 00:00
MHDA- 1997/01/01 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1997/01/01 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
PST - ppublish
SO  - Salud Publica Mex. 1997 Jan-Feb;39(1):32-43.

PMID- 12594391
OWN - NLM
STAT- MEDLINE
DCOM- 20030325
LR  - 20061115
IS  - 0242-6498 (Print)
IS  - 0242-6498 (Linking)
VI  - 22
IP  - 6
DP  - 2002 Dec
TI  - [Pulmonary veno-occlusive disease in a patient with HIV infection. A case report 
      with autopsy findings].
PG  - 472-5
AB  - We relate the autopsy findings of a case of pulmonary veno-occlusive disease which 
      occurred in an HIV-infected intravenous drug abuser. This exceedingly rare disease, 
      of unknown cause, is responsible for 10% of primary pulmonary hypertension. 
      Histologically, the disease is characterized by a fibrous intimal thickening of 
      small and medium sized pulmonary veins associated with congestive and dilated 
      capillary network and alveolar haemorrhage. The occurrence of primary pulmonary 
      hypertension in HIV positive patients is 25 times more frequent than in the general 
      population. This is the third reported case of pulmonary veno-occlusive disease 
      occurring in a HIV positive patient. It suggests the role of HIV in the pathogenesis 
      of these vascular lesions.
FAU - Hourseau, Muriel
AU  - Hourseau M
AD  - Service d'Anatomie et de Cytologie Pathologiques, Hôpital Avicenne, Bobigny. 
      imagerie.anapath@ap-hop-paris.fr
FAU - Capron, Frédérique
AU  - Capron F
FAU - Nunes, Hilario
AU  - Nunes H
FAU - Godmer, Pascal
AU  - Godmer P
FAU - Martin, Antoine
AU  - Martin A
FAU - Kambouchner, Marianne
AU  - Kambouchner M
LA  - fre
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - Maladie veino-occlusive pulmonaire et infection par le VIH.
PL  - France
TA  - Ann Pathol
JT  - Annales de pathologie
JID - 8106337
SB  - IM
MH  - Adult
MH  - Autopsy
MH  - Fatal Outcome
MH  - HIV Infections/complications/*pathology
MH  - Humans
MH  - Male
MH  - Pulmonary Veins/pathology
MH  - Pulmonary Veno-Occlusive Disease/*etiology/*pathology
EDAT- 2003/02/21 04:00
MHDA- 2003/03/26 05:00
CRDT- 2003/02/21 04:00
PHST- 2003/02/21 04:00 [pubmed]
PHST- 2003/03/26 05:00 [medline]
PHST- 2003/02/21 04:00 [entrez]
AID - MDOI-AP-12-2002-22-6-0242-6498-101019-ART7 [pii]
PST - ppublish
SO  - Ann Pathol. 2002 Dec;22(6):472-5.

PMID- 20185390
OWN - NLM
STAT- MEDLINE
DCOM- 20100409
LR  - 20100226
IS  - 1157-5999 (Print)
IS  - 1157-5999 (Linking)
VI  - 19
IP  - 3
DP  - 2009 Jul-Sep
TI  - [Implementation of a continuum of care for people living with HIV/AIDS in Hanoi 
      (Vietnam)].
PG  - 141-8
LID - 10.1684/san.2009.0169 [doi]
AB  - Caring for people living with HIV/AIDS (PLWHA) encompasses various tasks, from 
      prevention to palliative care. It involves a set of consistent and coordinated 
      actions. This article presents the first free-of-charge management programme 
      including antiretroviral treatment in Vietnam (as opposed to research and evaluation 
      programmes). It was launched in 2004 in Hanoi. Our study was conducted in 2003-2004 
      as part of a collaborative research programme led by IRD (Research Institute for 
      Development) and the National Economic University in Hanoi and was funded by ESTHER 
      (Together for a Therapeutic Solidarity in Hospital Network) group. Data collection 
      included 68 qualitative interviews with patients, members of their families and 
      members of the hospital staff, observations of outpatient consultations, and 
      analysis of inpatient files. The results show that patients, their families and 
      hospital staff members all perceive a comprehensive care and treatment programme as 
      very important and consider that it should include social and psychological care as 
      well as an integrated set of actions involving various types of participants. 
      Outpatient and inpatient care are closely linked: they take place in the same 
      hospital department, they involve patients with similar social and demographic 
      characteristics marked by multiple risk behaviours and recourse to several kinds of 
      healthcare services. The observation of outpatient consultations showed the 
      limitations of strictly biomedical care to which social and psychological care were 
      added only lately. One of the principal difficulties is patients' difficulties in 
      keeping their outpatient appointments. Overall, patients consider themselves lucky 
      to able to receive care and treatment with antiretroviral drugs. They nevertheless 
      complain about the lack of social and psychological support, which they expect 
      should help them to tolerate and adapt to their biomedical treatment and to include 
      counselling and information about this treatment and its consequences. Hospital 
      staff with the greatest contact with PLWHA report more frequent attempts to avoid 
      this contact. This stigmatisation is due to lack of information, failure to 
      implement workplace safety measures, and to pejorative representations of HIV/AIDS. 
      Official and unofficial discourse still follows the Ministry of Health in 
      associating HIV/AIDS with drug use and commercial sex, and HIV/AIDS prevention and 
      control policy is still linked to the "social evils" policy. Hospital staff also 
      emphasized the importance of community care for PLWHA in their interviews. Informal 
      care for PLWHA by family, close relatives, close friends and members of non-official 
      groups complements hospital care, which is sometimes limited to its biomedical 
      component and provides the material, moral, financial, social, economic and 
      relational care essential for PLWHA and their close relatives and friends. This 
      informal care has also some pernicious effects and leads to internal contradictions 
      due to the multiple social roles played by the many and various participants 
      involved. HIV/AIDS prevention and control policy relies on a series of choices 
      between more specificity through vertical programmes specialised in HIV/AIDS and the 
      synergy that can develop through more integrated health services. Vietnam has 
      developed links between HIV/AIDS prevention and control programmes on the one hand, 
      and harm reduction programmes for injecting drug users (access to substitution 
      products such as methadone) and condom distribution, on the other. Nonetheless, 
      HIV/AIDS prevention and control policy faces difficulties in reaching its 
      objectives. The results of this policy, intended to help achieve Millennium 
      Development Goal (MDG) n degrees 6, depends partly on the success for other MDGs, 
      including the fight against poverty, the promotion of gender equality and 
      empowerment of women, and the improvement of reproductive health. To be able to 
      succeed in implementing the continuum of care necessary for treating HIV/AIDS within 
      its institutions, Vietnam can apply the lessons of international experience, adapted 
      to fit local constraints and the social, cultural and political context. The 
      shortcomings encountered in this endeavour shows how difficult it is for this 
      country to implement such a complex set of measures at an accelerated pace. They 
      should not, however, hide or minimize the great efforts, the vigour, and the 
      capacity to adapt already demonstrated by local participants.
FAU - de Loenzien, Myriam
AU  - de Loenzien M
AD  - IRD-LPED, Université de Provence, Case 10, 3, place Victor Hugo, 13331 Marseille 
      cedex 03, France. loenzien@ird.fr
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Institutionnalisation d'un continuum de prise en charge des séropositifs VIH/sida à 
      Hanoï (Viêt-Nam).
PL  - France
TA  - Sante
JT  - Sante (Montrouge, France)
JID - 9212437
RN  - 0 (Anti-Retroviral Agents)
SB  - IM
MH  - Acquired Immunodeficiency Syndrome/epidemiology/prevention & control/*therapy
MH  - Aged
MH  - Anti-Retroviral Agents/administration & dosage/therapeutic use
MH  - Cohort Studies
MH  - Data Collection
MH  - Female
MH  - HIV Infections/epidemiology/prevention & control/*therapy
MH  - *HIV Seropositivity
MH  - Hospitalization
MH  - Humans
MH  - Male
MH  - Outpatients
MH  - Patient Compliance
MH  - Poverty
MH  - Socioeconomic Factors
MH  - Time Factors
MH  - Vietnam
EDAT- 2010/02/27 06:00
MHDA- 2010/04/10 06:00
CRDT- 2010/02/27 06:00
PHST- 2010/02/27 06:00 [entrez]
PHST- 2010/02/27 06:00 [pubmed]
PHST- 2010/04/10 06:00 [medline]
AID - san.2009.0169 [pii]
AID - 10.1684/san.2009.0169 [doi]
PST - ppublish
SO  - Sante. 2009 Jul-Sep;19(3):141-8. doi: 10.1684/san.2009.0169.

PMID- 19359238
OWN - NLM
STAT- MEDLINE
DCOM- 20090612
LR  - 20191210
IS  - 1157-5999 (Print)
IS  - 1157-5999 (Linking)
VI  - 18
IP  - 3
DP  - 2008 Jul-Sep
TI  - [Understanding and reaching young clandestine sex workers in Burkina Faso to improve 
      response to HIV].
PG  - 163-73
LID - 10.1684/san.2008.0120 [doi]
AB  - In 1998, researchers in Burkina Faso enrolled 300 women more or less involved in 
      commercial sex work in an open cohort to determine whether adequate management of 
      their sexually transmitted infections and exposure to well-designed, well-delivered, 
      and plentiful communication for behaviour change (CBC) might reduce their 
      vulnerability to HIV. In 2000, they observed that the non-professional sex workers 
      (occasional or clandestine sex workers) were more difficult to reach, to mobilize 
      and to keep involved in the project's different activities. This group was also 
      infected at the same or higher rates than professional sex workers because they did 
      not use condoms routinely. To accomplish the project objectives, they therefore 
      chose to recruit more non-professional sex workers in the new cohort of 700 women. 
      This social-anthropological study was conducted to help them to enrol young 
      clandestine sex workers. The overall objective of this study was to understand the 
      life of this category of sex workers and to identify strategic actors to reach them. 
      Using a qualitative method, social anthropologists reviewed literature, identified 
      and geo-referenced all local places suitable to encountering these women, obtained 
      life stories from some of them and interviewed key informants and participants in 
      the field. The results showed that in Bobo-Dioulasso (Burkina Faso): - most young 
      women who are clandestine sex workers are Burkinabe, and girls entering the sex 
      trade are increasingly young and increasingly uneducated; - most of them come from 
      families with low capital (financial, cultural, or social). The parents' 
      socioeconomic status (contextual poverty) results in unmet financial needs, which in 
      turn exposes them to starting work early, including commercial sex work; - of all 
      the income-generating activities available to unskilled young girls, commercial sex 
      work is one of the most profitable and easily accessible; - in the three-fold 
      context of an HIV epidemic, poverty, and unemployment, clandestine commercial sex 
      work is a rational action, insofar as condom use reduces the risk of HIV infection, 
      "clandestinity" reduces the risk of social stigma, and earnings increase financial 
      capital; - girls are coopted into sex work through an initiation process and the 
      initiator explains to the initiate how sex workers think, act, and live, as well as 
      the rules of the trade; - young clandestine commercial sex workers use various 
      strategies to do their work in secret, unidentified, by changing the time, place, 
      period, district, city or country of their work; - young clandestine commercial sex 
      workers maintain friendly relations with men or boys in but have no or conflictual 
      relationships with women and girls. Thus, only other participants in this trade, 
      peer counsellors, and room renters can serve as strategic actors to reach, mobilize 
      and keep these young girls in HIV programmes. Social anthropologists have concluded 
      that one problem in the fight against official or professional commercial sex work 
      is the development of clandestine commercial sex work, which is more dangerous, 
      firstly for its practitioners, who are harder to reach by messages about HIV and 
      thus do not change their behaviour, secondly, for their sexual partners who do not 
      use condoms systematically, and finally for society as a whole, to the extent that 
      social actors are embedded in an informal network, more or less extensive, of sexual 
      partners.
FAU - Berthé, Abdramane
AU  - Berthé A
AD  - Unité Sciences de l'homme pour l'aide à la décision, à l'action et à l'évaluation 
      des interventions (SHADEI) Centre Muraz 01 BP 390 Bobo-Dioulasso 01 Burkina Faso. 
      aberthe56@yahoo.fr
FAU - Huygens, Pierre
AU  - Huygens P
FAU - Ouattara, Cécile
AU  - Ouattara C
FAU - Sanon, Anselme
AU  - Sanon A
FAU - Ouédraogo, Abdoulaye
AU  - Ouédraogo A
FAU - Nagot, Nicolas
AU  - Nagot N
LA  - fre
PT  - Case Reports
PT  - Evaluation Study
PT  - Journal Article
TT  - Comprendre et atteindre les jeunes travailleuses du sexe clandestines du Burkina 
      Faso pour une meilleure riposte au VIH.
PL  - France
TA  - Sante
JT  - Sante (Montrouge, France)
JID - 9212437
SB  - IM
MH  - Adolescent
MH  - Age Factors
MH  - Anthropology
MH  - Burkina Faso
MH  - Cohort Studies
MH  - Condoms, Female/statistics & numerical data
MH  - Female
MH  - HIV Infections/*prevention & control/transmission
MH  - Humans
MH  - Interviews as Topic
MH  - Male
MH  - Risk Reduction Behavior
MH  - *Sex Work/psychology
MH  - Sexual Partners
MH  - Socioeconomic Factors
MH  - Young Adult
EDAT- 2009/04/11 09:00
MHDA- 2009/06/13 09:00
CRDT- 2009/04/11 09:00
PHST- 2009/04/11 09:00 [entrez]
PHST- 2009/04/11 09:00 [pubmed]
PHST- 2009/06/13 09:00 [medline]
AID - san.2008.0120 [pii]
AID - 10.1684/san.2008.0120 [doi]
PST - ppublish
SO  - Sante. 2008 Jul-Sep;18(3):163-73. doi: 10.1684/san.2008.0120.

PMID- 9289612
OWN - NLM
STAT- MEDLINE
DCOM- 19970911
LR  - 20061115
IS  - 0025-682X (Print)
IS  - 0025-682X (Linking)
VI  - 57
IP  - 1
DP  - 1997
TI  - [AIDS and HIV infection in the Federal Islamic Republic of Comores (1988-1995)].
PG  - 59-61
AB  - Since 1991 AIDS and HIV infection in the Federal Islamic Republic of the Comoros 
      have been monitored through a network of sentinel sites including predetermined 
      target populations. In all cases seropositivity for HIV was confirmed by western 
      blotting after two ELISA screening tests. AIDS was diagnosed on Bangui clinical 
      criteria and positive western blotting results. As of June 30, 1996, the cumulative 
      number of AIDS cases reported to the World Health Organization was 7 for a 
      prevalence of 1.4 per 100000 inhabitants. The prevalence of HIV antibodies has 
      remained at less than 1% in target populations, i.e. women undergoing prenatal 
      examinations, patients with newly diagnosed tuberculosis, blood donors, and patients 
      presenting sexually transmitted diseases (STD). This low stable prevalence rate 
      which is similar to those reported in other Indian Ocean countries is in sharp 
      contrast with the high incidence of syphilis and STD in the region.
FAU - Toyb, M
AU  - Toyb M
AD  - Programme National de Lutte contre le Sida et les MST, RFI des Comores, Moroni, 
      République Fédérale Islamique des Comores.
FAU - Lombart, J P
AU  - Lombart JP
FAU - Binti Abdou, A
AU  - Binti Abdou A
FAU - Oumadi, A
AU  - Oumadi A
FAU - Molines, C
AU  - Molines C
FAU - Josse, R
AU  - Josse R
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - SIDA et infection à VIH en République Fédérale Islamique des Comores (1988-1995).
PL  - France
TA  - Med Trop (Mars)
JT  - Medecine tropicale : revue du Corps de sante colonial
JID - 8710146
RN  - 0 (HIV Antibodies)
SB  - IM
MH  - Acquired Immunodeficiency Syndrome/*epidemiology
MH  - Adolescent
MH  - Adult
MH  - Blood Donors/statistics & numerical data
MH  - Blotting, Western
MH  - Comoros/epidemiology
MH  - Disease Notification
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - HIV Antibodies/blood
MH  - HIV Infections/*epidemiology
MH  - HIV Seropositivity/epidemiology
MH  - HIV Seroprevalence
MH  - Humans
MH  - Incidence
MH  - Indian Ocean Islands/epidemiology
MH  - Islam
MH  - Male
MH  - Middle Aged
MH  - Population Surveillance
MH  - Pregnancy/blood
MH  - Pregnancy Complications, Infectious/epidemiology
MH  - Sexually Transmitted Diseases/epidemiology
MH  - Syphilis/epidemiology
MH  - Tuberculosis/epidemiology
MH  - World Health Organization
EDAT- 1997/01/01 00:00
MHDA- 1997/01/01 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1997/01/01 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
PST - ppublish
SO  - Med Trop (Mars). 1997;57(1):59-61.

PMID- 12610445
OWN - NLM
STAT- MEDLINE
DCOM- 20030327
LR  - 20161209
IS  - 0755-4982 (Print)
IS  - 0755-4982 (Linking)
VI  - 32
IP  - 7
DP  - 2003 Feb 22
TI  - [NADIS 2000, development of an electronic medical record for patients infected by 
      HIV, HBV and HCV].
PG  - 299-303
AB  - OBJECTIVE: to develop an electronic medical record for patients living with HIV, HBV 
      or HCV in order to improve their management, facilitate communication between all 
      the caregivers, and to create a useful medical database for research and 
      assessments. This project (NADIS 2000) involved 6 centres of Infectious Diseases in 
      France in partnership with Fédialis Médica (subsidiary of the GSK group in France). 
      METHODS: A specifications sheets was drawn-up by a piloting Committee regrouping the 
      various correspondents in each centre and a computer expert representing Fédialis 
      Médica. A Scientific and Development committee regrouped the heads of departments of 
      each centre and the representatives from Fédialis Médica and GSK and was charged 
      with defining the general concept of the project and guaranteeing the scientific and 
      clinical aspects. RESULTS: NADIS 2000 version 1.0 was activated in the departments 
      of infectious diseases in Nice and Toulouse in November 2000 and in others Units at 
      the end of 2001. NADIS 2000 permitted real-time use by the physicians in the 
      Outpatients and Day-care Units and was easily handled by all the practitioners. Its 
      use was eased by the principles clearly defined before its application (department 
      project, progressive but exhaustive use), an intuitive interface simulating a 
      consultation, and functions proposing direct benefits for the physicians (graphical 
      visualization of the biological variables, printing of prescriptions and letters). 
      CONCLUSION: The activation and input methods of NADIS 2000 are user friendly and the 
      physicians find it rapidly easy to use. New functional aspects are being developed 
      as well as its use in other hospital departments.
FAU - Pugliese, P
AU  - Pugliese P
AD  - Service de maladies infectieuses, Hôpital l'Archet 1, CHU de Nice (06). 
      pugliese.p@chu-nice.fr
FAU - Cuzin, L
AU  - Cuzin L
FAU - Enel, P
AU  - Enel P
FAU - Agher, R
AU  - Agher R
FAU - Alfandari, S
AU  - Alfandari S
FAU - Billaud, E
AU  - Billaud E
FAU - Druard, P
AU  - Druard P
FAU - Duvivier, C
AU  - Duvivier C
FAU - Perez, M
AU  - Perez M
FAU - Salmi, D
AU  - Salmi D
FAU - Pradier, C
AU  - Pradier C
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - NADIS 2000, développement d'un dossier médical informatisé pour les patients 
      infectés par VIH, VHB et VHC.
PL  - France
TA  - Presse Med
JT  - Presse medicale (Paris, France : 1983)
JID - 8302490
SB  - IM
MH  - Computer Communication Networks/organization & administration
MH  - Computer Graphics
MH  - Databases, Factual
MH  - France
MH  - HIV Infections/diagnosis/*therapy
MH  - Hepatitis B/diagnosis/*therapy
MH  - Hepatitis C/diagnosis/*therapy
MH  - Humans
MH  - Medical Records Systems, Computerized/*organization & administration
MH  - Patient Care Team
MH  - Remote Consultation
MH  - Software
MH  - User-Computer Interface
EDAT- 2003/03/01 04:00
MHDA- 2003/03/28 05:00
CRDT- 2003/03/01 04:00
PHST- 2003/03/01 04:00 [pubmed]
PHST- 2003/03/28 05:00 [medline]
PHST- 2003/03/01 04:00 [entrez]
AID - MDOI-PM-02-2003-32-7-0755-4982-101019-ART4 [pii]
PST - ppublish
SO  - Presse Med. 2003 Feb 22;32(7):299-303.

PMID- 12038188
OWN - NLM
STAT- MEDLINE
DCOM- 20030213
LR  - 20061115
IS  - 0025-682X (Print)
IS  - 0025-682X (Linking)
VI  - 62
IP  - 1
DP  - 2002
TI  - [Status of resistance of HIV-1 strains in Africa: what is the role of viral 
      surveillance networks?].
PG  - 89-93
AB  - The human immunodeficiency virus (HIV-1) epidemic has spread dramatically in 
      sub-Saharan African countries. Implementation of active antiretroviral (ARV) therapy 
      programs is urgently needed. However this emergency situation must not extenuate the 
      importance of preliminary studies on ARV resistance of African HIV-1 isolates. 
      Findings show that genetic mutations underlying the resistance of African strains 
      are generally identical to those observed in HIV-1 subtype B in industrialized 
      countries. However the incidence of some mutations associated with mild resistance 
      to protease inhibitors (PI) appears higher in African isolates. The potential impact 
      of these mutations for development of frank resistance to PI is still unclear. The 
      incidence of high-grade resistance markers in untreated subjects is low. While these 
      results do not compromise use of ARV therapy in Africa, they underline the need to 
      set up local networks for patient follow-up and to carry out epidemiological 
      surveillance of HIV-1 resistance. Success of ARV therapies in Africa will also 
      depend on economic and social programs.
FAU - Grandadam, M
AU  - Grandadam M
AD  - Laboratoire de biologie clinique, HIA Val-de-Grâce, 74 Bd Port Royal, 75230 Paris. 
      5rt@filnet.fr
FAU - Nicand, E
AU  - Nicand E
FAU - Koeck, J L
AU  - Koeck JL
FAU - Caron, M
AU  - Caron M
FAU - Teyssou, R
AU  - Teyssou R
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Etat de la resistance des souches de VIH-1 en Afrique: quelle place pour les reseaux 
      de surveillance virologique?
PL  - France
TA  - Med Trop (Mars)
JT  - Medecine tropicale : revue du Corps de sante colonial
JID - 8710146
RN  - 0 (Anti-HIV Agents)
SB  - IM
MH  - Africa
MH  - Anti-HIV Agents/*pharmacology
MH  - *Drug Resistance, Viral
MH  - HIV Infections/*drug therapy/epidemiology
MH  - HIV-1/*drug effects
MH  - Humans
MH  - *Population Surveillance
EDAT- 2002/06/01 10:00
MHDA- 2003/02/14 04:00
CRDT- 2002/06/01 10:00
PHST- 2002/06/01 10:00 [pubmed]
PHST- 2003/02/14 04:00 [medline]
PHST- 2002/06/01 10:00 [entrez]
PST - ppublish
SO  - Med Trop (Mars). 2002;62(1):89-93.
